Biomarkers for vitiligo

ABSTRACT

Biomarkers are provided that are associated with or predictive of a subject&#39;s responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing vitiligo.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No.62/820,647, filed Mar. 19, 2019, and U.S. Provisional Application No.62/893,532, filed Aug. 29, 2019. The content of each of the foregoingapplications are incorporated by reference herein in their entirety.

TECHNICAL FIELD

The present invention relates generally to biomarkers and vitiligo.

BACKGROUND

Vitiligo occurs when the cells that produce melanin die or stopfunctioning, resulting in patchy loss of skin pigmentation. Nonsegmentalvitiligo involves depigmentation in patches of skin all over the body.Depigmentation typically occurs on the face, neck, and scalp, and aroundbody openings. Loss of pigmentation is also frequently seen in areasthat tend to experience rubbing, impact, or other trauma, such as thehands, and arms. Segmental vitiligo is associated with smaller patchesof depigmented skin that appear on one side of the body in a limitedarea.

Janus kinase (JAK) inhibitors have been developed as agents for thetreatment of vitiligo. However, as for any therapeutic, JAK inhibitorsmay not be equally effective in all subjects that have vitiligo. Thereis a need for means of identifying those subjects having vitiligo thatcould most benefit from treatment with a JAK inhibitor as well asidentifying those subjects that exhibit a therapeutic response totreatment with a JAK inhibitor.

SUMMARY

The present application is based, at least in part, on theidentification of biomarkers that identify a subject that has undergonea therapeutic response to a JAK inhibitor and biomarkers that arepredictive of a vitiligo subject's responsiveness to a JAK inhibitor.The change in level of certain proteins during the course of treatmentis identified as a useful identifier of responsiveness to a JAKinhibitor. In addition, the baseline level of certain proteins and thebaseline expression level of certain genes prior to treatment areidentified as useful predictors of responsiveness to a JAK inhibitor.Thus, the biomarkers and compositions described herein are useful, forexample, in identifying, stratifying, and/or selecting a patient or asubset of patients having, suspected of having, or at risk of developingvitiligo that could benefit, or have benefitted, from treatment with aJAK inhibitor. In addition, the methods described herein are useful, forexample, in selecting appropriate treatment modalities (e.g., a JAKinhibitor) for a subject suffering from, suspected of having, or at riskof developing vitiligo.

The disclosure features a method of treating a human subject having,suspected of having, or at risk of developing vitiligo by: measuring, ina first biological sample obtained from the human subject prior toadministering a JAK inhibitor, the concentration of CXCL9 and/or CXCL10;administering the JAK inhibitor to the human subject; and measuring, ina second biological sample obtained from the human subject afteradministering the JAK inhibitor, a reduced concentration, as compared tothe first biological sample, of CXCL9 and/or CXCL10. In someembodiments, administration of the JAK inhibitor is continued.

In some embodiments, the method entails: measuring, in the firstbiological sample obtained from the human subject prior to administeringthe JAK inhibitor, the concentration of CXCL9; administering the JAKinhibitor to the human subject; and measuring, in the second biologicalsample obtained from the human subject after administering the JAKinhibitor, a reduced concentration, as compared to the first biologicalsample, of CXCL9. In some embodiments, administration of the JAKinhibitor is continued.

In some embodiments, the concentration of CXCL9 is reduced by at least5% in the second biological sample as compared to the first biologicalsample.

In some embodiments, the concentration of CXCL9 is reduced by at least10% in the second biological sample as compared to the first biologicalsample.

In some embodiments, the concentration of CXCL9 is reduced by at least15% in the second biological sample as compared to the first biologicalsample.

In some embodiments, the method entails: measuring, in the firstbiological sample obtained from the human subject prior to administeringthe JAK inhibitor, the concentration of CXCL10; administering the JAKinhibitor to the human subject; and measuring, in the second biologicalsample obtained from the human subject after administering the JAKinhibitor, a reduced concentration, as compared to the first biologicalsample, of CXCL10. In some embodiments, administration of the JAKinhibitor is continued.

In some embodiments, the concentration of CXCL10 is reduced by at least5% in the second biological sample as compared to the first biologicalsample.

In some embodiments, the concentration of CXCL10 is reduced by at least10% in the second biological sample as compared to the first biologicalsample.

In some embodiments, the concentration of CXCL10 is reduced by at least15% in the second biological sample as compared to the first biologicalsample.

In some embodiments, the method entails: measuring, in the firstbiological sample obtained from the human subject prior to administeringthe JAK inhibitor, the concentration of CXCL9 and CXCL10; administeringthe JAK inhibitor to the human subject; and measuring, in the secondbiological sample obtained from the human subject after administeringthe JAK inhibitor, a reduced concentration, as compared to the firstbiological sample, of CXCL9 and CXCL10. In some embodiments,administration of the JAK inhibitor is continued.

In some embodiments, the concentration of CXCL9 and CXCL10 are eachreduced by at least 5% in the second biological sample as compared tothe first biological sample.

In some embodiments, the concentration of CXCL9 and CXCL10 are eachreduced by at least 10% in the second biological sample as compared tothe first biological sample.

In some embodiments, the concentration of CXCL9 and CXCL10 are eachreduced by at least 15% in the second biological sample as compared tothe first biological sample.

In some embodiments, the JAK inhibitor is administered to the humansubject at least once a week for a period of, e.g., at least 12 weeks(e.g., at least 3 months, at least 4 months, at least 5 months, at least6 months, at least 7 months, at least 8 months, at least 9 months, atleast 10 months, at least 11 months, or at least 12 months).

In some embodiments, the JAK inhibitor is administered to the humansubject at least once a day for a period of, e.g., at least 12 weeks(e.g., at least 3 months, at least 4 months, at least 5 months, at least6 months, at least 7 months, at least 8 months, at least 9 months, atleast 10 months, at least 11 months, or at least 12 months).

In some embodiments, the JAK inhibitor is administered to the humansubject at least two times each day for a period of, e.g., at least 12weeks (e.g., at least 3 months, at least 4 months, at least 5 months, atleast 6 months, at least 7 months, at least 8 months, at least 9 months,at least 10 months, at least 11 months, or at least 12 months).

In some embodiments, wherein the JAK inhibitor is topically administeredto the human subject.

In some embodiments, the second biological sample is obtained from thehuman subject at least 12 weeks after the first administration of theJAK inhibitor.

In some embodiments, the second biological sample is obtained from thehuman subject at least 24 weeks after the first administration of theJAK inhibitor.

In some embodiments, a second therapeutic agent is administered to thehuman subject in combination with the JAK inhibitor.

In another aspect, the disclosure features a method of identifying atherapeutic response (e.g., prior to visible skin improvement) of ahuman subject having, suspected of having, or at risk of developingvitiligo to a JAK inhibitor by: measuring the concentration of CXCL9and/or CXCL10 in a first biological sample obtained from the humansubject before administering the JAK inhibitor; and measuring theconcentration of CXCL9 and/or CXCL10 in a second biological sampleobtained from the subject after administering the JAK inhibitor, whereina reduced concentration in the second biological sample, as compared tothe first biological sample, of CXCL9 and/or CXCL10 indicates that thehuman subject has undergone a therapeutic response (e.g., prior tovisible skin improvement) to the JAK inhibitor.

In some embodiments, the concentration of CXCL9 is reduced by at least5% in the second biological sample as compared to the first biologicalsample. In some embodiments, the concentration of CXCL10 is reduced byat least 5% in the second biological sample as compared to the firstbiological sample. In some embodiments, the concentration of CXCL9 andCXCL10 are each reduced by at least 5% in the second biological sampleas compared to the first biological sample.

In some embodiments, the concentration of CXCL9 is reduced by at least10% in the second biological sample as compared to the first biologicalsample. In some embodiments, the concentration of CXCL10 is reduced byat least 10% in the second biological sample as compared to the firstbiological sample. In some embodiments, the concentration of CXCL9 andCXCL10 are each reduced by at least 10% in the second biological sampleas compared to the first biological sample.

In some embodiments, the concentration of CXCL9 is reduced by at least15% in the second biological sample as compared to the first biologicalsample. In some embodiments, the concentration of CXCL10 is reduced byat least 15% in the second biological sample as compared to the firstbiological sample. In some embodiments, the concentration of CXCL9 andCXCL10 are each reduced by at least 15% in the second biological sampleas compared to the first biological sample.

In another aspect, the disclosure features a method of treating a humansubject having, suspected of having, or at risk of developing vitiligoby: measuring, in a first biological sample obtained from the humansubject prior to administering a JAK inhibitor, the concentration of atleast one protein (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, or 20 proteins) selected from the groupconsisting of FAP, RET, CNTN5, FUCA1, ITGAV, ITGB5, THBS4, CD207, GDF-8,CDH6, MRC2, ICOSLG, TNXB, EDIL3, OSMR, GPC1, MIC-A/B, TGFR-2, LRRN1,TLR3, KIM1, ROBO2, CD70, CLMP, N-CDase, FCRL5, CTSV, SCARF2, PLXDC1,PRTG, ERBB4, MAGED1, CEACAM1, TSHB, PTK7, TGFR-2, ADAM 22, CTSC, DLK-1,USP8, SCARF2, TNFRSF13B, MB, TMPRSS5, NUDT5, MMP-3, MAEA, NEMO,IFN-gamma, IL18, AKT1S1, CASP-8, PPP1R2, ST2, VSIG4, SCGB3A2, HDGF,ICA1, IL13, PEBP1, PARK7, MAP4K5, FLI1, MMP-10, CCL24, TIMP4, MBL2,REG4, and CPA2; administering the JAK inhibitor to the human subject;and measuring, in a second biological sample obtained from the humansubject after administering the JAK inhibitor, a reduced concentration,as compared to the first biological sample, of at least one protein(e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, or 20 proteins) selected from the group consisting of FAP,RET, CNTN5, FUCA1, ITGAV, ITGB5, THBS4, CD207, GDF-8, CDH6, MRC2,ICOSLG, TNXB, EDIL3, OSMR, GPC1, MIC-A/B, TGFR-2, LRRN1, TLR3, KIM1,ROBO2, CD70, CLMP, N-CDase, FCRL5, CTSV, SCARF2, PLXDC1, PRTG, ERBB4,MAGED1, CEACAM1, TSHB, PTK7, TGFR-2, ADAM 22, CTSC, DLK-1, USP8, SCARF2,TNFRSF13B, MB, and TMPRSS5, and/or an increased concentration, ascompared to the first biological sample, of at least one protein (e.g.,at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, or 20 proteins) selected from the group consisting of NUDT5, MMP-3,MAEA, NEMO, IFN-gamma, IL18, AKT1S1, CASP-8, PPP1R2, ST2, VSIG4,SCGB3A2, HDGF, ICA1, IL13, PEBP1, PARK7, MAP4K5, FLI1, MMP-10, CCL24,TIMP4, MBL2, REG4, and CPA2. In some embodiments, administration of theJAK inhibitor is continued.

In some embodiments, the method entails measuring, in a first biologicalsample obtained from the human subject prior to administering a JAKinhibitor, the concentration of at least one protein (e.g., at least 1,2, 3, 4, 5, or 6 proteins) selected from the group consisting of FAP,RET, CNTN5, NUDT5, MMP-3, and MAEA; administering the JAK inhibitor tothe human subject; and measuring, in a second biological sample obtainedfrom the human subject after administering the JAK inhibitor, a reducedconcentration, as compared to the first biological sample, of at leastone protein (e.g., at least 1, 2, or 3 proteins) selected from the groupconsisting of FAP, RET, and CNTN5, and/or an increased concentration, ascompared to the first biological sample, of at least one protein (e.g.,at least 1, 2, or 3 proteins) selected from the group consisting ofNUDT5, MMP-3, and MAEA. In some embodiments, administration of the JAKinhibitor is continued.

In some embodiments, the method entails measuring, in a first biologicalsample obtained from the human subject prior to administering a JAKinhibitor, the concentration of at least one protein (e.g., at least 1,2, 3, or 4 proteins) selected from the group consisting of FAP, RET,NUDT5, and MMP-3; administering the JAK inhibitor to the human subject;and measuring, in a second biological sample obtained from the humansubject after administering the JAK inhibitor, a reduced concentration,as compared to the first biological sample, of at least one protein(e.g., at least 1 or 2 proteins) selected from the group consisting ofFAP and RET, and/or an increased concentration, as compared to the firstbiological sample, of at least one protein (e.g., at least 1 or 2proteins) selected from the group consisting of NUDT5 and MMP-3. In someembodiments, administration of the JAK inhibitor is continued.

In another aspect, the disclosure features a method of identifying atherapeutic response (e.g., prior to visible skin improvement) of ahuman subject having, suspected of having, or at risk of developingvitiligo to a JAK inhibitor by: measuring the concentration of at leastone protein (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20 proteins) selected from the groupconsisting of FAP, RET, CNTN5, FUCA1, ITGAV, ITGB5, THBS4, CD207, GDF-8,CDH6, MRC2, ICOSLG, TNXB, EDIL3, OSMR, GPC1, MIC-A/B, TGFR-2, LRRN1,TLR3, KIM1, ROBO2, CD70, CLMP, N-CDase, FCRL5, CTSV, SCARF2, PLXDC1,PRTG, ERBB4, MAGED1, CEACAM1, TSHB, PTK7, TGFR-2, ADAM 22, CTSC, DLK-1,USP8, SCARF2, TNFRSF13B, MB, TMPRSS5, NUDT5, MMP-3, MAEA, NEMO,IFN-gamma, IL18, AKT1S1, CASP-8, PPP1R2, ST2, VSIG4, SCGB3A2, HDGF,ICA1, IL13, PEBP1, PARK7, MAP4K5, FLI1, MMP-10, CCL24, TIMP4, MBL2,REG4, and CPA2 in a first biological sample obtained from the humansubject before administering the JAK inhibitor; and measuring theconcentration of at least one protein (e.g., at least 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 proteins)selected from the group consisting of FAP, RET, CNTN5, FUCA1, ITGAV,ITGB5, THBS4, CD207, GDF-8, CDH6, MRC2, ICOSLG, TNXB, EDIL3, OSMR, GPC1,MIC-AB, TGFR-2, LRRN1, TLR3, KIM1, ROBO2, CD70, CLMP, N-CDase, FCRL5,CTSV, SCARF2, PLXDC1, PRTG, ERBB4, MAGED1, CEACAM1, TSHB, PTK7, TGFR-2,ADAM 22, CTSC, DLK-1, USP8, SCARF2, TNFRSF13B, MB, TMPRSS5, NUDT5,MMP-3, MAEA, NEMO, IFN-gamma, IL18, AKT1S1, CASP-8, PPP1R2, ST2, VSIG4,SCGB3A2, HDGF, ICA1, IL13, PEBP1, PARK7, MAP4K5, FLI1, MMP-10, CCL24,TIMP4, MBL2, REG4, and CPA2 in a second biological sample obtained fromthe subject after administering the JAK inhibitor, wherein a reducedconcentration in the second biological sample, as compared to the firstbiological sample, of at least one protein (e.g., at least 1, 2, 3, 4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 proteins)selected from the group consisting of FAP, RET, CNTN5, FUCA1, ITGAV,ITGB5, THBS4, CD207, GDF-8, CDH6, MRC2, ICOSLG, TNXB, EDIL3, OSMR, GPC1,MIC-A/B, TGFR-2, LRRN1, TLR3, KIM1, ROBO2, CD70, CLMP, N-CDase, FCRL5,CTSV, SCARF2, PLXDC1, PRTG, ERBB4, MAGED1, CEACAM1, TSHB, PTK7, TGFR-2,ADAM 22, CTSC, DLK-1, USPS, SCARF2, TNFRSF13B, MB, and TMPRSS5, and/oran increased concentration in the second biological sample, as comparedto the first biological sample of at least one protein (e.g., at least1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20proteins) selected from the group consisting of NUDT5, MMP-3, MAEA,NEMO, IFN-gamma, IL18, AKT1S1, CASP-8, PPP1R2, ST2, VSIG4, SCGB3A2,HDGF, ICA1, IL13, PEBP1, PARK7, MAP4K5, FLI1, MMP-10, CCL24, TIMP4,MBL2, REG4, and CPA2 indicates that the human subject has undergone atherapeutic response (e.g., prior to visible skin improvement) to theJAK inhibitor.

In some embodiments, the method entails measuring the concentration ofat least one protein (e.g., at least 1, 2, 3, 4, 5, or 6 proteins)selected from the group consisting of FAP, RET, CNTN5, NUDT5, MMP-3, andMAEA in a first biological sample obtained from the human subject beforeadministering the JAK inhibitor; and measuring the concentration of atleast one protein (e.g., at least 1, 2, 3, 4, 5, or 6 proteins) selectedfrom the group consisting of FAP, RET, CNTN5, NUDT5, MMP-3, and MAEA ina second biological sample obtained from the subject after administeringthe JAK inhibitor, wherein a reduced concentration in the secondbiological sample, as compared to the first biological sample, of atleast one protein (e.g., at least 1, 2, or 3 proteins) selected from thegroup consisting of FAP, RET, and CNTN5, and/or an increasedconcentration in the second biological sample, as compared to the firstbiological sample of at least one protein (e.g., at least 1, 2, or 3proteins) selected from the group consisting of NUDT5, MMP-3, and MAEAindicates that the human subject has undergone a therapeutic response(e.g., prior to visible skin improvement) to the JAK inhibitor.

In some embodiments, the method entails measuring the concentration ofat least one protein (e.g., at least 1, 2, 3, or 4 proteins) selectedfrom the group consisting of FAP, RET, NUDT5, and MMP-3 in a firstbiological sample obtained from the human subject before administeringthe JAK inhibitor; and measuring the concentration of at least oneprotein (e.g., at least 1, 2, 3, or 4 proteins) selected from the groupconsisting of FAP, RET, NUDT5, and MMP-3 in a second biological sampleobtained from the subject after administering the JAK inhibitor, whereina reduced concentration in the second biological sample, as compared tothe first biological sample, of at least one protein (e.g., at least 1or 2 proteins) selected from the group consisting of FAP and RET, and/oran increased concentration in the second biological sample, as comparedto the first biological sample of at least one protein (e.g., at least 1or 2 proteins) selected from the group consisting of NUDT5 and MMP-3indicates that the human subject has undergone a therapeutic response(e.g., prior to visible skin improvement) to the JAK inhibitor.

In another aspect, the disclosure features a method of treating a humansubject having, suspected of having, or at risk of developing vitiligoby: measuring, in a first biological sample obtained from the humansubject prior to administering a JAK inhibitor, the concentration of atleast one protein (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, or 20 proteins) selected from the groupconsisting of DDR1, NTRK2, CES2, SCARA5, GDF-8, BOC, PAEP, ARTN, CDNF,TMPRSS5, FLRT2, ROBO2, SIGLEC10, PRTG, SCARF2, CDH3, GFR-alpha-1, TSHB,CD200R1, RGMB, KYNU, HS3ST3B1, CHRDL2, CNTN1, VSIG4, ARHGAP1, B4GAT1,STX8, CRELD2, ARSA, BCAM, SCARF1, CA13, DAG1, LAIR1, GUSB, PMVK, PEAR1,GP1BA, TACC3, PARK7, ARHGEF12, SEMA7A, ESAM, FKBP5, ARHGAP1, SCAMP3,ABL1, EGF, TACC3, FKBP5, BID, PRDX5, STX8, CD63, SCARF1, PTPN1, CLEC1B,ARSB, FKBP1B, YES1, SRC, TNFSF14, PLXNB3, LRMP, CD164, DAG1, PVALB,NAA10, TRIMS, ARHGEF12, HGF, CA13, SNAP23, SORT1, GP6, CTSS, PPIB, CRKL,MAP2K6, MANF, PMVK, ABHD14B, GUSB, FATC1, MAD1L1, EDAR, CEACAM8, GLB1,ST3GAL1, ARSA, ADAM 8, CD40, IFI30, ECE1, AXIN1, WFDC2, TBCB, CXCL13,ST1A1, KIF1BP, DPP7, VEGFA, CETN2, TGF-alpha, CD84, SNAP29, CASP-8,S100A11, GSTP1, CRADD, PRKAB1, HGF, STK4, RNASE3, SERPINB6, OSM, MK,FADD, CLEC11A, CD69, LOX-1, ITGA6, CLEC5A, BCAM, FES, TXNDC5, LAT2,CXCL11, PARP-1, APBB1IP, GZMB, and CRNN; administering the JAK inhibitorto the human subject; and measuring, in a second biological sampleobtained from the human subject after administering the JAK inhibitor, areduced concentration, as compared to the first biological sample, of atleast one protein (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, or 20 proteins) selected from the groupconsisting of DDR1, NTRK2, CES2, SCARA5, GDF-8, BOC, PAEP, ARTN, CDNF,TMPRSS5, FLRT2, ROBO2, SIGLEC10, PRTG, SCARF2, CDH3, GFR-alpha-1, TSHB,CD200R1, RGMB, KYNU, HS3ST3B1, CHRDL2, and CNTN1, and/or an increasedconcentration, as compared to the first biological sample, of at leastone protein (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20 proteins) selected from the groupconsisting of VSIG4, ARHGAP1, B4GAT1, STX8, CRELD2, ARSA, BCAM, SCARF1,CA13, DAG1, LAIR1, GUSB, PMVK, PEARL, GP1BA, TACC3, PARK7, ARHGEF12,SEMA7A, ESAM, FKBP5, ARHGAP1, SCAMP3, ABL1, EGF, TACC3, FKBP5, BID,PRDX5, STX8, CD63, SCARF1, PTPN1, CLEC1B, ARSB, FKBP1B, YES1, SRC,TNFSF14, PLXNB3, LRMP, CD164, DAG1, PVALB, NAA10, TRIMS, ARHGEF12, HGF,CA13, SNAP23, SORT1, GP6, CTSS, PPIB, CRKL, MAP2K6, MANF, PMVK, ABHD14B,GUSB, FATC1, MAD1L1, EDAR, CEACAM8, GLB1, ST3GAL1, ARSA, ADAM 8, CD40,IFI30, ECE1, AXIN1, WFDC2, TBCB, CXCL13, ST1A1, KIF1BP, DPP7, VEGFA,CETN2, TGF-alpha, CD84, SNAP29, CASP-8, S100A11, GSTP1, CRADD, PRKAB1,HGF, STK4, RNASE3, SERPINB6, OSM, MK, FADD, CLEC11A, CD69, LOX-1, ITGA6,CLEC5A, BCAM, FES, TXNDC5, LAT2, CXCL11, PARP-1, APBB1IP, GZMB, andCRNN.

In some embodiments, the method entails measuring, in a first biologicalsample obtained from the human subject prior to administering a JAKinhibitor, the concentration of at least one protein (e.g., at least 1,2, 3, 4, 5, or 6 proteins) selected from the group consisting of DDR1,NTRK2, CES2, VSIG4, ARHGAP1, and B4GAT1; administering the JAK inhibitorto the human subject; and measuring, in a second biological sampleobtained from the human subject after administering the JAK inhibitor, areduced concentration, as compared to the first biological sample, of atleast one protein (e.g., at least 1, 2, or 3 proteins) selected from thegroup consisting of DDR1, NTRK2, and CES2, and/or an increasedconcentration, as compared to the first biological sample, of at leastone protein (e.g., at least 1, 2, or 3 proteins) selected from the groupconsisting of VSIG4, ARHGAP1, and B4GAT1.

In some embodiments, the method entails measuring, in a first biologicalsample obtained from the human subject prior to administering a JAKinhibitor, the concentration of at least one protein (e.g., at least 1,2, 3, or 4 proteins) selected from the group consisting of DDR1, NTRK2,VSIG4, and ARHGAP1; administering the JAK inhibitor to the humansubject; and measuring, in a second biological sample obtained from thehuman subject after administering the JAK inhibitor, a reducedconcentration, as compared to the first biological sample, of at leastone protein (e.g., at least 1 or 2 proteins) selected from the groupconsisting of DDR1 and NTRK2, and/or an increased concentration, ascompared to the first biological sample, of at least one protein (e.g.,at least 1 or 2 proteins) selected from the group consisting of VSIG4and ARHGAP1.

In another aspect, the disclosure features a method of identifying atherapeutic response of a human subject having, suspected of having, orat risk of developing vitiligo to a JAK inhibitor by: measuring theconcentration of at least one protein (e.g., at least 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 proteins)selected from the group consisting of DDR1, NTRK2, CES2, SCARA5, GDF-8,BOC, PAEP, ARTN, CDNF, TMPRSS5, FLRT2, ROBO2, SIGLEC10, PRTG, SCARF2,CDH3, GFR-alpha-1, TSHB, CD200R1, RGMB, KYNU, HS3ST3B1, CHRDL2, CNTN1,VSIG4, ARHGAP1, B4GAT1, STX8, CRELD2, ARSA, BCAM, SCARF1, CA13, DAG1,LAIR1, GUSB, PMVK, PEARL, GP1BA, TACC3, PARK7, ARHGEF12, SEMA7A, ESAM,FKBP5, ARHGAP1, SCAMP3, ABL1, EGF, TACC3, FKBP5, BID, PRDX5, STX8, CD63,SCARF1, PTPN1, CLEC1B, ARSB, FKBP1B, YES1, SRC, TNFSF14, PLXNB3, LRMP,CD164, DAG1, PVALB, NAA10, TRIMS, ARHGEF12, HGF, CA13, SNAP23, SORT1,GP6, CTSS, PPIB, CRKL, MAP2K6, MANF, PMVK, ABHD14B, GUSB, FATC1, MAD1L1,EDAR, CEACAM8, GLB1, ST3GAL1, ARSA, ADAM 8, CD40, IFI30, ECE1, AXIN1,WFDC2, TBCB, CXCL13, ST1A1, KIF1BP, DPP7, VEGFA, CETN2, TGF-alpha, CD84,SNAP29, CASP-8, S100A11, GSTP1, CRADD, PRKAB1, HGF, STK4, RNASE3,SERPINB6, OSM, MK, FADD, CLEC11A, CD69, LOX-1, ITGA6, CLEC5A, BCAM, FES,TXNDC5, LAT2, CXCL11, PARP-1, APBB1IP, GZMB, and CRNN in a firstbiological sample obtained from the human subject before administeringthe JAK inhibitor; and measuring the concentration of at least oneprotein (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, or 20 proteins) selected from the group consistingof DDR1, NTRK2, CES2, SCARA5, GDF-8, BOC, PAEP, ARTN, CDNF, TMPRSS5,FLRT2, ROBO2, SIGLEC10, PRTG, SCARF2, CDH3, GFR-alpha-1, TSHB, CD200R1,RGMB, KYNU, HS3ST3B1, CHRDL2, CNTN1, VSIG4, ARHGAP1, B4GAT1, STX8,CRELD2, ARSA, BCAM, SCARF1, CA13, DAG1, LAIR1, GUSB, PMVK, PEARL, GP1BA,TACC3, PARK7, ARHGEF12, SEMA7A, ESAM, FKBP5, ARHGAP1, SCAMP3, ABL1, EGF,TACC3, FKBP5, BID, PRDX5, STX8, CD63, SCARF1, PTPN1, CLEC1B, ARSB,FKBP1B, YES1, SRC, TNFSF14, PLXNB3, LRMP, CD164, DAG1, PVALB, NAA10,TRIMS, ARHGEF12, HGF, CA13, SNAP23, SORT1, GP6, CTSS, PPIB, CRKL,MAP2K6, MANF, PMVK, ABHD14B, GUSB, FATC1, MAD1L1, EDAR, CEACAM8, GLB1,ST3GAL1, ARSA, ADAM 8, CD40, IFI30, ECE1, AXIN1, WFDC2, TBCB, CXCL13,ST1A1, KIF1BP, DPP7, VEGFA, CETN2, TGF-alpha, CD84, SNAP29, CASP-8,S100A11, GSTP1, CRADD, PRKAB1, HGF, STK4, RNASE3, SERPINB6, OSM, MK,FADD, CLEC11A, CD69, LOX-1, ITGA6, CLEC5A, BCAM, FES, TXNDC5, LAT2,CXCL11, PARP-1, APBB1IP, GZMB, and CRNN in a second biological sampleobtained from the subject after administering the JAK inhibitor, whereina reduced concentration in the second biological sample, as compared tothe first biological sample, of at least one protein (e.g., at least 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20proteins) selected from the group consisting of DDR1, NTRK2, CES2,SCARA5, GDF-8, BOC, PAEP, ARTN, CDNF, TMPRSS5, FLRT2, ROBO2, SIGLEC10,PRTG, SCARF2, CDH3, GFR-alpha-1, TSHB, CD200R1, RGMB, KYNU, HS3ST3B1,CHRDL2, and CNTN1, and/or an increased concentration in the secondbiological sample, as compared to the first biological sample of atleast one protein (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, or 20 proteins) selected from the groupconsisting of VSIG4, ARHGAP1, B4GAT1, STX8, CRELD2, ARSA, BCAM, SCARF1,CA13, DAG1, LAIR1, GUSB, PMVK, PEAR1, GP1BA, TACC3, PARK7, ARHGEF12,SEMA7A, ESAM, FKBP5, ARHGAP1, SCAMP3, ABL1, EGF, TACC3, FKBP5, BID,PRDX5, STX8, CD63, SCARF1, PTPN1, CLEC1B, ARSB, FKBP1B, YES1, SRC,TNFSF14, PLXNB3, LRMP, CD164, DAG1, PVALB, NAA10, TRIMS, ARHGEF12, HGF,CA13, SNAP23, SORT1, GP6, CTSS, PPIB, CRKL, MAP2K6, MANF, PMVK, ABHD14B,GUSB, FATC1, MAD1L1, EDAR, CEACAM8, GLB1, ST3GAL1, ARSA, ADAM 8, CD40,IFI30, ECE1, AXIN1, WFDC2, TBCB, CXCL13, ST1A1, KIF1BP, DPP7, VEGFA,CETN2, TGF-alpha, CD84, SNAP29, CASP-8, S100A11, GSTP1, CRADD, PRKAB1,HGF, STK4, RNASE3, SERPINB6, OSM, MK, FADD, CLEC11A, CD69, LOX-1, ITGA6,CLEC5A, BCAM, FES, TXNDC5, LAT2, CXCL11, PARP-1, APBB1IP, GZMB, and CRNNindicates that the human subject has not undergone a therapeuticresponse to the JAK inhibitor.

In some embodiments, the method entails measuring the concentration ofat least one protein (e.g., at least 1, 2, 3, 4, 5, or 6 proteins)selected from the group consisting of DDR1, NTRK2, CES2, VSIG4, ARHGAP1,and B4GAT1 in a first biological sample obtained from the human subjectbefore administering the JAK inhibitor; and measuring the concentrationof at least one protein (e.g., at least 1, 2, 3, 4, 5, or 6 proteins)selected from the group consisting of DDR1, NTRK2, CES2, VSIG4, ARHGAP1,and B4GAT1 in a second biological sample obtained from the subject afteradministering the JAK inhibitor, wherein a reduced concentration in thesecond biological sample, as compared to the first biological sample, ofat least one protein (e.g., at least 1, 2, or 3 proteins) selected fromthe group consisting of DDR1, NTRK2, and CES2, and/or an increasedconcentration in the second biological sample, as compared to the firstbiological sample of at least one protein (e.g., at least 1, 2, or 3proteins) selected from the group consisting of VSIG4, ARHGAP1, andB4GAT1 indicates that the human subject has not undergone a therapeuticresponse to the JAK inhibitor.

In some embodiments, the method entails measuring the concentration ofat least one protein (e.g., at least 1, 2, 3, or 4 proteins) selectedfrom the group consisting of DDR1, NTRK2, VSIG4, and ARHGAP1 in a firstbiological sample obtained from the human subject before administeringthe JAK inhibitor; and measuring the concentration of at least oneprotein (e.g., at least 1, 2, 3, or 4 proteins) selected from the groupconsisting of DDR1, NTRK2, VSIG4, and ARHGAP1 in a second biologicalsample obtained from the subject after administering the JAK inhibitor,wherein a reduced concentration in the second biological sample, ascompared to the first biological sample, of at least one protein (e.g.,at least 1 or 2 proteins) selected from the group consisting of DDR1 andNTRK2, and/or an increased concentration in the second biologicalsample, as compared to the first biological sample of at least oneprotein (e.g., at least 1 or 2 proteins) selected from the groupconsisting of VSIG4 and ARHGAP1 indicates that the human subject has notundergone a therapeutic response to the JAK inhibitor.

In another aspect, the disclosure features a method of treating a humansubject having, suspected of having, or at risk of developing vitiligo,comprising administering to the human subject a JAK inhibitor, whereinthe human subject has been previously determined to have (i) a baselineconcentration of at least one protein (e.g., at least 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 proteins)selected from the group consisting of SCF, CPA2, P4HB, SPARCL1, ST2,SCF, CNDP1, TRAIL, KIRREL2, EGFR, ISLR2, PPP3R1, FCGR3B, MMP-3, IL-18BP,Flt3L, PPY, LTA4H, ITGB2, PTN, GPNMB, SIRPB1, PLTP, PSP-D, COMP, PAMR1,VASN, F11, IL10, CA3, CXCL10, Notch 3, NCAM1, PROC, CLEC14A, IL-12B,IL10, CD40, and IFN-gamma in a biological sample obtained from the humansubject that is lower than a control, and/or (ii) a baselineconcentration of at least one protein (e.g., at least 1, 2, 3, 4, or 5proteins) selected from the group consisting of SERPINA12, GHRL, PREB,IL-20RA, and PON2 in a biological sample obtained from the human subjectthat is higher than a control.

In some embodiments, the method entails administering to the humansubject a JAK inhibitor, wherein the human subject has been previouslydetermined to have (i) a baseline concentration of at least one protein(e.g., at least 1, 2, or 3 proteins) selected from the group consistingof SCF, CPA2, and P4HB in a biological sample obtained from the humansubject that is lower than a control, and/or (ii) a baselineconcentration of at least one protein (e.g., at least 1, 2, or 3proteins) selected from the group consisting of SERPINA12, GHRL, andPREB in a biological sample obtained from the human subject that ishigher than a control.

In some embodiments, the method entails administering to the humansubject a JAK inhibitor, wherein the human subject has been previouslydetermined to have a baseline concentration of at least one protein(e.g., at least 1 or 2 proteins) selected from the group consisting ofIL-20RA and PON2 in a biological sample obtained from the human subjectthat is higher than a control.

In another aspect, the disclosure features a method of treating a humansubject having, suspected of having, or at risk of developing vitiligo,by: measuring in a biological sample obtained from the human subject areduced concentration, as compared to a control, of at least one protein(e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, or 20 proteins) selected from the group consisting of SCF,CPA2, P4HB, SPARCL1, ST2, SCF, CNDP1, TRAIL, KIRREL2, EGFR, ISLR2,PPP3R1, FCGR3B, MMP-3, IL-18BP, Flt3L, PPY, LTA4H, ITGB2, PTN, GPNMB,SIRPB1, PLTP, PSP-D, COMP, PAMR1, VASN, F11, IL10, CA3, CXCL10, Notch 3,NCAM1, PROC, CLEC14A, IL-12B, IL10, CD40, and IFN-gamma, and/or anincreased concentration, as compared to a control, of at least oneprotein (e.g., at least 1, 2, 3, 5, or 5 proteins) selected from thegroup consisting of SERPINA12, GHRL, PREB, IL-20RA, and PON2; andadministering a JAK inhibitor to the human subject.

In some embodiments, the method entails measuring in a biological sampleobtained from the human subject a reduced concentration, as compared toa control, of at least one protein (e.g., at least 1, 2, or 3 proteins)selected from the group consisting of SCF, CPA2, and P4HB, and/or anincreased concentration, as compared to a control, of at least oneprotein (e.g., at least 1, 2, or 3 proteins) selected from the groupconsisting of SERPINA12, GHRL, and PREB; and administering a JAKinhibitor to the human subject.

In some embodiments, the method entails measuring in a biological sampleobtained from the human subject an increased concentration, as comparedto a control, of at least one protein (e.g., at least 1 or 2 proteins)selected from the group consisting of IL-20RA and PON2; andadministering a JAK inhibitor to the human subject.

In another aspect, the disclosure features a method of predicting theresponse of a human subject having, suspected of having, or at risk ofdeveloping vitiligo to a JAK inhibitor by: measuring, in a biologicalsample obtained from the human subject before administration of the JAKinhibitor, the concentration of at least one protein (e.g., at least 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20proteins) selected from the group consisting of SCF, CPA2, P4HB,SPARCL1, ST2, SCF, CNDP1, TRAIL, KIRREL2, EGFR, ISLR2, PPP3R1, FCGR3B,MMP-3, IL-18BP, Flt3L, PPY, LTA4H, ITGB2, PTN, GPNMB, SIRPB1, PLTP,PSP-D, COMP, PAMR1, VASN, F11, IL10, CA3, CXCL10, Notch 3, NCAM1, PROC,CLEC14A, IL-12B, IL10, CD40, IFN-gamma, SERPINA12, GHRL, PREB, IL-20RA,and PON2, wherein a reduced concentration, as compared to a control, ofat least one of (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, or 20 of) SCF, CPA2, P4HB, SPARCL1, ST2,SCF, CNDP1, TRAIL, KIRREL2, EGFR, ISLR2, PPP3R1, FCGR3B, MMP-3, IL-18BP,Flt3L, PPY, LTA4H, ITGB2, PTN, GPNMB, SIRPB1, PLTP, PSP-D, COMP, PAMR1,VASN, F11, IL10, CA3, CXCL10, Notch 3, NCAM1, PROC, CLEC14A, IL-12B,IL10, CD40, and IFN-gamma and/or an increased concentration, as comparedto a control, of at least one of (e.g., at least 1, 2, 3, 4, or 5 of)SERPINA12, GHRL, PREB, IL-20RA, or PON2 is predictive that the subjectwill respond to the JAK inhibitor.

In some embodiments, the method entails measuring, in a biologicalsample obtained from the human subject before administration of the JAKinhibitor, the concentration of at least one protein (e.g., at least 1,2, 3, 4, 5, or 6 proteins) selected from the group consisting of SCF,CPA2, P4HB, SERPINA12, GHRL, and PREB, wherein a reduced concentration,as compared to a control, of at least one of (e.g., at least 1, 2, or 3of) SCF, CPA2, or P4HB, and/or an increased concentration, as comparedto a control, of at least one of (e.g., at least 1, 2, or 3 of)SERPINA12, GHRL, or PREB is predictive that the subject will respond tothe JAK inhibitor.

In some embodiments, the method entails measuring, in a biologicalsample obtained from the human subject before administration of the JAKinhibitor, the concentration of at least one protein (e.g., at least 1or 2 proteins) selected from the group consisting of IL-20RA and PON2,wherein increased concentration, as compared to a control, of at leastone of (e.g., at least 1 or 2 of) IL-20RA and PON2 is predictive thatthe subject will respond to the JAK inhibitor.

In another aspect, the disclosure features a method of predicting theresponse of a human subject having, suspected of having, or at risk ofdeveloping vitiligo to a JAK inhibitor by: measuring, in a biologicalsample obtained from the human subject before administration of the JAKinhibitor, the concentration of at least one protein (e.g., at least 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20proteins) selected from the group consisting of EPHA10, GH2, PARP-1,GLRX, ARSB, SCAMP3, t-PA, LDL receptor, DLK-1, SELE, EPHB4, GFRA2, PLC,LTBR, PAMR1, TACSTD2, FS, ICAM-2, AXL, PRSS8, SPINK5, AMN, NOMO1, PAI,and CPM, wherein a reduced concentration, as compared to a control, ofat least one of (e.g., at least 1, 2, 3, 4, 5, or 6 of) EPHA10, GH2,PARP-1, GLRX, ARSB, and SCAMP3 and/or an increased concentration, ascompared to a control, of at least one of (e.g., at least 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 of) t-PA, LDLreceptor, DLK-1, SELE, EPHB4, GFRA2, PLC, LTBR, PAMR1, TACSTD2, FS,ICAM-2, AXL, PRSS8, SPINK5, AMN, NOMO1, PAI, and CPM is predictive thatthe subject will not respond to the JAK inhibitor.

In some embodiments, the method entails measuring, in a biologicalsample obtained from the human subject before administration of the JAKinhibitor, the concentration of at least one protein (e.g., at least 1,2, 3, 4, 5, or 6 proteins) selected from the group consisting of EPHA10,GH2, PARP-1, t-PA, LDL receptor, DLK-1, and SELE, wherein a reducedconcentration, as compared to a control, of at least one of (e.g., atleast 1, 2, or 3 of) EPHA10, GH2, or PARP-1 and/or an increasedconcentration, as compared to a control, of at least one of (e.g., atleast 1, 2, or 3 of) t-PA, LDL receptor, or DLK-1 is predictive that thesubject will not respond to the JAK inhibitor.

The disclosure also features a method for measuring the amount of aprotein in a sample, by: providing a biological sample obtained from ahuman subject having, suspected of having, or at risk of developingvitiligo; and measuring the concentration of at least one protein (e.g.,at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, or 20 proteins) selected from the group consisting of FAP, RET,CNTN5, FUCA1, ITGAV, ITGB5, THBS4, CD207, GDF-8, CDH6, MRC2, ICOSLG,TNXB, EDIL3, OSMR, GPC1, MIC-A/B, TGFR-2, LRRN1, TLR3, KIM1, ROBO2,CD70, CLMP, N-CDase, FCRL5, CTSV, SCARF2, PLXDC1, PRTG, ERBB4, MAGED1,CEACAM1, TSHB, PTK7, TGFR-2, ADAM 22, CTSC, DLK-1, USPS, SCARF2,TNFRSF13B, MB, TMPRSS5, NUDT5, MMP-3, MAEA, NEMO, IFN-gamma, IL18,AKT1S1, CASP-8, PPP1R2, ST2, VSIG4, SCGB3A2, HDGF, ICA1, IL13, PEBP1,PARK7, MAP4K5, FLI1, MMP-10, CCL24, TIMP4, MBL2, REG4, and CPA2 in thebiological sample. In some embodiments of the methods described herein,the concentrations of no more than 50, 40, 30, 20, 15, 10, or 5 proteinsare measured.

The disclosure also features a method for measuring the amount of aprotein in a sample, by: providing a biological sample obtained from ahuman subject having, suspected of having, or at risk of developingvitiligo; and measuring the concentration of at least one protein (e.g.,at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, or 20 proteins) selected from the group consisting of DDR1, NTRK2,CES2, SCARA5, GDF-8, BOC, PAEP, ARTN, CDNF, TMPRSS5, FLRT2, ROBO2,SIGLEC10, PRTG, SCARF2, CDH3, GFR-alpha-1, TSHB, CD200R1, RGMB, KYNU,HS3ST3B1, CHRDL2, CNTN1, VSIG4, ARHGAP1, B4GAT1, STX8, CRELD2, ARSA,BCAM, SCARF1, CA13, DAG1, LAIR1, GUSB, PMVK, PEAR1, GP1BA, TACC3, PARK7,ARHGEF12, SEMA7A, ESAM, FKBP5, ARHGAP1, SCAMP3, ABL1, EGF, TACC3, FKBP5,BID, PRDX5, STX8, CD63, SCARF1, PTPN1, CLEC1B, ARSB, FKBP1B, YES1, SRC,TNFSF14, PLXNB3, LRMP, CD164, DAG1, PVALB, NAA10, TRIMS, ARHGEF12, HGF,CA13, SNAP23, SORT1, GP6, CTSS, PPIB, CRKL, MAP2K6, MANF, PMVK, ABHD14B,GUSB, FATC1, MAD1L1, EDAR, CEACAM8, GLB1, ST3GAL1, ARSA, ADAM 8, CD40,IFI30, ECE1, AXIN1, WFDC2, TBCB, CXCL13, ST1A1, KIF1BP, DPP7, VEGFA,CETN2, TGF-alpha, CD84, SNAP29, CASP-8, S100A11, GSTP1, CRADD, PRKAB1,HGF, STK4, RNASE3, SERPINB6, OSM, MK, FADD, CLEC11A, CD69, LOX-1, ITGA6,CLEC5A, BCAM, FES, TXNDC5, LAT2, CXCL11, PARP-1, APBB1IP, GZMB, and CRNNin the biological sample. In some embodiments of the methods describedherein, the concentrations of no more than 50, 40, 30, 20, 15, 10, or 5proteins are measured.

The disclosure also features a method for measuring the amount of aprotein in a sample, by: providing a biological sample obtained from ahuman subject having, suspected of having, or at risk of developingvitiligo; and measuring the concentration of at least one protein (e.g.,at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, or 20 proteins) selected from the group consisting of SCF, CPA2,P4HB, SPARCL1, ST2, SCF, CNDP1, TRAIL, KIRREL2, EGFR, ISLR2, PPP3R1,FCGR3B, MMP-3, IL-18BP, Flt3L, PPY, LTA4H, ITGB2, PTN, GPNMB, SIRPB1,PLTP, PSP-D, COMP, PAMR1, VASN, F11, IL10, CA3, CXCL10, Notch 3, NCAM1,PROC, CLEC14A, IL-12B, IL10, CD40, IFN-gamma, SERPINA12, GHRL, PREB,IL-20RA, and PON2 in the biological sample. In some embodiments of themethods described herein, the concentrations of no more than 50, 40, 30,20, 15, 10, or 5 proteins are measured.

The disclosure also features a method for measuring the amount of aprotein in a sample, by: providing a biological sample obtained from ahuman subject having, suspected of having, or at risk of developingvitiligo; and measuring the concentration of at least one protein (e.g.,at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, or 20 proteins) selected from the group consisting of EPHA10, GH2,PARP-1, GLRX, ARSB, SCAMP3, t-PA, LDL receptor, DLK-1, SELE, EPHB4,GFRA2, PLC, LTBR, PAMR1, TACSTD2, FS, ICAM-2, AXL, PRSS8, SPINK5, AMN,NOMO1, PAI, and CPM in the biological sample. In some embodiments of themethods described herein, the concentrations of no more than 50, 40, 30,20, 15, 10, or 5 proteins are measured.

In another aspect, the disclosure features a method of treating a humansubject having, suspected of having, or at risk of developing vitiligo,comprising administering to the human subject a JAK inhibitor, whereinthe human subject has been previously determined to have (i) a baselineexpression level of at least one gene (e.g., at least 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 genes) selectedfrom the group consisting of SLFN12, DLEU1, EDARADD, SH3BGR, IGFN1,APOBEC3G, TRPM2, RNF148, HMMR, SKA1, AHRR, LDHAL6A, SHCBP1, GBP3, RFC4,CTF1, RAB3IL1, GINS1, CD5, PRKG1, SRSF12, FAXC, PDIA5, TGIF2, EED,GORAB, NPAS3, AVPR1A, C9orf64, C1orf74, ACAN, RNF180, BCL2L12, XK, IQCG,and ZNF43 in a biological sample obtained from the human subject that islower than a control, and/or (ii) a baseline expression level of atleast one gene (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, or 20 genes) selected from the groupconsisting of OVCH2, ANKRD2, KCNJ1, TAS1R3, PPIAL4G, ZSCAN1, CACNA1F,IL17B, C1QL1, OR10A4, TAF1L, STK16, RFNG, CSAG1, PRR21, NHSL2, ZNF787,ZNRF1, PALD1, ZNF444, FAM219A, TMEM208, NMRK1, ARID3B, MPLKIP, CAB39L,ALKBH3, PLCE1, C12orf29, LSAMP, SMIM5, UQCC2, FAM96B, GID4, AKAP10,HMGCL, and C11orf49 in a biological sample obtained from the humansubject that is higher than a control.

The disclosure also features a method of treating a human subjecthaving, suspected of having, or at risk of developing vitiligo,comprising: measuring in a biological sample obtained from the humansubject a reduced expression level, as compared to a control, of atleast one gene (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, or 20 genes) selected from the groupconsisting of SLFN12, DLEU1, EDARADD, SH3BGR, IGFN1, APOBEC3G, TRPM2,RNF148, HMMR, SKA1, AHRR, LDHAL6A, SHCBP1, GBP3, RFC4, CTF1, RAB3IL1,GINS1, CD5, PRKG1, SRSF12, FAXC, PDIA5, TGIF2, EED, GORAB, NPAS3,AVPR1A, C9orf64, C1orf74, ACAN, RNF180, BCL2L12, XK, IQCG, and ZNF43,and/or an increased expression level, as compared to a control, of atleast one gene (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, or 20 genes) selected from the groupconsisting of OVCH2, ANKRD2, KCNJ1, TAS1R3, PPIAL4G, ZSCAN1, CACNA1F,IL17B, C1QL1, OR10A4, TAF1L, STK16, RFNG, CSAG1, PRR21, NHSL2, ZNF787,ZNRF1, PALD1, ZNF444, FAM219A, TMEM208, NMRK1, ARID3B, MPLKIP, CAB39L,ALKBH3, PLCE1, C12orf29, LSAMP, SMIM5, UQCC2, FAM96B, GID4, AKAP10,HMGCL, and C11orf49; and administering a JAK inhibitor to the humansubject.

The disclosure also features a method of predicting the response of ahuman subject having, suspected of having, or at risk of developingvitiligo to a JAK inhibitor, comprising: measuring, in a biologicalsample obtained from the human subject before administration of the JAKinhibitor, the expression level of at least one gene (e.g., at least 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20genes) selected from the group consisting of OVCH2, ANKRD2, KCNJ1,TAS1R3, PPIAL4G, ZSCAN1, CACNA1F, IL17B, C1QL1, OR10A4, TAF1L, STK16,RFNG, CSAG1, PRR21, NHSL2, ZNF787, ZNRF1, PALD1, ZNF444, FAM219A,TMEM208, NMRK1, ARID3B, MPLKIP, CAB39L, ALKBH3, PLCE1, C12orf29, LSAMP,SMIM5, UQCC2, FAM96B, GID4, AKAP10, HMGCL, C11orf49, SLFN12, DLEU1,EDARADD, SH3BGR, IGFN1, APOBEC3G, TRPM2, RNF148, HMMR, SKA1, AHRR,LDHAL6A, SHCBP1, GBP3, RFC4, CTF1, RAB3IL1, GINS1, CD5, PRKG1, SRSF12,FAXC, PDIA5, TGIF2, EED, GORAB, NPAS3, AVPR1A, C9orf64, C1orf74, ACAN,RNF180, BCL2L12, XK, IQCG, and ZNF43, wherein a reduced expressionlevel, as compared to a control, of at least one of SLFN12, DLEU1,EDARADD, SH3BGR, IGFN1, APOBEC3G, TRPM2, RNF148, HMMR, SKA1, AHRR,LDHAL6A, SHCBP1, GBP3, RFC4, CTF1, RAB3IL1, GINS1, CD5, PRKG1, SRSF12,FAXC, PDIA5, TGIF2, EED, GORAB, NPAS3, AVPR1A, C9orf64, C1orf74, ACAN,RNF180, BCL2L12, XK, IQCG, and ZNF43 and/or an increased expressionlevel, as compared to a control, of at least one of OVCH2, ANKRD2,KCNJ1, TAS1R3, PPIAL4G, ZSCAN1, CACNA1F, IL17B, C1QL1, OR10A4, TAF1L,STK16, RFNG, CSAG1, PRR21, NHSL2, ZNF787, ZNRF1, PALD1, ZNF444, FAM219A,TMEM208, NMRK1, ARID3B, MPLKIP, CAB39L, ALKBH3, PLCE1, C12orf29, LSAMP,SMIM5, UQCC2, FAM96B, GID4, AKAP10, HMGCL, and C11orf49 is predictivethat the subject will respond to the JAK inhibitor.

The disclosure also features a method of predicting the response of ahuman subject having, suspected of having, or at risk of developingvitiligo to a JAK inhibitor, comprising: measuring, in a biologicalsample obtained from the human subject before administration of the JAKinhibitor, the expression level of at least one gene (e.g., at least 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20genes) selected from the group consisting of OVCH2, ANKRD2, KCNJ1,TAS1R3, PPIAL4G, ZSCAN1, CACNA1F, IL17B, C1QL1, OR10A4, TAF1L, STK16,RFNG, CSAG1, PRR21, NHSL2, ZNF787, ZNRF1, PALD1, ZNF444, FAM219A,TMEM208, NMRK1, ARID3B, MPLKIP, CAB39L, ALKBH3, PLCE1, C12orf29, LSAMP,SMIM5, UQCC2, FAM96B, GID4, AKAP10, HMGCL, C11orf49, SLFN12, DLEU1,EDARADD, SH3BGR, IGFN1, APOBEC3G, TRPM2, RNF148, HMMR, SKA1, AHRR,LDHAL6A, SHCBP1, GBP3, RFC4, CTF1, RAB3IL1, GINS1, CD5, PRKG1, SRSF12,FAXC, PDIA5, TGIF2, EED, GORAB, NPAS3, AVPR1A, C9orf64, C1orf74, ACAN,RNF180, BCL2L12, XK, IQCG, and ZNF43, wherein a reduced expressionlevel, as compared to a control, of at least one of OVCH2, ANKRD2,KCNJ1, TAS1R3, PPIAL4G, ZSCAN1, CACNA1F, IL17B, C1QL1, OR10A4, TAF1L,STK16, RFNG, CSAG1, PRR21, NHSL2, ZNF787, ZNRF1, PALD1, ZNF444, FAM219A,TMEM208, NMRK1, ARID3B, MPLKIP, CAB39L, ALKBH3, PLCE1, C12orf29, LSAMP,SMIM5, UQCC2, FAM96B, GID4, AKAP10, HMGCL, and C11orf49 and/or anincreased expression level, as compared to a control, of at least one ofSLFN12, DLEU1, EDARADD, SH3BGR, IGFN1, APOBEC3G, TRPM2, RNF148, HMMR,SKA1, AHRR, LDHAL6A, SHCBP1, GBP3, RFC4, CTF1, RAB3IL1, GINS1, CD5,PRKG1, SRSF12, FAXC, PDIA5, TGIF2, EED, GORAB, NPAS3, AVPR1A, C9orf64,C1orf74, ACAN, RNF180, BCL2L12, XK, IQCG, and ZNF43 is predictive thatthe subject will not respond to the JAK inhibitor.

In another aspect, the disclosure features a method of treating a humansubject having, suspected of having, or at risk of developing vitiligo,comprising administering to the human subject a JAK inhibitor, whereinthe human subject has been previously determined to have (i) a baselineexpression level of at least one gene (e.g., at least 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, or 12 genes) selected from the group consisting ofSTK16, RFNG, ZNRF1, ARID3B, WSB2, JAK1, IL1RL2, PALD1, S100A1, BCL2L12,FAM219A, and TSHZ1 in a biological sample obtained from the humansubject that is lower than a control, and/or (ii) a baseline expressionlevel of at least one gene (e.g., at least 1, 2, 3, 4, 5, 6, or 7 genes)selected from the group consisting of PPIAL4G, CD5, IFI6, CCR4, CNTF,CD28, and RAB3IL1 in a biological sample obtained from the human subjectthat is higher than a control.

The disclosure also features a method of treating a human subjecthaving, suspected of having, or at risk of developing vitiligo,comprising: measuring in a biological sample obtained from the humansubject a reduced expression level, as compared to a control, of atleast one gene (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12genes) selected from the group consisting of STK16, RFNG, ZNRF1, ARID3B,WSB2, JAK1, IL1RL2, PALD1, S100A1, BCL2L12, FAM219A, and TSHZ1, and/oran increased expression level, as compared to a control, of at least onegene (e.g., at least 1, 2, 3, 4, 5, 6, or 7 genes) selected from thegroup consisting of PPIAL4G, CD5, IFI6, CCR4, CNTF, CD28, and RAB3IL1;and administering a JAK inhibitor to the human subject.

The disclosure also features a method of predicting the response of ahuman subject having, suspected of having, or at risk of developingvitiligo to a JAK inhibitor, comprising: measuring, in a biologicalsample obtained from the human subject before administration of the JAKinhibitor, the expression level of at least one gene (e.g., at least 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 genes)selected from the group consisting of PPIAL4G, CD5, IFI6, CCR4, CNTF,CD28, RAB3IL1, STK16, RFNG, ZNRF1, ARID3B, WSB2, JAK1, IL1RL2, PALD1,S100A1, BCL2L12, FAM219A, and TSHZ1, wherein a reduced expression level,as compared to a control, of at least one of STK16, RFNG, ZNRF1, ARID3B,WSB2, JAK1, IL1RL2, PALD1, S100A1, BCL2L12, FAM219A, and TSHZ1 and/or anincreased expression level, as compared to a control, of at least one ofPPIAL4G, CD5, IFI6, CCR4, CNTF, CD28, and RAB3IL1 is predictive that thesubject will respond to the JAK inhibitor.

The disclosure also features a method of predicting the response of ahuman subject having, suspected of having, or at risk of developingvitiligo to a JAK inhibitor, comprising: measuring, in a biologicalsample obtained from the human subject before administration of the JAKinhibitor, the expression level of at least one gene (e.g., at least 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 genes)selected from the group consisting of PPIAL4G, CD5, IFI6, CCR4, CNTF,CD28, RAB3IL1, STK16, RFNG, ZNRF1, ARID3B, WSB2, JAK1, IL1RL2, PALD1,S100A1, BCL2L12, FAM219A, and TSHZ1, wherein a reduced expression level,as compared to a control, of at least one of PPIAL4G, CD5, IFI6, CCR4,CNTF, CD28, and RAB3IL1 and/or an increased expression level, ascompared to a control, of at least one of STK16, RFNG, ZNRF1, ARID3B,WSB2, JAK1, IL1RL2, PALD1, S100A1, BCL2L12, FAM219A, and TSHZ1 ispredictive that the subject will not respond to the JAK inhibitor.

In some embodiments of the methods described herein, the biologicalsample is blood, serum, plasma, urine, spinal fluid, saliva, lacrimalfluid, or sweat. In some embodiments, the biological sample is blood,serum, or plasma.

In some embodiments of the methods described herein, the concentrationof the protein is measured by an immunological method (e.g., selectedfrom the group consisting of enzyme-linked immunosorbent assay, enzymeimmunoassay, radioimmunoassay, chemiluminescent immunoassay,electrochemiluminescence immunoassay, latex turbidimetric immunoassay,latex photometric immunoassay, immuno-chromatographic assay, and westernblotting).

In some embodiments of the methods described herein, the concentrationof the protein is measured by mass spectrometry.

In some embodiments of the methods described herein, the expressionlevel of the gene is measured by RNA sequencing or quantitative PCR.

In some embodiments of the methods described herein, the JAK inhibitoris ruxolitinib. In some embodiments, ruxolitinib is topicallyadministered to the human subject at least once a day in a creamcomprising at least 0.15% ruxolitinib. In some embodiments, ruxolitinibis topically administered to the human subject at least two times eachday in a cream comprising at least 0.15% ruxolitinib. In someembodiments, ruxolitinib is topically administered to the human subjectat least once a day in a cream comprising at least 0.5% ruxolitinib. Insome embodiments, ruxolitinib is topically administered to the humansubject at least two times each day in a cream comprising at least 0.5%ruxolitinib. In some embodiments, ruxolitinib is topically administeredto the human subject at least once a day in a cream comprising at least1.5% ruxolitinib. In some embodiments, ruxolitinib is topicallyadministered to the human subject at least two times each day in a creamcomprising at least 1.5% ruxolitinib.

In some embodiments of the methods described herein, the JAK inhibitoris itacitinib,4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamideor a pharmaceutically acceptable salt thereof, or((2R,5S)-5-{2-[(1R)-1-hydroxyethyl]-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-1-yl}tetrahydro-2H-pyran-2-yl)acetonitrileor a pharmaceutically acceptable salt thereof.

The term “baseline concentration” of protein refers to the concentrationof a protein in a subject prior to initiation of treatment with a JAKinhibitor.

The term “baseline expression level” of a gene refers to the expressionlevel of a gene in a subject prior to initiation of treatment with a JAKinhibitor.

The term “reduced concentration” means a concentration of the proteinbeing analyzed that is lower than the concentration of that protein in acontrol or in a previous sample. For example, the concentration of theprotein being analyzed can be at least 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10,20, 25, 50, 75, or 100 times lower, or at least 10%, 20%, 30%, 40%, 50%,60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%,900%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, or5,000% lower, than the concentration of that protein in a control.

The term “reduced expression level” means an expression level of thegene being analyzed that is lower than the expression level of that genein a control. For example, the expression level of the gene beinganalyzed can be at least 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 25, 50,75, or 100 times lower, or at least 10%, 20%, 30%, 40%, 50%, 60%, 70%,80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1,000%,1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, or 5,000% lower,than the expression level of that gene in a control.

The term “increased concentration” means a concentration of the proteinbeing analyzed that is higher than the concentration of that protein ina control or in a previous sample. For example, the concentration of theprotein being analyzed can be at least 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10,20, 25, 50, 75, or 100 times higher, or at least 10%, 20%, 30%, 40%,50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%,900%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, or5,000% higher, than the concentration of that protein in a control.

The term “increased expression level” means an expression level of thegene being analyzed that is higher than the expression level of thatgene in a control. For example, the expression level of the gene beinganalyzed can be at least 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 25, 50,75, or 100 times higher, or at least 10%, 20%, 30%, 40%, 50%, 60%, 70%,80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1,000%,1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, or 5,000%higher, than the expression level of that gene in a control.

The term “respond to a therapy” means that the subject administered withthe therapy shows a positive response to the JAK inhibitor therapyprovided.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the present invention, the exemplary methods andmaterials are described below. All publications, patent applications,patents, and other references mentioned herein are incorporated byreference in their entirety. In case of conflict, the presentapplication, including definitions, will control. The materials,methods, and examples are illustrative only and not intended to belimiting.

Other features and advantages of the invention will be apparent from thefollowing detailed description, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph depicting percent changes from baseline in CXCL9levels at weeks 12 and 24 following treatment with a vehicle control orruxolitinib-containing compositions.

FIG. 2 is a graph depicting percent changes from baseline in CXCL10levels at weeks 12 and 24 following treatment with a vehicle control orruxolitinib-containing compositions.

FIG. 3 depicts proteins in circulation that positively correlated withbaseline F-VASI.

FIG. 4 depicts fold change and p-values of paired t-tests from baselineto week 24 in select inflammatory mediators, by treatment group.

DETAILED DESCRIPTION

This disclosure provides methods and compositions for treating a subjecthaving, suspected of having, or at risk of developing vitiligo with aJAK inhibitor. The disclosure provides pharmacodynamics biomarkers(e.g., protein expression levels) to identify those subjects havingvitiligo that have undergone a therapeutic response (e.g., prior tovisible skin improvement) to a JAK inhibitor. The disclosure alsoprovides predictive biomarkers (e.g., protein expression levels) toidentify those subjects having, suspected of having, or at risk ofdeveloping vitiligo for whom administering a JAK inhibitor is likely tobe effective.

Methods of Identifying Therapeutic Responsiveness to a JAK Inhibitor

As described in Example 1, treatment of subjects having vitiligo with aJAK inhibitor resulted in a decrease in circulating CXCL9 and CXCL10levels. Changes in CXCL9 and CXCL10 levels during the course oftreatment can therefore be used in identifying therapeuticresponsiveness (e.g., improvement in disease scores and/or diseaseresolution) of a subject having vitiligo to a JAK inhibitor. A reducedCXCL9 and/or CXCL10 protein concentration in a biological sample (e.g.,plasma or serum) obtained from a subject after treatment with a JAKinhibitor, as compared to the baseline CXCL9 and/or CXCL10 expressionlevel in a biological sample obtained from the subject before treatmentwith the JAK inhibitor, is indicative that the subject has undergone atherapeutic response (e.g., prior to visible skin improvement) to theJAK inhibitor.

As described in Examples 2-4, proteomic profiling identified numerousproteins whose expression levels, in subjects who respond to treatmentwith a JAK inhibitor, change during the course of treatment and aretherefore useful in identifying therapeutic responsiveness (e.g.,improvement in disease scores and/or disease resolution) of a subjecthaving vitiligo to a JAK inhibitor. In addition, numerous proteins wereidentified whose expression levels, in subjects who did not respond totreatment with a JAK inhibitor, change during the course of treatmentand are therefore useful in identifying non-responsiveness (e.g.,non-improvement in disease scores and/or lack of disease resolution) ofa subject having vitiligo to a JAK inhibitor.

A reduced protein concentration in a biological sample (e.g., plasma orserum) obtained from a subject after treatment with a JAK inhibitor, ascompared to the baseline expression level in a biological sampleobtained from the subject before treatment with the JAK inhibitor, ofone or more (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20) of FAP, RET, CNTN5, FUCA1, ITGAV, ITGB5,THBS4, CD207, GDF-8, CDH6, MRC2, ICOSLG, TNXB, EDIL3, OSMR, GPC1,MIC-A/B, TGFR-2, LRRN1, TLR3, KIM1, ROBO2, CD70, CLMP, N-CDase, FCRL5,CTSV, SCARF2, PLXDC1, PRTG, ERBB4, MAGED1, CEACAM1, TSHB, PTK7, TGFR-2,ADAM 22, CTSC, DLK-1, USP8, SCARF2, TNFRSF13B, MB, or TMPRSS5 isindicative that the subject has undergone a therapeutic response (e.g.,prior to visible skin improvement) to the JAK inhibitor.

An increased protein concentration in a biological sample (e.g., plasmaor serum) obtained from a subject after treatment with a JAK inhibitor,as compared to the baseline expression level in a biological sampleobtained from the subject before treatment with the JAK inhibitor, ofone or more (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20) of NUDT5, MMP-3, MAEA, NEMO, IFN-gamma,IL18, AKT1S1, CASP-8, PPP1R2, ST2, VSIG4, SCGB3A2, HDGF, ICA1, IL13,PEBP1, PARK7, MAP4K5, FLI1, MMP-10, CCL24, TIMP4, MBL2, REG4, or CPA2 isindicative that the subject has undergone a therapeutic response (e.g.,prior to visible skin improvement) to the JAK inhibitor.

A reduced protein concentration in a biological sample (e.g., plasma orserum) obtained from a subject after treatment with a JAK inhibitor, ascompared to the baseline expression level in a biological sampleobtained from the subject before treatment with the JAK inhibitor, ofone or more (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20) of FAP, RET, CNTN5, FUCA1, ITGAV, ITGB5,THBS4, CD207, GDF-8, CDH6, MRC2, ICOSLG, TNXB, EDIL3, OSMR, GPC1,MIC-A/B, TGFR-2, LRRN1, TLR3, KIM1, ROBO2, CD70, CLMP, N-CDase, FCRL5,CTSV, SCARF2, PLXDC1, PRTG, ERBB4, MAGED1, CEACAM1, TSHB, PTK7, TGFR-2,ADAM 22, CTSC, DLK-1, USP8, SCARF2, TNFRSF13B, MB, or TMPRSS5 combinedwith an increased protein concentration in a biological sample (e.g.,plasma or serum) obtained from the subject after treatment with a JAKinhibitor, as compared to the baseline expression level in a biologicalsample obtained from the subject before treatment with the JAKinhibitor, of one or more (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) of NUDT5, MMP-3, MAEA, NEMO,IFN-gamma, IL18, AKT1S1, CASP-8, PPP1R2, ST2, VSIG4, SCGB3A2, HDGF,ICA1, IL13, PEBP1, PARK7, MAP4K5, FLI1, MMP-10, CCL24, TIMP4, MBL2,REG4, or CPA2 is indicative that the subject has undergone a therapeuticresponse (e.g., prior to visible skin improvement) to the JAK inhibitor.

A reduced protein concentration in a biological sample (e.g., plasma orserum) obtained from a subject after treatment with a JAK inhibitor, ascompared to the baseline expression level in a biological sampleobtained from the subject before treatment with the JAK inhibitor, ofone or more (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20) of DDR1, NTRK2, CES2, SCARA5, GDF-8, BOC,PAEP, ARTN, CDNF, TMPRSS5, FLRT2, ROBO2, SIGLEC10, PRTG, SCARF2, CDH3,GFR-alpha-1, TSHB, CD200R1, RGMB, KYNU, HS3ST3B1, CHRDL2, or CNTN1 isindicative that the subject has not undergone a therapeutic response tothe JAK inhibitor.

An increased protein concentration in a biological sample (e.g., plasmaor serum) obtained from a subject after treatment with a JAK inhibitor,as compared to the baseline expression level in a biological sampleobtained from the subject before treatment with the JAK inhibitor, ofone or more (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20) of VSIG4, ARHGAP1, B4GAT1, STX8, CRELD2,ARSA, BCAM, SCARF1, CA13, DAG1, LAIR1, GUSB, PMVK, PEAR1, GP1BA, TACC3,PARK7, ARHGEF12, SEMA7A, ESAM, FKBP5, ARHGAP1, SCAMP3, ABL1, EGF, TACC3,FKBP5, BID, PRDX5, STX8, CD63, SCARF1, PTPN1, CLEC1B, ARSB, FKBP1B,YES1, SRC, TNFSF14, PLXNB3, LRMP, CD164, DAG1, PVALB, NAA10, TRIMS,ARHGEF12, HGF, CA13, SNAP23, SORT1, GP6, CTSS, PPIB, CRKL, MAP2K6, MANF,PMVK, ABHD14B, GUSB, FATC1, MAD1L1, EDAR, CEACAM8, GLB1, ST3GAL1, ARSA,ADAM 8, CD40, IFI30, ECE1, AXIN1, WFDC2, TBCB, CXCL13, ST1A1, KIF1BP,DPP7, VEGFA, CETN2, TGF-alpha, CD84, SNAP29, CASP-8, S100A11, GSTP1,CRADD, PRKAB1, HGF, STK4, RNASE3, SERPINB6, OSM, MK, FADD, CLEC11A,CD69, LOX-1, ITGA6, CLEC5A, BCAM, FES, TXNDC5, LAT2, CXCL11, PARP-1,APBB1IP, GZMB, or CRNN is indicative that the subject has not undergonea therapeutic response to the JAK inhibitor.

A reduced protein concentration in a biological sample (e.g., plasma orserum) obtained from a subject after treatment with a JAK inhibitor, ascompared to the baseline expression level in a biological sampleobtained from the subject before treatment with the JAK inhibitor, ofone or more (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20) of DDR1, NTRK2, CES2, SCARA5, GDF-8, BOC,PAEP, ARTN, CDNF, TMPRSS5, FLRT2, ROBO2, SIGLEC10, PRTG, SCARF2, CDH3,GFR-alpha-1, TSHB, CD200R1, RGMB, KYNU, HS3ST3B1, CHRDL2, or CNTN1combined with an increased protein concentration in a biological sample(e.g., plasma or serum) obtained from the subject after treatment with aJAK inhibitor, as compared to the baseline expression level in abiological sample obtained from the subject before treatment with theJAK inhibitor, of one or more (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) of VSIG4, ARHGAP1,B4GAT1, STX8, CRELD2, ARSA, BCAM, SCARF1, CA13, DAG1, LAIR1, GUSB, PMVK,PEAR1, GP1BA, TACC3, PARK7, ARHGEF12, SEMA7A, ESAM, FKBP5, ARHGAP1,SCAMP3, ABL1, EGF, TACC3, FKBP5, BID, PRDX5, STX8, CD63, SCARF1, PTPN1,CLEC1B, ARSB, FKBP1B, YES1, SRC, TNFSF14, PLXNB3, LRMP, CD164, DAG1,PVALB, NAA10, TRIMS, ARHGEF12, HGF, CA13, SNAP23, SORT1, GP6, CTSS,PPIB, CRKL, MAP2K6, MANF, PMVK, ABHD14B, GUSB, FATC1, MAD1L1, EDAR,CEACAM8, GLB1, ST3GAL1, ARSA, ADAM 8, CD40, IFI30, ECE1, AXIN1, WFDC2,TBCB, CXCL13, ST1A1, KIF1BP, DPP7, VEGFA, CETN2, TGF-alpha, CD84,SNAP29, CASP-8, S100A11, GSTP1, CRADD, PRKAB1, HGF, STK4, RNASE3,SERPINB6, OSM, MK, FADD, CLEC11A, CD69, LOX-1, ITGA6, CLEC5A, BCAM, FES,TXNDC5, LAT2, CXCL11, PARP-1, APBB1IP, GZMB, or CRNN is indicative thatthe subject has not undergone a therapeutic response to the JAKinhibitor.

In some embodiments, the vitiligo is nonsegmental vitiligo. In otherembodiments, the vitiligo is segmental vitiligo.

Methods of Predicting Therapeutic Responsiveness to a JAK Inhibitor

Several proteins have been identified in the Examples whose baselineexpression levels are useful in predicting responsiveness (e.g.,improvement in disease scores and/or disease resolution) of a subjecthaving vitiligo to a JAK inhibitor. In addition, several proteins havebeen identified whose baseline expression levels are useful inpredicting non-responsiveness (e.g., non-improvement in disease scoresand/or lack of disease resolution) of a subject having vitiligo to a JAKinhibitor.

A reduced baseline protein concentration (e.g., in plasma or serum)compared to a control of one or more (e.g., at least 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, or 14) of SCF, CPA2, P4HB, SPARCL1, ST2, SCF,CNDP1, TRAIL, KIRREL2, EGFR, ISLR2, PPP3R1, FCGR3B, MMP-3, IL-18BP,Flt3L, PPY, LTA4H, ITGB2, PTN, GPNMB, SIRPB1, PLTP, PSP-D, COMP, PAMR1,VASN, F11, IL10, CA3, CXCL10, Notch 3, NCAM1, PROC, CLEC14A, IL-12B,IL10, CD40, or IFN-gamma is indicative/predictive that a subject thathas, is suspected of having, or is at risk of developing vitiligo willrespond to a JAK inhibitor. For example, low concentrations (compared toa control) of SPARCL1 protein in a biological sample obtained from asubject prior to treatment with the JAK inhibitor are predictive thatthe subject will respond to the JAK inhibitor.

An increased baseline protein concentration (e.g., in plasma or serum)compared to a control of one or more (e.g., at least 1, 2, or 3) ofSERPINA12, GHRL, PREB, IL-20RA, or PON2 is indicative/predictive that asubject that has, is suspected of having, or is at risk of developingvitiligo will respond to a JAK inhibitor. For example, increasedconcentrations (compared to a control) of SERPINA12 protein in abiological sample obtained from a subject prior to treatment with theJAK inhibitor are predictive that the subject will respond to the JAKinhibitor.

A reduced baseline protein concentration (e.g., in plasma or serum)compared to a control of one or more (e.g., at least 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, or 14) of SCF, CPA2, P4HB, SPARCL1, ST2, SCF,CNDP1, TRAIL, KIRREL2, EGFR, ISLR2, PPP3R1, FCGR3B, MMP-3, IL-18BP,Flt3L, PPY, LTA4H, ITGB2, PTN, GPNMB, SIRPB1, PLTP, PSP-D, COMP, PAMR1,VASN, F11, IL10, CA3, CXCL10, Notch 3, NCAM1, PROC, CLEC14A, IL-12B,IL10, CD40, or IFN-gamma combined with an increased baseline proteinconcentration compared to a control of one or more (e.g., at least 1, 2,or 3) of SERPINA12, GHRL, PREB, IL-20RA, or PON2 isindicative/predictive that a subject that has, is suspected of having,or is at risk of developing vitiligo will respond to a JAK inhibitor.For example, low concentrations (compared to a control) of SPARCL1protein and increased concentrations (compared to a control) ofSERPINA12 protein in a biological sample obtained from a subject priorto treatment with the JAK inhibitor are predictive that the subject willrespond to the JAK inhibitor.

A reduced baseline protein concentration (e.g., in plasma or serum)compared to a control of one or more (e.g., at least 1, 2, 3, 4, 5, or6) of EPHA10, GH2, PARP-1, GLRX, ARSB, or SCAMP3 isindicative/predictive that a subject that has, is suspected of having,or is at risk of developing vitiligo will not respond to a JAKinhibitor. For example, low concentrations (compared to a control) ofEPHA10 protein in a biological sample obtained from a subject prior totreatment with the JAK inhibitor are predictive that the subject willnot respond to the JAK inhibitor.

An increased baseline protein concentration (e.g., in plasma or serum)compared to a control of one or more (e.g., at least 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, or 14) oft-PA, LDL receptor, DLK-1, SELE,EPHB4, GFRA2, PLC, LTBR, PAMR1, TACSTD2, FS, ICAM-2, AXL, PRSS8, SPINK5,AMN, NOMO1, PAI, or CPM is indicative/predictive that a subject thathas, is suspected of having, or is at risk of developing vitiligo willnot respond to a JAK inhibitor. For example, increased concentrations(compared to a control) of EPHB4 protein in a biological sample obtainedfrom a subject prior to treatment with the JAK inhibitor are predictivethat the subject will not respond to the JAK inhibitor.

A reduced baseline protein concentration (e.g., in plasma or serum)compared to a control of one or more (e.g., at least 1, 2, 3, 4, 5, or6) of EPHA10, GH2, PARP-1, GLRX, ARSB, or SCAMP3 combined with anincreased baseline protein concentration (e.g., in plasma or serum)compared to a control of one or more (e.g., at least 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, or 14) oft-PA, LDL receptor, DLK-1, SELE,EPHB4, GFRA2, PLC, LTBR, PAMR1, TACSTD2, FS, ICAM-2, AXL, PRSS8, SPINK5,AMN, NOMO1, PAI, or CPM is indicative/predictive that a subject thathas, is suspected of having, or is at risk of developing vitiligo willnot respond to a JAK inhibitor. For example, low concentrations(compared to a control) of EPHA10 protein and increased concentrations(compared to a control) of EPHB4 protein in a biological sample obtainedfrom a subject prior to treatment with the JAK inhibitor are predictivethat the subject will not respond to the JAK inhibitor.

In some embodiments, the vitiligo is nonsegmental vitiligo. In otherembodiments, the vitiligo is segmental vitiligo.

Controls

As described above, the methods of the present invention can involvemeasuring the concentration of one or more proteins in a biologicalsample from a subject having, suspected of having or at risk ofdeveloping vitiligo, wherein the concentration of one or more proteins,compared to a control, predicts the response of a subject to a JAKinhibitor. In certain embodiments, when the concentration of a proteindescribed herein in a biological sample from a subject having, suspectedof having or at risk of developing vitiligo is lower than the control,the subject is identified as likely to respond to a JAK inhibitor. Inother embodiments, when the concentration of a protein described hereinin a biological sample from a subject having, suspected of having or atrisk of developing vitiligo is higher than the control, the subject isidentified as likely to respond to a JAK inhibitor. In this context, theterm “control” includes a sample (from the same tissue type) obtainedfrom a subject who is known to not respond to a JAK inhibitor. The term“control” also includes a sample (from the same tissue type) obtained inthe past from a subject who is known to not respond to a JAK inhibitorand used as a reference for future comparisons to test samples takenfrom subjects for which therapeutic responsiveness is to be predicted.The “control” expression level/concentration for a particular protein ina particular cell type or tissue may be pre-established by an analysisof protein expression in one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10,15, 20, 25, 30, 35, or 40 or more) subjects, of the same species, thathave not responded to treatment with a JAK inhibitor. Thispre-established reference value (which may be an average or medianexpression level/concentration taken from multiple subjects that havenot responded to the therapy) may then be used for the “control”concentration/expression level of the protein in the comparison with thetest sample. In such a comparison, the subject is predicted to respondto a JAK inhibitor if the expression level of the protein being analyzedis lower or higher than the pre-established reference.

The “control” concentration for a particular protein in a particularcell type or tissue may alternatively be pre-established by an analysisof protein expression in one or more subjects that have responded totreatment with a JAK inhibitor. This pre-established reference value(which may be an average or median expression level taken from multiplesubjects that have responded to the therapy) may then be used as the“control” expression level in the comparison with the test sample. Insuch a comparison, the subject is predicted to respond to a JAKinhibitor if the concentration of the protein being analyzed is the sameas, or comparable to (e.g., at least 85% but less than 100% of), thepre-established reference.

In certain embodiments, the “control” is a pre-established cut-offvalue. A cut-off value is typically a concentration of a protein aboveor below which is considered predictive of responsiveness of a subjectto a therapy of interest. Thus, in accordance with the methods andcompositions described herein, a reference protein concentration isidentified as a cut-off value, above or below of which is predictive ofresponsiveness to a JAK inhibitor. Cut-off values determined for use inthe methods described herein can be compared with, e.g., publishedranges of concentrations but can be individualized to the methodologyused and patient population.

In some embodiments, the concentration of the protein being analyzed isreduced as compared to the concentration of that protein in a control.For example, the concentration of the protein being analyzed can be atleast 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 25, 50, 75, or 100 timeslower, or at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%,200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1,000%, 1,500%, 2,000%,2,500%, 3,000%, 3,500%, 4,000%, 4,500%, or 5,000% lower, than theconcentration of that protein in a control.

In some embodiments, the concentration of the protein being analyzed isincreased as compared to the concentration of that protein in a control.For example, the concentration of the protein being analyzed can be atleast 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 25, 50, 75, or 100 timeshigher, or at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%,200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1,000%, 1,500%, 2,000%,2,500%, 3,000%, 3,500%, 4,000%, 4,500%, or 5,000% higher, than theconcentration of that protein in a control.

Biological Samples

Suitable biological samples for the methods described herein include anybiological fluid, cell, tissue, or fraction thereof, which includesproteins of interest. A biological sample can be, for example, aspecimen obtained from a human subject or can be derived from such asubject. For example, a biological sample can be a biological fluid suchas blood, serum, plasma, urine, spinal fluid, saliva, lacrimal fluid, orsweat, or such a sample absorbed onto a substrate (e.g., glass, polymer,or paper).

A biological sample can be obtained from a subject having, suspected ofhaving, or at risk of developing, vitiligo. In certain embodiments, thesubject has nonsegmental vitiligo. In some embodiments, the subject hassegmental vitiligo.

Methods for obtaining and/or storing samples that preserve the activityor integrity of molecules (e.g., proteins) in the sample are well knownto those skilled in the art. For example, a biological sample can befurther contacted with one or more additional agents such as buffersand/or inhibitors, including one or more of nuclease, protease, andphosphatase inhibitors, which preserve or minimize changes in themolecules in the sample.

Determining Expression Levels/Concentrations of Biomarkers

The expression level (amount) of a gene product can be determined bydetecting and/or measuring the level of protein expression of the gene.

In one embodiment, the expression of a gene can be determined bydetecting and/or measuring expression or concentration of a proteinencoded by the gene. Methods of determining proteinexpression/concentration are well known in the art. A generally usedmethod involves the use of antibodies specific for the target protein ofinterest. For example, methods of determining protein expressioninclude, but are not limited to, western blot or dot blot analysis,immunohistochemistry (e.g., quantitative immunohistochemistry),immunocytochemistry, enzyme-linked immunosorbent assay (ELISA),enzyme-linked immunosorbent spot (ELISPOT; Coligan, J. E., et al., eds.(1995) Current Protocols in Immunology. Wiley, New York),radioimmunoassay, chemiluminescent immunoassay, electrochemiluminescenceimmunoassay, latex turbidimetric immunoassay, latex photometricimmunoassay, immuno-chromatographic assay, and antibody array analysis(see, e.g., U.S. Publication Nos. 20030013208 and 2004171068, thedisclosures of each of which are incorporated herein by reference intheir entirety).

In one example, the presence or amount of protein expression of a genecan be determined using a western blotting technique. For example, alysate can be prepared from a biological sample, or the biologicalsample itself, can be contacted with Laemmli buffer and subjected tosodium-dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).SDS-PAGE-resolved proteins, separated by size, can then be transferredto a filter membrane (e.g., nitrocellulose) and subjected toimmunoblotting techniques using a detectably-labeled antibody specificto the protein of interest. The presence or amount of bounddetectably-labeled antibody indicates the presence or amount of proteinin the biological sample.

In another example, an immunoassay can be used for detecting and/ormeasuring the protein expression of a gene. As above, for the purposesof detection, an immunoassay can be performed with an antibody thatbears a detection moiety (e.g., a fluorescent agent or enzyme). Proteinsfrom a biological sample can be conjugated directly to a solid-phasematrix (e.g., a multi-well assay plate, nitrocellulose, agarose,sepharose, encoded particles, or magnetic beads) or it can be conjugatedto a first member of a specific binding pair (e.g., biotin orstreptavidin) that attaches to a solid-phase matrix upon binding to asecond member of the specific binding pair (e.g., streptavidin orbiotin). Such attachment to a solid-phase matrix allows the proteins tobe purified away from other interfering or irrelevant components of thebiological sample prior to contact with the detection antibody and alsoallows for subsequent washing of unbound antibody. Here as above, thepresence or amount of bound detectably-labeled antibody indicates thepresence or amount of protein in the biological sample.

There is no particular restriction as to the form of the antibody andthe present disclosure includes polyclonal antibodies, as well asmonoclonal antibodies. The antiserum obtained by immunizing animals,such as rabbits with a protein or fragment thereof, as well polyclonaland monoclonal antibodies of all classes, human antibodies, andhumanized antibodies produced by genetic recombination, are alsoincluded. Antibodies or antibody fragments specific for a proteinencoded by one or more biomarkers can also be generated by in vitromethods such as phage display. Moreover, the antibody may be an antibodyfragment or modified-antibody, so long as it binds to a protein encodedby a biomarker of the invention. For instance, Fab, F (ab′) 2, Fv, orsingle chain Fv (scFv) in which the H chain Fv and the L chain Fv aresuitably linked by a linker (Huston et al., Proc. Natl. Acad. Sci. USA,85:5879-5883, (1988)) can be given as antibody fragments.

The antibodies may be conjugated to various molecules, such asfluorescent substances, radioactive substances, and luminescentsubstances. Methods to attach such moieties to an antibody are alreadyestablished and conventional in the field (see, e.g., U.S. Pat. Nos.5,057,313 and 5,156,840).

Examples of methods that assay the antigen-binding activity of theantibodies include, for example, measurement of absorbance,enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA),radioimmunoassay (RIA), and/or immunofluorescence. For example, whenusing ELISA, a protein encoded by a biomarker of the invention is addedto a plate coated with the antibodies of the present disclosure, andthen, the antibody sample, for example, culture supernatants ofantibody-producing cells, or purified antibodies are added. Then,secondary antibody recognizing the primary antibody, which is labeled byalkaline phosphatase and such enzymes, is added, the plate is incubatedand washed, and the absorbance is measured to evaluate theantigen-binding activity after adding an enzyme substrate such asp-nitrophenyl phosphate. As the protein, a protein fragment, forexample, a fragment comprising a C-terminus, or a fragment comprising anN-terminus may be used. To evaluate the activity of the antibody of theinvention, BIAcore (GE Healthcare) may be used.

By using these methods, the antibody and a sample presumed to contain aprotein of interest are contacted, and the protein encoded by abiomarker of the invention is detected or assayed by detecting orassaying the immune complex formed between the above-mentioned antibodyand the protein.

Mass spectrometry based quantitation assay methods, for example, but notlimited to, multiple reaction monitoring (MRM)-based approaches incombination with stable-isotope labeled internal standards, are analternative to immunoassays for quantitative measurement of proteins.These approaches do not require the use of antibodies (see, for example,Addona et al., Nat. Biotechnol., 27:633-641, 2009; Kuzyk et al., Mol.Cell Proteomics, 8:1860-1877, 2009; Paulovich et al., Proteomics Clin.Appl., 2:1386-1402, 2008). In addition, MRM offers superior multiplexingcapabilities, allowing for the simultaneous quantification of numerousproteins in parallel. The basic theory of these methods has beenwell-established and widely utilized for drug metabolism andpharmacokinetics analysis of small molecules.

In some embodiments, the concentration of two proteins, three proteins,four proteins, five proteins, six proteins, seven proteins, eightproteins, nine proteins, 10 proteins, 11 proteins, 12 proteins, 13proteins, or 14 proteins, or at least two proteins, at least threeproteins, at least four proteins, at least five proteins, at least sixproteins, at least seven proteins, at least eight proteins, at leastnine proteins, at least 10 proteins, at least 11 proteins, at least 12proteins, at least 13 proteins, at least 14 proteins, at least 15proteins, at least 16 proteins, at least 17 proteins, at least 18proteins, at least 19 proteins, or at least 20 proteins can be assessedand/or measured.

JAK Inhibitors

In some embodiments, the JAK inhibitor is a compound that inhibits JAK1,JAK2, JAK3, and/or TYK2. In some embodiments, the JAK inhibitor isselective for JAK1 and JAK2 over JAK3 and TYK2. In some embodiments, theJAK inhibitor is selective for JAK1 over JAK2, JAK3, and TYK2. Forexample, some of the compounds described herein, or a pharmaceuticallyacceptable salt thereof, preferentially inhibit JAK1 over one or more ofJAK2, JAK3, and TYK2. In some embodiments, the compounds or saltsinhibit JAK1 preferentially over JAK2 (e.g., have a JAK2/JAK1 IC₅₀ratio>1). In some embodiments, the compounds or salts are about 10-foldmore selective for JAK1 over JAK2. In some embodiments, the compounds orsalts are about 3-fold, about 5-fold, about 10-fold, about 15-fold, orabout 20-fold more selective for JAK1 over JAK2 as calculated bymeasuring IC₅₀ at 1 mM ATP.

In some embodiments, the JAK inhibitor is3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile.

In some embodiments, the JAK inhibitor is(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile(ruxolitinib; also known as INCB018424).

3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrileand ruxolitinib can be made by the procedure described in U.S. Pat. No.7,598,257 (Example 67), filed Dec. 12, 2006, which is incorporatedherein by reference in its entirety.

In some embodiments, the JAK inhibitor is(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrilephosphoric acid salt.

In some embodiments, the JAK inhibitor is barcitinib, tofacitinib,oclacitinib, filgotinib, gandotinib, lestaurtinib, momelotinib,bacritinib, PF-04965842, upadacitinib, peficitinib, fedratinib,cucurbitacin I, ATI-501 (Aclaris), ATI-502 (Aclaris), JTE052 (Leo Pharmaand Japan Tobacco), or CHZ868.

In some embodiments, the JAK inhibitor can be an isotopically-labeledcompound, or a pharmaceutically acceptable salt thereof. An“isotopically” or “radio-labeled” compound is a compound of thedisclosure where one or more atoms are replaced or substituted by anatom having an atomic mass or mass number different from the atomic massor mass number typically found in nature (i.e., naturally occurring).Suitable radionuclides that may be incorporated in compounds of thepresent disclosure include but are not limited to ²H (also written as Dfor deuterium), ³H (also written as T for tritium), ¹¹C, ¹³C, ¹⁴C, ¹³N,¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O, ¹⁸F, ³⁵ s, ³⁶Cl, ⁸²Br, ⁷⁵Br, ⁷⁶Br, ⁷⁷Br, ¹²³I, ¹²⁴I,¹²⁵I, and ¹³¹I. For example, one or more hydrogen atoms in a compound ofthe present disclosure can be replaced by deuterium atoms (e.g., one ormore hydrogen atoms of a C₁₋₆ alkyl group of Formula (I) can beoptionally substituted with deuterium atoms, such as —CD₃ beingsubstituted for —CH₃).

One or more constituent atoms of the compounds described herein can bereplaced or substituted with isotopes of the atoms in natural ornon-natural abundance. In some embodiments, the compound includes atleast one deuterium atom. In some embodiments, the compound includes twoor more deuterium atoms. In some embodiments, the compound includes 1-2,1-3, 1-4, 1-5, or 1-6 deuterium atoms. In some embodiments, all of thehydrogen atoms in a compound can be replaced or substituted by deuteriumatoms.

Synthetic methods for including isotopes into organic compounds areknown in the art (Deuterium Labeling in Organic Chemistry by Alan F.Thomas (New York, N.Y., Appleton-Century-Crofts, 1971; The Renaissanceof H/D Exchange by Jens Atzrodt, Volker Derdau, Thorsten Fey and JochenZimmermann, Angew. Chem. Int. Ed. 2007, 7744-7765; The Organic Chemistryof Isotopic Labelling by James R. Hanson, Royal Society of Chemistry,2011). Isotopically labeled compounds can be used in various studiessuch as NMR spectroscopy, metabolism experiments, and/or assays.

Substitution with heavier isotopes, such as deuterium, may affordcertain therapeutic advantages resulting from greater metabolicstability, for example, increased in vivo half-life or reduced dosagerequirements, and hence may be preferred in some circumstances. (seee.g., A. Kerekes et. al. J. Med. Chem. 2011, 54, 201-210; R. Xu et. al.J. Label Compd. Radiopharm. 2015, 58, 308-312). In particular,substitution at one or more metabolism sites may afford one or more ofthe therapeutic advantages.

Accordingly, in some embodiments, the JAK inhibitor is a compound,wherein one or more hydrogen atoms in the compound are replaced bydeuterium atoms, or a pharmaceutically acceptable salt thereof.

In some embodiments, the JAK inhibitor is ruxolitinib, wherein one ormore hydrogen atoms are replaced by deuterium atoms, or apharmaceutically acceptable salt thereof. In some embodiments, the JAKinhibitor is any of the compounds in U.S. Pat. No. 9,249,149 (which isincorporated herein by reference in its entirety), or a pharmaceuticallyacceptable salt thereof. In some embodiments, the JAK inhibitor isCTP-543, or a pharmaceutically acceptable salt thereof. In someembodiments, the compound is a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is Selected from H and D;

each R² is independently selected from H and D, provided that each R²attached to a common carbon is the same;

each R³ is independently selected from H and D, provided that each R³attached to a common carbon is the same;

R⁴ is selected from H and D;

each R⁵ is the same and is selected from H and D; and

R⁶, R⁷, and R⁸ are each independently selected from H and D; providedthat when R¹ is H, each R² and each R³ are H, R⁴ is H, and each of R⁶,R⁷, and R⁸ is H, then each R⁵ is D.

In some embodiments, the JAK inhibitor is a compound of Formula Iselected from the following compounds 100-130 in the table below(wherein R⁶, R⁷, and R⁸ are each H), or a pharmaceutically acceptablesalt thereof. In some embodiments, the JAK inhibitor is a compound ofFormula I selected from the following compounds 200-231 in the tablebelow (wherein R⁶, R⁷, and R⁸ are each D), or a pharmaceuticallyacceptable salt thereof.

Compound R¹ Each R² Each R³ R⁴ Each R⁵ 100 H H H D H 101 H H H H D 102 HH H D D 103 H H D H H 104 H H D D H 105 H H D H D 106 H H D D D 107 H DH H H 108 H D H D H 109 H D H H D 110 H D H D D 111 H D D H H 112 H D DD H 113 H D D H D 114 H D D D D 115 D H H H H 116 D H H D H 117 D H H HD 118 D H H D D 119 D H D H H 120 D H D D H 121 D H D H D 122 D H D D D123 D D H H H 124 D D H D H 125 D D H H D 126 D D H D D 127 D D D H H128 D D D D H 129 D D D H D 130 D D D D D 200 H H H D H 201 H H H H D202 H H H D D 203 H H D H H 204 H H D D H 205 H H D H D 206 H H D D D207 H D H H H 208 H D H D H 209 H D H H D 210 H D H D D 211 H D D H H212 H D D D H 213 H D D H D 214 H D D D D 215 D H H H H 216 D H H D H217 D H H H D 218 D H H D D 219 D H D H H 220 D H D D H 221 D H D H D222 D H D D D 223 D D H H H 224 D D H D H 225 D D H H D 226 D D H D D227 D D D H H 228 D D D D H 229 D D D H D 230 D D D D D 231 H H H H H

In some embodiments, the JAK inhibitor is baricitinib, wherein one ormore hydrogen atoms are replaced by deuterium atoms, or apharmaceutically acceptable salt thereof. In some embodiments, the JAKinhibitor is any of the compounds in U.S. Pat. No. 9,540,367 (which isincorporated herein by reference in its entirety), or a pharmaceuticallyacceptable salt thereof.

In some embodiments, the JAK inhibitor is a compound of Table A, or apharmaceutically acceptable salt thereof. The compounds in Table A areselective JAK1 inhibitors (selective over JAK2, JAK3, and TYK2).

TABLE A Examples of JAK inhibitors Comp. No. Prep. Name Structure 1 US2011/ 0224190 (Example 1) {1-{1-[3-Fluoro-2-(trifluoromethyl)isonicotinoyl] piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile (itacitinib; also known as INCB039110)

2 US 2011/ 0224190 (Example 154) 4-{3-(Cyanomethyl)-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-1H- pyrazol-1-yl]azetidin-1-yl}-N-[4-fluoro-2- (trifluoromethyl)phenyl] piperidine-1-carboxamide

3 US 2011/ 0224190 (Example 85) [3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H- pyrazol-1-yl]-1-(1-{[2-(trifluoromethyl)pyrimidin- 4-yl]carbonyl}piperidin-4-yl)azetidin-3-yl]acetonitrile

4 US 2014/ 0343030 (Example 7) 4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′- bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2- trifluoro-1- methylethyl]benzamide

5 US 2014/ 0121198 (Example 20) ((2R,5S)-5-{2-[(1R)-1- hydroxyethyl]-1H-imidazo[4,5-d]thieno[3,2- b]pyridin-1-yl}tetrahydro-2H-pyran-2-yl)acetonitrile

6 US 2010/ 0298334 (Example 2) 3-[1-(6-chloropyridin-2-yl)pyrrolidin-3-yl]-3-[4-(7H- pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1- yl]propanenitrile

7 US 2010/ 0298334 (Example 13c) 3-(1-[1,3]oxazolo[5,4-b]pyridin-2-ylpyrrolidin-3- yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H- pyrazol-1-yl]propanenitrile

8 US 2011/ 0059951 (Example 12) 4-[(4-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)-1H-pyrazol-1- yl]propyl}piperazin-1-yl)carbonyl]-3- fluorobenzonitrile

9 US 2011/ 0059951 (Example 13) 4-[(4-{3-cyano-2-[3-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)-1H-pyrrol-1- yl]propyl}piperazin-1-yl)carbonyl]-3- fluorobenzonitrile

10 US 2012/ 0149681 (Example 7b) [trans-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H- pyrazol-1-yl]-3-(4-{[2-(trifluoromethyl)pyrimidin- 4-yl]carbonyl}piperazin-1-yl)cyclobutyl]acetonitrile

11 US 2012/ 0149681 (Example 157) {trans-3-(4-{[4-[(3-hydroxyazetidin-1- yl)methyl]-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4- (7H-pyrrolo[2,3- d]pyrimidin-4-yl)-1H-pyrazol-1- yl]cyclobutyl}acetonitrile

12 US 2012/ 0149681 (Example 161) {trans-3-(4-{[4-{[(2S)-2-(hydroxymethyl)pyrrolidin- 1-yl]methyl}-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4- (7H-pyrrolo[2,3- d]pyrimidin-4-yl)-1H-pyrazol-1- yl]cyclobutyl}acetonitrile

13 US 2012/ 0149681 (Example 162) {trans-3-(4-{[4-{[(2R)-2-(hydroxymethyl)pyrrolidin- 1-yl]methyl}-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4- (7H-pyrrolo[2,3- d]pyrimidin-4-yl)-1H-pyrazol-1- yl]cyclobutyl}acetonitrile

14 US 2012/ 0149682 (Example 20) 4-(4-{3- [(dimethylamino)methyl]-5-fluorophenoxy}piperidin-1- yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H- pyrazol-1-yl]butanenitrile

15 US 2013/ 0018034 (Example 18) 5-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-1H- pyrazol-1-yl]azetidin-1-yl}-N-isopropylpyrazine-2- carboxamide

16 US 2013/ 0018034 (Example 28) 4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-1H- pyrazol-1-yl]azetidin-1-yl}-2,5-difluoro-N-[(1S)-2,2,2- trifluoro-1- methylethyl]benzamide

17 US 2013/ 0018034 (Example 34) 5-{3-(cyanomethyl)-3-[4-(1H-pyrrolo[2,3-b]pyridin-4- yl)-1H-pyrazol-1-yl]azetidin-1-yl}-N-isopropylpyrazine- 2-carboxamide

18 US 2013/ 0045963 (Example 45) {1-(cis-4-{[6-(2- hydroxyethyl)-2-(trifluoromethyl)pyrimidin- 4-yl]oxy}cyclohexyl)-3-[4- (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H- pyrazol-1-yl]azetidin-3- yl}acetonitrile

19 US 2013/ 0045963 (Example 65) {1-(cis-4-{[4- [(ethylamino)methyl]-6-(trifluoromethyl)pyridin-2- yl]oxy}cyclohexyl)-3-[4- (7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H- pyrazol-1-yl]azetidin-3- yl}acetonitrile

20 US 2013/ 0045963 (Example 69) {1-(cis-4-{[4-(1-hydroxy-1-methylethyl)-6- (trifluoromethyl)pyridin-2- yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-1H- pyrazol-1-yl]azetidin-3-yl}acetonitrile

21 US 2013/ 0045963 (Example 95) {1-(cis-4-{[4-{[(3R)-3-hydroxypyrrolidin-1- yl]methyl}-6- (trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4- (7H-pyrrolo[2,3- d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3- yl}acetonitrile

22 US 2013/ 0045963 (Example 95) {1-(cis-4-{[4-{[(3S)-3-hydroxypyrrolidin-1- yl]methyl}-6- (trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4- (7H-pyrrolo[2,3- d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3- yl}acetonitrile

23 US 2014/ 0005166 (Example 1) {trans-3-(4-{[4-({[(1S)-2- hydroxy-1-methylethyl]amino}methyl)- 6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1-[4- (7H-pyrrolo[2,3- d]pyrimidin-4-yl)-1H-pyrazol-1- yl]cyclobutyl}acetonitrile

24 US 2014/ 0005166 (Example 14) {trans-3-(4-{[4-({[(2R)-2-hydroxypropyl]amino}methyl)- 6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1- [4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-1H-pyrazol-1- yl]cyclobutyl}acetonitrile

25 US 2014/ 0005166 (Example 15) {trans-3-(4-{[4-({[(2S)-2-hydroxypropyl]amino}methyl)- 6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-1-yl)-1- [4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-1H-pyrazol-1- yl]cyclobutyl}acetonitrile

26 US 2014/ 0005166 (Example 20) {trans-3-(4-{[4-(2- hydroxyethyl)-6-(trifluoromethyl)pyridin-2- yl]oxy}piperidin-1-yl)-1-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-1H- pyrazol-1-yl]cyclobutyl}acetonitrile

In some embodiments, the JAK inhibitor is{1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile,or a pharmaceutically acceptable salt thereof.

In some embodiments, the JAK inhibitor is{1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrileadipic acid salt.

The synthesis and preparation of {1-{1-[3-fluoro(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrileand the adipic acid salt of the same can be found, e.g., in US PatentPubl. No. 2011/0224190, filed Mar. 9, 2011, US Patent Publ. No.2013/0060026, filed Sep. 6, 2012, and US Patent Publ. No. 2014/0256941,filed Mar. 5, 2014, each of which is incorporated herein by reference inits entirety.

In some embodiments, the JAK inhibitor is4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoromethylethyl]benzamide, or a pharmaceutically acceptable salt thereof.

In some embodiments, the JAK inhibitor is4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide phosphoric acid salt.

The synthesis and preparation of4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamideand the phosphoric acid salt of the same can be found, e.g., in USPatent Publ. No. US 2014/0343030, filed May 16, 2014, which isincorporated herein by reference in its entirety.

In some embodiments, the JAK inhibitor is((2R,5S)-5-{2-[(1R)-1-hydroxyethyl]-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-1-yl}tetrahydro-2H-pyran-2-yl)acetonitrile,or a pharmaceutically acceptable salt thereof.

In some embodiments, the JAK inhibitor is((2R,5S)-5-{2-[(1R)-1-hydroxyethyl]-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-1-yl}tetrahydro-2H-pyran-2-yl)acetonitrilemonohydrate.

Synthesis of ((2R,5S)-5-{2-[(1R)-1-hydroxyethyl]-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-1-yl}tetrahydro-2H-pyran-2-yl)acetonitrileand characterization of the anhydrous and monohydrate forms of the sameare described in US Patent Publ. No. 2014/0121198, filed Oct. 31, 2013and US Patent Publ. No. 2015/0344497, filed Apr. 29, 2015, each of whichis incorporated herein by reference in its entirety.

In some embodiments, the compounds of Table A are prepared by thesynthetic procedures described in US Patent Publ. No. 2011/0224190,filed Mar. 9, 2011, US Patent Publ. No. 2014/0343030, filed May 16,2014, US Patent Publ. No. 2014/0121198, filed Oct. 31, 2013, US PatentPubl. No. 2010/0298334, filed May 21, 2010, US Patent Publ. No.2011/0059951, filed Aug. 31, 2010, US Patent Publ. No. 2012/0149681,filed Nov. 18, 2011, US Patent Publ. No. 2012/0149682, filed Nov. 18,2011, US Patent Publ. 2013/0018034, filed Jun. 19, 2012, US Patent Publ.No. 2013/0045963, filed Aug. 17, 2012, and US Patent Publ. No.2014/0005166, filed May 17, 2013, each of which is incorporated hereinby reference in its entirety.

In some embodiments, JAK inhibitor is selected from the compounds, orpharmaceutically acceptable salts thereof, of US Patent Publ. No.2011/0224190, filed Mar. 9, 2011, US Patent Publ. No. 2014/0343030,filed May 16, 2014, US Patent Publ. No. 2014/0121198, filed Oct. 31,2013, US Patent Publ. No. 2010/0298334, filed May 21, 2010, US PatentPubl. No. 2011/0059951, filed Aug. 31, 2010, US Patent Publ. No.2012/0149681, filed Nov. 18, 2011, US Patent Publ. No. 2012/0149682,filed Nov. 18, 2011, US Patent Publ. 2013/0018034, filed Jun. 19, 2012,US Patent Publ. No. 2013/0045963, filed Aug. 17, 2012, and US PatentPubl. No. 2014/0005166, filed May 17, 2013, each of which isincorporated herein by reference in its entirety.

Methods of Treatment

The methods disclosed herein enable the assessment of whether or not asubject having, suspected of having or at risk of developing vitiligo isresponding or is likely to respond (e.g., likely to have greaterimprovement in disease as evidenced by reduced disease severity and/ordisease remission/resolution) to a JAK inhibitor. A subject having,suspected of having or at risk of developing vitiligo who is likely torespond to a JAK inhibitor can be administered a JAK inhibitor (e.g.,ruxolitinib). Conversely, a subject having, suspected of having or atrisk of developing vitiligo who is less likely to respond to a JAKinhibitor (e.g., ruxolitinib) can be administered an additional therapythat is suitable for treatment of vitiligo.

The methods of this disclosure also enable the stratification ofsubjects having, suspected of having or at risk of developing vitiligointo groups of subjects that are more likely to benefit, and groups ofsubjects that are less likely to benefit, from treatment comprising aJAK inhibitor. The ability to select such subjects from a pool ofvitiligo subjects who are being considered for treatment with a JAKinhibitor is beneficial for administering an effective treatment to thesubject.

In one embodiment, the subject to be treated with a JAK inhibitor (e.g.,ruxolitinib) has, is suspected of having, or is likely to developvitiligo. In certain embodiments, the subject to be treated with a JAKinhibitor (e.g., ruxolitinib) has, is suspected of having, or is likelyto develop nonsegmental vitiligo. In other embodiments, the subject tobe treated with a JAK inhibitor (e.g., ruxolitinib) has, is suspected ofhaving, or is likely to develop segmental vitiligo.

If the subject having vitiligo is more likely to respond to a JAKinhibitor, the subject can then be administered an effective amount ofthe JAK inhibitor (e.g., ruxolitinib). An effective amount of the JAKinhibitor can suitably be determined by a health care practitionertaking into account, for example, the characteristics of the patient(age, sex, weight, race, etc.), the progression of the disease, andprior exposure to the drug. If the subject is less likely to respond toa JAK inhibitor, the subject can then be optionally administered atherapy that does not comprise a JAK inhibitor.

The methods can also be applied to individuals at risk of developingvitiligo.

After stratifying or selecting a subject based on whether the subjectwill be more likely or less likely to respond to a JAK inhibitor, amedical practitioner (e.g., a doctor) can administer the appropriatetherapeutic modality to the subject. Methods of administering a JAKinhibitor are well known in the art.

In cases where the subject having vitiligo and predicted to respond to aJAK inhibitor has been previously administered one or more non-JAKinhibitor therapies, the JAK inhibitor can replace or augment apreviously or currently administered therapy. For example, upon treatingwith the JAK inhibitor, administration of the one or more non-JAKinhibitor therapies can cease or diminish, e.g., be administered atlower levels. Administration of the previous therapy can be maintainedwhile the JAK inhibitor is administered. In some embodiments, a previoustherapy can be maintained until the level of the JAK inhibitor reaches alevel sufficient to provide a therapeutic effect.

A subject treated with a JAK inhibitor (e.g., ruxolitinib) according tothe methods described herein can be treated in combination with one ormore additional compositions that are effective for treatment ofvitiligo. Examples of compositions that can be used in such combinationtreatment include corticosteroids (e.g., methylprednisolone orprednisone), alcineurin inhibitors, vitamin D analogues, pseudocatalase,depigmenting agents, tacrolimus, pimecrolimus, oxsoralen, psoralen,khellin.

The following are examples of the practice of the invention. They arenot to be construed as limiting the scope of the invention in any way.

EXAMPLES Example 1: Human Serum CXCL9, CXCL10, and IFN-γ Levels inSubjects with Vitiligo Treated with Ruxolitinib

Study subjects had a clinical diagnosis of vitiligo, with depigmentedareas including at least 0.5% of the total body surface area on the faceand at least 3% of the total body surface area on nonfacial areasaffected using the palmar (or handprint) method (palm plus 5 digits).

CXCL9, CXCL10, and IFN-γ levels were evaluated in the sera of 134vitiligo subjects at baseline (before treatment) and also at weeks 12and 24 following topical treatment with one of the following fiveregimens: ruxolitinib cream 0.15% QD (once daily), ruxolitinib cream0.5% QD (once daily), ruxolitinib cream 1.5% QD (once daily),ruxolitinib cream 1.5% BID (twice daily), and vehicle BID (twice daily).“%” in the various treatments refers to percent of total weight of thecream that is ruxolitinib.

Serum was collected from each subject in an 8.5 mL serum-separating tube(SST). Immediately following collection, the SST was inverted 5 times tomix clot activator with blood. Blood was allowed to clot for 30 minutesat room temperature in a vertical position. The SST was then centrifugedbetween 1100 and 1300×g for 10 minutes for swing-head units or 15minutes for fixed angle units at room temperature (approximately 25°C.). The sera was collected from SST, aliquots were made then frozen andstored at −70° C. until tested.

CXCL9, CXCL10, and IFN-γ protein concentrations were measured in thesera of each subject using the Simple Plex cartridge kit (Catalog#SPCKC-PS-002038; Protein Simple-Biotechne, San Jose, Calif.) accordingto the manufacturer's guidelines. Samples were tested in duplicate andexpressed as the mean of the duplicates for each subject. Statisticalanalysis was conducted using Graph Pad Prism (San Diego, Calif.). Dataare presented as mean±standard error. Statistical differences betweenthe vehicle and each treatment group were evaluated using a Mann-Whitneytest. Specifically, baseline levels of CXCL9, CXCL10, and IFN-γ werecalculated for individual subjects within each treatment group of thestudy and compared to the vehicle-treated subjects for statisticaldifferences. The percent change from baseline in CXCL9, CXCL10, andIFN-γ levels was calculated for each individual and then averaged foreach group. Statistical differences in the percent change from baselinewere determined by comparing each treatment group with the vehicle usinga nonparametric Mann-Whitney test.

The baseline CXCL9 concentrations of the 134 subjects tested in thisstudy ranged from 151.7 to 13,016 pg/mL, with a median concentration of479.3 pg/mL. No statistically significant differences in baseline CXCL9concentrations were observed between the treatment groups.

Mean percent changes in CXCL9 levels from baseline to Week 24 for eachtreatment group are shown in FIG. 1 . Levels of CXCL9 for most subjectsfell within a given range for each treatment group; however, there wereoutliers in the vehicle (n=1), 0.15% QD (n=1), 0.5% QD (n=1), 1.5% QD,and 1.5% BID (n=1) groups. Despite these outlying values, application ofruxolitinib cream 1.5% BID for 24 weeks significantly (p<0.05) reducedthe CXCL9 levels in circulation as compared to vehicle (FIG. 1 ).Removal of the outliers did not result in any changes to the observedsignificance. Additionally, when comparing the directionality of thechange in CXCL9 levels, 17 of 24 in the ruxolitinib cream 1.5% QD (71%)and 24 of 30 (80%) in the ruxolitinib cream 1.5% BID treatment groupssaw reductions in circulating CXCL9 levels between the baseline and Week24. As a comparison, only 13 of 26 (50%) vehicle-treated subjects, 15 of26 (58%) ruxolitinib cream 0.15% QD-treated subjects, and 10 of 28 (36%)ruxolitinib cream 0.5% QD-treated subjects moved in a similar manner.

The baseline CXCL10 concentrations of the 134 subjects tested in thisstudy ranged from 56.5 to 507.3 pg/mL, with a median concentration of145.6 pg/mL. No statistically significant differences in baseline CXCL10concentrations were observed between the treatment groups.

Mean percent changes in CXCL10 levels from baseline to Week 24 for eachtreatment group are shown in FIG. 2 . Levels of CXCL10 for most subjectsfell within a given range for each treatment group; however, there wereoutliers in the ruxolitinib cream 1.5% QD (n=2) group. Despite theseoutlying values, application of ruxolitinib cream 1.5% QD or BID for 24weeks significantly (p<0.05) reduced the CXCL10 levels in circulation ascompared to vehicle (FIG. 2 ). Removal of the outliers did not result inany changes to the observed significance. Additionally, when comparingthe directionality of the change in CXCL10 levels, 20 of 24 in theruxolitinib cream 1.5% QD (83%) and 23 of 30 (77%) in the ruxolitinibcream 1.5% BID treatment groups saw reductions in circulating CXCL10levels between the baseline and Week 24. As a comparison, only 13 of 26(50%) vehicle-treated subjects, 15 of 26 (58%) ruxolitinib cream 0.15%QD-treated subjects, and 15 of 28 (54%) ruxolitinib cream 0.5%QD-treated subjects moved in a similar manner.

The changes in serum CXCL9 and CXCL10 levels, reflected in absolutevalues and percent change, from baseline to week 24 are depicted inTable B.

TABLE B Change in serum CXCL9 and CXCL10 levels from baseline to week 24Baseline Week 24 Absolute Value Absolute Value % Change Treatment Meanpg/mL ± Minimum Maximum Mean pg/mL ± Minimum Maximum from Baseline ArmSEM (pg/mL) (pg/mL) SEM (pg/mL) (pg/mL) Mean ± SEM CXCL9 Vehicle 633.7 ±78.3 183.9 2034.7 655.8 ± 80.9 157.9 2093.9  6.12 ± 6.4 0.15% QD  708.6± 210.7 249.2 5890.4 469.2 ± 33.4 160.9 904.6 −5.80 ± 6.7 0.5% QD 1009.7± 449.1 214.6 13016.0  760.5 ± 209.3 158.1 6070.5  12.44 ± 10.3 1.5% QD519.8 ± 84.1 151.7 2334.3 422.2 ± 44.0 125.3 1073.8  −4.26 ± 10.6 1.5%BID  767.0 ± 144.6 247.7 4616.8  655.4 ± 137.1 148.5 3443.9 −18.17 ±5.8  CXCL10 Vehicle 177.6 ± 15.1 80.9 408.2 177.4 ± 15.4 56.6 380.2 0.39 ± 3.6 0.15% QD 152.0 ± 11.8 78.9 323.0 135.8 ± 9.1  56.2 232.3−5.64 ± 5.2 0.5% QD 181.3 ± 18.0 79.0 507.3 162.4 ± 12.7 80.3 381.8−2.53 ± 5.6 1.5% QD 149.4 ± 16.5 73.1 405.6 119.6 ± 15.7 49.5 446.1−15.49 ± 6.7  1.5% BID 177.0 ± 12.7 56.5 361.3 138.3 ± 13.9 54.0 340.7−19.74 ± 6.6 

The baseline IFN-γ concentrations of 16 out of 137 subjects were abovethe lower limit of detection. The baseline levels of those 16 subjectsranged from 1.14 to 5.07 pg/mL, with a median concentration of 1.78pg/mL. No statistically significant differences in baseline IFN-γconcentrations were observed between the treatment groups. Mean percentchanges in IFN-γ levels from baseline to Weeks 12 and 24 for eachtreatment group are shown in Table C. No significant differences in thepercent change of IFN-γ were observed between groups.

TABLE C Mean percent change serum IFN-γ levels from baseline to weeks 12and 24 % Change in % Change in Serum IFN-γ Serum IFN-γ Number Levelsfrom Levels from Treatment of Baseline to Baseline to Group SubjectsWeek 12^(a) Week 24^(a) Vehicle 3 −44.8 ± 22.8 −35.2 ± 14.5 0.15% QD 3 6.8 ± 17.4 −8.6 ± 7.2 0.5% QD 2 −58.3 ± 41.7 −44.9 ± 55.1 1.5% QD 3−23.3 ± 31.7 −49.9 ± 17.9 1.5% BID 5 −20.5 ± 20.5 −10.7 ± 26.8 ^(a)Datapresented as mean ± standard error

Example 2: Identification of Proteins Significantly Modulated inVitiligo Patients Treated with Ruxolitinib

Serum samples were collected from individuals enrolled in the studydescribed in Example 1. Once collected, serum samples underwent broadproteomic profiling using OLINK™, which allows analysis of greater than1000 proteins. Samples were separated into groups based on treatmentgroup with topical ruxolitinib. Broad proteomic analysis of serumidentified significantly modulated proteins from baseline to weeks 12and/or 24 within each group. See Tables 1A through 7B. Down-regulatedproteins are proteins whose expression decreased over time, whileup-regulated proteins are proteins whose expression increased over time.Fold change in expression is shown for each protein, which is a ratio ofprotein expression level post-treatment (week 12 or week 24) toexpression level pre-treatment (baseline). Values greater than 1indicate an increase from baseline, whereas values less than 1 indicatea decrease from baseline.

TABLE 1A Significantly modulated proteins in Vehicle at week 12Treatment Week Assay p-value Fold Change Significantly down-regulatedproteins at week 12 Vehicle BID 12 GLB1 0.026 0.82 Vehicle BID 12 CD630.007 0.87 Vehicle BID 12 SERPINA12 0.044 0.87 Vehicle BID 12 WISP-10.010 0.89 Vehicle BID 12 CTSV 0.011 0.90 Vehicle BID 12 SERPINA5 0.0380.92 Vehicle BID 12 ITGAV 0.026 0.92 Vehicle BID 12 CRIM1 0.041 0.93Vehicle BID 12 HSD11B1 0.033 0.93 Vehicle BID 12 FGF-BP1 0.020 0.93Vehicle BID 12 DPP10 0.049 0.94 Vehicle BID 12 LEPR 0.022 0.95 VehicleBID 12 Siglec-9 0.041 0.96 Significantly up-regulated proteins at week12 Vehicle BID 12 TNFSF13B 0.024 1.05 Vehicle BID 12 RAGE 0.041 1.06Vehicle BID 12 CDHR5 0.050 1.06 Vehicle BID 12 Gal-9 0.014 1.07 VehicleBID 12 AMN 0.034 1.07 Vehicle BID 12 PDGFC 0.019 1.07 Vehicle BID 12TRAIL 0.034 1.09 Vehicle BID 12 MAX 0.011 1.09 Vehicle BID 12 FAM19A50.024 1.09 Vehicle BID 12 CST6 0.004 1.10 Vehicle BID 12 IL18 0.035 1.10Vehicle BID 12 TYMP 0.050 1.11 Vehicle BID 12 CDSN 0.013 1.13 VehicleBID 12 MMP-10 0.029 1.14 Vehicle BID 12 CALCA 0.020 1.16 Vehicle BID 12MB 0.045 1.19

TABLE 1B Significantly modulated proteins in Vehicle at week 24 TRT01AWeek Assay wk24probt Wk24FC Proteins significantly down-regulated atweek 24 Vehicle BID 24 TANK 0.005 0.74 Vehicle BID 24 LAG3 0.025 0.93Vehicle BID 24 LEPR 0.011 0.94 Proteins significantly up-regulated atweek 24 Vehicle BID 24 MAX 0.021 1.05 Vehicle BID 24 CSF-1 0.024 1.05Vehicle BID 24 TRAIL 0.013 1.06 Vehicle BID 24 TNFRSF9 0.026 1.06Vehicle BID 24 CD5 0.024 1.06 Vehicle BID 24 FSTL3 0.042 1.06 VehicleBID 24 MRC2 0.021 1.06 Vehicle BID 24 TNFSF13B 0.018 1.06 Vehicle BID 24PILRB 0.049 1.06 Vehicle BID 24 OPG 0.042 1.07 Vehicle BID 24 CD1630.035 1.07 Vehicle BID 24 LRP11 0.048 1.07 Vehicle BID 24 CRHBP 0.0451.07 Vehicle BID 24 LAIR1 0.016 1.07 Vehicle BID 24 VEGFA 0.027 1.07Vehicle BID 24 SIGLEC10 0.004 1.07 Vehicle BID 24 TNF-R1 0.024 1.08Vehicle BID 24 PTN 0.046 1.08 Vehicle BID 24 IGSF3 0.020 1.08 VehicleBID 24 MFGE8 0.010 1.08 Vehicle BID 24 MATN2 0.005 1.08 Vehicle BID 24CCL25 0.039 1.09 Vehicle BID 24 TXNDC5 0.020 1.09 Vehicle BID 24 CST60.029 1.09 Vehicle BID 24 CLSTN2 0.020 1.09 Vehicle BID 24 NECTIN2 0.0091.10 Vehicle BID 24 SCGB3A2 0.020 1.10 Vehicle BID 24 IL18 0.016 1.10Vehicle BID 24 SEZ6L2 0.008 1.10 Vehicle BID 24 FAM19A5 0.036 1.11Vehicle BID 24 MESDC2 0.044 1.11 Vehicle BID 24 SUMF2 0.014 1.11 VehicleBID 24 IL10 0.013 1.12 Vehicle BID 24 PPP1R2 0.045 1.12 Vehicle BID 24DAPP1 0.033 1.12 Vehicle BID 24 DDAH1 0.025 1.12 Vehicle BID 24 CDSN0.016 1.13 Vehicle BID 24 FLI1 0.031 1.13 Vehicle BID 24 REG4 0.026 1.14Vehicle BID 24 DDC 0.006 1.15 Vehicle BID 24 PARK7 0.040 1.15 VehicleBID 24 ICA1 0.024 1.17 Vehicle BID 24 LEP 0.006 1.17 Vehicle BID 24ERBB2IP 0.047 1.18 Vehicle BID 24 BCR 0.008 1.19 Vehicle BID 24 INPPL10.016 1.20 Vehicle BID 24 AGR2 0.046 1.21 Vehicle BID 24 PEBP1 0.0301.21 Vehicle BID 24 MAP4K5 0.037 1.23 Vehicle BID 24 Ep-CAM 0.031 1.27Vehicle BID 24 SIRT2 0.029 1.29 Vehicle BID 24 GCG 0.017 1.34 VehicleBID 24 TSHB 0.031 1.42

TABLE 2A Significantly modulated proteins in 0.15% ruxolitinib QD atweek 12 Treatment Week Assay p-value Fold Change Significantlydown-regulated proteins at week 12 INCB018424 0.15% QD 12 BANK1 0.0100.61 INCB018424 0.15% QD 12 AXIN1 0.005 0.68 INCB018424 0.15% QD 12 EREG0.046 0.69 INCB018424 0.15% QD 12 ST1A1 0.034 0.70 INCB018424 0.15% QD12 FATC1 0.022 0.72 INCB018424 0.15% QD 12 INPPL1 0.019 0.75 INCB0184240.15% QD 12 NEMO 0.047 0.76 INCB018424 0.15% QD 12 TANK 0.035 0.77INCB018424 0.15% QD 12 CDKN1A 0.043 0.79 INCB018424 0.15% QD 12 PPP1R9B0.015 0.79 INCB018424 0.15% QD 12 ZBTB16 0.037 0.80 INCB018424 0.15% QD12 TXLNA 0.030 0.81 INCB018424 0.15% QD 12 MGMT 0.022 0.82 INCB0184240.15% QD 12 BCR 0.044 0.83 INCB018424 0.15% QD 12 GRAP2 0.036 0.83INCB018424 0.15% QD 12 WWP2 0.030 0.85 INCB018424 0.15% QD 12 G-CSF0.030 0.85 INCB018424 0.15% QD 12 ANXA10 0.037 0.85 INCB018424 0.15% QD12 STX6 0.011 0.86 INCB018424 0.15% QD 12 CRX 0.044 0.86 INCB0184240.15% QD 12 IL-20 0.012 0.88 INCB018424 0.15% QD 12 WASF1 0.016 0.89INCB018424 0.15% QD 12 NTF4 0.037 0.90 INCB018424 0.15% QD 12 IL13 0.0220.90 INCB018424 0.15% QD 12 NCR1 0.025 0.91 INCB018424 0.15% QD 12IL-10RA 0.014 0.91 INCB018424 0.15% QD 12 HTRA2 0.023 0.91 INCB0184240.15% QD 12 CTRC 0.028 0.92 INCB018424 0.15% QD 12 DDAH1 0.035 0.93INCB018424 0.15% QD 12 PLXNB2 0.016 0.94 INCB018424 0.15% QD 12 IL1RL20.034 0.94 INCB018424 0.15% QD 12 CLEC4G 0.040 0.94 INCB018424 0.15% QD12 IL-17D 0.013 0.94 INCB018424 0.15% QD 12 CFC1 0.041 0.95 INCB0184240.15% QD 12 FKBP7 0.049 0.95 INCB018424 0.15% QD 12 COL18A1 0.036 0.95INCB018424 0.15% QD 12 CCL14 0.040 0.95 INCB018424 0.15% QD 12 LILRB10.029 0.95 INCB018424 0.15% QD 12 OSMR 0.044 0.96 INCB018424 0.15% QD 12AMBP 0.049 0.97 Significantly up-regulated proteins at week 12INCB018424 0.15% QD 12 Gal-1 0.037 1.05 INCB018424 0.15% QD 12 CLSPN0.047 1.06 INCB018424 0.15% QD 12 CPE 0.049 1.06 INCB018424 0.15% QD 12PVRL4 0.018 1.06 INCB018424 0.15% QD 12 ACP6 0.049 1.06 INCB018424 0.15%QD 12 FR-alpha 0.031 1.06 INCB018424 0.15% QD 12 hK11 0.008 1.07INCB018424 0.15% QD 12 ITGB5 0.017 1.08 INCB018424 0.15% QD 12 FURIN0.031 1.08 INCB018424 0.15% QD 12 hK8 0.014 1.09 INCB018424 0.15% QD 12CLSTN2 0.023 1.10 INCB018424 0.15% QD 12 hK14 0.011 1.10 INCB0184240.15% QD 12 CXL17 0.020 1.11 INCB018424 0.15% QD 12 TFPI-2 0.019 1.11INCB018424 0.15% QD 12 TNFRSF12A 0.019 1.13 INCB018424 0.15% QD 12 MYOC0.028 1.13 INCB018424 0.15% QD 12 ESM-1 0.008 1.13

TABLE 2B Significantly modulated proteins in 0.15% ruxolitinib QD atweek 24 Treatment Week Assay p-value Fold Change Proteins significantlydown-regulated at week 24 INCB018424 0.15% QD 24 PPY 0.033 0.71INCB018424 0.15% QD 24 TANK 0.043 0.76 INCB018424 0.15% QD 24 ANXA100.029 0.82 INCB018424 0.15% QD 24 PRTFDC1 0.021 0.90 INCB018424 0.15% QD24 CDH17 0.021 0.91 INCB018424 0.15% QD 24 FKBP7 0.031 0.92 INCB0184240.15% QD 24 STXBP3 0.044 0.93 INCB018424 0.15% QD 24 CFC1 0.016 0.93INCB018424 0.15% QD 24 SMOC1 0.045 0.94 INCB018424 0.15% QD 24 PRDX30.037 0.95 Proteins significantly up-regulated at week 24 INCB0184240.15% QD 24 ACP6 0.037 1.06 INCB018424 0.15% QD 24 PRSS8 0.030 1.06INCB018424 0.15% QD 24 CDCP1 0.032 1.08 INCB018424 0.15% QD 24 CSTB0.025 1.08 INCB018424 0.15% QD 24 SH2D1A 0.028 1.09 INCB018424 0.15% QD24 FGF-BP1 0.005 1.10 INCB018424 0.15% QD 24 TFPI-2 0.026 1.10INCB018424 0.15% QD 24 HNMT 0.008 1.11 INCB018424 0.15% QD 24 MSLN 0.0151.12 INCB018424 0.15% QD 24 SERPINA9 0.020 1.12 INCB018424 0.15% QD 24t-PA 0.033 1.13 INCB018424 0.15% QD 24 FABP4 0.028 1.13 INCB018424 0.15%QD 24 PTN 0.018 1.14 INCB018424 0.15% QD 24 CGA 0.045 1.19 INCB0184240.15% QD 24 MAGED1 0.014 1.24 INCB018424 0.15% QD 24 IGFBP-1 0.047 1.34INCB018424 0.15% QD 24 FGF-21 0.032 1.42 INCB018424 0.15% QD 24 FGF-210.024 1.44

TABLE 3A Significantly modulated proteins 0.5% ruxolitinib QD at week 12Treatment Week Assay p-value Fold Change Significantly down-regulatedproteins at week 12 INCB018424 0.5% QD 12 CA2 0.043 0.78 INCB018424 0.5%QD 12 GLO1 0.016 0.82 INCB018424 0.5% QD 12 CASP-8 0.010 0.84 INCB0184240.5% QD 12 AARSD1 0.041 0.85 INCB018424 0.5% QD 12 ATG4A 0.041 0.85INCB018424 0.5% QD 12 MMP12 0.017 0.85 INCB018424 0.5% QD 12 TRANCE0.038 0.87 INCB018424 0.5% QD 12 FGF-23 0.019 0.88 INCB018424 0.5% QD 12DFFA 0.040 0.88 INCB018424 0.5% QD 12 KLRD1 0.003 0.88 INCB018424 0.5%QD 12 BACH1 0.029 0.89 INCB018424 0.5% QD 12 BLVRB 0.028 0.89 INCB0184240.5% QD 12 IL2-RA 0.003 0.89 INCB018424 0.5% QD 12 PAPPA 0.023 0.89INCB018424 0.5% QD 12 IL16 0.036 0.90 INCB018424 0.5% QD 12 XCL1 0.0200.90 INCB018424 0.5% QD 12 DRAXIN 0.035 0.90 INCB018424 0.5% QD 12 DCTN20.023 0.90 INCB018424 0.5% QD 12 MAEA 0.008 0.90 INCB018424 0.5% QD 12FCRL6 <<0.00011 0.91 INCB018424 0.5% QD 12 FES 0.045 0.91 INCB0184240.5% QD 12 NCR1 0.016 0.91 INCB018424 0.5% QD 12 FASLG 0.011 0.91INCB018424 0.5% QD 12 IL-18BP 0.046 0.92 INCB018424 0.5% QD 12 NFKBIE0.014 0.92 INCB018424 0.5% QD 12 ZBTB17 0.050 0.92 INCB018424 0.5% QD 12SRPK2 0.033 0.93 INCB018424 0.5% QD 12 IGFBP-2 0.037 0.93 INCB0184240.5% QD 12 GRN 0.028 0.93 INCB018424 0.5% QD 12 TNFSF13B 0.038 0.93INCB018424 0.5% QD 12 BOC 0.050 0.95 Significantly up-regulated proteinsat week 12 INCB018424 0.5% QD 12 IL15 0.023 1.05 INCB018424 0.5% QD 12VAMP5 0.027 1.06 INCB018424 0.5% QD 12 PRSS8 0.015 1.06 INCB018424 0.5%QD 12 PCOLCE 0.028 1.07 INCB018424 0.5% QD 12 CD300LG 0.038 1.07INCB018424 0.5% QD 12 SMOC1 0.027 1.08 INCB018424 0.5% QD 12 CTSF 0.0491.09 INCB018424 0.5% QD 12 PCSK9 0.040 1.09 INCB018424 0.5% QD 12 LPL0.041 1.10 INCB018424 0.5% QD 12 RSPO3 0.023 1.10 INCB018424 0.5% QD 12SUMF2 0.031 1.10 INCB018424 0.5% QD 12 NT-3 0.006 1.11 INCB018424 0.5%QD 12 CST6 0.010 1.12 INCB018424 0.5% QD 12 PTN 0.005 1.13 INCB0184240.5% QD 12 SERPINA9 0.002 1.13 INCB018424 0.5% QD 12 IL6 0.025 1.14INCB018424 0.5% QD 12 CHI3L1 0.045 1.15 INCB018424 0.5% QD 12 SFRP10.003 1.23 INCB018424 0.5% QD 12 CES1 0.021 1.27

TABLE 3B Significantly modulated proteins 0.5% ruxolitinib QD at week 24Treatment Week Assay p-value Fold Change Proteins significantlydown-regulated at week 24 INCB018424 0.5% QD 24 BMP-6 0.009 0.80INCB018424 0.5% QD 24 GHRL 0.024 0.80 INCB018424 0.5% QD 24 TNFRSF6B0.007 0.81 INCB018424 0.5% QD 24 DAPP1 0.006 0.82 INCB018424 0.5% QD 24BCL2L11 0.003 0.83 INCB018424 0.5% QD 24 SPINT2 0.021 0.84 INCB0184240.5% QD 24 CRH 0.027 0.87 INCB018424 0.5% QD 24 DRAXIN 0.026 0.88INCB018424 0.5% QD 24 OPN 0.004 0.89 INCB018424 0.5% QD 24 RASA1 0.0130.89 INCB018424 0.5% QD 24 MMP-3 0.044 0.90 INCB018424 0.5% QD 24 CLSTN20.017 0.90 INCB018424 0.5% QD 24 CD8A 0.047 0.91 INCB018424 0.5% QD 24PDGFC 0.011 0.91 INCB018424 0.5% QD 24 IL2-RA 0.017 0.92 INCB018424 0.5%QD 24 NCR1 0.015 0.92 INCB018424 0.5% QD 24 FLI1 0.046 0.93 INCB0184240.5% QD 24 FCRL6 0.042 0.93 INCB018424 0.5% QD 24 BOC 0.035 0.94INCB018424 0.5% QD 24 LYPD1 0.031 0.94 Proteins significantlyup-regulated at Week 24 INCB018424 0.5% QD 24 QPCT 0.027 1.04 INCB0184240.5% QD 24 ITGAV 0.033 1.04 INCB018424 0.5% QD 24 DPEP1 0.039 1.05INCB018424 0.5% QD 24 FGFR2 0.040 1.05 INCB018424 0.5% QD 24 NCAM1 0.0501.05 INCB018424 0.5% QD 24 ERBB4 0.037 1.06 INCB018424 0.5% QD 24 IGF1R0.045 1.06 INCB018424 0.5% QD 24 DPP4 0.026 1.06 INCB018424 0.5% QD 24TRAIL-R2 0.030 1.06 INCB018424 0.5% QD 24 PAM 0.016 1.06 INCB018424 0.5%QD 24 PEAR1 0.046 1.07 INCB018424 0.5% QD 24 ITGB5 0.015 1.07 INCB0184240.5% QD 24 SIRPB1 0.034 1.07 INCB018424 0.5% QD 24 CCL16 0.033 1.07INCB018424 0.5% QD 24 ASGR1 0.038 1.07 INCB018424 0.5% QD 24 CR2 0.0421.07 INCB018424 0.5% QD 24 CCL14 0.016 1.07 INCB018424 0.5% QD 24 ICOSLG0.044 1.07 INCB018424 0.5% QD 24 TNFRSF19 0.042 1.08 INCB018424 0.5% QD24 Gal-4 0.042 1.08 INCB018424 0.5% QD 24 PLC 0.024 1.08 INCB018424 0.5%QD 24 CRTAC1 0.015 1.09 INCB018424 0.5% QD 24 RELT 0.032 1.09 INCB0184240.5% QD 24 RNF31 0.038 1.09 INCB018424 0.5% QD 24 CD59 0.035 1.09INCB018424 0.5% QD 24 VEGFA 0.046 1.10 INCB018424 0.5% QD 24 CTSF 0.0371.10 INCB018424 0.5% QD 24 FCGR3B 0.008 1.10 INCB018424 0.5% QD 24IGFBP6 0.013 1.10 INCB018424 0.5% QD 24 TGFBI 0.018 1.10 INCB018424 0.5%QD 24 MMP7 0.001 1.11 INCB018424 0.5% QD 24 CD300LG 0.029 1.11INCB018424 0.5% QD 24 COCH 0.037 1.11 INCB018424 0.5% QD 24 SCGB1A10.005 1.12 INCB018424 0.5% QD 24 SCGB3A2 0.018 1.12 INCB018424 0.5% QD24 SCGB3A1 0.001 1.12 INCB018424 0.5% QD 24 EPHA10 0.037 1.12 INCB0184240.5% QD 24 TFPI-2 0.041 1.13 INCB018424 0.5% QD 24 ECE1 0.014 1.13INCB018424 0.5% QD 24 MUC-16 0.031 1.14 INCB018424 0.5% QD 24 SERPINA5<<0.00011 1.16 INCB018424 0.5% QD 24 PTN 0.043 1.16 INCB018424 0.5% QD24 TP53 0.029 1.17 INCB018424 0.5% QD 24 CHI3L1 0.022 1.17 INCB0184240.5% QD 24 ITGAM 0.014 1.17 INCB018424 0.5% QD 24 NRP2 0.035 1.20INCB018424 0.5% QD 24 SNCG 0.006 1.21 INCB018424 0.5% QD 24 LEP 0.0401.24 INCB018424 0.5% QD 24 FGF-21 0.003 1.31 INCB018424 0.5% QD 24FGF-21 0.004 1.33 INCB018424 0.5% QD 24 FGF-21 0.002 1.40

TABLE 4A Significantly modulated proteins 1.5% ruxolitinib QD at week 12Treatment Week Assay p-value Fold Change Significantly down-regulatedproteins at week 12 INCB018424 1.5% QD 12 CCL19 <.0001 0.73 INCB0184241.5% QD 12 NCR1 <.0001 0.79 INCB018424 1.5% QD 12 LAIR-2 <.0001 0.79INCB018424 1.5% QD 12 FASLG <.0001 0.83 INCB018424 1.5% QD 12 TNFRSF9<.0001 0.84 INCB018424 1.5% QD 12 CRTAM <.0001 0.85 INCB018424 1.5% QD12 CD6 <.0001 0.86 INCB018424 1.5% QD 12 DEFB4A 0.032 0.72 INCB0184241.5% QD 12 IGFBP-1 0.028 0.74 INCB018424 1.5% QD 12 CXCL10 <<0.000110.74 INCB018424 1.5% QD 12 GZMH 0.001 0.80 INCB018424 1.5% QD 12 FS0.011 0.80 INCB018424 1.5% QD 12 KIR2DL3 0.025 0.81 INCB018424 1.5% QD12 GZMB 0.005 0.82 INCB018424 1.5% QD 12 IFNL1 0.001 0.82 INCB0184241.5% QD 12 DRAXIN 0.018 0.83 INCB018424 1.5% QD 12 SH2D1A 0.007 0.84INCB018424 1.5% QD 12 IL-12B <0.0001 0.84 INCB018424 1.5% QD 12 CXCL110.041 0.85 INCB018424 1.5% QD 12 KLRD1 <0.0001 0.85 INCB018424 1.5% QD12 CD160 <0.0001 0.85 INCB018424 1.5% QD 12 GZMA <0.0001 0.86 INCB0184241.5% QD 12 FCRL6 0.001 0.86 INCB018424 1.5% QD 12 MCP-4 0.027 0.86INCB018424 1.5% QD 12 IL12 0.001 0.87 INCB018424 1.5% QD 12 XCL1 0.0110.87 INCB018424 1.5% QD 12 ANGPTL4 0.027 0.87 INCB018424 1.5% QD 12CCL21 0.001 0.87 INCB018424 1.5% QD 12 IL6 0.026 0.87 INCB018424 1.5% QD12 MMP12 0.003 0.87 INCB018424 1.5% QD 12 TYMP 0.005 0.87 INCB0184241.5% QD 12 CD5 <0.0001 0.88 INCB018424 1.5% QD 12 CCL18 0.018 0.88INCB018424 1.5% QD 12 ITGB2 <0.0001 0.88 INCB018424 1.5% QD 12 TNFB0.008 0.89 INCB018424 1.5% QD 12 CD8A 0.018 0.89 INCB018424 1.5% QD 12ARTN 0.015 0.89 INCB018424 1.5% QD 12 SIGLEC1 0.004 0.90 INCB018424 1.5%QD 12 IL-15RA 0.034 0.90 INCB018424 1.5% QD 12 CD163 <0.0001 0.90INCB018424 1.5% QD 12 SLAMF1 0.049 0.90 INCB018424 1.5% QD 12 RETN 0.0060.90 INCB018424 1.5% QD 12 TNFSF13B 0.005 0.91 INCB018424 1.5% QD 12CLEC6A 0.036 0.91 INCB018424 1.5% QD 12 PAPPA 0.036 0.91 INCB018424 1.5%QD 12 CLEC10A 0.002 0.91 INCB018424 1.5% QD 12 SELE 0.017 0.92INCB018424 1.5% QD 12 ADAM 8 0.012 0.92 INCB018424 1.5% QD 12 GDF-150.025 0.92 INCB018424 1.5% QD 12 IL-1RT1 0.007 0.92 INCB018424 1.5% QD12 CD244 0.015 0.92 INCB018424 1.5% QD 12 CLM-1 0.009 0.93 INCB0184241.5% QD 12 DSC2 0.006 0.93 INCB018424 1.5% QD 12 FOLR2 0.001 0.93INCB018424 1.5% QD 12 TNF-R2 0.019 0.93 INCB018424 1.5% QD 12 LIF-R0.014 0.93 INCB018424 1.5% QD 12 IL12RB1 0.017 0.93 INCB018424 1.5% QD12 CDH3 0.032 0.93 INCB018424 1.5% QD 12 CLEC4G 0.020 0.93 INCB0184241.5% QD 12 CD79B 0.037 0.93 INCB018424 1.5% QD 12 IL-18BP 0.028 0.93INCB018424 1.5% QD 12 GM-CSF- 0.026 0.94 R-alpha INCB018424 1.5% QD 12CD1C 0.005 0.94 INCB018424 1.5% QD 12 ST2 0.034 0.94 INCB018424 1.5% QD12 MSR1 0.015 0.94 INCB018424 1.5% QD 12 PDCD1 0.022 0.94 INCB0184241.5% QD 12 CSF-1 0.046 0.94 INCB018424 1.5% QD 12 FcRL2 0.016 0.94INCB018424 1.5% QD 12 LY9 0.032 0.95 INCB018424 1.5% QD 12 CD27 0.0260.95 INCB018424 1.5% QD 12 CD48 0.024 0.95 INCB018424 1.5% QD 12 CD200R10.013 0.95 INCB018424 1.5% QD 12 hOSCAR 0.030 0.96 Significantlyup-regulated proteins at week 12 INCB018424 1.5% QD 12 CD300LG <.00011.10 INCB018424 1.5% QD 12 hK11 <.0001 1.11 INCB018424 1.5% QD 12 IL15<.0001 1.12 INCB018424 1.5% QD 12 KLK10 <.0001 1.12 INCB018424 1.5% QD12 FGF-BP1 <.0001 1.23 INCB018424 1.5% QD 12 MYOC <.0001 1.29 INCB0184241.5% QD 12 GPNMB 0.035 1.04 INCB018424 1.5% QD 12 CAMKK1 0.028 1.04INCB018424 1.5% QD 12 ITGB1 0.012 1.04 INCB018424 1.5% QD 12 PDGFRB0.013 1.04 INCB018424 1.5% QD 12 TYRO3 0.030 1.04 INCB018424 1.5% QD 12B4GAT1 0.035 1.05 INCB018424 1.5% QD 12 CLEC4A 0.017 1.05 INCB0184241.5% QD 12 GFRA2 0.026 1.05 INCB018424 1.5% QD 12 ENTPD6 0.021 1.05INCB018424 1.5% QD 12 SPON2 0.005 1.05 INCB018424 1.5% QD 12 TCL1B 0.0481.05 INCB018424 1.5% QD 12 GALNT2 0.042 1.06 INCB018424 1.5% QD 12CRISP2 0.042 1.06 INCB018424 1.5% QD 12 CA14 0.034 1.06 INCB018424 1.5%QD 12 IGF2R 0.038 1.06 INCB018424 1.5% QD 12 MRC2 0.015 1.06 INCB0184241.5% QD 12 CD200 0.025 1.06 INCB018424 1.5% QD 12 LRRN1 0.023 1.06INCB018424 1.5% QD 12 TCN2 0.034 1.06 INCB018424 1.5% QD 12 DPP4 0.0101.06 INCB018424 1.5% QD 12 ESAM 0.031 1.07 INCB018424 1.5% QD 12 SCGB3A10.039 1.07 INCB018424 1.5% QD 12 AOC3 0.016 1.07 INCB018424 1.5% QD 12BCAM 0.003 1.07 INCB018424 1.5% QD 12 WFIKKN2 0.003 1.07 INCB018424 1.5%QD 12 IGSF3 0.029 1.07 INCB018424 1.5% QD 12 ENTPD6 0.012 1.07INCB018424 1.5% QD 12 SMAD1 0.043 1.07 INCB018424 1.5% QD 12 SAA4 0.0271.07 INCB018424 1.5% QD 12 ANG-1 0.027 1.07 INCB018424 1.5% QD 12 SEZ6L20.024 1.07 INCB018424 1.5% QD 12 APOM 0.005 1.07 INCB018424 1.5% QD 12IGFBPL1 0.016 1.07 INCB018424 1.5% QD 12 ITGB5 0.006 1.07 INCB0184241.5% QD 12 CPXM1 0.004 1.07 INCB018424 1.5% QD 12 METRNL 0.002 1.07INCB018424 1.5% QD 12 ENAH 0.020 1.08 INCB018424 1.5% QD 12 LRP11 0.0171.08 INCB018424 1.5% QD 12 SOD2 0.020 1.08 INCB018424 1.5% QD 12 DCBLD20.049 1.08 INCB018424 1.5% QD 12 VEGFA 0.040 1.08 INCB018424 1.5% QD 12MFAP5 0.045 1.08 INCB018424 1.5% QD 12 MCFD2 0.020 1.08 INCB018424 1.5%QD 12 RAGE 0.003 1.08 INCB018424 1.5% QD 12 KLK6 0.033 1.08 INCB0184241.5% QD 12 SPINK5 0.002 1.08 INCB018424 1.5% QD 12 NCAM1 0.003 1.08INCB018424 1.5% QD 12 FR-alpha 0.008 1.08 INCB018424 1.5% QD 12 CLUL10.006 1.08 INCB018424 1.5% QD 12 CXCL16 0.011 1.08 INCB018424 1.5% QD 12TACSTD2 <0.0001 1.08 INCB018424 1.5% QD 12 ENTPD2 0.035 1.09 INCB0184241.5% QD 12 VEGFC 0.005 1.09 INCB018424 1.5% QD 12 CNTN2 0.022 1.09INCB018424 1.5% QD 12 PAI 0.050 1.09 INCB018424 1.5% QD 12 GPC1 0.0051.09 INCB018424 1.5% QD 12 Flt3L 0.027 1.09 INCB018424 1.5% QD 12 DKK30.002 1.09 INCB018424 1.5% QD 12 VEGFD 0.007 1.09 INCB018424 1.5% QD 12hK14 0.011 1.09 INCB018424 1.5% QD 12 APP 0.018 1.09 INCB018424 1.5% QD12 ISLR2 0.030 1.09 INCB018424 1.5% QD 12 PVRL4 0.002 1.10 INCB0184241.5% QD 12 DDC 0.039 1.10 INCB018424 1.5% QD 12 SCGB3A2 <0.0001 1.10INCB018424 1.5% QD 12 CLMP 0.006 1.10 INCB018424 1.5% QD 12 REG4 0.0301.10 INCB018424 1.5% QD 12 KAZALD1 0.003 1.10 INCB018424 1.5% QD 12 DPP70.042 1.10 INCB018424 1.5% QD 12 ANGPTL7 0.001 1.10 INCB018424 1.5% QD12 CD46 0.043 1.10 INCB018424 1.5% QD 12 TIMP1 0.001 1.11 INCB0184241.5% QD 12 COCH 0.015 1.11 INCB018424 1.5% QD 12 ROR1 0.004 1.11INCB018424 1.5% QD 12 FAM3B 0.020 1.11 INCB018424 1.5% QD 12 IL7R 0.0421.11 INCB018424 1.5% QD 12 CXCL5 0.048 1.11 INCB018424 1.5% QD 12 PROC<0.0001 1.11 INCB018424 1.5% QD 12 IGFBP6 0.001 1.11 INCB018424 1.5% QD12 CYR61 0.021 1.11 INCB018424 1.5% QD 12 PAM <0.0001 1.11 INCB0184241.5% QD 12 MSLN <0.0001 1.11 INCB018424 1.5% QD 12 SYND1 0.038 1.11INCB018424 1.5% QD 12 CCL11 0.017 1.12 INCB018424 1.5% QD 12 CA6 0.0061.12 INCB018424 1.5% QD 12 KLK13 0.012 1.12 INCB018424 1.5% QD 12 CLSTN20.047 1.12 INCB018424 1.5% QD 12 MMP-3 0.022 1.12 INCB018424 1.5% QD 12COMP 0.006 1.12 INCB018424 1.5% QD 12 DPP6 0.017 1.12 INCB018424 1.5% QD12 MMP-1 0.001 1.12 INCB018424 1.5% QD 12 ST6GAL1 0.002 1.12 INCB0184241.5% QD 12 SOST 0.002 1.12 INCB018424 1.5% QD 12 ANGPTL3 0.001 1.12INCB018424 1.5% QD 12 CST6 0.038 1.13 INCB018424 1.5% QD 12 DSG4 <0.00011.13 INCB018424 1.5% QD 12 CXCL1 0.013 1.13 INCB018424 1.5% QD 12 FAM3C0.007 1.13 INCB018424 1.5% QD 12 NID1 0.011 1.13 INCB018424 1.5% QD 12PLTP 0.003 1.13 INCB018424 1.5% QD 12 CPE 0.007 1.13 INCB018424 1.5% QD12 MOG 0.001 1.14 INCB018424 1.5% QD 12 CA4 0.010 1.14 INCB018424 1.5%QD 12 SERPINA9 0.003 1.15 INCB018424 1.5% QD 12 LEP 0.025 1.15INCB018424 1.5% QD 12 CRTAC1 <0.0001 1.15 INCB018424 1.5% QD 12 F110.029 1.17 INCB018424 1.5% QD 12 APLP1 0.040 1.17 INCB018424 1.5% QD 12hK8 <0.0001 1.18 INCB018424 1.5% QD 12 MAP4K5 0.049 1.20 INCB018424 1.5%QD 12 CES2 0.047 1.23 INCB018424 1.5% QD 12 GAL 0.001 1.24 INCB0184241.5% QD 12 CEACAM5 0.003 1.25 INCB018424 1.5% QD 12 EPO 0.021 1.25INCB018424 1.5% QD 12 CCL5 0.010 1.28 INCB018424 1.5% QD 12 OMG 0.0101.28

TABLE 4B Significantly modulated proteins 1.5% ruxolitinib QD at week 24Treatment Week Assay p-value Fold Change Proteins significantlydown-regulated at Week 24 INCB018424 1.5% QD 24 CXCL10 0.002 0.70INCB018424 1.5% QD 24 CCL19 <0.0001 0.70 INCB018424 1.5% QD 24 DEFB4A0.008 0.74 INCB018424 1.5% QD 24 CXCL11 0.005 0.76 INCB018424 1.5% QD 24DRAXIN 0.011 0.76 INCB018424 1.5% QD 24 XCL1 0.016 0.76 INCB018424 1.5%QD 24 LAIR-2 <.0001 0.76 INCB018424 1.5% QD 24 GZMH 0.002 0.77INCB018424 1.5% QD 24 TRANCE 0.013 0.78 INCB018424 1.5% QD 24 CD8A 0.0050.78 INCB018424 1.5% QD 24 CD160 <.0001 0.78 INCB018424 1.5% QD 24 GZMB0.013 0.79 INCB018424 1.5% QD 24 TNFRSF6B 0.045 0.79 INCB018424 1.5% QD24 IL5 0.037 0.79 INCB018424 1.5% QD 24 FASLG <.0001 0.79 INCB0184241.5% QD 24 TNFRSF9 <0.0001 0.79 INCB018424 1.5% QD 24 CRTAM <.0001 0.80INCB018424 1.5% QD 24 IL12 <0.0001 0.80 INCB018424 1.5% QD 24 IL-12B<.0001 0.81 INCB018424 1.5% QD 24 KLRD1 0.001 0.81 INCB018424 1.5% QD 24NCR1 <0.0001 0.81 INCB018424 1.5% QD 24 FCRL6 0.001 0.81 INCB018424 1.5%QD 24 GZMA <0.0001 0.82 INCB018424 1.5% QD 24 IL2-RA 0.001 0.82INCB018424 1.5% QD 24 CD6 0.001 0.82 INCB018424 1.5% QD 24 MCP-4 0.0020.83 INCB018424 1.5% QD 24 SH2D1A 0.006 0.83 INCB018424 1.5% QD 24 CRH0.046 0.84 INCB018424 1.5% QD 24 CD5 <0.0001 0.84 INCB018424 1.5% QD 24MBL2 0.040 0.84 INCB018424 1.5% QD 24 TNFB 0.001 0.85 INCB018424 1.5% QD24 IL10 0.027 0.85 INCB018424 1.5% QD 24 CCL18 0.017 0.85 INCB0184241.5% QD 24 PTH1R 0.029 0.86 INCB018424 1.5% QD 24 IL6 0.044 0.86INCB018424 1.5% QD 24 MMP12 0.021 0.86 INCB018424 1.5% QD 24 PTX3 0.0410.87 INCB018424 1.5% QD 24 PAPPA 0.001 0.87 INCB018424 1.5% QD 24 IL100.042 0.87 INCB018424 1.5% QD 24 SIGLEC1 0.008 0.87 INCB018424 1.5% QD24 sFRP-3 0.024 0.88 INCB018424 1.5% QD 24 IL-15RA 0.045 0.88 INCB0184241.5% QD 24 CCL23 0.030 0.88 INCB018424 1.5% QD 24 ADAM 8 0.001 0.88INCB018424 1.5% QD 24 SLAMF1 0.018 0.89 INCB018424 1.5% QD 24 TNFRSF40.012 0.89 INCB018424 1.5% QD 24 ESM-1 0.028 0.89 INCB018424 1.5% QD 24CLM-1 0.001 0.89 INCB018424 1.5% QD 24 CDH3 0.002 0.89 INCB018424 1.5%QD 24 CLEC4C 0.004 0.89 INCB018424 1.5% QD 24 CCL21 0.024 0.89INCB018424 1.5% QD 24 PON2 0.027 0.89 INCB018424 1.5% QD 24 TNC 0.0360.89 INCB018424 1.5% QD 24 IL12RB1 0.019 0.89 INCB018424 1.5% QD 24FcRL2 0.004 0.90 INCB018424 1.5% QD 24 CD48 <0.0001 0.90 INCB018424 1.5%QD 24 COL4A3BP 0.010 0.90 INCB018424 1.5% QD 24 CD27 0.001 0.90INCB018424 1.5% QD 24 CD1C 0.001 0.90 INCB018424 1.5% QD 24 CD79B 0.0420.90 INCB018424 1.5% QD 24 GM-CSF-R- 0.014 0.90 alpha INCB018424 1.5% QD24 PDCD1 0.009 0.91 INCB018424 1.5% QD 24 CD83 0.011 0.91 INCB0184241.5% QD 24 CLEC10A 0.006 0.91 INCB018424 1.5% QD 24 IL-1RT1 0.026 0.91INCB018424 1.5% QD 24 CD244 0.012 0.91 INCB018424 1.5% QD 24 LY9 <0.00010.91 INCB018424 1.5% QD 24 FCRL1 0.042 0.92 INCB018424 1.5% QD 24 PD-L10.022 0.92 INCB018424 1.5% QD 24 IL17RB 0.040 0.92 INCB018424 1.5% QD 24TNFRSF13B 0.018 0.92 INCB018424 1.5% QD 24 CLEC7A 0.040 0.92 INCB0184241.5% QD 24 LIF-R 0.031 0.92 INCB018424 1.5% QD 24 SIRT5 0.029 0.93INCB018424 1.5% QD 24 IFNLR1 0.043 0.93 INCB018424 1.5% QD 24 CD200R10.026 0.93 INCB018424 1.5% QD 24 IL-5R-alpha 0.015 0.93 INCB018424 1.5%QD 24 PDGF-R- 0.009 0.93 alpha INCB018424 1.5% QD 24 TNF-R2 0.031 0.93INCB018424 1.5% QD 24 TM 0.021 0.93 INCB018424 1.5% QD 24 WFIKKN1 0.0420.93 INCB018424 1.5% QD 24 CSF-1 0.024 0.94 INCB018424 1.5% QD 24 EFNA40.006 0.94 INCB018424 1.5% QD 24 CLM-6 0.010 0.94 INCB018424 1.5% QD 24N2DL-2 0.038 0.94 INCB018424 1.5% QD 24 GFR-alpha-1 0.033 0.95INCB018424 1.5% QD 24 THBS2 0.011 0.95 INCB018424 1.5% QD 24 LY75 0.0440.95 INCB018424 1.5% QD 24 NBL1 0.040 0.97 Proteins significantlyup-regulated at week 24 INCB018424 1.5% QD 24 TACSTD2 0.035 1.04INCB018424 1.5% QD 24 GALNT2 0.034 1.05 INCB018424 1.5% QD 24 EGFR 0.0421.05 INCB018424 1.5% QD 24 BAMBI 0.040 1.05 INCB018424 1.5% QD 24 AOC30.038 1.06 INCB018424 1.5% QD 24 CNDP1 0.047 1.06 INCB018424 1.5% QD 24ITGB5 0.010 1.06 INCB018424 1.5% QD 24 CLEC4A 0.022 1.07 INCB018424 1.5%QD 24 ST6GAL1 0.025 1.07 INCB018424 1.5% QD 24 MEP1B 0.002 1.07INCB018424 1.5% QD 24 CNTN1 0.032 1.07 INCB018424 1.5% QD 24 B4GAT10.031 1.07 INCB018424 1.5% QD 24 CA4 0.048 1.07 INCB018424 1.5% QD 24KIT 0.008 1.07 INCB018424 1.5% QD 24 TIMP1 0.028 1.08 INCB018424 1.5% QD24 DPP4 0.009 1.08 INCB018424 1.5% QD 24 CD300LG 0.016 1.08 INCB0184241.5% QD 24 Flt3L 0.038 1.08 INCB018424 1.5% QD 24 NCAM1 0.006 1.08INCB018424 1.5% QD 24 DPP6 0.031 1.08 INCB018424 1.5% QD 24 ADGRG2 0.0071.08 INCB018424 1.5% QD 24 DKK3 0.028 1.09 INCB018424 1.5% QD 24 SPINK50.002 1.09 INCB018424 1.5% QD 24 TF 0.040 1.09 INCB018424 1.5% QD 24 BLM0.047 1.09 hydrolase INCB018424 1.5% QD 24 VEGFD 0.016 1.09 INCB0184241.5% QD 24 IGF2R 0.006 1.09 INCB018424 1.5% QD 24 ISLR2 0.041 1.09INCB018424 1.5% QD 24 WFIKKN2 0.019 1.09 INCB018424 1.5% QD 24 KLK60.006 1.09 INCB018424 1.5% QD 24 PAI 0.006 1.10 INCB018424 1.5% QD 24CXCL5 0.021 1.10 INCB018424 1.5% QD 24 PROC 0.003 1.10 INCB018424 1.5%QD 24 CLMP 0.035 1.10 INCB018424 1.5% QD 24 KLK10 0.007 1.10 INCB0184241.5% QD 24 ITGB1 0.036 1.10 INCB018424 1.5% QD 24 TGFBI 0.004 1.10INCB018424 1.5% QD 24 MOG 0.024 1.10 INCB018424 1.5% QD 24 PDGF 0.0171.11 subunit A INCB018424 1.5% QD 24 hK8 0.031 1.11 INCB018424 1.5% QD24 EDIL3 0.036 1.11 INCB018424 1.5% QD 24 CA6 0.020 1.11 INCB018424 1.5%QD 24 BCAM 0.048 1.11 INCB018424 1.5% QD 24 KLK13 0.023 1.11 INCB0184241.5% QD 24 COCH 0.010 1.11 INCB018424 1.5% QD 24 CRTAC1 0.023 1.12INCB018424 1.5% QD 24 MMP-1 0.003 1.12 INCB018424 1.5% QD 24 CA3 0.0401.12 INCB018424 1.5% QD 24 IGFBP6 <.0001 1.12 INCB018424 1.5% QD 24 MB0.032 1.13 INCB018424 1.5% QD 24 KYAT1 0.042 1.13 INCB018424 1.5% QD 24CXCL16 <.0001 1.13 INCB018424 1.5% QD 24 SNCG 0.034 1.13 INCB018424 1.5%QD 24 SPINK1 0.006 1.14 INCB018424 1.5% QD 24 SCGB3A2 0.010 1.14INCB018424 1.5% QD 24 IL15 <0.0001 1.14 INCB018424 1.5% QD 24 Gal-40.018 1.15 INCB018424 1.5% QD 24 DDC 0.009 1.16 INCB018424 1.5% QD 24MMP-3 0.015 1.16 INCB018424 1.5% QD 24 LGALS7 0.006 1.16 INCB018424 1.5%QD 24 PLIN1 0.018 1.17 INCB018424 1.5% QD 24 TIMP4 0.023 1.17 INCB0184241.5% QD 24 PCSK9 0.001 1.17 INCB018424 1.5% QD 24 F11 0.018 1.17INCB018424 1.5% QD 24 FAM3C 0.001 1.18 INCB018424 1.5% QD 24 FGF-BP1<.0001 1.19 INCB018424 1.5% QD 24 CES2 0.040 1.19 INCB018424 1.5% QD 24CES1 0.026 1.22 INCB018424 1.5% QD 24 P4HB 0.015 1.22 INCB018424 1.5% QD24 LEP 0.014 1.23 INCB018424 1.5% QD 24 TMPRSS15 0.025 1.24 INCB0184241.5% QD 24 Ep-CAM 0.010 1.26 INCB018424 1.5% QD 24 FABP4 0.001 1.28

TABLE 5A Significantly modulated proteins 1.5% ruxolitinib BID at week12 Treatment Week Assay p-value Fold Change Significantly down-regulatedproteins at week 12 INCB018424 1.5% BID 12 FASLG <.0001 0.78 INCB0184241.5% BID 12 TRANCE <.0001 0.78 INCB018424 1.5% BID 12 CD160 <.0001 0.79INCB018424 1.5% BID 12 FCRL6 <.0001 0.79 INCB018424 1.5% BID 12 TNFB<.0001 0.82 INCB018424 1.5% BID 12 TNFRSF9 <.0001 0.84 INCB018424 1.5%BID 12 ITGB2 <.0001 0.85 INCB018424 1.5% BID 12 TIMD4 <.0001 0.86INCB018424 1.5% BID 12 CD5 <.0001 0.88 INCB018424 1.5% BID 12 RNASE30.024 0.73 INCB018424 1.5% BID 12 CCL19 <0.0001 0.75 INCB018424 1.5% BID12 MCP-4 0.002 0.78 INCB018424 1.5% BID 12 CXCL9 <0.0001 0.78 INCB0184241.5% BID 12 CCL18 0.002 0.79 INCB018424 1.5% BID 12 CRH 0.007 0.79INCB018424 1.5% BID 12 KLRD1 <0.0001 0.81 INCB018424 1.5% BID 12 CXCL100.044 0.82 INCB018424 1.5% BID 12 LAIR-2 <0.0001 0.83 INCB018424 1.5%BID 12 NCR1 <0.0001 0.84 INCB018424 1.5% BID 12 IL2-RA <0.0001 0.84INCB018424 1.5% BID 12 IL-12B 0.001 0.85 INCB018424 1.5% BID 12 XCL1<0.0001 0.85 INCB018424 1.5% BID 12 TCL1B 0.024 0.85 INCB018424 1.5% BID12 CA5A 0.028 0.86 INCB018424 1.5% BID 12 DRAXIN 0.003 0.86 INCB0184241.5% BID 12 TNFRSF6B 0.004 0.86 INCB018424 1.5% BID 12 CHIT1 0.013 0.87INCB018424 1.5% BID 12 TGF-alpha 0.025 0.87 INCB018424 1.5% BID 12 CD6<0.0001 0.87 INCB018424 1.5% BID 12 OSM 0.043 0.87 INCB018424 1.5% BID12 CD1C <0.001 0.87 INCB018424 1.5% BID 12 CRTAM 0.001 0.87 INCB0184241.5% BID 12 PRTN3 0.021 0.88 INCB018424 1.5% BID 12 MBL2 0.002 0.88INCB018424 1.5% BID 12 KIR2DL3 0.001 0.88 INCB018424 1.5% BID 12 IL50.006 0.88 INCB018424 1.5% BID 12 TNFSF13B <0.0001 0.88 INCB018424 1.5%BID 12 ADAM 8 <0.0001 0.88 INCB018424 1.5% BID 12 GZMB 0.045 0.89INCB018424 1.5% BID 12 CCL21 0.001 0.89 INCB018424 1.5% BID 12 MMP120.041 0.89 INCB018424 1.5% BID 12 PAPPA 0.009 0.89 INCB018424 1.5% BID12 CLEC4D 0.039 0.89 INCB018424 1.5% BID 12 IFNL1 0.007 0.89 INCB0184241.5% BID 12 COL1A1 0.001 0.89 INCB018424 1.5% BID 12 CLEC4C 0.026 0.89INCB018424 1.5% BID 12 LIF 0.020 0.90 INCB018424 1.5% BID 12 IL-2RB0.033 0.90 INCB018424 1.5% BID 12 NOV 0.005 0.90 INCB018424 1.5% BID 12IL12 0.030 0.90 INCB018424 1.5% BID 12 TNC 0.044 0.90 INCB018424 1.5%BID 12 VSTM1 0.002 0.91 INCB018424 1.5% BID 12 DSC2 0.002 0.91INCB018424 1.5% BID 12 WISP-1 0.002 0.91 INCB018424 1.5% BID 12TNFRSF10C 0.015 0.91 INCB018424 1.5% BID 12 CD163 0.003 0.92 INCB0184241.5% BID 12 IL3RA 0.010 0.92 INCB018424 1.5% BID 12 PGLYRP1 0.040 0.92INCB018424 1.5% BID 12 RETN 0.021 0.92 INCB018424 1.5% BID 12 ICAM30.001 0.92 INCB018424 1.5% BID 12 ICAM1 0.003 0.92 INCB018424 1.5% BID12 FCRL5 0.005 0.92 INCB018424 1.5% BID 12 IL-18BP 0.008 0.92 INCB0184241.5% BID 12 IL-1RT1 0.004 0.92 INCB018424 1.5% BID 12 CLEC7A 0.004 0.92INCB018424 1.5% BID 12 VCAM1 0.002 0.92 INCB018424 1.5% BID 12 SLAMF80.024 0.92 INCB018424 1.5% BID 12 CDON 0.011 0.92 INCB018424 1.5% BID 12FCER2 0.006 0.93 INCB018424 1.5% BID 12 SELL 0.013 0.93 INCB018424 1.5%BID 12 PON2 0.029 0.93 INCB018424 1.5% BID 12 CD244 0.006 0.93INCB018424 1.5% BID 12 CD48 0.003 0.93 INCB018424 1.5% BID 12 TNF-R20.028 0.94 INCB018424 1.5% BID 12 CD209 0.023 0.94 INCB018424 1.5% BID12 IL-10RB 0.010 0.94 INCB018424 1.5% BID 12 ARTN 0.028 0.94 INCB0184241.5% BID 12 LAIR1 0.022 0.94 INCB018424 1.5% BID 12 TNF-R1 0.037 0.94INCB018424 1.5% BID 12 KIRREL2 0.027 0.94 INCB018424 1.5% BID 12 FCRL10.004 0.94 INCB018424 1.5% BID 12 LY9 0.044 0.95 INCB018424 1.5% BID 12MILR1 0.049 0.95 INCB018424 1.5% BID 12 CD79B 0.015 0.95 INCB018424 1.5%BID 12 CD27 0.034 0.95 INCB018424 1.5% BID 12 hOSCAR 0.006 0.96INCB018424 1.5% BID 12 HAVCR2 0.017 0.96 INCB018424 1.5% BID 12 KPNA10.029 0.96 INCB018424 1.5% BID 12 TGFR-2 0.036 0.96 Significantlyup-regulated proteins at week 12 INCB018424 1.5% BID 12 NTRK3 <.00011.10 INCB018424 1.5% BID 12 TF <.0001 1.12 INCB018424 1.5% BID 12 KLK13<.0001 1.14 INCB018424 1.5% BID 12 FGF-BP1 <.0001 1.27 INCB018424 1.5%BID 12 EPO <.0001 1.59 INCB018424 1.5% BID 12 Gal-1 0.012 1.04INCB018424 1.5% BID 12 ITGAV 0.035 1.04 INCB018424 1.5% BID 12 ERBB30.016 1.04 INCB018424 1.5% BID 12 ITGB1 0.038 1.05 INCB018424 1.5% BID12 CLEC14A 0.044 1.05 INCB018424 1.5% BID 12 GALNT2 0.027 1.05INCB018424 1.5% BID 12 ERBB4 0.008 1.05 INCB018424 1.5% BID 12 Nr-CAM0.005 1.05 INCB018424 1.5% BID 12 CRISP2 0.048 1.05 INCB018424 1.5% BID12 ENTPD6 0.019 1.05 INCB018424 1.5% BID 12 NTRK2 0.010 1.05 INCB0184241.5% BID 12 EDA2R 0.028 1.05 INCB018424 1.5% BID 12 LTBP2 0.045 1.05INCB018424 1.5% BID 12 CD300LG 0.029 1.05 INCB018424 1.5% BID 12 DKKL10.007 1.05 INCB018424 1.5% BID 12 CD58 0.004 1.06 INCB018424 1.5% BID 12Gal-3 0.035 1.06 INCB018424 1.5% BID 12 DPP4 0.022 1.06 INCB018424 1.5%BID 12 AOC3 0.031 1.06 INCB018424 1.5% BID 12 GDNFR-alpha-3 0.013 1.06INCB018424 1.5% BID 12 FABP9 0.029 1.06 INCB018424 1.5% BID 12Alpha-2-MRAP 0.045 1.06 INCB018424 1.5% BID 12 PRELP 0.008 1.06INCB018424 1.5% BID 12 DPEP1 0.019 1.06 INCB018424 1.5% BID 12 hK110.008 1.06 INCB018424 1.5% BID 12 DCBLD2 0.042 1.06 INCB018424 1.5% BID12 ANGPTL7 0.035 1.06 INCB018424 1.5% BID 12 MMP7 0.025 1.06 INCB0184241.5% BID 12 SCARB2 0.032 1.06 INCB018424 1.5% BID 12 B4GAT1 0.011 1.06INCB018424 1.5% BID 12 ITGB5 0.010 1.06 INCB018424 1.5% BID 12 BAMBI0.047 1.06 INCB018424 1.5% BID 12 SPINK5 0.001 1.06 INCB018424 1.5% BID12 ACAN 0.010 1.06 INCB018424 1.5% BID 12 TACSTD2 0.002 1.06 INCB0184241.5% BID 12 DCN 0.002 1.07 INCB018424 1.5% BID 12 PEAR1 0.017 1.07INCB018424 1.5% BID 12 PODXL2 0.011 1.07 INCB018424 1.5% BID 12 VWC20.025 1.07 INCB018424 1.5% BID 12 BLM hydrolase 0.008 1.07 INCB0184241.5% BID 12 CCL25 0.028 1.07 INCB018424 1.5% BID 12 VEGFD 0.029 1.07INCB018424 1.5% BID 12 FAM3C 0.024 1.07 INCB018424 1.5% BID 12 SCARF20.011 1.07 INCB018424 1.5% BID 12 CLUL1 0.009 1.07 INCB018424 1.5% BID12 EZR 0.008 1.07 INCB018424 1.5% BID 12 OPTC 0.007 1.07 INCB018424 1.5%BID 12 SOD2 0.003 1.07 INCB018424 1.5% BID 12 EPHB6 0.015 1.07INCB018424 1.5% BID 12 PVR 0.002 1.07 INCB018424 1.5% BID 12 DPP10 0.0171.07 INCB018424 1.5% BID 12 PRTG 0.002 1.08 INCB018424 1.5% BID 12TMPRSS5 0.004 1.08 INCB018424 1.5% BID 12 CPE 0.012 1.08 INCB018424 1.5%BID 12 CD70 0.035 1.08 INCB018424 1.5% BID 12 hK8 0.023 1.08 INCB0184241.5% BID 12 CXCL16 0.004 1.08 INCB018424 1.5% BID 12 THPO 0.026 1.08INCB018424 1.5% BID 12 KIM1 0.038 1.08 INCB018424 1.5% BID 12 GPC1 0.0021.08 INCB018424 1.5% BID 12 VEGFD 0.003 1.08 INCB018424 1.5% BID 12ROBO2 0.003 1.08 INCB018424 1.5% BID 12 DKK3 0.036 1.08 INCB018424 1.5%BID 12 CLEC4A 0.009 1.08 INCB018424 1.5% BID 12 CDNF 0.014 1.09INCB018424 1.5% BID 12 SPOCK1 0.012 1.09 INCB018424 1.5% BID 12 ST3GAL10.022 1.09 INCB018424 1.5% BID 12 CNTN5 0.001 1.09 INCB018424 1.5% BID12 GCP5 0.032 1.09 INCB018424 1.5% BID 12 GP1BA 0.032 1.09 INCB0184241.5% BID 12 KLK6 0.018 1.09 INCB018424 1.5% BID 12 hK14 0.011 1.09INCB018424 1.5% BID 12 RGMB 0.001 1.09 INCB018424 1.5% BID 12 LGALS70.025 1.09 INCB018424 1.5% BID 12 RAGE 0.003 1.10 INCB018424 1.5% BID 12KLK10 0.003 1.10 INCB018424 1.5% BID 12 FUT8 0.041 1.10 INCB018424 1.5%BID 12 FAM3B 0.011 1.10 INCB018424 1.5% BID 12 CXADR 0.038 1.10INCB018424 1.5% BID 12 CD200 <0.0001 1.10 INCB018424 1.5% BID 12 MATN30.013 1.10 INCB018424 1.5% BID 12 SCF 0.001 1.10 INCB018424 1.5% BID 12SCF <0.0001 1.10 INCB018424 1.5% BID 12 NCAN <0.0001 1.10 INCB0184241.5% BID 12 GDF-2 0.016 1.10 INCB018424 1.5% BID 12 TFPI-2 0.001 1.10INCB018424 1.5% BID 12 CAIX 0.037 1.10 INCB018424 1.5% BID 12 WFIKKN2<0.0001 1.10 INCB018424 1.5% BID 12 RGMA <0.0001 1.10 INCB018424 1.5%BID 12 SFRP1 0.042 1.11 INCB018424 1.5% BID 12 NPTXR 0.001 1.11INCB018424 1.5% BID 12 PHOSPHO1 0.005 1.11 INCB018424 1.5% BID 12 STX60.018 1.11 INCB018424 1.5% BID 12 CA6 0.005 1.11 INCB018424 1.5% BID 12PON3 0.003 1.11 INCB018424 1.5% BID 12 gal-8 0.003 1.11 INCB018424 1.5%BID 12 NCAM1 <0.0001 1.12 INCB018424 1.5% BID 12 CADM3 0.001 1.12INCB018424 1.5% BID 12 CX3CL1 0.009 1.12 INCB018424 1.5% BID 12 SCF<0.0001 1.12 INCB018424 1.5% BID 12 PADI2 0.025 1.12 INCB018424 1.5% BID12 PREB 0.039 1.12 INCB018424 1.5% BID 12 DDC 0.004 1.12 INCB018424 1.5%BID 12 MDGA1 <0.0001 1.13 INCB018424 1.5% BID 12 SCGB1A1 0.004 1.13INCB018424 1.5% BID 12 IL-17A 0.035 1.13 INCB018424 1.5% BID 12 SCGB3A20.037 1.13 INCB018424 1.5% BID 12 NEFL 0.005 1.13 INCB018424 1.5% BID 12GIF 0.014 1.13 INCB018424 1.5% BID 12 TN-R 0.001 1.13 INCB018424 1.5%BID 12 MOG 0.001 1.14 INCB018424 1.5% BID 12 CCL11 0.008 1.14 INCB0184241.5% BID 12 ITM2A <0.0001 1.14 INCB018424 1.5% BID 12 PLXNB3 0.016 1.14INCB018424 1.5% BID 12 CYR61 <0.0001 1.14 INCB018424 1.5% BID 12 SMOC2<0.0001 1.14 INCB018424 1.5% BID 12 Dkk-4 0.002 1.14 INCB018424 1.5% BID12 IL15 0.006 1.14 INCB018424 1.5% BID 12 BCAN <0.0001 1.14 INCB0184241.5% BID 12 MFGE8 0.024 1.14 INCB018424 1.5% BID 12 Flt3L <0.0001 1.15INCB018424 1.5% BID 12 CEACAM5 0.049 1.16 INCB018424 1.5% BID 12 G-CSF0.007 1.16 INCB018424 1.5% BID 12 P4HB 0.006 1.16 INCB018424 1.5% BID 12MMP-3 0.024 1.17 INCB018424 1.5% BID 12 MYOC 0.001 1.19 INCB018424 1.5%BID 12 PLIN1 0.006 1.20 INCB018424 1.5% BID 12 TNFRSF12A 0.001 1.21INCB018424 1.5% BID 12 GAL 0.002 1.22 INCB018424 1.5% BID 12 APLP1 0.0011.23 INCB018424 1.5% BID 12 AGR3 0.025 1.23 INCB018424 1.5% BID 12Ep-CAM 0.005 1.27 INCB018424 1.5% BID 12 TSHB 0.011 1.27 INCB018424 1.5%BID 12 TNNI3 0.019 1.59

TABLE 5B Significantly modulated proteins 1.5% ruxolitinib BID at week24 Fold Treatment Week Assay p-value Change Proteins significantlydown-regulated at Week 24 INCB018424 1.5% BID 24 CXCL10 <0.0001 0.68INCB018424 1.5% BID 24 CCL19 <0.0001 0.71 INCB018424 1.5% BID 24 CXCL9<.0001 0.73 INCB018424 1.5% BID 24 TRANCE <.0001 0.74 INCB018424 1.5%BID 24 CCL18 0.001 0.76 INCB018424 1.5% BID 24 IL2-RA <.0001 0.79INCB018424 1.5% BID 24 FCRL6 <.0001 0.79 INCB018424 1.5% BID 24 TNFB<.0001 0.80 INCB018424 1.5% BID 24 CRH 0.001 0.80 INCB018424 1.5% BID 24GZMB 0.002 0.80 INCB018424 1.5% BID 24 TNFRSF9 <.0001 0.80 INCB0184241.5% BID 24 KLRD1 <.0001 0.81 INCB018424 1.5% BID 24 IL-12B <.0001 0.81INCB018424 1.5% BID 24 FASLG <.0001 0.81 INCB018424 1.5% BID 24 MMP120.001 0.81 INCB018424 1.5% BID 24 CD160 <.0001 0.82 INCB018424 1.5% BID24 XCL1 <.0001 0.82 INCB018424 1.5% BID 24 CXCL11 0.019 0.82 INCB0184241.5% BID 24 LAIR-2 0.003 0.82 INCB018424 1.5% BID 24 MCP-4 0.010 0.84INCB018424 1.5% BID 24 NCR1 <0.0001 0.84 INCB018424 1.5% BID 24 IL-2RB0.003 0.84 INCB018424 1.5% BID 24 DRAXIN 0.008 0.85 INCB018424 1.5% BID24 IL12 0.001 0.85 INCB018424 1.5% BID 24 TNFRSF6B 0.001 0.85 INCB0184241.5% BID 24 COL1A1 0.001 0.86 INCB018424 1.5% BID 24 CD8A <0.0001 0.86INCB018424 1.5% BID 24 KIR2DL3 0.008 0.86 INCB018424 1.5% BID 24 SIGLEC1<0.0001 0.86 INCB018424 1.5% BID 24 LAP TGF-beta-1 0.018 0.86 INCB0184241.5% BID 24 CHIT1 0.016 0.86 INCB018424 1.5% BID 24 OPN 0.011 0.87INCB018424 1.5% BID 24 CD6 <.0001 0.87 INCB018424 1.5% BID 24 IFNL10.037 0.87 INCB018424 1.5% BID 24 CLEC4C 0.001 0.87 INCB018424 1.5% BID24 CD5 <.0001 0.88 INCB018424 1.5% BID 24 CRTAM 0.015 0.88 INCB0184241.5% BID 24 CCL21 0.002 0.88 INCB018424 1.5% BID 24 ITGB2 <.0001 0.88INCB018424 1.5% BID 24 SLAMF8 0.001 0.88 INCB018424 1.5% BID 24 ADAM 80.001 0.88 INCB018424 1.5% BID 24 IL10 0.040 0.88 INCB018424 1.5% BID 24IL-18BP 0.001 0.89 INCB018424 1.5% BID 24 CLEC7A <.0001 0.89 INCB0184241.5% BID 24 SLAMF1 0.003 0.90 INCB018424 1.5% BID 24 TNFSF13B 0.003 0.90INCB018424 1.5% BID 24 LILRB4 0.001 0.90 INCB018424 1.5% BID 24 FCER20.001 0.90 INCB018424 1.5% BID 24 CCL23 0.010 0.90 INCB018424 1.5% BID24 CD1C <0.0001 0.90 INCB018424 1.5% BID 24 TIMD4 0.008 0.91 INCB0184241.5% BID 24 MBL2 0.011 0.91 INCB018424 1.5% BID 24 TNF-R2 0.001 0.91INCB018424 1.5% BID 24 IL12RB1 0.006 0.91 INCB018424 1.5% BID 24 CD1630.010 0.91 INCB018424 1.5% BID 24 MILR1 0.002 0.91 INCB018424 1.5% BID24 NOV 0.022 0.92 INCB018424 1.5% BID 24 CD48 0.001 0.92 INCB018424 1.5%BID 24 GZMA 0.014 0.92 INCB018424 1.5% BID 24 IL-18R1 0.012 0.92INCB018424 1.5% BID 24 IL-1RT1 0.010 0.92 INCB018424 1.5% BID 24 TRAIL0.009 0.92 INCB018424 1.5% BID 24 GM-CSF-R-alpha 0.015 0.92 INCB0184241.5% BID 24 CDON 0.006 0.92 INCB018424 1.5% BID 24 PAPPA 0.046 0.92INCB018424 1.5% BID 24 WISP-1 0.004 0.92 INCB018424 1.5% BID 24 TNFRSF40.016 0.93 INCB018424 1.5% BID 24 IFNLR1 0.011 0.93 INCB018424 1.5% BID24 CD244 0.018 0.93 INCB018424 1.5% BID 24 PGF 0.014 0.93 INCB0184241.5% BID 24 CLEC4G 0.008 0.93 INCB018424 1.5% BID 24 SELL 0.006 0.93INCB018424 1.5% BID 24 CSF-1 0.003 0.93 INCB018424 1.5% BID 24 ICAM10.022 0.93 INCB018424 1.5% BID 24 VCAM1 0.014 0.94 INCB018424 1.5% BID24 IL32 0.048 0.94 INCB018424 1.5% BID 24 CD27 0.006 0.94 INCB0184241.5% BID 24 CD83 0.008 0.94 INCB018424 1.5% BID 24 PON2 0.050 0.94INCB018424 1.5% BID 24 LY9 0.014 0.94 INCB018424 1.5% BID 24 PILRA 0.0040.94 INCB018424 1.5% BID 24 DSC2 0.007 0.94 INCB018424 1.5% BID 24 RELT0.021 0.94 INCB018424 1.5% BID 24 KIRREL2 0.027 0.94 INCB018424 1.5% BID24 FcRL2 0.037 0.95 INCB018424 1.5% BID 24 ICAM3 0.050 0.95 INCB0184241.5% BID 24 DLL1 0.012 0.95 INCB018424 1.5% BID 24 Gal-9 0.017 0.95INCB018424 1.5% BID 24 CLEC10A 0.043 0.95 INCB018424 1.5% BID 24 TRAIL0.045 0.95 INCB018424 1.5% BID 24 PDCD1 0.035 0.95 INCB018424 1.5% BID24 CLM-6 0.015 0.95 INCB018424 1.5% BID 24 SIRPB1 0.042 0.95 INCB0184241.5% BID 24 SIGLEC10 0.018 0.95 INCB018424 1.5% BID 24 SIGLEC6 0.0300.95 INCB018424 1.5% BID 24 hOSCAR 0.020 0.96 INCB018424 1.5% BID 24SHPS-1 0.038 0.96 Proteins Significantly Up-Regulated at Week 24INCB018424 1.5% BID 24 CLEC14A 0.044 1.04 INCB018424 1.5% BID 24 SPINT10.040 1.05 INCB018424 1.5% BID 24 TACSTD2 0.026 1.05 INCB018424 1.5% BID24 ROBO1 0.035 1.05 INCB018424 1.5% BID 24 DCN 0.011 1.05 INCB0184241.5% BID 24 ITGB1 0.021 1.05 INCB018424 1.5% BID 24 PRELP 0.004 1.05INCB018424 1.5% BID 24 IGF2R 0.027 1.05 INCB018424 1.5% BID 24 MMP70.018 1.05 INCB018424 1.5% BID 24 PVR 0.026 1.05 INCB018424 1.5% BID 24CDH1 0.049 1.06 INCB018424 1.5% BID 24 RGMA 0.023 1.06 INCB018424 1.5%BID 24 TMPRSS5 0.036 1.06 INCB018424 1.5% BID 24 GDNFR-alpha-3 0.0231.06 INCB018424 1.5% BID 24 GPC1 0.039 1.06 INCB018424 1.5% BID 24 LYPD30.039 1.06 INCB018424 1.5% BID 24 ITM2A 0.034 1.06 INCB018424 1.5% BID24 Notch 3 0.041 1.06 INCB018424 1.5% BID 24 ACAN 0.030 1.06 INCB0184241.5% BID 24 hK11 0.028 1.06 INCB018424 1.5% BID 24 MSMB 0.003 1.07INCB018424 1.5% BID 24 SCF 0.013 1.07 INCB018424 1.5% BID 24 CNTN1 0.0231.07 INCB018424 1.5% BID 24 RGMB 0.045 1.07 INCB018424 1.5% BID 24 AOC30.016 1.07 INCB018424 1.5% BID 24 PRSS27 0.037 1.07 INCB018424 1.5% BID24 VEGFD 0.004 1.07 INCB018424 1.5% BID 24 DPP4 0.020 1.07 INCB0184241.5% BID 24 CLEC4A 0.033 1.07 INCB018424 1.5% BID 24 PEAR1 0.032 1.07INCB018424 1.5% BID 24 CRISP2 0.030 1.07 INCB018424 1.5% BID 24 CD300LG0.005 1.07 INCB018424 1.5% BID 24 DKK3 0.027 1.07 INCB018424 1.5% BID 24SPINK5 0.002 1.07 INCB018424 1.5% BID 24 CNTN5 0.021 1.07 INCB0184241.5% BID 24 CXCL16 0.018 1.07 INCB018424 1.5% BID 24 B4GAT1 0.004 1.07INCB018424 1.5% BID 24 PRTG 0.007 1.07 INCB018424 1.5% BID 24 FABP90.006 1.07 INCB018424 1.5% BID 24 PAM 0.011 1.07 INCB018424 1.5% BID 24BLM hydrolase 0.012 1.07 INCB018424 1.5% BID 24 RAGE 0.027 1.08INCB018424 1.5% BID 24 IGFBP6 0.027 1.08 INCB018424 1.5% BID 24 BCAM<.0001 1.08 INCB018424 1.5% BID 24 MFAP5 0.003 1.08 INCB018424 1.5% BID24 NTRK3 0.006 1.08 INCB018424 1.5% BID 24 TGFBI 0.041 1.08 INCB0184241.5% BID 24 PON3 0.043 1.08 INCB018424 1.5% BID 24 ISLR2 0.039 1.08INCB018424 1.5% BID 24 SOST 0.046 1.08 INCB018424 1.5% BID 24 DPP100.008 1.08 INCB018424 1.5% BID 24 SCF <0.0001 1.08 INCB018424 1.5% BID24 CRIM1 0.035 1.08 INCB018424 1.5% BID 24 ITGB5 0.010 1.09 INCB0184241.5% BID 24 TF 0.014 1.09 INCB018424 1.5% BID 24 CLUL1 0.001 1.09INCB018424 1.5% BID 24 CTSV 0.020 1.09 INCB018424 1.5% BID 24 KLK100.030 1.09 INCB018424 1.5% BID 24 WFIKKN2 0.001 1.09 INCB018424 1.5% BID24 DPEP1 0.001 1.10 INCB018424 1.5% BID 24 hK8 0.048 1.10 INCB0184241.5% BID 24 SCF 0.001 1.10 INCB018424 1.5% BID 24 hK14 0.002 1.10INCB018424 1.5% BID 24 COMP 0.030 1.10 INCB018424 1.5% BID 24 MDGA10.004 1.10 INCB018424 1.5% BID 24 GDF-2 0.009 1.10 INCB018424 1.5% BID24 Gal-4 0.046 1.10 INCB018424 1.5% BID 24 SMOC2 0.026 1.10 INCB0184241.5% BID 24 SNCG 0.031 1.11 INCB018424 1.5% BID 24 COCH 0.018 1.11INCB018424 1.5% BID 24 F11 0.006 1.11 INCB018424 1.5% BID 24 NPTXR 0.0071.11 INCB018424 1.5% BID 24 PHOSPHO1 0.001 1.11 INCB018424 1.5% BID 24NCAM1 0.002 1.11 INCB018424 1.5% BID 24 TNXB 0.012 1.12 INCB018424 1.5%BID 24 SCGB3A1 0.002 1.12 INCB018424 1.5% BID 24 Flt3L 0.015 1.12INCB018424 1.5% BID 24 MFGE8 0.048 1.12 INCB018424 1.5% BID 24 IL150.009 1.12 INCB018424 1.5% BID 24 CYR61 0.026 1.13 INCB018424 1.5% BID24 SCGB1A1 0.004 1.13 INCB018424 1.5% BID 24 DDC 0.042 1.13 INCB0184241.5% BID 24 TN-R <0.0001 1.13 INCB018424 1.5% BID 24 WASF1 0.042 1.13INCB018424 1.5% BID 24 CPA2 0.034 1.14 INCB018424 1.5% BID 24 CRTAC10.001 1.14 INCB018424 1.5% BID 24 P4HB 0.009 1.14 INCB018424 1.5% BID 24PADI2 0.041 1.14 INCB018424 1.5% BID 24 BAG6 0.016 1.14 INCB018424 1.5%BID 24 PLIN1 0.002 1.15 INCB018424 1.5% BID 24 CA6 <0.0001 1.15INCB018424 1.5% BID 24 GAL 0.005 1.15 INCB018424 1.5% BID 24 NAAA 0.0131.15 INCB018424 1.5% BID 24 KLK13 <0.0001 1.16 INCB018424 1.5% BID 24REG4 0.002 1.16 INCB018424 1.5% BID 24 GIF 0.006 1.17 INCB018424 1.5%BID 24 PTN 0.026 1.17 INCB018424 1.5% BID 24 NID2 0.026 1.17 INCB0184241.5% BID 24 GSAP 0.014 1.17 INCB018424 1.5% BID 24 TNFRSF12A 0.001 1.19INCB018424 1.5% BID 24 SCGB3A2 0.007 1.19 INCB018424 1.5% BID 24 Ep-CAM0.049 1.19 INCB018424 1.5% BID 24 NEFL 0.014 1.19 INCB018424 1.5% BID 24MYOC <0.0001 1.21 INCB018424 1.5% BID 24 CEACAM5 0.007 1.22 INCB0184241.5% BID 24 FGF-BP1 <.0001 1.24 INCB018424 1.5% BID 24 EPO 0.003 1.41

TABLE 6A Proteins down-regulated in 1.5% ruxolitinib QD and 1.5%ruxolitinib BID at week 12 Unique to Both 1.5% QD Unique to 1.5% QD and1.5% BID 1.5% BID DEFB4A CD160 TIMD4 IGFBP-1 TNFB RNASE3 GZMH TNFRSF9CXCL9 FS ITGB2 CRH SH2D1A CD5 TCL1B CXCL11 CCL19 CA5A GZMA MCP-4TNFRSF6B ANGPTL4 CCL18 CHIT1 IL6 CXCL10 TGF-alpha TYMP LAIR-2 OSM CD8AIL-12B PRTN3 SIGLEC1 CD6 MBL2 IL-15RA CD1C IL5 SLAMF1 CRTAM CLEC4DCLEC6A KIR2DL3 COL1A1 CLEC10A ADAM 8 CLEC4C SELE GZMB LIF GDF-15 CCL21IL-2RB CLM-1 IFNL1 NOV FOLR2 IL12 TNC LIF-R DSC2 VSTM1 IL12RB1 CD163WISP-1 CDH3 RETN TNFRSF10C GM-CSF-R-alpha IL-1RT1 IL3RA ST2 CD244PGLYRP1 MSR1 CD48 ICAM3 PDCD1 TNF-R2 ICAM1 CSF-1 ARTN FCRL5 FcRL2 LY9CLEC7A CD200R1 CD79B VCAM1 SLAMF8 CDON FCER2 SELL PON2 CD209 IL-10RBLAIR1 TNF-R1 KIRREL2 FCRL1 MILR1 HAVCR2 KPNA1 TGFR-2

TABLE 6B Proteins down-regulated in 1.5% ruxolitinib QD and 1.5%ruxolitinib BID at week 24 Unique to Both 1.5% QD Unique to 1.5% QD and1.5% BID 1.5% BID DEFB4A CXCL10 CXCL9 GZMH CCL19 IL-2RB IL5 TRANCECOL1A1 SH2D1A CCL18 KIR2DL3 PTH1R TNFB LAP TGF-beta-1 IL6 GZMB CHIT1PTX3 TNFRSF9 IFNL1 sFRP-3 KLRD1 ITGB2 IL-15RA IL-12B SLAMF8 ESM-1 FASLGIL-18BP CLM-1 MMP12 TNFSF13B CDH3 CD160 LILRB4 TNC XCL1 FCER2 COL4A3BPCXCL11 TIMD4 CD79B LAIR-2 CD163 FCRL1 MCP-4 MILR1 PD-L1 IL12 NOV IL17RBSIGLEC1 IL-18R1 TNFRSF13B CD6 TRAIL LIF-R CLEC4C CDON SIRT5 CD5 WISP-1CD200R1 CRTAM PGF IL-5R-alpha CCL21 CLEC4G PDGF-R-alpha ADAM 8 SELL TMIL10 ICAM1 WFIKKN1 CLEC7A VCAM1 EFNA4 SLAMF1 IL32 N2DL-2 CCL23 PILRAGFR-alpha-1 CD1C DSC2 THBS2 MBL2 RELT LY75 TNF-R2 KIRREL2 NBL1 IL12RB1ICAM3 CD48 DLL1 GZMA Gal-9 IL-1RT1 SIRPB1 GM-CSF-R-alpha SIGLEC10 PAPPASIGLEC6 TNFRSF4 hOSCAR IFNLR1 SHPS-1 CD244 CSF-1 CD27 CD83 PON2 LY9FcRL2 CLEC10A PDCD1 CLM-6

TABLE 7A Proteins up-regulated in 1.5% ruxolitinib QD and 1.5%ruxolitinib BID at week 12 Both 1.5% QD Unique to 1.5% QD and 1.5% BIDUnique to 1.5% BID GPNMB KLK13 NTRK3 CAMKK1 FGF-BP1 TF PDGFRB EPO ITGAVTYRO3 ITGB1 ERBB3 GFRA2 GALNT2 CLEC14A SPON2 CRISP2 ERBB4 TCL1B ENTPD6Nr-CAM CA14 DPP4 NTRK2 IGF2R AOC3 EDA2R MRC2 DCBLD2 LTBP2 LRRN1 ANGPTL7DKKL1 TCN2 B4GAT1 CD58 ESAM SPINK5 Gal-3 SCGB3A1 TACSTD2 GDNFR-alpha-3BCAM VEGFD FABP9 IGSF3 FAM3C Alpha-2-MRAP SMAD1 CLUL1 PRELP SAA4 SOD2DPEP1 ANG-1 CXCL16 MMP7 SEZ6L2 GPC1 SCARB2 APOM DKK3 BAMBI IGFBPL1CLEC4A ACAN CPXM1 KLK6 DCN METRNL RAGE PEAR1 ENAH KLK10 PODXL2 LRP11FAM3B VWC2 VEGFA CD200 BLM hydrolase MFAP5 WFIKKN2 CCL25 MCFD2 CA6SCARF2 ENTPD2 NCAM1 EZR VEGFC DDC OPTC CNTN2 SCGB3A2 EPHB6 PAI MOG PVRAPP CCL11 DPP10 ISLR2 CYR61 PRTG CLMP Flt3L TMPRSS5 REG4 CEACAM5 CD70KAZALD1 MMP-3 THPO DPP7 GAL KIM1 CD46 APLP1 ROBO2 TIMP1 CDNF COCH SPOCK1ROR1 ST3GAL1 IL7R CNTN5 CXCL5 GCP5 PROC GP1BA IGFBP6 RGMB PAM LGALS7MSLN FUT8 SYND1 CXADR COMP MATN3 DPP6 SCF MMP-1 NCAN ST6GAL1 GDF-2 SOSTCAIX ANGPTL3 RGMA DSG4 NPTXR CXCL1 PHOSPHO1 NID1 STX6 PLTP PON3 CA4gal-8 LEP CADM3 CRTAC1 CX3CL1 F11 PADI2 MAP4K5 PREB CES2 MDGA1 CCL5SCGB1A1 OMG IL-17A NEFL GIF TN-R ITM2A PLXNB3 SMOC2 Dkk-4 BCAN MFGE8G-CSF P4HB PLIN1 AGR3 Ep-CAM TSHB TNNI3

TABLE 7B Proteins up-regulated in 1.5% ruxolitinib QD and 1.5%ruxolitinib BID at week 24 Both 1.5% QD Unique to 1.5% QD and 1.5% BIDUnique to 1.5% BID GALNT2 TACSTD2 CLEC14A EGFR ITGB1 SPINT1 BAMBI IGF2RROBO1 CNDP1 CNTN1 DCN ST6GAL1 AOC3 PRELP MEP1B VEGFD PVR CA4 CLEC4A CDH1KIT DKK3 RGMA TIMP1 SPINK5 TMPRSS5 DPP6 CXCL16 GDNFR-alpha-3 ADGRG2B4GAT1 GPC1 KLK6 BLM hydrolase LYPD3 PAI BCAM ITM2A CXCL5 ISLR2 Notch 3PROC TF ACAN CLMP KLK10 hK11 MOG WFIKKN2 MSMB PDGF subunit A hK8 SCFEDIL3 F11 RGMB MMP-1 Flt3L PRSS27 CA3 IL15 CRISP2 MB DDC CNTN5 KYAT1P4HB PRTG SPINK1 PLIN1 FABP9 MMP-3 CA6 RAGE LGALS7 KLK13 MFAP5 TIMP4Ep-CAM NTRK3 PCSK9 PON3 FAM3C SOST CES2 DPP10 CES1 CRIM1 TMPRSS15 CLUL1CTSV hK14 COMP MDGA1 GDF-2 SMOC2 NPTXR PHOSPHO1 TNXB MFGE8 CYR61 TN-RWASF1 CPA2 PADI2 BAG6 GAL NAAA REG4 GIF NID2 GSAP TNFRSF12A NEFL MYOCCEACAM5 EPO

The effects of topical treatment with ruxolitinib cream on inflammatorymediator expression in circulation was investigated. Sera from 130participants (n=23 vehicle, n=26 0.15% once daily [QD], n=27 0.5% QD,n=24 1.5% QD, n=30 1.5% twice daily [BID]) with baseline and Week 24samples were analyzed for broad proteomic changes. Paired t-testsestablished significant changes within treatment groups at a cutoff ofp<0.05. Baseline biomarkers and facial Vitiligo Area Scoring Index(F-VASI) were assessed for significance using Spearman's correlation.Proteins in circulation that positively correlated with baseline F-VASIare depicted in FIG. 3 . Fold change from baseline to week 24 in selectinflammatory mediators is depicted in FIG. 4 (values greater than 1indicate an increase, while values less than 1 indicate a decrease).Overall, topical treatment with ruxolitinib cream, and the associatedskin improvement, corresponded with dose-dependent modulation ofcirculating inflammatory mediators. All inflammatory mediators stayedsteady or increased slightly with vehicle BID treatment Inflammatorymediators decreased more significantly with increasing doses ofruxolitinib cream.

Example 3: Correlations Between Percent Change in Facial Vitiligo AreaScoring Index and Proteins at Baseline, Fold Change from Baseline toWeek 12, and Fold Change from Baseline to Week 24

Correlations between percent change in facial Vitiligo Area ScoringIndex (VASI) and proteins at baseline, fold change from baseline to week12, and fold change from baseline to week 24 were investigated. Spearmancorrelation values >|0.3| and p-values <0.05 indicated a moderatecorrelation. Correlations were completed for a) all patients, b)responders, and c) non-responders. All correlation calculations excludedthe vehicle cohort. Proteins moderately correlated with percent changein facial VASI are presented.

The following tables describe associations of percent change in facialVASI with a) baseline protein levels; b) fold change in proteinexpression from baseline to week 12; and c) fold change in proteinexpression from baseline to week 24. The cut-off value for correlationswas Spearman Correlation>|0.3| and p<0.05 to indicate a moderatelysignificant correlation.

TABLE 8A Association between percent change in facial VASI and Baselineprotein levels Assay Spearman Correlation p-value IL-20RA 0.34 <0.00013PON2 0.34 <0.00013

TABLE 8B Association between percent change in facial VASI and foldchange in protein expression from baseline to week 12 Assay SpearmanCorrelation p-value DEFA1 −0.30 0.002 DKKL1 −0.35 <0.00012

TABLE 8C Association between percent change in facial VASI and foldchange in protein expression from baseline to week 24 Assay SpearmanCorrelation p-value GH 0.33 <0.00016

TABLE 9A Association between percent change in facial VASI and Baselineprotein levels in Responders Spearman Response Assay Correlation p-valueBaseline proteins negativey correlated with Percent Change in FacialVASI in responders Responders SCF −0.35 0.017 Responders CPA2 −0.340.019 Responders P4HB −0.34 0.019 Responders SPARCL1 −0.34 0.021Responders ST2 −0.34 0.021 Responders SCF −0.33 0.023 Responders CNDP1−0.33 0.024 Responders TRAIL −0.32 0.027 Responders KIRREL2 −0.32 0.028Responders SCF −0.32 0.029 Responders EGFR −0.32 0.030 Responders ISLR2−0.32 0.030 Responders PPP3R1 −0.32 0.030 Responders FCGR3B −0.31 0.031Responders MMP-3 −0.31 0.031 Responders IL-18BP −0.31 0.033 RespondersFlt3L −0.31 0.035 Responders PPY −0.31 0.036 Responders LTA4H −0.310.036 Responders ITGB2 −0.30 0.037 Responders PTN −0.30 0.038 RespondersGPNMB −0.30 0.039 Responders SIRPB1 −0.30 0.040 Responders PLTP −0.350.017 Responders PSP-D −0.34 0.019 Responders COMP −0.34 0.019Responders PAMR1 −0.34 0.021 Responders VASN −0.34 0.021 Responders F11−0.33 0.023 Responders IL10 −0.33 0.024 Responders CA3 −0.32 0.027Responders CXCL10 −0.32 0.028 Responders Notch 3 −0.32 0.029 RespondersNCAM1 −0.32 0.030 Responders PROC −0.32 0.030 Responders CLEC14A −0.320.030 Responders IL-12B −0.31 0.031 Responders IL10 −0.31 0.031Responders CD40 −0.31 0.033 Responders IFN-gamma −0.31 0.035 Baselineproteins positively correlated with Percent Change in Facial VASI inresponders Responders SERPINA12 12 0.34 0.019 Responders GHRL 12 0.340.019 Responders PREB 12 0.31 0.036

TABLE 9B Association between percent change in facial VASI and Baselineprotein levels in Non-Responders Spearman Response Assay Correlationp-value Baseline proteins negatively correlated with Percent Change inFacial VASI in non-responders Non-Responders EPHA10 −0.46 0.001Non-Responders GH2 −0.36 0.005 Non-Responders PARP-1 −0.35 0.005Non-Responders GLRX −0.32 0.012 Non-Responders ARSB −0.31 0.013Non-Responders SCAMP3 −0.30 0.016 Baseline proteins positivelycorrelated with Percent Change in Facial VASI in non-respondersNon-Responders t-PA 0.48 <0.0001 Non-Responders LDL 0.45 <0.0001receptor Non-Responders DLK-1 0.44 <0.0001 Non-Responders SELE 0.400.001 Non-Responders EPHB4 0.39 0.002 Non-Responders GFRA2 0.38 0.002Non-Responders PLC 0.37 0.003 Non-Responders LTBR 0.35 0.005Non-Responders PAMR1 0.35 0.006 Non-Responders TACSTD2 0.35 0.006Non-Responders FS 0.34 0.006 Non-Responders ICAM-2 0.34 0.007Non-Responders AXL 0.34 0.007 Non-Responders PRSS8 0.33 0.009Non-Responders SPINK5 0.32 0.010 Non-Responders AMN 0.32 0.011Non-Responders NOMO1 0.31 0.014 Non-Responders PAI 0.31 0.015Non-Responders CPM 0.30 0.017

TABLE 10A Association between percent change in facial VASI and FoldChange in protein levels in Responders from either baseline to week 12or base ine to week 24 Spearman Response Assay Week Correlation p-valueFold Change proteins negatively correlated with Percent Change in FacialVASI in responders Responders FAP 12 −0.45 0.002 Responders RET 12 −0.440.002 Responders CNTN5 12 −0.40 0.005 Responders FUCA1 12 −0.40 0.006Responders ITGAV 12 −0.39 0.007 Responders ITGB5 12 −0.39 0.008Responders THBS4 12 −0.38 0.009 Responders CD207 12 −0.36 0.013Responders GDF-8 12 −0.36 0.013 Responders CDH6 12 −0.36 0.013Responders MRC2 12 −0.36 0.015 Responders ICOSLG 12 −0.36 0.015Responders TNXB 12 −0.35 0.017 Responders EDIL3 12 −0.35 0.018Responders OSMR 12 −0.35 0.019 Responders GPC1 12 −0.34 0.020 RespondersMIC-A/B 12 −0.34 0.021 Responders TGFR-2 12 −0.34 0.022 Responders LRRN112 −0.34 0.022 Responders TLR3 12 −0.33 0.024 Responders KIM1 12 −0.320.029 Responders ROBO2 12 −0.32 0.030 Responders CD70 12 −0.32 0.032Responders CLMP 12 −0.31 0.033 Responders N-CDase 12 −0.31 0.034Responders FCRL5 12 −0.31 0.035 Responders CTSV 12 −0.31 0.037Responders SCARF2 12 −0.31 0.037 Responders KIMI 12 −0.31 0.038Responders PLXDC1 12 −0.31 0.038 Responders PRTG 12 −0.31 0.039Responders ERBB4 12 −0.30 0.040 Responders MAGED1 12 −0.30 0.040Responders CEACAM1 12 −0.30 0.042 Responders TSHB 24 −0.54 <0.0001Responders PTK7 24 −0.46 0.001 Responders ICOSLG 24 −0.36 0.014Responders TGFR-2 24 −0.34 0.023 Responders RET 24 −0.33 0.027Responders ADAM 22 24 −0.32 0.030 Responders CTSC 24 −0.32 0.031Responders DLK-1 24 −0.32 0.032 Responders USP8 24 −0.32 0.035Responders SCARF2 24 −0.31 0.037 Responders TNFRSF13B 24 −0.31 0.038Responders MB 24 −0.31 0.038 Responders TMPRSS5 24 −0.30 0.044 FoldChange proteins positively correlated with Percent Change in Facial VASIin responders Responders NUDT5 12 0.38 0.010 Responders MMP-3 12 0.370.010 Responders MAEA 12 0.36 0.013 Responders NEMO 12 0.35 0.019Responders IFN-gamma 12 0.34 0.020 Responders IL18 12 0.33 0.024Responders AKT1S1 12 0.33 0.025 Responders CASP-8 12 0.33 0.025Responders PPP1R2 12 0.33 0.026 Responders ST2 12 0.33 0.027 RespondersVSIG4 12 0.32 0.028 Responders SCGB3A2 12 0.32 0.028 Responders HDGF 120.32 0.029 Responders ICA1 12 0.32 0.030 Responders IL13 12 0.32 0.032Responders PEBP1 12 0.31 0.033 Responders PARK7 12 0.31 0.035 RespondersMAP4K5 12 0.31 0.036 Responders FLI1 12 0.31 0.038 Responders MMP-3 240.45 0.002 Responders MMP-10 24 0.43 0.003 Responders ST2 24 0.43 0.003Responders CCL24 24 0.42 0.004 Responders TIMP4 24 0.41 0.006 RespondersMBL2 24 0.35 0.018 Responders FLI1 24 0.33 0.029 Responders IL18 24 0.320.030 Responders REG4 24 0.32 0.032 Responders IFN-gamma 24 0.32 0.034Responders CPA2 24 0.31 0.037

TABLE 10B Association between percent change in facial VASI and FoldChange in protein levels in Non-Responders from either baseline to week12 or baseline to week 24 Spearman Response Assay Week Correlationp-value Fold Change proteins negatively correlated with Percent Changein Facial VASI in non-responders Non-Responders DDR1 12 −0.40 0.001Non-Responders NTRK2 12 −0.38 0.003 Non-Responders CES2 12 −0.38 0.003Non-Responders SCARA5 12 −0.37 0.003 Non-Responders GDF-8 12 −0.35 0.006Non-Responders BOC 12 −0.35 0.007 Non-Responders PAEP 12 −0.35 0.007Non-Responders ARTN 12 −0.35 0.007 Non-Responders CDNF 12 −0.34 0.008Non-Responders TMPRSS5 12 −0.34 0.008 Non-Responders FLRT2 12 −0.340.009 Non-Responders ROBO2 12 −0.33 0.011 Non-Responders SIGLEC10 12−0.33 0.011 Non-Responders PRTG 12 −0.32 0.012 Non-Responders SCARF2 12−0.32 0.014 Non-Responders CDH3 12 −0.32 0.014 Non-RespondersGFR-alpha-1 12 −0.31 0.015 Non-Responders TSHB 12 −0.31 0.015Non-Responders CD200R1 12 −0.31 0.017 Non-Responders RGMB 12 −0.31 0.017Non-Responders KYNU 12 −0.30 0.018 Non-Responders HS3ST3B1 24 −0.370.004 Non-Responders CHRDL2 24 −0.33 0.010 Non-Responders CNTN1 24 −0.300.019 Fold Change proteins positively correlated with Percent Change inFacial VASI in non-responders Non-Responders VSIG4 12 0.38 0.002Non-Responders ARHGAP1 12 0.38 0.003 Non-Responders B4GAT1 12 0.37 0.003Non-Responders STX8 12 0.37 0.004 Non-Responders CRELD2 12 0.37 0.004Non-Responders ARSA 12 0.36 0.004 Non-Responders BCAM 12 0.35 0.005Non-Responders SCARF1 12 0.34 0.007 Non-Responders CA13 12 0.34 0.009Non-Responders DAG1 12 0.34 0.009 Non-Responders LAIR1 12 0.33 0.009Non-Responders GUSB 12 0.33 0.009 Non-Responders PMVK 12 0.33 0.009Non-Responders PEAR1 12 0.33 0.010 Non-Responders GP1BA 12 0.33 0.011Non-Responders TACC3 12 0.32 0.013 Non-Responders PARK7 12 0.31 0.016Non-Responders ARHGEF12 12 0.31 0.017 Non-Responders SEMA7A 12 0.300.018 Non-Responders ESAM 12 0.30 0.019 Non-Responders FKBP5 12 0.300.020 Non-Responders ARHGAP1 24 0.49 <0.0001 Non-Responders SCAMP3 240.48 <0.0001 Non-Responders ABL1 24 0.48 <0.0001 Non-Responders EGF 240.48 <0.0001 Non-Responders TACC3 24 0.47 <0.0001 Non-Responders FKBP524 0.47 <0.0001 Non-Responders BID 24 0.47 <0.0001 Non-Responders PRDX524 0.47 <0.0001 Non-Responders STX8 24 0.46 <0.0001 Non-Responders CD6324 0.46 <0.0001 Non-Responders SCARF1 24 0.45 <0.0001 Non-RespondersPTPN1 24 0.45 <0.0001 Non-Responders CLEC1B 24 0.44 <0.0001Non-Responders ARSB 24 0.44 <0.0001 Non-Responders FKBP1B 24 0.43 0.001Non-Responders YES1 24 0.43 0.001 Non-Responders SRC 24 0.43 0.001Non-Responders TNFSF14 24 0.42 0.001 Non-Responders PLXNB3 24 0.42 0.001Non-Responders LRMP 24 0.42 0.001 Non-Responders CD164 24 0.42 0.001Non-Responders DAG1 24 0.41 0.001 Non-Responders PVALB 24 0.41 0.001Non-Responders NAA10 24 0.41 0.001 Non-Responders TRIM5 24 0.41 0.001Non-Responders ARHGEF12 24 0.41 0.001 Non-Responders HGF 24 0.40 0.001Non-Responders CA13 24 0.40 0.001 Non-Responders SNAP23 24 0.40 0.002Non-Responders SORT1 24 0.40 0.002 Non-Responders GP6 24 0.39 0.002Non-Responders CTSS 24 0.39 0.002 Non-Responders PPIB 24 0.39 0.002Non-Responders CRKL 24 0.38 0.003 Non-Responders MAP2K6 24 0.38 0.003Non-Responders MANF 24 0.38 0.003 Non-Responders PMVK 24 0.38 0.003Non-Responders ABHD14B 24 0.38 0.003 Non-Responders GUSB 24 0.38 0.003Non-Responders FATC1 24 0.38 0.003 Non-Responders MAD1L1 24 0.37 0.003Non-Responders EDAR 24 0.37 0.004 Non-Responders CEACAM8 24 0.37 0.004Non-Responders GLB1 24 0.36 0.004 Non-Responders ST3GAL1 24 0.36 0.004Non-Responders ARSA 24 0.36 0.005 Non-Responders ADAM 8 24 0.36 0.005Non-Responders CD40 24 0.36 0.005 Non-Responders IFI30 24 0.36 0.005Non-Responders ECE1 24 0.35 0.006 Non-Responders AXIN1 24 0.35 0.006Non-Responders WFDC2 24 0.35 0.006 Non-Responders TBCB 24 0.35 0.007Non-Responders CXCL13 24 0.35 0.007 Non-Responders ST1A1 24 0.35 0.007Non-Responders KIF1BP 24 0.35 0.007 Non-Responders DPP7 24 0.34 0.007Non-Responders VEGFA 24 0.34 0.007 Non-Responders CETN2 24 0.34 0.007Non-Responders TGF-alpha 24 0.34 0.008 Non-Responders CD84 24 0.34 0.009Non-Responders SNAP29 24 0.34 0.009 Non-Responders CASP-8 24 0.33 0.010Non-Responders S100A11 24 0.33 0.010 Non-Responders GSTP1 24 0.33 0.010Non-Responders CRADD 24 0.33 0.010 Non-Responders PRKAB1 24 0.33 0.011Non-Responders HGF 24 0.33 0.011 Non-Responders STK4 24 0.33 0.011Non-Responders RNASE3 24 0.33 0.011 Non-Responders SERPINB6 24 0.320.012 Non-Responders OSM 24 0.32 0.012 Non-Responders MK 24 0.32 0.012Non-Responders FADD 24 0.32 0.013 Non-Responders CLEC11A 24 0.32 0.013Non-Responders CD69 24 0.32 0.013 Non-Responders LOX-1 24 0.32 0.013Non-Responders ITGA6 24 0.31 0.015 Non-Responders CLEC5A 24 0.31 0.015Non-Responders BCAM 24 0.31 0.015 Non-Responders FES 24 0.31 0.016Non-Responders TXNDC5 24 0.31 0.016 Non-Responders LAT2 24 0.31 0.018Non-Responders CXCL11 24 0.30 0.018 Non-Responders PARP-1 24 0.30 0.018Non-Responders APBB1IP 24 0.30 0.018 Non-Responders GZMB 24 0.30 0.019Non-Responders CRNN 24 0.30 0.019

Example 4: Proteomic Changes from Baseline Between Responders and withinResponders at Weeks 12 and 24

Proteomic changes from baseline were investigated between responders andwithin responders at week 12 and week 24. Paired t-tests were conductedand significance conferred at p<0.05. The tables below show theproteomic changes that differed significantly between responders andnon-responders. Response was defined as percent change in facialVASI>50%.

TABLE 11A Differences in proteomic changes between responders andnon-responders (excluding vehicle) at week 12 Non- Responder ResponderFold Fold Assay Week p-value Change Change WAS 12 0.001 1.26 0.90 TRIM2112 0.001 1.07 0.92 DDAH1 12 0.002 1.11 0.97 PSIP1 12 0.002 1.18 0.93IRF9 12 0.002 1.11 0.88 FGF-BP1 12 0.002 1.19 1.06 LGALS7 12 0.002 1.130.98 TACSTD2 12 0.002 1.06 1.00 CTSC 12 0.003 1.08 0.93 GDF-15 12 0.0030.92 1.02 GLB1 12 0.003 1.19 0.88 HDGF 12 0.003 1.13 0.92 AMIGO2 120.003 1.05 0.97 GSAP 12 0.004 1.12 0.93 CD1C 12 0.004 0.90 0.98 CCL11 120.004 1.12 1.00 SIRT5 12 0.005 0.96 1.04 APBB1IP 12 0.005 1.09 0.91COL4A3BP 12 0.006 1.04 0.93 LRMP 12 0.006 1.11 0.93 ADAM-TS13 12 0.0061.03 0.98 DDX58 12 0.007 1.13 0.93 PIK3AP1 12 0.007 1.09 0.87 IL32 120.009 1.03 0.95 DKKL1 12 0.009 1.05 0.99 HS6ST1 12 0.010 1.07 0.97 ILKAP12 0.010 1.17 0.93 PRKRA 12 0.010 1.06 0.95 FES 12 0.011 1.07 0.93 VEGFD12 0.011 1.08 1.01 CCL23 12 0.011 0.90 1.01 CXCL1 12 0.011 1.12 1.00ARSB 12 0.012 1.11 0.94 TRIM5 12 0.013 1.13 0.90 SPRY2 12 0.013 1.130.92 ENTPD6 12 0.013 1.06 1.00 CRISP2 12 0.013 1.06 0.99 TOP2B 12 0.0141.15 0.84 CASP-8 12 0.014 1.04 0.88 CCL15 12 0.015 0.96 1.03 CCL27 120.015 1.03 0.97 IL15 12 0.016 1.12 1.04 PRDX5 12 0.016 1.13 0.86 SNCG 120.016 1.08 0.98 TNFRSF10C 12 0.016 0.91 0.98 DFFA 12 0.017 1.04 0.90PLXNB3 12 0.017 1.13 0.97 METRNL 12 0.017 1.01 1.06 NPM1 12 0.018 1.140.95 PFKM 12 0.019 1.17 0.97 BST2 12 0.019 1.05 0.98 CD160 12 0.020 0.850.93 SERPINA5 12 0.020 1.05 0.97 BNP 12 0.021 1.06 0.98 DPP7 12 0.0211.10 0.98 CXCL1 12 0.021 1.10 1.00 SLITRK2 12 0.021 1.05 0.98 CCL11 120.022 1.10 1.00 LRRN1 12 0.022 1.08 1.01 SIGLEC6 12 0.022 1.03 0.97 FHIT12 0.022 1.05 0.95 CBL 12 0.022 1.06 0.88 PHOSPHO1 12 0.023 1.08 1.00DCTN2 12 0.025 1.07 0.94 GSTP1 12 0.025 1.06 0.97 DSG3 12 0.025 1.030.96 NMNAT1 12 0.026 1.14 0.89 SRP14 12 0.026 1.15 0.90 NAAA 12 0.0271.06 0.96 DEFA1 12 0.027 1.26 0.96 S100A4 12 0.027 1.08 0.94 Siglec-9 120.028 1.02 0.98 ARSA 12 0.028 1.09 0.97 CD46 12 0.030 1.06 0.99 S100A1112 0.030 1.05 0.96 NPDC1 12 0.031 0.99 1.06 FLI1 12 0.031 1.04 0.94CD79B 12 0.032 0.95 1.00 IGFBP-2 12 0.033 0.95 1.04 IL5 12 0.033 0.881.02 GCP5 12 0.033 1.07 0.98 UMOD 12 0.033 1.04 0.99 SOD2 12 0.034 1.061.01 gal-8 12 0.035 1.08 0.98 HCLS1 12 0.035 1.07 0.85 SORT1 12 0.0361.05 0.98 ATP6V1F 12 0.036 1.06 0.96 XCL1 12 0.036 0.86 0.94 LIF 120.036 0.92 1.01 Flt3L 12 0.037 1.12 1.04 ABHD14B 12 0.037 1.06 0.93PPP1R9B 12 0.037 1.03 0.89 MMP-1 12 0.039 1.11 1.00 APOM 12 0.039 1.051.00 SCGB3A1 12 0.039 1.08 1.01 IL-17D 12 0.039 1.04 0.99 HNMT 12 0.0391.05 0.98 RBKS 12 0.040 1.06 0.94 MAD1L1 12 0.041 1.08 0.97 PODXL2 120.041 1.05 1.00 OPN 12 0.042 0.90 0.99 DPEP1 12 0.042 1.06 0.99 FURIN 120.044 1.07 0.99 ANXA1 12 0.044 1.12 0.96 NCAM1 12 0.045 1.08 1.02 PADI212 0.046 1.09 1.00 GFRA2 12 0.046 1.03 0.99 IL2-RA 12 0.046 0.86 0.95CEACAM5 12 0.048 1.19 1.03 IRAK1 12 0.048 1.04 0.92 BTC 12 0.049 1.140.94 ARHGAP1 12 0.050 1.18 0.82

TABLE 11B Differences in proteomic changes between responders andnon-responders (excluding vehicle) at week 24 Non- Responder ResponderFold Fold Assay Visit p-value Change Change WAS 24 0.001 1.09 0.99TRIM21 24 0.001 1.05 0.97 DDAH1 24 0.002 1.07 1.01 PSIP1 24 0.002 1.210.98 IRF9 24 0.002 1.02 0.93 FGF-BP1 24 0.002 1.18 1.08 LGALS7 24 0.0021.11 1.04 TACSTD2 24 0.002 1.05 1.00 CTSC 24 0.003 1.06 0.98 GDF-15 240.003 0.98 1.06 HDGF 24 0.003 1.13 1.02 GLB1 24 0.003 1.10 0.99 AMIGO224 0.003 1.03 1.00 GSAP 24 0.004 1.14 0.95 CD1C 24 0.004 0.90 0.99 CCL1124 0.004 1.11 0.99 SIRT5 24 0.005 0.98 1.01 APBB1IP 24 0.005 1.11 1.00COL4A3BP 24 0.006 0.99 0.97 LRMP 24 0.006 1.04 0.99 ADAM-TS13 24 0.0061.01 1.01 DDX58 24 0.007 1.09 0.98 PIK3AP1 24 0.007 1.16 0.99 IL32 240.009 1.01 0.96 DKKL1 24 0.009 1.02 0.99 HS6ST1 24 0.010 1.06 0.99 ILKAP24 0.010 1.07 0.98 PRKRA 24 0.010 1.06 0.99 FES 24 0.011 1.04 1.00 VEGFD24 0.011 1.08 1.04 CCL23 24 0.011 0.89 0.99 CXCL1 24 0.011 1.05 1.00ARSB 24 0.012 1.08 1.01 SPRY2 24 0.013 1.14 0.88 TRIM5 24 0.013 1.120.95 ENTPD6 24 0.013 1.03 0.99 CRISP2 24 0.013 1.06 1.00 TOP2B 24 0.0141.13 0.98 CASP-8 24 0.014 1.08 0.99 CCL15 24 0.015 0.99 1.04 CCL27 240.015 1.02 0.99 IL15 24 0.016 1.11 1.04 PRDX5 24 0.016 1.13 0.96 SNCG 240.016 1.13 1.06 TNFRSF10C 24 0.016 0.97 1.02 DFFA 24 0.017 1.06 0.98PLXNB3 24 0.017 1.09 1.01 METRNL 24 0.017 1.02 1.04 NPM1 24 0.018 1.161.04 PFKM 24 0.019 1.09 1.03 BST2 24 0.019 1.05 0.99 CD160 24 0.020 0.840.95 SERPINA5 24 0.020 1.11 1.03 BNP 24 0.021 1.01 0.99 DPP7 24 0.0211.07 1.03 CXCL1 24 0.021 1.05 0.99 SLITRK2 24 0.021 1.01 1.01 CCL11 240.022 1.11 1.00 LRRN1 24 0.022 1.08 1.01 SIGLEC6 24 0.022 0.99 0.98 FHIT24 0.022 1.04 1.00 CBL 24 0.022 1.10 0.97 PHOSPHO1 24 0.023 1.07 1.02DCTN2 24 0.025 1.11 1.01 GSTP1 24 0.025 1.03 0.99 DSG3 24 0.025 0.990.99 NMNAT1 24 0.026 1.14 1.05 SRP14 24 0.026 1.15 1.04 NAAA 24 0.0271.09 1.02 S100A4 24 0.027 1.09 1.04 DEFA1 24 0.027 1.03 0.97 Siglec-9 240.028 1.02 1.00 ARSA 24 0.028 1.06 1.02 S100A11 24 0.030 1.07 0.99 CD4624 0.030 1.06 1.03 NPDC1 24 0.031 1.00 1.07 FLI1 24 0.031 1.05 0.98CD79B 24 0.032 0.96 0.99 IGFBP-2 24 0.033 0.94 1.04 IL5 24 0.033 0.911.03 GCP5 24 0.033 1.03 1.00 UMOD 24 0.033 1.04 1.01 SOD2 24 0.034 1.051.02 gal-8 24 0.035 1.07 1.02 HCLS1 24 0.035 1.15 0.95 SORT1 24 0.0361.02 1.00 ATP6V1F 24 0.036 1.01 1.02 XCL1 24 0.036 0.84 0.93 LIF 240.036 0.99 1.02 Flt3L 24 0.037 1.13 1.05 ABHD14B 24 0.037 1.05 1.02PPP1R9B 24 0.037 1.01 0.96 MMP-1 24 0.039 1.13 1.01 APOM 24 0.039 1.080.99 SCGB3A1 24 0.039 1.07 1.08 IL-17D 24 0.039 1.02 0.98 HNMT 24 0.0391.08 1.01 RBKS 24 0.040 1.11 1.02 MAD1L1 24 0.041 1.03 1.03 PODXL2 240.041 1.01 1.00 OPN 24 0.042 0.83 0.97 DPEP1 24 0.042 1.04 1.01 FURIN 240.044 1.07 1.00 ANXA1 24 0.044 1.12 1.01 NCAM1 24 0.045 1.09 1.02 PADI224 0.046 1.10 0.98 GFRA2 24 0.046 1.01 0.99 IL2-RA 24 0.046 0.83 0.94CEACAM5 24 0.048 1.25 1.04 IRAK1 24 0.048 1.02 0.99 BTC 24 0.049 1.090.97 ARHGAP1 24 0.050 1.15 0.98

Example 5: Interferon-Gamma and Tumor Necrosis-Alpha Induced JanusKinase Expression in Keratinocyte and Subsequent Production ofInflammatory Mediators

Transformed human keratinocyte (HaCaT) cells were purchased fromAddexBio (Catalog #T0020001) and cultured in Optimized Dulbecco'sModified Eagle's Medium (AddexBio, Catalog #C0003-02) supplemented with10% Fetal Bovine Serum (Hyclone, Catalog #16140-071) and 1×Penicillin/Streptomycin (Gibco, Catalog #15140-122). When cells reached80-90% confluency they were washed with 1×DPBS then detached from tissueculture flasks by incubation with 0.25% Trypsin (Gibco, Catalog#25200-056) for 3-5 minutes at 37° C./5% CO₂. Cell culture media wasadded to trypsinized cells then cell suspension was transferred to asterile 15 mL centrifuge tube to be spun down for 10 minutes at 1300rpms. Media containing trypsin was aspirated from the cell pellet andthen the pellet was re-suspended in 10 mL of cell culture media. Cellswere counted using a Countess II automated cell counter then seeded intotissue culture treated 24 well plates at a concentration of 4×10⁴cells/mL and incubated for 48 hours at 37° C./5% CO₂. After 48 hoursmedia was removed and replaced with 500 uL of either cell culture mediaor a combinatory stimulation of Recombinant Human Interferon gamma (R&DSystems, Catalog #285-IF-100) and Recombinant Human Tumor NecrosisFactor alpha (R&D Systems, Catalog #210-TA-020). HaCaT cells treatedwith the combinatory cytokine stimulation were treated at finalconcentrations of 10 ng/mL, 25 ng/mL, 50 ng/mL, or 100 ng/mL of eachcytokine. Treated plates were mixed by gentle agitation for 30 secondsthen incubated for 24 hours at 37° C./5% CO₂. At the end of the 24 hourincubation, media was immediately removed from each plate.

RNA was isolated from HaCaT cells using the QuantiGene Plex Assayreagents and protocols (Affymetrix, Catalog #QGP-232-M18042302). Cellswere washed with 1×DPBS then lysed by incubation with providedQuantiGene lysis buffer for 30 minutes at 50-55° C. Cell lysates wereincubated for 18-24 hours at 55° C. with capture beads and probe setdesigned to specifically hybridize to mRNA from targets of interest. Thepanel of 32 targets of interest included housekeeping genes used for thenormalization of the results. After the 18-24 hour incubation signal wasamplified utilizing branched DNA methodologies, according to themanufacturer's procedures (Affymetrix, Catalog #QGP-232-M18042302).After hybridization and wash steps assay plate was read on the Luminex200 and data were expressed as Net Median Fluorescence Intensity. Datawas then normalized to the Net Median Fluorescence Intensity of thehousekeeping gene HPRT1 (Table 12).

TABLE 12 Stimulation of Human Keratinocytes with TNFα and IFNγ Inducesthe JAK/STAT Pathway and Pro-Inflammatory Cytokines Gene TreatmentMFI^(a) p-value JAK1 Vehicle 126.7 ± 6.55  — 10 ng/ml TNFα/IFNγ 178.19 ±3.41  <.0001 25 ng/ml TNFα/IFNγ 195.02 ± 3.47  <.0001 50 ng/ml TNFα/IFNγ198.23 ± 2.52  <.0001 100 ng/ml TNFα/IFNγ 207.34 ± 3.91  <.0001 JAK2Vehicle 21.7 ± 0.53 — 10 ng/ml TNFα/IFNγ 154.13 ± 11.65  <.0001 25 ng/mlTNFα/IFNγ 174.07 ± 12.34  <.0001 50 ng/ml TNFα/IFNγ 180.71 ± 13.63 <.0001 100 ng/ml TNFα/IFNγ 187.94 ± 13.12  <.0001 JAK3 Vehicle  0.1 ±0.02 — 10 ng/ml TNFα/IFNγ 0.16 ± 0.05 0.8111 25 ng/ml TNFα/IFNγ 0.18 ±0.05 0.596 50 ng/ml TNFα/IFNγ 0.33 ± 0.06 0.0082 100 ng/ml TNFα/IFNγ0.28 ± 0.06 0.0532 TYK2 Vehicle 167.84 ± 2.25  — 10 ng/ml TNFα/IFNγ240.49 ± 4.4   <.0001 25 ng/ml TNFα/IFNγ 250.15 ± 3.41  <.0001 50 ng/mlTNFα/IFNγ 257.24 ± 3.55  <.0001 100 ng/ml TNFα/IFNγ 265.37 ± 3.1  <.0001 STAT1 Vehicle 484.33 ± 4.52  — 10 ng/ml TNFα/IFNγ 3834.09 ±65.62  <.0001 25 ng/ml TNFα/IFNγ 3935.51 ± 66.15  <.0001 50 ng/mlTNFα/IFNγ 3943.03 ± 63.05  <.0001 100 ng/ml TNFα/IFNγ 4136.09 ± 67.06 <.0001 STAT3 Vehicle 606.76 ± 11.51  — 10 ng/ml TNFα/IFNγ 1561.14 ±40.35  <.0001 25 ng/ml TNFα/IFNγ 1652.97 ± 39.53  <.0001 50 ng/mlTNFα/IFNγ 1666.52 ± 52.15  <.0001 100 ng/ml TNFα/IFNγ 1742.81 ± 38.26 <.0001 STAT4 Vehicle 2.27 ± 0.12 — 10 ng/ml TNFα/IFNγ 3.78 ± 0.22 <.000125 ng/ml TNFα/IFNγ 3.84 ± 0.23 <.0001 50 ng/ml TNFα/IFNγ 3.72 ± 0.25<.0001 100 ng/ml TNFα/IFNγ 3.61 ± 0.28 0.0003 STAT5A Vehicle 1.03 ± 0.1 — 10 ng/ml TNFα/IFNγ 26.06 ± 3.1  <.0001 25 ng/ml TNFα/IFNγ 28.58 ±3.23  <.0001 50 ng/ml TNFα/IFNγ 31.01 ± 3.37  <.0001 100 ng/ml TNFα/IFNγ29.61 ± 2.91  <.0001 STAT5B Vehicle 37.04 ± 1.85  — 10 ng/ml TNFα/IFNγ28.06 ± 0.7  0.0002 25 ng/ml TNFα/IFNγ 31.37 ± 1.24  0.0288 50 ng/mlTNFα/IFNγ 34.89 ± 0.88  0.693 100 ng/ml TNFα/IFNγ 41.66 ± 2.17  0.0978STAT6 Vehicle 626.95 ± 22    — 10 ng/ml TNFα/IFNγ 1010.38 ± 14.28 <.0001 25 ng/ml TNFα/IFNγ 1044.97 ± 12.71  <.0001 50 ng/ml TNFα/IFNγ1039.59 ± 10.5   <.0001 100 ng/ml TNFα/IFNγ 1059.01 ± 13.45  <.0001 IL1AVehicle 156.9 ± 1.89  — 10 ng/ml TNFα/IFNγ 1786.44 ± 31.13  <.0001 25ng/ml TNFα/IFNγ 2135.03 ± 66.58  <.0001 50 ng/ml TNFα/IFNγ 2256.89 ±90.79  <.0001 100 ng/ml TNFα/IFNγ 2459.6 ± 106.2  <.0001 IL6 Vehicle5.89 ± 0.19 — 10 ng/ml TNFα/IFNγ 311.31 ± 38.81  0.0002 25 ng/mlTNFα/IFNγ 410.93 ± 52.93  <.0001 50 ng/ml TNFα/IFNγ 464.27 ± 61.46 <.0001 100 ng/ml TNFα/IFNγ 519.31 ± 68.04  <.0001 AREG Vehicle 400.84 ±7.25  — 10 ng/ml TNFα/IFNγ 1265.9 ± 28.84  <.0001 25 ng/ml TNFα/IFNγ1336.82 ± 61.28  <.0001 50 ng/ml TNFα/IFNγ 1403.44 ± 80.21  <.0001 100ng/ml TNFα/IFNγ 1644.4 ± 105.83 <.0001 CCL17 Vehicle 400.84 ± 7.25  — 10ng/ml TNFα/IFNγ 1265.9 ± 28.84  <.0001 25 ng/ml TNFα/IFNγ 1336.82 ±61.28  <.0001 50 ng/ml TNFα/IFNγ 1403.44 ± 80.21  <.0001 100 ng/mlTNFα/IFNγ 1644.4 ± 105.83 <.0001 CCL18 Vehicle 400.84 ± 7.25  — 10 ng/mlTNFα/IFNγ 1265.9 ± 28.84  <.0001 25 ng/ml TNFα/IFNγ 1336.82 ± 61.28 <.0001 50 ng/ml TNFα/IFNγ 1403.44 ± 80.21  <.0001 100 ng/ml TNFα/IFNγ1644.4 ± 105.83 <.0001 FLG Vehicle 400.84 ± 7.25  — 10 ng/ml TNFα/IFNγ1265.9 ± 28.84  <.0001 25 ng/ml TNFα/IFNγ 1336.82 ± 61.28  <.0001 50ng/ml TNFα/IFNγ 1403.44 ± 80.21  <.0001 100 ng/ml TNFα/IFNγ 1644.4 ±105.83 <.0001 IL-17A Vehicle 0.15 ± 0.02 — 10 ng/ml TNFα/IFNγ 0.44 ±0.07 0.0957 25 ng/ml TNFα/IFNγ 0.49 ± 0.07 0.0367 50 ng/ml TNFα/IFNγ 0.6± 0.1 0.0032 100 ng/ml TNFα/IFNγ 0.71 ± 0.15 0.0002 IL-1A Vehicle 156.9± 1.89  — 10 ng/ml TNFα/IFNγ 1786.44 ± 31.13  <.0001 25 ng/ml TNFα/IFNγ2135.03 ± 66.58  <.0001 50 ng/ml TNFα/IFNγ 2256.89 ± 90.79  <.0001 100ng/ml TNFα/IFNγ 2459.6 ± 106.2  <.0001 IL-22 Vehicle 0.23 ± 0.03 — 10ng/ml TNFα/IFNγ 0.41 ± 0.09 0.388 25 ng/ml TNFα/IFNγ 0.47 ± 0.09 0.153950 ng/ml TNFα/IFNγ 0.48 ± 0.11 0.1227 100 ng/ml TNFα/IFNγ 0.67 ± 0.090.0015 IL-23A Vehicle 12.76 ± 0.37  — 10 ng/ml TNFα/IFNγ 38.09 ± 2.39 <.0001 25 ng/ml TNFα/IFNγ 39.07 ± 2.15  <.0001 50 ng/ml TNFα/IFNγ 42.28± 1.89  <.0001 100 ng/ml TNFα/IFNγ 47.07 ± 1.65  <.0001 IL-31 Vehicle0.04 ± 0.01 — 10 ng/ml TNFα/IFNγ 0.22 ± 0.07 0.3665 25 ng/ml TNFα/IFNγ0.11 ± 0.04 0.9472 50 ng/ml TNFα/IFNγ 0.32 ± 0.09 0.0847 100 ng/mlTNFα/IFNγ 0.86 ± 0.15 <.0001 IL-8 Vehicle 74.64 ± 3.13  — 10 ng/mlTNFα/IFNγ 617.68 ± 42.23  <.0001 25 ng/ml TNFα/IFNγ 728.81 ± 54.99 <.0001 50 ng/ml TNFα/IFNγ 802.14 ± 74.58  <.0001 100 ng/ml TNFα/IFNγ911.16 ± 81.8  <.0001 LOR Vehicle 0.04 ± 0.01 — 10 ng/ml TNFα/IFNγ 0.22± 0.07 0.3665 25 ng/ml TNFα/IFNγ 0.11 ± 0.04 0.9472 50 ng/ml TNFα/IFNγ0.32 ± 0.09 0.0847 100 ng/ml TNFα/IFNγ 0.86 ± 0.15 <.0001 S100A12Vehicle 0.04 ± 0.01 — 10 ng/ml TNFα/IFNγ 0.22 ± 0.07 0.3665 25 ng/mlTNFα/IFNγ 0.11 ± 0.04 0.9472 50 ng/ml TNFα/IFNγ 0.32 ± 0.09 0.0847 100ng/ml TNFα/IFNγ 0.86 ± 0.15 <.0001 S100A7 Vehicle 0.04 ± 0.01 — 10 ng/mlTNFα/IFNγ 0.22 ± 0.07 0.3665 25 ng/ml TNFα/IFNγ 0.11 ± 0.04 0.9472 50ng/ml TNFα/IFNγ 0.32 ± 0.09 0.0847 100 ng/ml TNFα/IFNγ 0.86 ± 0.15<.0001 SERPINB3 Vehicle 0.04 ± 0.01 — 10 ng/ml TNFα/IFNγ 0.22 ± 0.070.3665 25 ng/ml TNFα/IFNγ 0.11 ± 0.04 0.9472 50 ng/ml TNFα/IFNγ 0.32 ±0.09 0.0847 100 ng/ml TNFα/IFNγ 0.86 ± 0.15 <.0001 SERPINB4 Vehicle 0.04± 0.01 — 10 ng/ml TNFα/IFNγ 0.22 ± 0.07 0.3665 25 ng/ml TNFα/IFNγ 0.11 ±0.04 0.9472 50 ng/ml TNFα/IFNγ 0.32 ± 0.09 0.0847 100 ng/ml TNFα/IFNγ0.86 ± 0.15 <.0001 TNF-α Vehicle 2.18 ± 0.17 — 10 ng/ml TNFα/IFNγ 41.6 ±4.36 <.0001 25 ng/ml TNFα/IFNγ 47.25 ± 4.66  <.0001 50 ng/ml TNFα/IFNγ49.39 ± 5.12  <.0001 100 ng/ml TNFα/IFNγ 46.97 ± 3.58  <.0001 VEGFAVehicle  280 ± 5.86 — 10 ng/ml TNFα/IFNγ 777.83 ± 43.18  <.0001 25 ng/mlTNFα/IFNγ 828.3 ± 42.48 <.0001 50 ng/ml TNFα/IFNγ 874.08 ± 47.85  <.0001100 ng/ml TNFα/IFNγ 941.78 ± 48.85  <.0001 ^(a)Data are presented as themean ± standard error (SEM)

Target proteins of interest in the media were detected and quantifiedusing the ProCarta Multiplex Immunoassay reagents and protocols(Invitrogen, Catalog #EPX450-12171-901). Media was incubated withantibody conjugated beads designed to bind to the epitopes of specifictarget proteins and identify the bound protein through the bead'sdistinctive spectral pattern. Biotinylated detection antibodies,designed to bind to different epitopes of the same target proteins, andStreptavidin-PE are added to assay plates to quantify the amount of thetarget protein. Assay plates were read on the Luminex 200 and data wereexpressed as Net Median Fluorescence Intensity. The Net MedianFluorescence Intensity values for the antigen standard curve, preparedaccording to the manufacturer's procedures (Invitrogen, Catalog#EPX450-12171-901) were plotted against the expected concentrations foreach standard. The concentration of each protein was extrapolated fromthe antigen standard curve and concentrations were expressed as pg/mL(Table 13).

TABLE 13 Stimulation of Human Keratinocytes with TNFα and IFNγ Inducesthe Pro-Inflammatory Cytokine Production Protein Treatment pg/mL^(a)p-value BDNF Vehicle 4.15 ± 0.08 — 10 ng/ml TNF/IFN 4.15 ± 0.19 >0.999925 ng/ml TNF/IFN 4.09 ± 0.16 0.9977 50 ng/ml TNF/IFN 3.84 ± 0.17 0.4162100 ng/ml TNF/IFN 3.68 ± 0.14 0.1121 EGF Vehicle 0.83 ± 0.13 — 10 ng/mlTNF/IFN  0.9 ± 0.08 0.9983 25 ng/ml TNF/IFN 1.44 ± 0.16 0.1401 50 ng/mlTNF/IFN 2.55 ± 0.22 <.0001 100 ng/ml TNF/IFN 5.49 ± 0.35 <.0001 EotaxinVehicle 2.95 ± 0.33 — 10 ng/ml TNF/IFN 9.46 ± 0.33 <.0001 25 ng/mlTNF/IFN 9.67 ± 0.34 <.0001 50 ng/ml TNF/IFN 9.49 ± 0.39 <.0001 100 ng/mlTNF/IFN 9.83 ± 0.37 <.0001 FGF-2 Vehicle 20.84 ± 1.64  — 10 ng/mlTNF/IFN 40.98 ± 3.26  <.0001 25 ng/ml TNF/IFN 40.02 ± 3.17  <.0001 50ng/ml TNF/IFN 39.86 ± 3.16  <.0001 100 ng/ml TNF/IFN 38.08 ± 2.95 0.0003 GM-CSF Vehicle 25.71 ± 2.38  — 10 ng/ml TNF/IFN 134.07 ± 3.66 <.0001 25 ng/ml TNF/IFN 141.84 ± 4.48  <.0001 50 ng/ml TNF/IFN 142.45 ±5.69  <.0001 100 ng/ml TNF/IFN 140.49 ± 4.62  <.0001 GRO Vehicle 305.38± 40.82  — alpha 10 ng/ml TNF/IFN 688.25 ± 83.68  0.0009 25 ng/mlTNF/IFN 698.98 ± 81.47  0.0006 50 ng/ml TNF/IFN 610.81 ± 69.54  0.0103100 ng/ml TNF/IFN 548.83 ± 66.13  0.0546 HGF Vehicle 7.57 ± 0.65 — 10ng/ml TNF/IFN 14.55 ± 1.05  0.0006 25 ng/ml TNF/IFN 16.49 ± 1.01  <.000150 ng/ml TNF/IFN 19.3 ± 1.44 <.0001 100 ng/ml TNF/IFN 27.71 ± 1.76 <.0001 IFN Vehicle 0.21 ± 0.02 — alpha 10 ng/ml TNF/IFN 0.26 ± 0  0.0144 25 ng/ml TNF/IFN 0.26 ± 0   0.0144 50 ng/ml TNF/IFN 0.26 ± 0  0.0144 100 ng/ml TNF/IFN 0.25 ± 0.01 0.1082 IFN Vehicle 6.79 ± 0.41 —gamma 10 ng/ml TNF/IFN 15919.19 ± 802.52  <.0001 25 ng/ml TNF/IFN23228.32 ± 780.43  <.0001 50 ng/ml TNF/IFN 22666.44 ± 788.93  <.0001 100ng/ml TNF/IFN 19582.48 ± 496.94  <.0001 IL1 Vehicle 0.37 ± 0.05 — alpha10 ng/ml TNF/IFN 13.22 ± 1.24  <.0001 25 ng/ml TNF/IFN 15.12 ± 1.48 <.0001 50 ng/ml TNF/IFN 14.74 ± 1.45  <.0001 100 ng/ml TNF/IFN 13.64 ±1.29  <.0001 IL1 Vehicle 0.69 ± 0.09 — beta 10 ng/ml TNF/IFN 9.79 ± 0.64<.0001 25 ng/ml TNF/IFN 11.45 ± 0.8  <.0001 50 ng/ml TNF/IFN 14.14 ±0.98  <.0001 100 ng/ml TNF/IFN 23.46 ± 1.72  <.0001 IL10 Vehicle 0.28 ±0.07 — 10 ng/ml TNF/IFN 0.37 ± 0.03 0.9194 25 ng/ml TNF/IFN 0.47 ± 0.040.4732 50 ng/ml TNF/IFN 0.95 ± 0.06 <.0001 100 ng/ml TNF/IFN 2.4 ± 0.2<.0001 IL12p70 Vehicle 0.59 ± 0.04 — 10 ng/ml TNF/IFN 1.07 ± 0.03 <.000125 ng/ml TNF/IFN 1.18 ± 0.04 <.0001 50 ng/ml TNF/IFN 1.37 ± 0.04 <.0001100 ng/ml TNF/IFN 1.55 ± 0.04 <.0001 IL13 Vehicle 1.28 ± 0.05 — 10 ng/mlTNF/IFN 1.41 ± 0.19 0.9825 25 ng/ml TNF/IFN  2.3 ± 0.23 0.0052 50 ng/mlTNF/IFN 2.79 ± 0.3  <.0001 100 ng/ml TNF/IFN 2.98 ± 0.23 <.0001 IL15Vehicle 1.39 ± 0   — 10 ng/ml TNF/IFN 1.43 ± 0.14 0.9999 25 ng/mlTNF/IFN 1.62 ± 0.18 0.9145 50 ng/ml TNF/IFN 1.79 ± 0.35 0.6378 100 ng/mlTNF/IFN 3.16 ± 0.39 <.0001 IL17A Vehicle 1.21 ± 0.13 — 10 ng/ml TNF/IFN2.14 ± 0.15 0.7274 25 ng/ml TNF/IFN 3.27 ± 0.34 0.104 50 ng/ml TNF/IFN6.05 ± 0.65 <.0001 100 ng/ml TNF/IFN 14.95 ± 1.29  <.0001 IL18 Vehicle4.38 ± 0.69 — 10 ng/ml TNF/IFN 110.9 ± 2.53  <.0001 25 ng/ml TNF/IFN122.55 ± 1.91  <.0001 50 ng/ml TNF/IFN 120.77 ± 1.51  <.0001 100 ng/mlTNF/IFN 118.99 ± 1.8   <.0001 IL1RA Vehicle 585.47 ± 72.44  — 10 ng/mlTNF/IFN 7383.84 ± 804.86  <.0001 25 ng/ml TNF/IFN 7420.07 ± 815.17 <.0001 50 ng/ml TNF/IFN 7311.36 ± 802.4  <.0001 100 ng/ml TNF/IFN7548.02 ± 827.05  <.0001 IL2 Vehicle 3.54 ± 0.43 — 10 ng/ml TNF/IFN 16.3± 1.24 0.0082 25 ng/ml TNF/IFN 23.72 ± 1.43  <.0001 50 ng/ml TNF/IFN37.7 ± 2.7  <.0001 100 ng/ml TNF/IFN 70.58 ± 5.44  <.0001 IL21 Vehicle2.62 ± 0.18 — 10 ng/ml TNF/IFN 2.88 ± 0   0.0911 25 ng/ml TNF/IFN 2.88 ±0   0.0911 50 ng/ml TNF/IFN 2.88 ± 0   0.0911 100 ng/ml TNF/IFN 2.88 ±0   0.0911 IL22 Vehicle 8.41 ± 0.71 — 10 ng/ml TNF/IFN 8.68 ± 0.220.9808 25 ng/ml TNF/IFN 8.9 ± 0  0.8618 50 ng/ml TNF/IFN 8.21 ± 0.470.994 100 ng/ml TNF/IFN 8.24 ± 0.52 0.997 IL23 Vehicle 5.68 ± 0.71 — 10ng/ml TNF/IFN 6.64 ± 0.55 0.413 25 ng/ml TNF/IFN 7.07 ± 0.36 0.1265 50ng/ml TNF/IFN 7.43 ± 0   0.036 100 ng/ml TNF/IFN   7 ± 0.44 0.1598 IL27Vehicle 8.55 ± 1.54 — 10 ng/ml TNF/IFN 6.61 ± 0.18 0.946 25 ng/mlTNF/IFN 6.59 ± 0.81 0.9441 50 ng/ml TNF/IFN 10.05 ± 2.65  0.9777 100ng/ml TNF/IFN 19.3 ± 4.41 0.009 IL31 Vehicle 2.99 ± 0.4  — 10 ng/mlTNF/IFN 4.34 ± 0.81 0.2722 25 ng/ml TNF/IFN 4.52 ± 0.56 0.1789 50 ng/mlTNF/IFN 3.55 ± 0.39 0.8899 100 ng/ml TNF/IFN 4.06 ± 0.55 0.4739 IL4Vehicle 5.48 ± 0.44 — 10 ng/ml TNF/IFN 4.99 ± 0.68 0.9822 25 ng/mlTNF/IFN 6.4 ± 0.7 0.8529 50 ng/ml TNF/IFN 7.24 ± 1   0.3834 100 ng/mlTNF/IFN 8.75 ± 1.18 0.0261 IL5 Vehicle 3.72 ± 0   — 10 ng/ml TNF/IFN26.46 ± 1.88  <.0001 25 ng/ml TNF/IFN 29.73 ± 1.67  <.0001 50 ng/mlTNF/IFN 33.05 ± 2.37  <.0001 100 ng/ml TNF/IFN 47.28 ± 3.85  <.0001 IL6Vehicle 72.86 ± 9.77  — 10 ng/ml TNF/IFN 2012.1 ± 337.23 0.0001 25 ng/mlTNF/IFN 2329.01 ± 384.78  <.0001 50 ng/ml TNF/IFN 2208.6 ± 370.81 <.0001100 ng/ml TNF/IFN 1889.75 ± 298.39  0.0004 IL7 Vehicle 2.55 ± 0.19 — 10ng/ml TNF/IFN 2.12 ± 0.14 0.1103 25 ng/ml TNF/IFN 2.06 ± 0.1  0.0537 50ng/ml TNF/IFN 2.03 ± 0.12 0.0378 100 ng/ml TNF/IFN 2.14 ± 0.14 0.137 IL8Vehicle 659.4 ± 97.41 — 10 ng/ml TNF/IFN 3799.39 ± 339.11  <.0001 25ng/ml TNF/IFN 3995.6 ± 356.89 <.0001 50 ng/ml TNF/IFN 3698.94 ± 353.51 <.0001 100 ng/ml TNF/IFN 3292.06 ± 314.73  <.0001 IL9 Vehicle 6.01 ±1.19 — 10 ng/ml TNF/IFN 3.99 ± 0.48 0.2022 25 ng/ml TNF/IFN 3.91 ± 0.4 0.1747 50 ng/ml TNF/IFN 5.08 ± 0.69 0.8074 100 ng/ml TNF/IFN 5.47 ± 0.820.9645 IP-10/ Vehicle 16.61 ± 1.6  — CXCL10 10 ng/ml TNF/IFN 3275.51 ±174.48  <.0001 25 ng/ml TNF/IFN 3243.28 ± 178.41  <.0001 50 ng/mlTNF/IFN 3209.56 ± 211.43  <.0001 100 ng/ml TNF/IFN 2978.45 ± 167.27 <.0001 LIF Vehicle 60.23 ± 7    — 10 ng/ml TNF/IFN 121.31 ± 11.64 0.0002 25 ng/ml TNF/IFN 120.23 ± 11.48  0.0002 50 ng/ml TNF/IFN 112.18 ±10.84  0.0017 100 ng/ml TNF/IFN 100.63 ± 8.12  0.0195 MCP1 Vehicle575.07 ± 57.34  — 10 ng/ml TNF/IFN 99191.31 ± 42809.9  >0.9999 25 ng/mlTNF/IFN 711985.75 ± 650934.52 0.9442 50 ng/ml TNF/IFN 43521.49 ±10251.23 >0.9999 100 ng/ml TNF/IFN 1906255.02 ± 1861136.23 0.3587 MIP1Vehicle 7.47 ± 1.13 — alpha 10 ng/ml TNF/IFN 525.75 ± 87.5  <.0001 25ng/ml TNF/IFN 546.69 ± 92.35  <.0001 50 ng/ml TNF/IFN 531.55 ± 91.88 <.0001 100 ng/ml TNF/IFN 409.14 ± 60.62  0.0012 MIP1 Vehicle 133.69 ±15.91  — beta 10 ng/ml TNF/IFN 312.85 ± 20.44  <.0001 25 ng/ml TNF/IFN319.91 ± 20.09  <.0001 50 ng/ml TNF/IFN 305.48 ± 20.78  <.0001 100 ng/mlTNF/IFN 281.82 ± 17.93  <.0001 PDGF-BB Vehicle 3.88 ± 0.47 — 10 ng/mlTNF/IFN 7.89 ± 0.95 0.0039 25 ng/ml TNF/IFN 8.11 ± 0.99 0.0022 50 ng/mlTNF/IFN 7.52 ± 0.92 0.01 100 ng/ml TNF/IFN 6.52 ± 0.72 0.0902 PIGF-1Vehicle 43.42 ± 4.08  — 10 ng/ml TNF/IFN 81.42 ± 4.94  <.0001 25 ng/mlTNF/IFN 79.48 ± 4.09  <.0001 50 ng/ml TNF/IFN 73.14 ± 4.31  <.0001 100ng/ml TNF/IFN 61.36 ± 3.52  0.0127 RANTES Vehicle 11.78 ± 1.41  — 10ng/ml TNF/IFN 126.13 ± 5.15  <.0001 25 ng/ml TNF/IFN 127.73 ± 2.8  <.0001 50 ng/ml TNF/IFN 119.95 ± 4.67  <.0001 100 ng/ml TNF/IFN 103.48 ±7.09  <.0001 SCF Vehicle 1.94 ± 0.06 — 10 ng/ml TNF/IFN 3.14 ± 0.05<.0001 25 ng/ml TNF/IFN 3.13 ± 0.05 <.0001 50 ng/ml TNF/IFN 2.95 ± 0.06<.0001 100 ng/ml TNF/IFN 2.89 ± 0.07 <.0001 SDF-1 Vehicle 1118.99 ±135.41  — alpha 10 ng/ml TNF/IFN 3192.57 ± 228.82  <.0001 25 ng/mlTNF/IFN 3205.2 ± 218.97 <.0001 50 ng/ml TNF/IFN 3032.51 ± 212.4  <.0001100 ng/ml TNF/IFN 2658.04 ± 190.6  <.0001 TNF Vehicle 2.91 ± 0.61 —alpha 10 ng/ml TNF/IFN 3939.26 ± 53.96  0.9636 25 ng/ml TNF/IFN 17995.73± 1620.77  0.0793 50 ng/ml TNF/IFN 57409.04 ± 12245.5  <.0001 100 ng/mlTNF/IFN 41410 ± 610  <.0001 TNF Vehicle 4.34 ± 0.38 — beta 10 ng/mlTNF/IFN  4.9 ± 0.45 0.8774 25 ng/ml TNF/IFN 4.55 ± 0.29 0.9964 50 ng/mlTNF/IFN  5.6 ± 0.97 0.3051 100 ng/ml TNF/IFN  4.2 ± 0.38 0.9994 VEGF-AVehicle 1293.03 ± 126.33  — 10 ng/ml TNF/IFN 2226.76 ± 233.38  0.0016 25ng/ml TNF/IFN 2066.69 ± 194.45  0.0113 50 ng/ml TNF/IFN 1829.38 ±195.87  0.1193 100 ng/ml TNF/IFN 1372.76 ± 118.46  0.9935 VEGF-D Vehicle7.77 ± 0.61 — 10 ng/ml TNF/IFN 11.87 ± 0.67  <.0001 25 ng/ml TNF/IFN12.02 ± 0.45  <.0001 50 ng/ml TNF/IFN 11.83 ± 0.67  <.0001 100 ng/mlTNF/IFN 10.98 ± 0.5  0.0009 bNGF Vehicle 7.59 ± 1.1  — 10 ng/ml TNF/IFN11.65 ± 0.89  0.03 25 ng/ml TNF/IFN 10.97 ± 1.04  0.0893 50 ng/mlTNF/IFN 10.01 ± 1.32  0.3156 100 ng/ml TNF/IFN  8.2 ± 0.92 0.9829^(a)Data are presented as the mean ± standard error (SEM)

Example 6: Janus Kinase Inhibitors Interfere with Interferon-Gamma andTumor Necrosis-Alpha Mediated Inflammation in Keratinocytes

Transformed human keratinocyte (HaCaT) cells were purchased fromAddexBio (Catalog #T0020001) and cultured as outlined in Example 5. Fourcompounds A-D (Cpd A: ruxolitinib, Cpd B: itacitinib({1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile),Cpd C:4-[3-(Cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide,Cpd D: ((2R,5 S)-5-{2-[(1R)-1-Hydroxyethyl]-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-1-yl}tetrahydro-2H-pyran-2-yl) acetonitrile) werereconstituted in DMSO then each compound was serial diluted with cellculture media to 400 nM, 200 nM, 100 nM, and 50 nM concentrations. After48 hours, cell culture media was removed from 24 well plates andreplaced with 250 uL of media containing serial diluted drug, thenincubated for 15 minutes at 37° C./5% CO₂. After drug incubation, 250 uLof combinatory stimulation containing Recombinant Human Interferon gamma(R&D Systems, Catalog #285-IF-100) and Recombinant Human Tumor NecrosisFactor alpha (R&D Systems, Catalog #210-TA-020) was added to plates. Thefinal concentration of Recombinant Human Interferon gamma andRecombinant Human Tumor Necrosis Factor alpha was 25 ng/mL of eachcytokine. Cytokine stimulation added to wells containing drug broughtthe final concentrations for each drug treatment to 25 nM, 50 nM, 100nM, and 200 nM. Treated plates were mixed by gentle agitation for 30seconds then incubated for 24 hours at 37° C./5% CO₂. At the end of the24 hour incubation media was immediately removed from each plate.

RNA was isolated from HaCaT cells using the QuantiGene Plex Assayreagents and protocols (Affymetrix, Catalog #QGP-232-M18042302)according to the manufacturer's guidelines. Cells were washed with1×DPBS then lysed by incubation with provided QuantiGene lysis bufferfor 30 minutes at 50-55° C. Cell lysates were incubated for 18-24 hoursat 55° C. with capture beads and probe set designed to specificallyhybridize to mRNA from targets of interest. Genes included housekeepinggenes (e.g., HPRT1 and GAPDH) used for the normalization of the results.After the 18-24 hour incubation signal was amplified utilizing branchedDNA methodologies, according to the manufacturer's procedures(Affymetrix, Catalog #QGP-232-M18042302). After hybridization and washsteps assay plate was read on the Luminex 200 and data were expressed asNet Median Fluorescence Intensity. Data was then normalized to the NetMedian Fluorescence Intensity of the housekeeping gene HPRT1 (Table 14).

TABLE 14 Normalized Expression of Target Genes in Human Keratinocytecells Stimulated with TNFα and IFNγ in the Presence/Absence of JAKInhibitors Cpd A Cpd B Gene Stimulation^(a) Drug Conc MFI^(b)p-value^(c) MFI^(b) — — 280.78 ± 16.51  AREG 25 ng/mL 751.69 ±31.99^(¥ ) — 200 nM 260.77 ± 22.45  0.9518 260.61 ± 14.67  25 ng/mL 25nM 760.69 ± 22.09  0.9975 737.85 ± 22.1  25 ng/mL 50 nM 777.53 ± 28.12 0.8906 701.57 ± 12.75  25 ng/mL 100 nM 729.54 ± 20.47  0.933 731.24 ±25.4  25 ng/mL 200 nM 699.96 ± 26.4  0.4532 730.41 ± 24.58  CCL17 — —1.24 ± 0.32 25 ng/mL  2.58 ± 0.39^(€) — 200 nM 1.91 ± 0.63 0.6035 1.56 ±0.38 25 ng/mL 25 nM 3.2 ± 0.5 0.7354 3.37 ± 0.54 25 ng/mL 50 nM  2.5 ±0.39 0.9999 3.06 ± 0.34 25 ng/mL 100 nM 2.99 ± 0.35 0.9168 2.87 ± 0.3325 ng/mL 200 nM 3.86 ± 0.64 0.1754 3.13 ± 0.48 CCL18 — —  1.7 ± 0.53 25ng/mL 1.86 ± 0.21 — 200 nM 1.17 ± 0.27 0.8529 1.49 ± 0.37 25 ng/mL 25 nM1.92 ± 0.33 0.9997 2.12 ± 0.32 25 ng/mL 50 nM 1.89 ± 0.37 1  2.2 ± 0.3525 ng/mL 100 nM  1.7 ± 0.37 0.9909 2.01 ± 0.44 25 ng/mL 200 nM 1.52 ±0.37 0.8881 1.68 ± 0.32 FLG — — 258.99 ± 34.78  25 ng/mL 66.67 ± 9.89  —200 nM 251.29 ± 35.44  0.9999 256.93 ± 36.45  25 ng/mL 25 nM 100.31 ±13.92  0.4228 71.57 ± 9.14  25 ng/mL 50 nM 119.05 ± 15.88  0.0981 74.31± 8.77  25 ng/mL 100 nM 142.19 ± 17.68  0.0083 74.99 ± 8.16  25 ng/mL200 nM 182.45 ± 24.67  <.0001 87.37 ± 10.99 IL17A — — 0.62 ± 0.14 25ng/mL 0.73 ± 0.15 — 200 nM 0.47 ± 0.11 0.8112 0.46 ± 0.1  25 ng/mL 25 nM0.86 ± 0.17 0.8935 0.88 ± 0.13 25 ng/mL 50 nM 0.73 ± 0.11 1 0.92 ± 0.1425 ng/mL 100 nM 0.66 ± 0.11 0.9916 0.85 ± 0.15 25 ng/mL 200 nM 0.55 ±0.12 0.7651 0.91 ± 0.17 ILIA — — 95.72 ± 5.84  25 ng/mL 1405.01 ±27.93^(¥ )  — 200 nM 85.16 ± 6.5  0.9724 92.67 ± 5.54  25 ng/mL 25 nM1115.1 ± 18.96  <.0001 1288.02 ± 20    25 ng/mL 50 nM 962.51 ± 23   <.0001 1258.76 ± 23.63  25 ng/mL 100 nM 839.16 ± 21.04  <.0001 1162.35 ±23.34  25 ng/mL 200 nM 755.65 ± 16.88  <.0001 1126.94 ± 26.22  IL22 — —0.66 ± 0.15 25 ng/mL 0.92 ± 0.27 — 200 nM  0.7 ± 0.11 0.9999 0.61 ± 0.1325 ng/mL 25 nM 1.07 ± 0.18 0.953 1.21 ± 0.24 25 ng/mL 50 nM 1.03 ± 0.140.9841 1.15 ± 0.18 25 ng/mL 100 nM 0.85 ± 0.18 0.9975   1 ± 0.17 25ng/mL 200 nM  0.9 ± 0.19 1 1.01 ± 0.19 IL23A — — 12.36 ± 1.2  25 ng/mL36.02 ± 2.45^(¥ ) — 200 nM 10.88 ± 1.35  0.939 11.41 ± 1.43  25 ng/mL 25nM 60.64 ± 3.34  0.0006 43.92 ± 1.89  25 ng/mL 50 nM 75.92 ± 4.61 <.0001 45.85 ± 2.3  25 ng/mL 100 nM 89.83 ± 5.03  <.0001 53.05 ± 3.22 25 ng/mL 200 nM 104.5 ± 5.55  <.0001 59.53 ± 3.83  IL31 — — 0.61 ± 0.1625 ng/mL 1.08 ± 0.38 — 200 nM 0.65 ± 0.18 >0.999 0.72 ± 0.18 25 ng/mL 25nM 1.19 ± 0.32 0.9975 1.33 ± 0.33 25 ng/mL 50 nM 1.27 ± 0.3  0.9833 1.22± 0.29 25 ng/mL 100 nM 1.02 ± 0.31 0.9997 1.04 ± 0.31 25 ng/mL 200 nM0.95 ± 0.29 0.9948 1.14 ± 0.32 IL6 — — 5.86 ± 0.38 25 ng/mL 170.83 ±5.28^(¥ )  — 200 nM 4.98 ± 0.28 0.999  4.7 ± 0.32 25 ng/mL 25 nM 93.79 ±4.03  <.0001 130.24 ± 3.84  25 ng/mL 50 nM 69.7 ± 2.81 <.0001 122.69 ±4.36  25 ng/mL 100 nM 51.01 ± 1.57  <.0001 111.07 ± 4.74  25 ng/mL 200nM 40.39 ± 2.19  <.0001 93.03 ± 3.25  IL8 — — 69.62 ± 3.87  25 ng/mL361.15 ± 12.15^(¥ ) — 200 nM 57.85 ± 4.65  0.6023 61.71 ± 4.86  25 ng/mL25 nM 420.45 ± 10.71  0.0534 381.74 ± 10.25  25 ng/mL 50 nM 475.48 ±17.32  <.0001 376.41 ± 13.16  25 ng/mL 100 nM 559.43 ± 18.52  <.0001387.33 ± 19.5  25 ng/mL 200 nM 650.22 ± 24.17  <.0001 377.69 ± 20.45 JAK1 — — 183.21 ± 7.55  25 ng/mL 213.93 ± 5.55^(€ )  — 200 nM 177.67 ±11.84  0.9936 177.97 ± 14.91  25 ng/mL 25 nM 206.18 ± 7.99  0.894 216.23± 6.41  25 ng/mL 50 nM 195.48 ± 9.54  0.2925 210.42 ± 10.89  25 ng/mL100 nM 186.97 ± 7.49  0.0621 205.03 ± 11.49  25 ng/mL 200 nM 180.99 ±8.58  0.0191 195.97 ± 10.45  JAK2 — — 25.35 ± 0.95  25 ng/mL 126.63 ±4.89^(¥ )  — 200 nM 25.67 ± 1.03  >0.999 25.21 ± 1.12  25 ng/mL 25 nM89.4 ± 2.21 <.0001 109.39 ± 2.8   25 ng/mL 50 nM 69.7 ± 1.78 <.0001  101± 2.26 25 ng/mL 100 nM 54.4 ± 1.8  <.0001 94.5 ± 2.65 25 ng/mL 200 nM40.25 ± 1.3  <.0001 89.16 ± 3.43  JAK3 — — 0.66 ± 0.14 25 ng/mL 0.52 ±0.16 — 200 nM 0.71 ± 0.15 0.9996 0.68 ± 0.17 25 ng/mL 25 nM 0.81 ± 0.150.5284 0.84 ± 0.12 25 ng/mL 50 nM 1.01 ± 0.23 0.1284 0.83 ± 0.15 25ng/mL 100 nM 0.84 ± 0.13 0.4473 0.92 ± 0.13 25 ng/mL 200 nM 0.68 ± 0.130.9133 0.79 ± 0.15 LOR — — 27.47 ± 9.25  25 ng/mL 31.02 ± 9.83  — 200 nM24.61 ± 7.5  0.9994 23.78 ± 7.16  25 ng/mL 25 nM 40.79 ± 15.11 0.9505 43.2 ± 14.11 25 ng/mL 50 nM 42.06 ± 14.64 0.9258 43.96 ± 15.87 25 ng/mL100 nM 33.46 ± 10.9  0.9997  31.4 ± 10.44 25 ng/mL 200 nM 29.98 ± 11.671 38.46 ± 14.1  S100A12 — — 1.00 ± 0.31 25 ng/mL 1.13 ± 0.12 — 200 nM0.81 ± 0.22 0.9379  0.8 ± 0.13 25 ng/mL 25 nM 1.16 ± 0.18 0.9997 1.21 ±0.16 25 ng/mL 50 nM 1.11 ± 0.18 1 1.04 ± 0.15 25 ng/mL 100 nM 1.02 ±0.12 0.969   1 ± 0.17 25 ng/mL 200 nM 0.98 ± 0.2  0.9219 1.14 ± 0.16S100A7 — —  5.2 ± 1.46 25 ng/mL 6.28 ± 1.61 — 200 nM  4.4 ± 1.41 0.99284.94 ± 1.59 25 ng/mL 25 nM 6.28 ± 1.42 1 5.45 ± 1.02 25 ng/mL 50 nM 6.12± 1.82 1 7.08 ± 1.99 25 ng/mL 100 nM   4 ± 0.77 0.6092 3.83 ± 1.02 25ng/mL 200 nM 3.91 ± 1.18 0.5945 5.73 ± 1.59 SERPINB3 — — 2.66 ± 0.74 25ng/mL 2.65 ± 0.39 — 200 nM 2.86 ± 0.72 0.9995 2.25 ± 0.49 25 ng/mL 25 nM2.53 ± 0.36 0.9984 3.16 ± 0.43 25 ng/mL 50 nM 2.32 ± 0.44 0.9304  2.3 ±0.34 25 ng/mL 100 nM 2.23 ± 0.39 0.8555  2.2 ± 0.35 25 ng/mL 200 nM 1.97± 0.32 0.552 2.21 ± 0.44 SERPINB4 — — 4.45 ± 1.4  25 ng/mL 3.72 ± 0.37 —200 nM  3.6 ± 0.97 0.9677 3.39 ± 0.89 25 ng/mL 25 nM 3.39 ± 0.81 0.99394.23 ± 0.7  25 ng/mL 50 nM 4.07 ± 1.17 0.9925 3.76 ± 0.66 25 ng/mL 100nM 3.02 ± 0.7  0.9158 2.87 ± 0.48 25 ng/mL 200 nM 2.84 ± 0.5  0.84193.19 ± 0.7  STAT1 — — 538.44 ± 16.19  25 ng/mL 3092.83 ± 221.46^(¥ ) —200 nM 548.21 ± 11.82  >0.999 529.16 ± 21.86  25 ng/mL 25 nM 2899.48 ±209.59  0.8799 2861.37 ± 204.56  25 ng/mL 50 nM 2896.02 ± 176.39  0.87332855.28 ± 166.89  25 ng/mL 100 nM 2705.87 ± 184.25  0.406 2783.68 ±179.19  25 ng/mL 200 nM 2468.6 ± 137.34 0.0837 2850.04 ± 177.51  STAT3 —— 751.2 ± 14.97 25 ng/mL 1608.39 ± 70.09^(¥ )  — 200 nM 746.17 ±16.73  >0.999 732.19 ± 23.03  25 ng/mL 25 nM 1434.08 ± 43.26  0.0741466.73 ± 66.75  25 ng/mL 50 nM 1301.55 ± 51.7   0.0005 1437.28 ± 60.69 25 ng/mL 100 nM 1150.46 ± 52.66  <.0001 1373.34 ± 55.51  25 ng/mL 200 nM1082.84 ± 39.32  <.0001 1400.77 ± 58.44  STAT4 — — 4.52 ± 0.64 25 ng/mL 6.19 ± 0.53^(€) — 200 nM 4.32 ± 0.53 0.999 4.28 ± 0.61 25 ng/mL 25 nM6.15 ± 0.47 1   6 ± 0.46 25 ng/mL 50 nM 5.57 ± 0.53 0.7712 6.22 ± 0.4225 ng/mL 100 nM 5.63 ± 0.39 0.8269 6.21 ± 0.48 25 ng/mL 200 nM 5.25 ±0.45 0.4653 6.27 ± 0.56 STAT5A — — 2.17 ± 0.54 25 ng/mL 26.41 ±2.26^(¥ ) — 200 nM 1.99 ± 0.51 >0.999 1.75 ± 0.44 25 ng/mL 25 nM 19.04 ±1.94  0.0111 23.69 ± 1.63  25 ng/mL 50 nM 16.18 ± 1.66  0.0003 22.32 ±2.16  25 ng/mL 100 nM 12.94 ± 1.27  <.0001 20.87 ± 2.1  25 ng/mL 200 nM9.48 ± 0.86 <.0001 19.2 ± 1.94 STAT5B — — 58.77 ± 4.23  25 ng/mL 41.69 ±2.3^(€ )  — 200 nM 57.17 ± 5.38  0.9994 58.85 ± 6.21  25 ng/mL 25 nM42.26 ± 2.35  0.9997 40.74 ± 2.3  25 ng/mL 50 nM 43.63 ± 3.24  0.966542.9 ± 2.44 25 ng/mL 100 nM 41.63 ± 2.76  1 40.75 ± 2.41  25 ng/mL 200nM 44.1 ± 3.37 0.9356  41 ± 3.46 STAT6 — — 749.34 ± 20.85  25 ng/mL1045.99 ± 26.73^(¥ )  — 200 nM 777.03 ± 29.31  0.8981 740.11 ± 34.98  25ng/mL 25 nM 1043.96 ± 20.37  1 1004.82 ± 23.76  25 ng/mL 50 nM 1016.85 ±25.68  0.8028 990.05 ± 21.06  25 ng/mL 100 nM 966.76 ± 28.58  0.0739987.64 ± 15.75  25 ng/mL 200 nM 976.22 ± 14.93  0.1487 985.17 ± 29.31 TNF — — 3.3 ± 1  25 ng/mL 26.79 ± 1.26^(¥ ) — 200 nM 2.39 ± 0.5  0.88822.58 ± 0.57 25 ng/mL 25 nM 27.95 ± 2.01  0.9797 28.04 ± 1.24  25 ng/mL50 nM 26.21 ± 2.55  0.9986 28.66 ± 2.58  25 ng/mL 100 nM 24.59 ± 1.6 0.8367 29.5 ± 2.82 25 ng/mL 200 nM 24.02 ± 2.04  0.7181 28.31 ± 2.97 IYK2 — — 217.4 ± 8.13  25 ng/mL 296.98 ± 6.92  — 200 nM 220.78 ± 12.01 0.9996 217.28 ± 14.28  25 ng/mL 25 nM 298.27 ± 10.83  1 292.92 ± 7.99 25 ng/mL 50 nM 287.93 ± 16.28  0.9305 287.31 ± 11.08  25 ng/mL 100 nM260.21 ± 7.05  0.0546 284.15 ± 9.62  25 ng/mL 200 nM 264.75 ± 8.44 0.1204 277.52 ± 8.67  VEGFA — — 214.26 ± 7.51  25 ng/mL 614.31 ±19.03^(¥ ) — 200 nM 200.65 ± 9.3   0.8794 211.13 ± 12.18  25 ng/mL 25 nM538.79 ± 9.54  0.0006 553.23 ± 11.38  25 ng/mL 50 nM 479.91 ± 16.23 <.0001 545.93 ± 9.71  25 ng/mL 100 nM 415.36 ± 8.5   <.0001 524.82 ±13.65  25 ng/mL 200 nM 398.41 ± 8.58  <.0001 516.11 ± 14.7  Cpd B Cpd CCpd D Gene p-value^(c) MFI^(b) p-value^(c) MFI^(b) p-value^(c) AREG280.78 ± 16.51  751.69 ± 31.99^(¥ ) 0.9502  242.5 ± 16.14 0.6149 251.8 ±23.68 0.8192 0.9832 703.71 ± 20.69 0.5239 725.6 ± 33.78 0.9652 0.3979719.73 ± 30.82 0.8126 778.42 ± 44.28  0.9621 0.9345 669.44 ± 30.130.1075 703.3 ± 37.3  0.7655 0.9254 681.68 ± 16.1  0.206 713.33 ± 37.27 0.8774 CCL17 1.24 ± 0.32  2.58 ± 0.39^(€) 0.9645  0.99 ± 0.28 0.98850.94 ± 0.14 0.9724 0.487 2.63 ± 0.4 0.9999 3.08 ± 0.64 0.8407 0.8373 2.94 ± 0.35 0.9148 2.71 ± 0.41 0.9987 0.9682  3.06 ± 0.47 0.8012 2.86 ±0.3  0.9756 0.7611  2.59 ± 0.34 1 2.34 ± 0.4  0.9873 CCL18  1.7 ± 0.531.86 ± 0.21 0.997  1.56 ± 0.73 0.9995 0.95 ± 0.19 0.6111 0.949  2.11 ±0.28 0.9923 1.89 ± 0.28 0.9999 0.8808  2.13 ± 0.46 0.9891 2.16 ± 0.220.8129 0.9932  2.55 ± 0.87 0.775 1.74 ± 0.26 0.9928 0.9872  1.74 ± 0.620.9996 1.57 ± 0.3  0.847 FLG 258.99 ± 34.78  66.67 ± 9.89  >0.999 211.48± 29.55 0.7251 219.44 ± 34.83  0.8406 0.9882  62.5 ± 8.63 0.9921 71.27 ±11.09 0.994 0.9434 59.01 ± 8.69 0.9315 78.47 ± 10.63 0.8468 0.925 65.04± 9.31 0.9998 69.64 ± 9.33  0.9989 0.3487 68.26 ± 8.04 0.9998 72.06 ±11.85 0.9891 IL17A 0.62 ± 0.14 0.73 ± 0.15 0.7849 0.51 ± 0.1 0.9335 0.43± 0.08 0.6608 0.8705  0.87 ± 0.14 0.8988 1.05 ± 0.18 0.4119 0.7718  1.07± 0.16 0.3001 1.06 ± 0.15 0.3772 0.9406  0.89 ± 0.16 0.8425 0.84 ± 0.160.9649 0.7898  0.87 ± 0.13 0.8859 0.82 ± 0.13 0.9778 ILIA 95.72 ± 5.84 1405.01 ± 27.93^(¥ )  0.9999 88.72 ± 5.9  0.9955 84.51 ± 7.04  0.96470.0047 1370.52 ± 35.28  0.8379 1269.66 ± 50.59  0.0744 0.0003 1308.7 ±45.12 0.0933 1336.95 ± 50.97  0.5871 <.0001 1194.29 ± 12.27  <.00011244.96 ± 41.03  0.0264 <.0001 1151.31 ± 20.01  <.0001 1163.14 ± 26.71 0.0004 IL22 0.66 ± 0.15 0.92 ± 0.27 0.9997  0.71 ± 0.11 0.9996 0.62 ±0.11 0.9999 0.7351  1.23 ± 0.21 0.729 1.39 ± 0.23 0.4163 0.8649  1.4 ±0.19 0.3761  1.4 ± 0.21 0.392 0.9963 1.19 ± 0.2 0.8132 1.24 ± 0.220.7256 0.9936  1.14 ± 0.25 0.8924 1.28 ± 0.2  0.628 IL23A 12.36 ± 1.2 36.02 ± 2.45^(¥ ) 0.9902  9.42 ± 0.97 0.5247 9.55 ± 1.15 0.5682 0.162442.15 ± 1.61 0.2312 48.01 ± 2.69  0.0213 0.0568 45.16 ± 2.92 0.033956.64 ± 3.44  <.0001 0.0003 48.11 ± 1.85 0.0031 51.42 ± 2.55  0.0021<.0001 51.86 ± 2.95 <.0001 53.83 ± 3.54  0.0003 IL31 0.61 ± 0.16 1.08 ±0.38 0.997 0.79 ± 0.2 0.977 0.91 ± 0.23 0.8412 0.9546  1.52 ± 0.370.7954 1.99 ± 0.4  0.2952 0.9951  1.59 ± 0.33 0.6922 1.82 ± 0.44 0.47190.9999  1.49 ± 0.35 0.8327 1.61 ± 0.35 0.7377 0.9999  1.32 ± 0.34 0.96971.51 ± 0.36 0.8459 IL6 5.86 ± 0.38 170.83 ± 5.28^(¥ )  0.9964  4.97 ±0.36 0.999 5.15 ± 0.31 0.9997 <.0001 135.32 ± 3.36  <.0001 132.28 ±7.41  <.0001 <.0001 128.14 ± 6.83  <.0001 137.61 ± 5.87  0.0006 <.0001112.13 ± 3.37  <.0001 122.46 ± 5.35  <.0001 <.0001 101.17 ± 2.91  <.0001119.49 ± 4.42  <.0001 IL8 69.62 ± 3.87  361.15 ± 12.15^(¥ ) 0.8713 55.48± 3.11 0.4288 58.9 ± 5.89 0.6821 0.759 387.86 ± 17.53 0.5469 398.64 ±22.41  0.5547 0.8968 369.89 ± 17.71 0.9832 417.47 ± 21.97  0.2108 0.584361.05 ± 16.02 1 410.72 ± 29.84  0.3111 0.8684  350.6 ± 11.85 0.967367.56 ± 17.81  0.9986 JAK1 183.21 ± 7.55  213.93 ± 5.55^(€ )  0.995159.13 ± 7.08  0.2871 171.53 ± 9.49  0.8675 0.9993 206.29 ± 6.84  0.7834200.4 ± 9.84  0.5654 0.9965 194.2 ± 8.24 0.0808 210.52 ± 7.73  0.99420.9026 193.28 ± 4.55  0.0631 200.25 ± 8.15  0.5562 0.4597 182.86 ± 4.07 0.0023 190.53 ± 7.68  0.1286 JAK2 25.35 ± 0.95  126.63 ±4.89^(¥ )  >0.999 23.67 ± 0.92 0.9806 25.25 ± 1.04  >0.999 0.0021 114.94± 2.16  0.0419 108.89 ± 3.25  0.0165 <.0001 107.16 ± 2.86  0.0003 106.83± 5.94  0.0063 <.0001 95.51 ± 3.13 <.0001 102.64 ± 3.52  0.0007 <.000191.17 ± 2.15 <.0001 92.21 ± 2.9  <.0001 JAK3 0.66 ± 0.14 0.52 ±0.16 >0.999 0.63 ± 0.1 0.9998 0.53 ± 0.09 0.9429 0.3247  1.02 ± 0.190.1022 0.97 ± 0.18 0.2187 0.3497  0.99 ± 0.16 0.1451 0.99 ± 0.2  0.18540.1608  0.99 ± 0.15 0.1449 1.01 ± 0.17 0.1531 0.4876  0.85 ± 0.15 0.4250.86 ± 0.16 0.4442 LOR 27.47 ± 9.25  31.02 ± 9.83  0.998 19.48 ± 9.660.9402 12.79 ± 4.84  0.6024 0.9107  23.22 ± 10.14 0.9976  23 ± 9.470.9343 0.892  32.81 ± 17.47 1 28.28 ± 10.86 0.9987 1  65.94 ± 37.890.6538 21.29 ± 9.59  0.8792 0.9836  37.49 ± 25.57 0.9988  17 ± 7.280.6804 S100A12 1.00 ± 0.31 1.13 ± 0.12 0.9172  0.72 ± 0.18 0.7495 0.61 ±0.11 0.4876 0.9829  1.31 ± 0.16 0.9298 1.31 ± 0.18 0.8142 0.983  1.18 ±0.18 0.9991 1.11 ± 0.18 1 0.942  1.48 ± 0.32 0.5855 1.12 ± 0.15 1 1 1.06± 0.2 0.9978 0.91 ± 0.14 0.7081 S100A7  5.2 ± 1.46 6.28 ± 1.61 >0.999 4.38 ± 1.15 0.992 3.69 ± 0.84 0.9024 0.9847  5.33 ± 1.21 0.948 5.37 ±1.3  0.9715 0.987  3.62 ± 0.78 0.3469 5.94 ± 1.23 0.9993 0.6011  4.3 ±1.17 0.6007  4.6 ± 1.68 0.8016 0.9968  3.95 ± 1.14 0.4638 3.77 ± 0.910.5084 SERPINB3 2.66 ± 0.74 2.65 ± 0.39 0.9843  2.31 ± 0.77 0.9925  1.5± 0.27 0.5042 0.7675  2.58 ± 0.41 1  2 ± 0.3 0.4027 0.9228  2.6 ± 0.69 12.54 ± 0.33 0.9973 0.8326  3.63 ± 1.32 0.7776   2 ± 0.26 0.4053 0.8518 2.14 ± 0.67 0.9734 1.69 ± 0.29 0.1148 SERPINB4 4.45 ± 1.4  3.72 ± 0.370.9238  3.37 ± 1.57 0.918 1.84 ± 0.42 0.2699 0.9325 3.53 ± 0.5 1 2.78 ±0.31 0.2638 1 4.24 ± 1.6 0.9991  3.2 ± 0.53 0.7515 0.7071  7.56 ± 3.670.4349 2.64 ± 0.3  0.1667 0.9217 3.54 ± 1.5 1 2.33 ± 0.38 0.0489 STAT1538.44 ± 16.19  3092.83 ± 221.46^(¥ ) >0.999 522.12 ± 14.19 >0.999549.79 ± 12.18  >0.999 0.8059 3103.89 ± 185.88 1 3156.82 ± 244.78 0.9981 0.7919 3049.62 ± 159.5  0.9993 3009.6 ± 169.64 0.9948 0.61113028.93 ± 125.19 0.9969 2991.9 ± 200.56 0.9892 0.7796 2977.26 ± 166.850.9717 3154.11 ± 139.56  0.9984 STAT3 751.2 ± 14.97 0.9952 728.97 ±20.48 0.9903 750.9 ± 27.68 >0.999 0.3206 1557.84 ± 58.15  0.9399 1572.76± 65.5   0.988 0.1762 1519.61 ± 69.92  0.6963 1543.4 ± 58.65  0.90420.0352 1457.24 ± 54.48  0.2524 1549.17 ± 89.41  0.9288 0.0738 1483.1 ±51.73 0.4109 1570.19 ± 51.51  0.9845 STAT4 4.52 ± 0.64  6.19 ± 0.53^(€)0.9975  4.01 ± 0.45 0.9392 3.75 ± 0.33 0.7552 0.9967  5.65 ± 0.44 0.7981 5.4 ± 0.45 0.5462 1  5.41 ± 0.33 0.5294  6.1 ± 0.36 0.9997 1  5.32 ±0.46 0.4306 5.83 ± 0.34 0.9448 0.9999  5.04 ± 0.36 0.1955 5.42 ± 0.520.5691 STAT5A 2.17 ± 0.54 26.41 ± 2.26^(¥ ) 0.9988  1.44 ± 0.41 0.98391.12 ± 0.19 0.9305 0.7471 22.82 ± 1.77 0.452 20.12 ± 1.29  0.0428 0.422520.71 ± 1.77 0.1041 22.69 ± 1.71  0.3629 0.1784 18.44 ± 1.85 0.012219.54 ± 1.34  0.0233 0.0505 17.64 ± 1.46 0.0051 18.33 ± 1.83  0.0059STAT5B 58.77 ± 4.23  41.69 ± 2.3^(€ )  >0.999 50.91 ± 4.38 0.6377 54.64± 4.79  0.9556 0.997 40.13 ± 1.97 0.9485 38.56 ± 2.02  0.6509 0.992338.42 ± 2.28 0.5958 40.76 ± 1.91  0.9926 0.9971 36.56 ± 1.18 0.215440.91 ± 2.17  0.9963 0.9991 36.34 ± 1.97 0.1863 36.62 ± 1.7  0.2421STAT6 749.34 ± 20.85  1045.99 ± 26.73^(¥ )  0.9991 723.56 ± 20.76 0.9214762.04 ± 9.44  0.9961 0.5557 1020.89 ± 23.57  0.8238 1042.76 ± 29.23  10.2895 982.62 ± 14.34 0.1296 1046.46 ± 29.12  1 0.2557 943.66 ± 25.990.005 985.1 ± 39.79 0.3955 0.224 966.51 ± 12.3  0.0388 1013.25 ± 17.15 0.8453 TNF 3.3 ± 1  26.79 ± 1.26^(¥ ) 0.9528  2.19 ± 0.56 0.7829 1.59 ±0.22 0.417 0.9859 24.07 ± 1.43 0.5138 26.07 ± 1.13  0.9962 0.9421 26.51± 1.84 0.9998 29.31 ± 2.52  0.7374 0.8206 25.93 ± 1.59 0.9829 27.59 ±1.64  0.994 0.9717 24.73 ± 1.29 0.733 27.63 ± 2.3  0.9928 IYK2 217.4 ±8.13  296.98 ± 6.92  >0.999 205.57 ± 10.87 0.8924 217.28 ± 10.09  >0.9990.9929 283.97 ± 8.59  0.5015 283.93 ± 8.16  0.7981 0.8603 273.68 ± 7.44 0.076 307.36 ± 14.87  0.8958 0.7043  266 ± 6.82 0.0108 280.63 ± 10.46 0.65 0.3578 263.49 ± 5.05  0.0053 283.28 ± 10.88  0.7707 VEGFA 214.26 ±7.51  614.31 ± 19.03^(¥ ) 0.9998 199.88 ± 6.52  0.8548 210.34 ± 9.72 0.9995 0.0119 570.27 ± 10.88 0.0433 600.98 ± 13.99  0.9438 0.0041 531.53± 11.24 <.0001 582.24 ± 17.89  0.4554 0.0001 514.04 ± 7.46  <.0001 572.2± 19.67 0.2261 <.0001 492.12 ± 8.32  <.0001 541.01 ± 9.94  0.0098^(a)Stimulation with TNFα (25 ng/mL) and IFNγ (25 ng/mL) ^(b)Data ispresented as mean ± standard error ^(c)Significant differences comparedback to stimulation with TNFα and IFNγ alone ^(¥)Indicates significantdifference of p < 0.0001 from vehicle (no stimulation and no drugconcentration) alone ^(€)Indicates significant difference of p < 0.1from vehicle

Target proteins of interest in the media were detected and quantifiedusing the ProCarta Multiplex Immunoassay reagents and protocols(Invitrogen, Catalog #EPX450-12171-901). Media was incubated withantibody conjugated beads designed to bind to the epitopes of specifictarget proteins and identify the bound protein through the bead'sdistinctive spectral pattern. Biotinylated detection antibodies,designed to bind to different epitopes of the same target proteins, andStreptavidin-PE are added to assay plates to quantify the amount of thetarget proteins. Assay plates were read on the Luminex 200 and data wereexpressed as Net Median Fluorescence Intensity. The net medianflorescence values for the antigen standard curve, prepared according tothe manufacturer's procedures (Invitrogen, Catalog #EPX450-12171-901)was plotted against the expected concentrations for each standard. Theconcentration of each protein was extrapolated from the antigen standardcurve and concentrations were expressed as pg/mL (Table 15).

TABLE 15 Concentrations of Inflammatory Mediators Produced by HumanKeratinocyte cells Stimulated with TNFα and IFNγ in the Presence/Absenceof JAK Inhibitors Cpd A Cpc B Protein Stimulation^(a) Drug Concentrationpg/mL^(b) p-value^(c) pg/mL^(b) BDNF 5.91 ± 0.28 25 ng/ml  4.11 ±0.15^(¥) 200 nM 5.59 ± 0.34 0.9116 5.35 ± 0.34 25 ng/ml 25 nM 4.13 ±0.18 >0.999 4.05 ± 0.19 25 ng/ml 50 nM 4.16 ± 0.29 0.9996 4.04 ± 0.24 25ng/ml 100 nM 4.22 ± 0.24 0.9928 4.06 ± 0.26 25 ng/ml 200 nM  4.3 ± 0.260.9394  4.1 ± 0.24 bNGF 2.13 ± 0.39 25 ng/ml  6.86 ± 0.53^(¥) 200 nM3.81 ± 0.48 0.1269 3.84 ± 0.71 25 ng/ml 25 nM 7.4 ± 0.5 0.9486  7.7 ±0.55 25 ng/ml 50 nM 6.73 ± 0.69 0.9998 7.09 ± 0.71 25 ng/ml 100 nM 6.54± 0.88 0.993 7.04 ± 0.59 25 ng/ml 200 nM 7.72 ± 0.76 0.7846 6.52 ± 0.69EGF  1.2 ± 0.13 25 ng/ml 1.33 ± 0.08 200 nM 0.97 ± 0.18 0.6107 1.06 ±0.14 25 ng/ml 25 nM 1.87 ± 0.17 0.1339 1.76 ± 0.17 25 ng/ml 50 nM 1.57 ±0.24 0.7734 1.67 ± 0.15 25 ng/ml 100 nM 1.75 ± 0.22 0.3094 1.56 ± 0.2 25 ng/ml 200 nM 1.82 ± 0.16 0.1796 1.52 ± 0.1  Eotaxin 2.16 ± 0.08 25ng/ml  9.63 ± 0.17^(¥) 200 nM 2.28 ± 0.07 0.8577 2.22 ± 0.09 25 ng/ml 25nM 10.33 ± 0.15  0.0307 10.22 ± 0.15  25 ng/ml 50 nM 10.2 ± 0.26 0.10199.92 ± 0.2  25 ng/ml 100 nM 10.67 ± 0.11  0.0007 10.09 ± 0.19  25 ng/ml200 nM 11.02 ± 0.17  <.0001 10.05 ± 0.19  FGF-2 9.44 ± 1.18 25 ng/ml22.39 ± 0.9^(¥ )  200 nM 9.44 ± 0.62 >0.999  8.5 ± 0.95 25 ng/ml 25 nM21.29 ± 1.39  0.9364 20.63 ± 1.49  25 ng/ml 50 nM 20.92 ± 1.66  0.845619.94 ± 1.49  25 ng/ml 100 nM 20.8 ± 1.16 0.8096 20.42 ± 1.5  25 ng/ml200 nM 20.13 ± 1.33  0.5458 21.39 ± 1.61  GM-CSF 7.58 ± 1.05 25 ng/ml122.09 ± 2.57^(¥ )  200 nM 11.32 ± 1.46  0.3826 8.69 ± 1.22 25 ng/ml 25nM 136.85 ± 3    0.0058 130.13 ± 2.13  25 ng/ml 50 nM 137.01 ± 3.11 0.0052 128.05 ± 2.9   25 ng/ml 100 nM 138.7 ± 3.64  0.0017 133.06 ±4.24  25 ng/ml 200 nM 136.87 ± 2.98  0.0045 134.13 ± 3.74  GRO 244.73 ±8.14  alpha 25 ng/ml 529.34 ± 24.39  200 nM 245.8 ± 12.99 >0.999 228.97± 14.45  25 ng/ml 25 nM 592.61 ± 42.91  0.8763 547.38 ± 31.41  25 ng/ml50 nM 650.74 ± 57.35  0.4383 544.63 ± 38.3  25 ng/ml 100 nM 784.21 ±70.75  0.018 568.49 ± 35.18  25 ng/ml 200 nM 879.13 ± 83.38  0.0006563.61 ± 42.17  HGF 4.37 ± 0.38 25 ng/ml 13.82 ± 0.29^(¥ ) 200 nM 4.54 ±0.39 0.998 4.44 ± 0.32 25 ng/ml 25 nM 14.89 ± 0.34  0.3296 14.15 ± 0.3 25 ng/ml 50 nM 15.05 ± 0.56  0.2218 13.65 ± 0.53  25 ng/ml 100 nM 15.5 ±0.43 0.0549 14.41 ± 0.55  25 ng/ml 200 nM 15.62 ± 0.61  0.0302 13.5 ±0.57 IFN 0.24 ± 0.03 alpha 25 ng/ml 0.26 ± 0   200 nM 0.22 ± 0.03 0.9830.23 ± 0.02 25 ng/ml 25 nM 0.24 ± 0.02 0.3231 0.24 ± 0.02 25 ng/ml 50 nM0.26 ± 0   >0.999 0.26 ± 0   25 ng/ml 100 nM 0.26 ± 0   >0.999 0.26 ±0   25 ng/ml 200 nM 0.26 ± 0   >0.999 0.26 ± 0   IFN 4.81 ± 0.71 gamma25 ng/ml 25004.72 ± 3327.44^(¥ ) 200 nM 3.02 ± 0.54 >0.999 3.39 ± 0.6925 ng/ml 25 nM 24518.59 ± 2794.62  0.9999 35023.68 ± 10759.49 25 ng/ml50 nM 24118.43 ± 3991.24  0.9993 28977.92 ± 7400.61  25 ng/ml 100 nM27210.77 ± 4144.05  0.9787 29276.66 ± 7697.74  25 ng/ml 200 nM 24961.65± 3542.59  >0.999 25272.53 ± 3796.83  IL1 0.29 ± 0.03 alpha 25 ng/ml 7.82 ± 0.18^(¥) 200 nM 0.31 ± 0.04 >0.999 0.29 ± 0.03 25 ng/ml 25 nM5.93 ± 0.29 <.0001 7.34 ± 0.31 25 ng/ml 50 nM 4.9 ± 0.3 <.0001 7.06 ±0.37 25 ng/ml 100 nM 4.12 ± 0.26 <.0001   7 ± 0.41 25 ng/ml 200 nM 3.45± 0.23 <.0001 6.16 ± 0.35 IL1 0.94 ± 0.1  beta 25 ng/ml  8.29 ± 0.44^(¥)200 nM  0.7 ± 0.13 0.8893 0.98 ± 0.14 25 ng/ml 25 nM 9.68 ± 0.61 0.11819.53 ± 0.3  25 ng/ml 50 nM 8.96 ± 0.56 0.6835 8.96 ± 0.43 25 ng/ml 100nM 8.21 ± 0.33 0.9999 8.66 ± 0.41 25 ng/ml 200 nM 8.04 ± 0.27 0.98518.43 ± 0.29 IL10 0.38 ± 0.08 25 ng/ml  0.84 ± 0.08^(¥) 200 nM  0.3 ±0.08 0.9638 0.32 ± 0.07 25 ng/ml 25 nM 0.96 ± 0.06 0.5558 0.87 ± 0.06 25ng/ml 50 nM 0.95 ± 0.06 0.6701 0.85 ± 0.05 25 ng/ml 100 nM 0.87 ± 0.060.9985 0.88 ± 0.06 25 ng/ml 200 nM 0.91 ± 0.06 0.8842 0.84 ± 0.06IL12p70 2.34 ± 0.27 25 ng/ml 1.75 ± 0.23 200 nM 2.17 ± 0.25 0.9859 1.55± 0.29 25 ng/ml 25 nM 1.91 ± 0.2  0.9534 2.01 ± 0.21 25 ng/ml 50 nM 1.71± 0.23 0.9999 1.68 ± 0.21 25 ng/ml 100 nM 1.76 ± 0.21 >0.999 1.77 ± 0.1825 ng/ml 200 nM 1.82 ± 0.2  0.9966 1.87 ± 0.16 IL13  1.2 ± 0.13 25 ng/ml 2.19 ± 0.42^(¥) 200 nM 1.22 ± 0.11 >0.999 1.14 ± 0.13 25 ng/ml 25 nM3.12 ± 0.27 0.1649 2.79 ± 0.33 25 ng/ml 50 nM 2.46 ± 0.31 0.9449 2.73 ±0.23 25 ng/ml 100 nM 2.16 ± 0.27 >0.999 2.55 ± 0.33 25 ng/ml 200 nM 2.44± 0.35 0.9547 2.52 ± 0.3  IL15 1.84 ± 0.29 25 ng/ml 2.75 ± 0.78 200 nM1.64 ± 0.22 0.999 2.22 ± 0.42 25 ng/ml 25 nM 2.95 ± 0.78 0.9977  3.3 ±0.93 25 ng/ml 50 nM 2.36 ± 0.41 0.9731 2.71 ± 0.65 25 ng/ml 100 nM 2.31± 0.39 0.9576 2.58 ± 0.68 25 ng/ml 200 nM 2.88 ± 0.46 0.9994 2.57 ± 0.54IL17A 1.03 ± 0.09 25 ng/ml  3.91 ± 0.36^(¥) 200 nM 1.26 ± 0.22 0.9429 1.2 ± 0.29 25 ng/ml 25 nM 4.97 ± 0.36 0.1478 4.6 ± 0.5 25 ng/ml 50 nM4.7 ± 0.5 0.3725 4.09 ± 0.43 25 ng/ml 100 nM 5.05 ± 0.15 0.1065 4.84 ±0.34 25 ng/ml 200 nM 4.91 ± 0.36 0.1703 4.43 ± 0.26 IL18 6.51 ± 0.55 25ng/ml 155.14 ± 2.91^(¥ )  200 nM 7.11 ± 0.21 0.997 6.04 ± 0.5  25 ng/ml25 nM 159.94 ± 3.38  0.7069 162.16 ± 4.98  25 ng/ml 50 nM 151.44 ± 4.51 0.851 153.4 ± 3.46  25 ng/ml 100 nM 151.88 ± 3.38  0.8983 156.06 ± 3.24 25 ng/ml 200 nM 150.47 ± 2.29  0.7082 159.36 ± 4.73  IL1RA 513.38 ±56.01  25 ng/ml 6231.09 ± 271.61^(¥ ) 200 nM 559.82 ± 69.13  0.999502.58 ± 57.22  25 ng/ml 25 nM 5863.67 ± 328.02  0.8215 5944.59 ±264.97  25 ng/ml 50 nM 5640.46 ± 363    0.4817 5840.44 ± 314.35  25ng/ml 100 nM 5417.9 ± 272.66 0.2149 5953.24 ± 309.78  25 ng/ml 200 nM 5320 ± 306.58 0.1274 5710.44 ± 269.38  IL2 2.99 ± 0.33 25 ng/ml   29 ±1.27^(¥) 200 nM 3.57 ± 0.62 0.955 3.32 ± 0.6  25 ng/ml 25 nM 35.39 ±2.01  0.0508 33.62 ± 1.88  25 ng/ml 50 nM 34.31 ± 2.49  0.1292 31.96 ±1.47  25 ng/ml 100 nM 35.16 ± 1.54  0.0629 31.33 ± 1.43  25 ng/ml 200 nM34.65 ± 1.35  0.0871 31.86 ± 1.25  IL21 2.88 ± 0   25 ng/ml 2.88 ± 0  200 nM 2.63 ± 0.24 0.9101 2.43 ± 0.31 25 ng/ml 25 nM 2.55 ± 0.26 0.62162.66 ± 0.22 25 ng/ml 50 nM 2.77 ± 0.11 0.9855 2.45 ± 0.29 25 ng/ml 100nM 2.33 ± 0.31 0.1873 2.36 ± 0.35 25 ng/ml 200 nM 2.68 ± 0.18 0.883 2.47± 0.28 IL22 8.9 ± 0  25 ng/ml 7.92 ± 0.65 200 nM 7.74 ± 0.8  0.74 8.13 ±0.77 25 ng/ml 25 nM 8.69 ± 0.42 0.7682 8.69 ± 0.42 25 ng/ml 50 nM 8.24 ±0.66 0.9868 8.9 ± 0  25 ng/ml 100 nM 8.9 ± 0  0.596 8.03 ± 0.87 25 ng/ml200 nM 7.48 ± 0.79 0.9547 7.74 ± 0.78 IL23 7.35 ± 0.54 25 ng/ml 5.56 ±0.97 200 nM 6.18 ± 0.76 0.8627  5.8 ± 1.11 25 ng/ml 25 nM 7.43 ± 0  0.0716 7.28 ± 0.16 25 ng/ml 50 nM 6.82 ± 0.61 0.3244 7.43 ± 0   25 ng/ml100 nM  6.9 ± 0.53 0.2733 6.44 ± 0.69 25 ng/ml 200 nM  7.5 ± 0.06 0.05257.41 ± 0.5  IL27 6.93 ± 0.9  25 ng/ml 6.23 ± 0.97 200 nM 8.91 ± 2.620.9348 7.57 ± 2.22 25 ng/ml 25 nM 6.59 ± 1.92 0.9997 8.03 ± 1.71 25ng/ml 50 nM 7.67 ± 1.39 0.9418 6.95 ± 0.83 25 ng/ml 100 nM 7.11 ± 1.170.9899 5.36 ± 0.73 25 ng/ml 200 nM 11.45 ± 2.57  0.1198 8.04 ± 1.65 IL313.67 ± 0   25 ng/ml  2.6 ± 0.63 200 nM 3.32 ± 0.35 0.9393 3.01 ± 0.44 25ng/ml 25 nM 3.33 ± 0.36 0.5388  3.6 ± 0.28 25 ng/ml 50 nM 3.32 ± 0.350.5468 3.22 ± 0.38 25 ng/ml 100 nM 3.19 ± 0.34 0.7047 3.35 ± 0.44 25ng/ml 200 nM  3.2 ± 0.29 0.6722 3.93 ± 0.4  IL4 4.72 ± 0.44 25 ng/ml6.73 ± 1.28 200 nM  3.6 ± 0.51 0.8423 4.61 ± 0.7  25 ng/ml 25 nM 8.29 ±1.89 0.771 6.74 ± 1.65 25 ng/ml 50 nM 3.75 ± 0.54 0.2516 5.74 ± 1.1  25ng/ml 100 nM 3.94 ± 0.7  0.304 5.78 ± 0.72 25 ng/ml 200 nM 6.49 ± 1.1 0.9997 6.42 ± 1.24 IL5  2.7 ± 0.43 25 ng/ml 28.59 ± 1.29^(¥ ) 200 nM2.42 ± 0.45 0.9981 2.84 ± 0.38 25 ng/ml 25 nM 25.21 ± 1.58  0.4178 27.31± 1.32  25 ng/ml 50 nM 26.88 ± 2.14  0.8782 25.5 ± 1.65 25 ng/ml 100 nM26.65 ± 1.6  0.8262 26.52 ± 1.54  25 ng/ml 200 nM 25.3 ± 1.55 0.422625.88 ± 1.37  IL6 30.57 ± 2.89  25 ng/ml 862.33 ± 17.95^(¥ ) 200 nM28.79 ± 2.91  0.9999 26.86 ± 2.62  25 ng/ml 25 nM 594.5 ± 25.17 <.0001749.64 ± 32.94  25 ng/ml 50 nM 446.35 ± 19.73  <.0001 674.21 ± 27.15  25ng/ml 100 nM 362.14 ± 18.73  <.0001 643.8 ± 27.14 25 ng/ml 200 nM 295.21± 15.22  <.0001 568.73 ± 24.74  IL7 3.22 ± 0.12 25 ng/ml  2.26 ±0.09^(¥) 200 nM 3.29 ± 0.21 0.9973 3.03 ± 0.2  25 ng/ml 25 nM  2.1 ±0.15 0.8024 2.14 ± 0.12 25 ng/ml 50 nM 1.96 ± 0.11 0.2854  1.9 ± 0.12 25ng/ml 100 nM 2.05 ± 0.11 0.5818 2.12 ± 0.14 25 ng/ml 200 nM 2.18 ± 0.140.9803 2.09 ± 0.14 IL8 271.75 ± 7.98  25 ng/ml 2577.97 ± 63.03^(¥ )  200nM 273.06 ± 11.28  >0.999 261.92 ± 12.12  25 ng/ml 25 nM 3240.19 ±156.41  0.5347 2837.03 ± 135.03  25 ng/ml 50 nM 3611.64 ± 221.79  0.17082862.21 ± 240.57  25 ng/ml 100 nM 4865.79 ± 574.48  0.0003 2980.9 ±173.36 25 ng/ml 200 nM 5827.91 ± 500.48  <.0001 3023.88 ± 193.36  IL93.33 ± 0.37 25 ng/ml 3.7 ± 0  200 nM 3.93 ± 0.33 0.5698 3.91 ± 0.48 25ng/ml 25 nM 3.7 ± 0  >0.999 4.55 ± 0.85 25 ng/ml 50 nM 3.27 ± 0.320.3649 4.13 ± 0.43 25 ng/ml 100 nM 4.02 ± 0.31 0.6282 4.13 ± 0.43 25ng/ml 200 nM 3.62 ± 0.08 0.9958 3.28 ± 0.35 IP-10/ 20.14 ± 0.36  CXCL1025 ng/ml 3935.46 ± 375.68^(¥ ) 200 nM 20.39 ± 0.57  >0.999 19.75 ± 0.42 25 ng/ml 25 nM 3497.56 ± 194.81  0.6232 4068.98 ± 507.12  25 ng/ml 50 nM3599.04 ± 402.58  0.7995 3872.74 ± 295.01  25 ng/ml 100 nM 3158.24 ±189.25  0.1574 4050.7 ± 471.31 25 ng/ml 200 nM 2662.18 ± 89.27  0.00594071.78 ± 411.22  LIF 23.57 ± 0.93  25 ng/ml 63.3 ± 2.1^(¥ ) 200 nM24.61 ± 0.9  0.9625 23.25 ± 0.99  25 ng/ml 25 nM 74.41 ± 2.51  0.024368.82 ± 2.51  25 ng/ml 50 nM 74.64 ± 3.23  0.0209 67.89 ± 3.08  25 ng/ml100 nM 80.58 ± 2.89  0.0003 70.3 ± 3.65 25 ng/ml 200 nM 86.79 ± 2.87 <.0001 71.92 ± 2.82  MCP1 1288.79 ± 44.4   25 ng/ml 15200 ± 0^(¥  )  200 nM 1231.38 ± 54.82  0.8558 1125.31 ± 55.12  25 ng/ml 25 nM  31401.9± 12245.69 0.6168 29762.04 ± 13226.23 25 ng/ml 50 nM 21656.92 ± 6456.92 0.9745 27471.13 ± 12271.13 25 ng/ml 100 nM 32481.08 ± 17281.08 0.56415200 ± 0   25 ng/ml 200 nM 20201.73 ± 5001.73  0.989 17302.89 ±2102.89  MIP1 3.14 ± 0.24 alpha 25 ng/ml 105.63 ± 3.74^(¥ )  200 nM 3.11± 0.28 >0.999 2.63 ± 0.35 25 ng/ml 25 nM 82.56 ± 3.1  <.0001 103.81 ±3.29  25 ng/ml 50 nM 70.57 ± 3.32  <.0001 100.64 ± 4.66  25 ng/ml 100 nM50.91 ± 1.6  <.0001 91.52 ± 5.05  25 ng/ml 200 nM 40.36 ± 0.88  <.000183.1 ± 2.77 MIP1 122.07 ± 4.05  beta 25 ng/ml 313.11 ± 5.46^(¥ )  200 nM116.79 ± 5.02  0.8764 113.94 ± 3.76  25 ng/ml 25 nM 328.74 ± 7.75 0.4072 319.77 ± 6.92  25 ng/ml 50 nM 335.46 ± 9.56  0.1354 318.84 ±8.17  25 ng/ml 100 nM 348.55 ± 7.71  0.007 323.13 ± 6.82  25 ng/ml 200nM 361.86 ± 6.8   0.0001 318.83 ± 8.71  PDGF-BB 2.13 ± 0.17 25 ng/ml 4.27 ± 0.22^(¥) 200 nM 1.95 ± 0.21 0.936 2.15 ± 0.13 25 ng/ml 25 nM5.15 ± 0.21 0.0234 5.19 ± 0.15 25 ng/ml 50 nM 5.09 ± 0.22 0.0366 5.28 ±0.18 25 ng/ml 100 nM 5.09 ± 0.22 0.0373  5.4 ± 0.16 25 ng/ml 200 nM 5.18± 0.22 0.0154 5.28 ± 0.15 PIGF-1 20.75 ± 0.87  25 ng/ml 55.66 ±1.47^(¥ ) 200 nM 21.21 ± 1.23  0.9989 20.17 ± 1.26  25 ng/ml 25 nM 59.03± 2.6  0.7932 56.69 ± 2.37  25 ng/ml 50 nM 56.18 ± 3.04  0.9997 53.92 ±2.81  25 ng/ml 100 nM 57.5 ± 3.14 0.9689 54.67 ± 3.27  25 ng/ml 200 nM58.88 ± 2.87  0.8058 54.61 ± 2.69  RANTES 9.56 ± 0.42 25 ng/ml 230.17 ±9.43^(¥ )  200 nM 9.51 ± 0.56 >0.999 8.42 ± 0.51 25 ng/ml 25 nM  192 ±12.74 0.0311 203.77 ± 12.55  25 ng/ml 50 nM 165.12 ± 11.76  0.0001198.35 ± 15.1  25 ng/ml 100 nM 136.24 ± 7.8   <.0001 194.21 ± 12.67  25ng/ml 200 nM 111.94 ± 6.48  <.0001 183.18 ± 13.92  SCF 2.01 ± 0.08 25ng/ml  4.16 ± 0.08^(¥) 200 nM 1.99 ± 0.14 >0.999 1.93 ± 0.13 25 ng/ml 25nM 4.41 ± 0.13 0.6315 4.33 ± 0.18 25 ng/ml 50 nM 4.41 ± 0.22 0.6213 4.16± 0.18 25 ng/ml 100 nM 4.58 ± 0.16 0.203 4.26 ± 0.17 25 ng/ml 200 nM4.49 ± 0.16 0.3684  4.2 ± 0.17 SDF-1 1075.14 ± 36.63  alpha 25 ng/ml3307.18 ± 98.57^(¥ )  200 nM 1050.43 ± 48.77  0.9981 1003.25 ± 40.97  25ng/ml 25 nM 3610.22 ± 119.33  0.2517 3430.87 ± 111.52  25 ng/ml 50 nM3666.62 ± 135.83  0.1361 3356.32 ± 136.22  25 ng/ml 100 nM 3794.59 ±134.61  0.0252 3471.01 ± 111.77  25 ng/ml 200 nM 3962.77 ± 116.03 0.0013 3481.04 ± 134.24  TNF 1.49 ± 0.59 alpha 25 ng/ml  9159.41 ±1060.96^(¥) 200 nM 2.61 ± 0.65 >0.999  2.4 ± 0.71 25 ng/ml 25 nM10472.77 ± 779.28  0.9989 10574.99 ± 753.02  25 ng/ml 50 nM 10873.61 ±631.64  0.9969 11776.9 ± 1658.47 25 ng/ml 100 nM 21115.64 ± 10093.980.2343 11722.68 ± 1259.67  25 ng/ml 200 nM 13938.92 ± 2924.27  0.875511233.91 ± 945.2   TNF  4.5 ± 0.48 beta 25 ng/ml 4.86 ± 0.09 200 nM 3.53± 0.62 0.4426  4.7 ± 0.28 25 ng/ml 25 nM 3.85 ± 0.63 0.4631 4.91 ± 0.7925 ng/ml 50 nM  4.6 ± 0.68 0.9896 4.13 ± 0.5  25 ng/ml 100 nM 4.31 ±0.56 0.8742   4 ± 0.51 25 ng/ml 200 nM 4.48 ± 0.44 0.9598 4.42 ± 0.45VEGF-A 633.68 ± 16.37  25 ng/ml 1322.08 ± 42.07^(¥ )  200 nM 610.03 ±18.16  0.9435 554.18 ± 29.76  25 ng/ml 25 nM 1285.27 ± 48.3   0.95081249.75 ± 44.89  25 ng/ml 50 nM 1251.08 ± 47.7   0.6733 1242.76 ± 50.39 25 ng/ml 100 nM 1270.06 ± 51.71  0.8536 1262.01 ± 46.28  25 ng/ml 200 nM1206.81 ± 45.57  0.2491 1232.36 ± 49.33  VEGF-D 3.63 ± 0.39 25 ng/ml 8.37 ± 0.77^(¥) 200 nM 2.98 ± 0.51 0.9007 3.19 ± 0.57 25 ng/ml 25 nM8.47 ± 0.59 0.9999 9.22 ± 0.87 25 ng/ml 50 nM 8.05 ± 0.73 0.9939 9.72 ±0.75 25 ng/ml 100 nM 8.13 ± 0.8  0.9979 8.71 ± 0.65 25 ng/ml 200 nM 7.76± 0.75 0.9332 9.12 ± 0.78 Cpc B Cpc C Cpc D Protein p-value^(c)pg/mL^(b) p-value^(c) pg/mL^(b) p-value^(c) 5.91 ± 0.28 BDNF  4.11 ±0.15^(¥) 0.5647  5.7 ± 0.31 0.9821 5.66 ± 0.38 0.9648 0.9989 4.01 ± 0.190.9922 4.08 ± 0.26 >0.999 0.9972   4 ± 0.23 0.9887 3.97 ± 0.25 0.98480.9993 4.24 ± 0.26 0.9819 4.18 ± 0.28 0.9989 >0.999 3.97 ± 0.22 0.97094.03 ± 0.28 0.9972 bNGF 2.13 ± 0.39  6.86 ± 0.53^(¥) 0.1179 3.73 ± 0.630.1582 3.47 ± 0.48 0.2975 0.743 7.86 ± 0.56 0.7301 7.44 ± 0.63 0.92680.9968 6.86 ± 0.6  >0.999 6.17 ± 0.74 0.8786 0.9987 6.93 ± 1.04 >0.9997.12 ± 0.8  0.9962 0.9855  5.7 ± 0.76 0.6114 6.73 ± 0.61 0.9997 EGF  1.2± 0.13 1.33 ± 0.08 0.8987 1.12 ± 0.14 0.9912 1.24 ± 0.09 0.9998 0.14751.54 ± 0.13 0.7273 1.49 ± 0.14 0.8865 0.3115 1.14 ± 0.17 0.7846 1.31 ±0.19 0.9999 0.6457 1.35 ± 0.18 0.9999 1.23 ± 0.16 0.9666 0.7548 1.46 ±0.17 0.9337 1.45 ± 0.17 0.9445 Eotaxin 2.16 ± 0.08  9.63 ± 0.17^(¥)0.9939 2.28 ± 0.07 0.853 2.08 ± 0.07 0.9688 0.093 10.08 ± 0.15  0.3539.82 ± 0.2  0.8778 0.6424 9.84 ± 0.25 0.8797 9.58 ± 0.21 0.9991 0.24569.89 ± 0.22 0.7879 10.02 ± 0.19  0.3925 0.2976 9.89 ± 0.21 0.7655 9.85 ±0.17 0.8038 FGF-2 9.44 ± 1.18 22.39 ± 0.9^(¥ )  0.9283 8.77 ± 0.790.9818 8.19 ± 1.07 0.8096 0.802 21.41 ± 1.39  0.9536 22.89 ± 1.39 0.9968 0.571 20.77 ± 1.37  0.7882 20.96 ± 1.43  0.8636 0.735 20.84 ±1.31  0.8113 21.77 ± 1.51  0.9924 0.9627 20.93 ± 1.37  0.8282 20.96 ±1.34  0.8551 GM-CSF 7.58 ± 1.05 122.09 ± 2.57^(¥ )  0.9865 9.48 ± 1.480.8873 8.49 ± 1.84 0.9945 0.2541  130 ± 3.15 0.3521 126.24 ± 3.53 0.8083 0.5101 126.18 ± 3.4   0.8392 124.89 ± 3.37  0.9418 0.0714 134.94± 4.45  0.052 133.19 ± 3.97  0.0881 0.0359 132.6 ± 3.95  0.1275 130.42 ±3.44  0.2505 GRO — alpha <.0001 0.9163 236.87 ± 11.04  0.9955 234.42 ±14.21  0.985 0.989 548.93 ± 27.91  0.987 539.42 ± 38.03  0.9995 0.9941544.74 ± 37.71  0.9947 555.54 ± 44.74  0.9797 0.8502 575.98 ± 43.22 0.7813 578.28 ± 48.32  0.842 0.8918 560.99 ± 43.32  0.925 564.53 ±52.35  0.9386 HGF 4.37 ± 0.38 13.82 ± 0.29^(¥ ) >0.999 4.74 ± 0.470.9368 3.68 ± 0.39 0.5616 0.9692 13.66 ± 0.51  0.9966 13.47 ± 0.45 0.9402 0.9972 13.04 ± 0.28  0.5379 13.27 ± 0.45  0.7642 0.7955 13.53 ±0.5  0.9722 13.75 ± 0.4  0.9998 0.9669 13.6 ± 0.53 0.9881 13.8 ±0.48 >0.999 IFN 0.24 ± 0.03 alpha 0.26 ± 0   >0.999  0.2 ± 0.03 0.72790.22 ± 0.03 0.986 0.3231 0.25 ± 0.01 0.3231 0.26 ± 0.01 0.9405 >0.9990.26 ± 0   >0.999 0.26 ± 0   >0.999 >0.999 0.26 ± 0   >0.999 0.26 ±0   >0.999 >0.999 0.26 ± 0   >0.999 0.25 ± 0.02 0.4509 IFN 4.81 ± 0.71gamma 25004.72 ± 3327.44^(¥ ) >0.999 3.81 ± 0.74 >0.999 4.52 ±0.68 >0.999 0.7134 27765.18 ± 4653.71  0.9432 24180.78 ± 2901.94  0.99960.9843 23531.94 ± 2644.35  0.9941 25506.14 ± 3960.86  >0.999 0.979623113.79 ± 2086.62  0.985 29392.77 ± 4832.25  0.8463 >0.999 25179.01 ±3591.71  >0.999 26972.77 ± 4164.13  0.9888 IL1 0.29 ± 0.03 alpha  7.82 ±0.18^(¥) >0.999  0.3 ± 0.05 >0.999 0.26 ± 0.05 0.9989 0.7043 7.74 ± 0.360.9994  6.8 ± 0.39 0.1498 0.3281 7.01 ± 0.39 0.3537 6.76 ± 0.4  0.12490.2631 7.27 ± 0.47 0.6747 6.92 ± 0.4  0.2281 0.0034 6.45 ± 0.38 0.0358 6.3 ± 0.35 0.0121 IL1 0.94 ± 0.1  beta  8.29 ± 0.44^(¥) >0.999 0.93 ±0.17 >0.999 0.98 ± 0.12 >0.999 0.0812 8.88 ± 0.35 0.7302 8.92 ± 0.420.64 0.5388 8.72 ± 0.47 0.8871 8.82 ± 0.46 0.7601 0.8899 8.55 ± 0.340.9788 8.63 ± 0.36 0.9366 0.9966 8.71 ± 0.5  0.8878 8.81 ± 0.35 0.759IL10 0.38 ± 0.08  0.84 ± 0.08^(¥) 0.9855  0.4 ± 0.11 0.9998 0.43 ± 0.110.993 0.9913 0.75 ± 0.05 0.729 0.76 ± 0.08 0.8444 >0.999 0.74 ± 0.060.667 0.67 ± 0.07 0.3152 0.9871 0.75 ± 0.07 0.7279 0.81 ± 0.070.9892 >0.999 0.84 ± 0.08 >0.999 0.84 ± 0.08 >0.999 IL12p70 2.34 ± 0.271.75 ± 0.23 0.1466 1.52 ± 0.29 0.1263 2.15 ± 0.26 0.9799 0.7679 1.97 ±0.22 0.8905 1.88 ± 0.19 0.9744 0.9979 1.72 ± 0.2  >0.999 1.69 ± 0.190.9988 0.9999 1.75 ± 0.23 >0.999 1.75 ± 0.22 >0.999 0.9787 1.79 ± 0.230.9997 1.7 ± 0.2 0.9996 IL13 0.9998 1.08 ± 0.13 0.9929 1.26 ± 0.150.9996 0.5041 2.93 ± 0.41 0.402 2.67 ± 0.24 0.7568 0.5946 2.24 ± 0.280.9999 2.21 ± 0.27 >0.999 0.8523 2.58 ± 0.36 0.8525 2.98 ± 0.4  0.3630.8751 2.12 ± 0.3  0.9996 2.52 ± 0.42 0.9127 IL15 1.84 ± 0.29 2.75 ±0.78 0.9814 1.98 ± 0.49 0.9999  3.2 ± 0.71 0.2474 0.9541 3.97 ± 0.710.4062  4.2 ± 0.86 0.5333 >0.999 2.29 ± 0.44 0.9517 2.82 ± 0.72 >0.9990.9995 2.42 ± 0.54 0.9859 3.29 ± 0.9  0.972 0.9994 2.32 ± 0.44 0.9593.37 ± 0.8  0.9493 IL17A 1.03 ± 0.09  3.91 ± 0.36^(¥) 0.9838 1.39 ± 0.220.7488 1.22 ± 0.2  0.9738 0.5215 4.27 ± 0.42 0.9116 3.84 ± 0.3  0.99990.991 3.48 ± 0.39 0.8568 4.15 ± 0.57 0.986 0.2722 3.77 ± 0.42 0.99743.57 ± 0.45 0.9569 0.729   4 ± 0.34 0.9993 4.04 ± 0.49 0.9984 IL18 6.51± 0.55 155.14 ± 2.91^(¥ )  0.9991 5.89 ± 0.58 0.9968 6.54 ± 0.37 >0.90.5501 163.63 ± 3.29  0.4124 159.38 ± 4.31  0.8787 0.994 156.41 ± 4.19 0.9984 156.12 ± 3.47  0.9994 0.9995 162.12 ± 5.14  0.5817 156.97 ± 5.2  0.9934 0.8617 157.36 ± 4.56  0.9856 155.77 ± 4.15  0.9999 IL1RA 513.38 ±56.01  6231.09 ± 271.61^(¥ ) >0.999 488.84 ± 49.85  >0.999 461.3 1 ±30.68  0.9982 0.8905 6175.66 ± 277.7  0.9998 5760.33 ± 367.09  0.78330.7411  6065 ± 325.72 0.9881 5709.52 ± 391.3  0.7198 0.9003 6167.55 ±367.54  0.9997 5879.83 ± 410.09  0.9069 0.501 5756.59 ± 328.24  0.66035450.17 ± 388.11  0.3705 IL2 2.99 ± 0.33   29 ± 1.27^(¥) 0.9961 2.65 ±0.28 0.9954  2.4 ± 0.09 0.9515 0.1037 31.39 ± 1.44  0.578 31.46 ± 1.56 0.6728 0.4299 29.87 ± 1.38  0.9779 29.16 ± 2.01  >0.999 0.6329 30.51 ±1.23  0.8659 29.23 ± 1.62  0.9999 0.4421 30.68 ± 1.62  0.8062 31.88 ±1.61  0.5284 IL21 2.88 ± 0   2.88 ± 0   0.5085 2.33 ± 0.29 0.3239 2.5 ±0.3 0.6612 0.9387 2.71 ± 0.18 0.9285 2.71 ± 0.18 0.942 0.5954 2.88 ±0   >0.999 2.13 ± 0.39 0.0587 0.4301  2.6 ± 0.28 0.733 2.64 ± 0.240.8512 0.6156 2.45 ± 0.29 0.3546 2.84 ± 0.04 0.9996 IL22 8.9 ± 0  7.92 ±0.65 0.9345 7.16 ± 1.16 0.3838 8.08 ± 0.82 0.9165 0.8119 7.15 ± 1.160.9285 7.83 ± 0.75 0.9999 0.6582 8.03 ± 0.87 >0.999 8.9 ± 0  0.59130.9999 7.31 ± 1.07 0.9662 8.21 ± 0.69 0.9909 0.9988 8.24 ± 0.53 0.99668.39 ± 0.51 0.94 IL23 7.35 ± 0.54 5.56 ± 0.97 0.6828 6.54 ± 1   0.96426.43 ± 1.28 0.9407 0.1332 7.43 ± 0   0.0906 7.43 ± 0   0.0117 0.089 7.43± 0   0.0906 7.43 ± 0   0.0117 0.667  6.7 ± 0.73 0.4485 7.43 ± 0  0.0117 0.084 6.95 ± 0.48 0.2634 7.43 ± 0   0.0096 IL27 6.93 ± 0.9  6.23± 0.97 0.9996 9.17 ± 2.36 0.8968 11.9 ± 2.31 0.2941 0.7164 8.88 ± 1.640.3282 7.42 ± 0.9  0.8475 0.9844 5.98 ± 1.08 0.9996 5.51 ± 1.25 0.96950.9686  5.7 ± 1.04 0.993 5.92 ± 0.88 0.9988 0.6958 6.59 ± 0.99 0.99828.3 ± 1.2 0.4393 IL31 3.67 ± 0    2.6 ± 0.63 0.5865 3.28 ± 0.31 0.9074 3.7 ± 0.06 >0.999 0.3255 3.52 ± 0.53 0.559 2.97 ± 0.37 0.9353 0.7223.36 ± 0.27 0.7072 3.43 ± 0.31 0.4939 0.5741 2.95 ± 0.38 0.9708 4.14 ±0.48 0.0632 0.1137 3.34 ± 0.69 0.7103 3.05 ± 0.38 0.875 IL4 4.72 ± 0.446.73 ± 1.28 >0.999 4.89 ± 1.18 >0.999 5.34 ± 0.89 0.9842 >0.999 8.31 ±2.19 0.8432  7.2 ± 1.25 0.9963 0.9463 5.24 ± 0.99 0.8657  5.9 ± 1.180.968 0.9522 6.26 ± 1.35 0.9978 5.13 ± 0.78 0.7576 0.9992 7.07 ± 0.880.9994 8.19 ± 1.39 0.8006 IL5  2.7 ± 0.43 28.59 ± 1.29^(¥ ) 0.9999 3.04± 0.41 0.9956 2.88 ± 0.36 0.9998 0.9256 27.03 ± 1.35  0.8768 26.66 ±1.72  0.8703 0.3753 26.49 ± 1.58  0.7237 28.49 ± 1.85  >0.999 0.707328.64 ± 1.4  >0.999 27.43 ± 2.11  0.9759 0.472 27.1 ± 1.76 0.886 25.61 ±1.98  0.59 IL6 30.57 ± 2.89  862.33 ± 17.95^(¥ ) 0.997 28.49 ± 2.89 0.9998 28.84 ± 1.89  0.9999 0.0158 774.87 ± 31.09  0.1794 743.07 ± 36.3 0.0476 <.0001 710.89 ± 36.7  0.006 698.04 ± 29.79  0.0037 <.0001 690.4 ±35.25 0.0016 703.99 ± 42.22  0.0054 <.0001 621.7 9 ± 33.44  <.0001 646.2± 32.46 <.0001 IL7 3.22 ± 0.12  2.26 ± 0.09^(¥) 0.8957 3.35 ± 0.180.9726 3.44 ± 0.16 0.7986 0.9135 2.18 ± 0.15 0.9587 2.16 ± 0.11 0.92910.1612 2.02 ± 0.07 0.3795 2.14 ± 0.07 0.8446 0.8633 2.04 ± 0.11 0.44492.15 ± 0.14 0.8923 0.7513 1.91 ± 0.11 0.0979 2.14 ± 0.12 0.8584 IL8271.75 ± 7.98  2577.97 ± 63.03^(¥ )  0.9992 269.53 ± 10.35  >0.999257.62 ± 7.07  0.9957 0.6768 2879.27 ± 117.07  0.4575 2820.21 ± 159.05 0.7286 0.6054 2869.74 ± 167.65  0.4857 2907.08 ± 193.16  0.4877 0.3063035.52 ± 206.85  0.1337 3061.2 ± 217.26 0.1753 0.2093 2874.26 ± 169.59 0.4518 2893.51 ± 190.51  0.5041 IL9 3.33 ± 0.37 3.7 ± 0  0.5942 3.65 ±0.2  0.9404 3.98 ± 0.36 0.4998 0.5554 3.37 ± 0.33 0.7599 3.7 ± 0  >0.9990.9285 3.7 ± 0  >0.999 3.37 ± 0.33 0.8739 0.9285 4.16 ± 0.46 0.5047 3.58± 0.24 0.9965 0.9249 3.66 ± 0.04 0.9999 4.44 ± 0.54 0.2822 IP-10/ 20.14± 0.36  CXCL10 3935.46 ± 375.68^(¥ ) >0.999 19.83 ± 0.4  >0.999 20.23 ±0.48  >0.999 0.9982 3999.9 ± 370.53 0.9998 3903.67 ± 366.97  >0.9990.9999 3665.2 ± 277.11 0.9431 3998.62 ± 456.34  0.9999 0.999 3860.41 ±323.05  0.9995 4100.26 ± 502.48  0.9978 0.9979 3835.78 ± 304.58  0.99844407.56 ± 645.63  0.8945 LIF 23.57 ± 0.93  63.3 ± 2.1^(¥ ) 0.9998 24.24± 1.14  0.9947 22.66 ± 0.82  0.9784 0.4762 67.72 ± 2.04  0.6687 65.71 ±2.6  0.9551 0.6301 67.64 ± 3.17  0.6825 66.01 ± 3.21  0.9336 0.272373.12 ± 3.62  0.0743 70.02 ± 3.89  0.3858 0.117 70.66 ± 3.22  0.226167.62 ± 3.58  0.7257 MCP1 1288.79 ± 44.4   15200 ± 0^(¥  )   0.06771158.23 ± 47.13  0.1939 1306.83 ± 54.65  0.9989 0.5166 15200 ±0   >0.999 21968.74 ± 4662.32  0.7846 0.6564 33175.72 ± 17975.72 0.488925836.84 ± 10636.84 0.4403 >0.999 26334.64 ± 11134.64 0.8276 15200 ±0   >0.999 0.9991 19811.45 ± 4611.45  0.9903 18512.1 ± 3312.1  0.9759MIP1 3.14 ± 0.24 alpha 105.63 ± 3.74^(¥ )  0.9995  2.9 ± 0.21 >0.9992.75 ± 0.26 0.9999 0.9925 101.71 ± 3.84  0.931 102.06 ± 4.18  0.93030.7866 104.54 ± 6.56  0.9994 96.35 ± 3.57  0.3335 0.0532 96.4 ± 4.180.4229 96.22 ± 3.58  0.3215 0.0007 98.72 ± 3.87  0.6469 88.49 ± 5.06 0.016 MIP1 122.07 ± 4.05  beta 313.11 ± 5.46^(¥ )  0.5849 117.97 ± 3.75 0.9512 113.08 ± 4.82  0.4912 0.9203 318.92 ± 6.03  0.9606 313.64 ±8.9   >0.999 0.9516 318.37 ± 9.88  0.9722 316.87 ± 10.18  0.9939 0.7439324.42 ± 8.52  0.7136 317.95 ± 8.1   0.9843 0.9479 318.74 ± 8.72  0.9617316.74 ± 9.29  0.9942 PDGF-BB 2.13 ± 0.17  4.27 ± 0.22^(¥) >0.999 2.19 ±0.17 0.9993 1.93 ± 0.18 0.8993 0.002 4.93 ± 0.21 0.1721 4.23 ± 0.180.9995 0.0007 5.22 ± 0.25 0.0254 4.36 ± 0.18 0.9926 0.0001 5.57 ± 0.230.0015 4.71 ± 0.23 0.329 0.0005 5.52 ± 0.27 0.0017 4.75 ± 0.16 0.2397PIGF-1 20.75 ± 0.87  55.66 ± 1.47^(¥ ) 0.9968 21.19 ± 1.05  0.9991 20.55± 1.16  >0.999 0.9958 58.04 ± 2.17  0.9291 59.56 ± 3.2  0.7867 0.971455.59 ± 2.74  >0.999 56.72 ± 3.48  0.9975 0.9965 58.69 ± 3.37  0.850659.49 ± 3.52  0.7971 0.9951 55.71 ± 3.28  >0.999 55.63 ± 3.23  >0.999RANTES 9.56 ± 0.42 230.17 ± 9.43^(¥ )  0.9997 8.61 ± 0.52 0.9999 10.17 ±0.54  >0.999 0.4195 216.88 ± 13.45  0.9096 237.57 ± 17.46  0.9967 0.262201.93 ± 15.44  0.439 237.55 ± 21.78  0.9967 0.1736 207.79 ± 17.38 0.6354 241.39 ± 22.79  0.9841 0.0416 189.62 ± 13.78  0.1403 238.51 ±23.12  0.9942 SCF 2.01 ± 0.08  4.16 ± 0.08^(¥) 0.9847  2 ± 0.1 >0.9991.91 ± 0.15 0.9538 0.8691 4.34 ± 0.19 0.9047 4.18 ± 0.24 >0.999 >0.9994.25 ± 0.22 0.9888  4.1 ± 0.21 0.9989 0.9739 4.59 ± 0.25 0.3051 4.29 ±0.29 0.9805 0.9988 4.23 ± 0.15 0.9962 4.07 ± 0.21 0.9952 SDF-1 1075.14 ±36.63  alpha 3307.18 ± 98.57^(¥ )  0.8391 1028.82 ± 43.21  0.9683 990.69± 48.87  0.7402 0.8805 3503.89 ± 90.15  0.6507 3456.41 ± 158.06  0.88740.9953 3471.01 ± 141.19  0.7742 3450.69 ± 158.13  0.9001 0.7414 3521.98± 154.06  0.5807 3563.68 ± 157.35  0.5609 0.6851 3436.48 ± 134.91 0.8755 3464.97 ± 155.2  0.8577 TNF 1.49 ± 0.59 alpha  9159.41 ±1060.96^(¥) >0.999 2.82 ± 0.72 >0.999 2.41 ± 0.7  >0.999 0.8099 11212.78± 1168.53  0.4872 8951.15 ± 870.67  0.9997 0.3395 10367.04 ± 1016.28 0.8503 9862.6 ± 1041  0.9662 0.3574 10632.61 ± 795.65  0.7448 10525.46 ±1077.11  0.7438 0.5219 10619.05 ± 1276.72  0.7358 9777.73 ± 966.87 0.9767 TNF  4.5 ± 0.48 beta 4.86 ± 0.09 0.9978 4.5 ± 0.5 >0.999 4.42 ±0.57 >0.999 1 5.68 ± 1.4  0.8542 4.62 ± 0.49 0.9848 0.7159 5.54 ± 0.560.9179 5.03 ± 0.38 0.9959 0.5971  4.6 ± 0.46 0.9976 4.47 ± 0.37 0.9150.9271 3.78 ± 0.57 0.686 4.96 ± 0.56 0.9994 VEGF-A 633.68 ± 16.37 1322.08 ± 42.07^(¥ )  0.1114 609.51 ± 15.83  0.9386 598.11 ± 16.67 0.7728 0.6545 1261.47 ± 37.95  0.8399 1303.84 ± 56.86  0.9983 0.58131268.91 ± 59.05  0.8911 1286.84 ± 61.29  0.9801 0.7787 1335.99 ± 63.65 0.9992 1346.72 ± 67.56  0.9947 0.4555 1262.36 ± 57.42  0.836 1256.89 ±60.57  0.8386 VEGF-D 3.63 ± 0.39  8.37 ± 0.77^(¥) 0.9787 3.63 ±0.6  >0.999 3.55 ± 0.66 >0.999 0.8543  8.6 ± 0.74 0.9982  8.7 ± 0.520.9949 0.5549 8.44 ± 0.66 >0.999 8.49 ± 0.72 0.9999 0.9936 9.25 ± 0.7 0.8045 9.64 ± 0.91 0.6256 0.8932 8.82 ± 0.7  0.9752 8.03 ± 0.93 0.9933^(a)Stimulation with TNFα (25 ng/mL) and IFNγ (25 ng/mL) ^(b)Data ispresented as mean ± standard error ^(c)Significant differences comparedback to stimulation with TNFα and IFNγ alone ^(¥)Indicates significantdifference of p < 0.01 from vehicle (no stimulation and no drugconcentration) alone

Example 7: Identification of Genes Differentially Expressed in Patientswith Vitiligo that are Complete Responders to Treatment with RuxolitinibCream

Using non-invasive skin tape, skin tissue was collected from eachsubject with vitiligo enrolled in a study of ruxolitinib cream(INCB018424) for the treatment of subjects with a clinical diagnosis ofvitiligo, depigmented areas including at least 0.5% of the total bodysurface area on the face, and at least 3% of the total body surface areaon nonfacial areas affected using the palmar (or handprint) method (palmplus 5 digits). All subjects consented to the skin tissue collection andmet the inclusion and exclusion criteria outlined in the clinicalprotocol. Once collected, skin tissue was processed from thenon-invasive skin tape into ribonucleic acid (RNA) for further analysisand subsequently analyzed using RNA sequencing. Samples were separatedinto to two groups based on clinical response to treatment with topicalINCB018424. Specifically, samples were classified as “responder” or“non-responder” based on their therapeutic response at Week 24 oftreatment (“F-VASI” refers to facial-vitiligo area and severity index).Individuals were topically applied INCB018424 either once or twice dailyat dose strengths of 0.15%, 0.5%, or 1.5%. Twice daily applications wereat least 10 hours apart in a cream formulation.

RNA-sequencing was conducted on all biopsy samples by Beijing GenomicsInstitute using the Illumina HiSeq 4000 system. Data was then alignedand quality controlled in OmicSoft Array Studio using the Human GenomeB38 library. The Fragments Per Kilobase of transcript per Million (FPKM)mapped reads (the relative expression of a transcript) were generatedand used in all downstream analysis. Significant differences indifferentially expressed genes between groups were identified usingANOVA tests. RNA-sequencing identified differentially expressed genesbetween the responder and non-responder groups at baseline (with rawp-value<0.05). Three hundred sixty-nine genes were increased and 339genes were decreased in responders compared to non-responders (Table16).

TABLE 16 Differentially Expressed Genes in the Skin Biopsies ofResponders Compared to Non-Responders Up-regulated in Responders vs.Down-regulated in Responders vs. Non-Responders Non-Responders Gene FoldRaw Gene Fold Raw Symbol Change P-value Symbol Change P-value TBC1D368.0367 0.0006 RARRES3 −153.032 0.0012 MT1E 53.8104 0.0182 CXCL10−62.5312 0.0345 RBPMS2 37.1356 0.0044 ABLIM2 −62.3872 2.79E−07 HIST1H2AK29.0245 0.038 FMO4 −61.6695 0.0002 ARHGAP19-SLIT1 27.4855 0.003 ZSCAN31−57.6809 0.0003 DRC3 23.4005 0.0236 FAM153C −45.9711 0.0102 OVCH221.9183 0.0201 VCAM1 −43.9304 0.0137 CCDC78 20.8539 0.0031 CDC42EP5−41.845 0.0002 UGT1A6 19.6003 0.0445 KCNRG −41.3377 0.0023 CCDC10518.5561 0.0098 PRR5 −40.7814 0.0003 KCNAB3 16.7528 0.019 HIST1H2AB−40.7575 0.0413 ECE2 16.4402 0.0264 GOLGA8Q −38.142 0.0103 ANKRD215.9273 0.0213 PRR7 −37.6323 0.0002 ACVR1C 15.3089 0.0301 C10orf128−37.3554 0.002 B3GNT4 14.755 0.0352 CXCL11 −36.054 0.0286 IYD 14.18140.0484 NUDT6 −34.7085 0.0029 TWIST2 13.314 0.0346 CD3E −32.0222 0.0272DERL3 13.0597 0.0178 LDHD −31.0204 0.0024 KCNJ1 12.9249 0.013 CTAGE15−30.8756 0.0263 SYT12 12.6703 0.0193 SLFN12 −30.8518 0.0104 GPR6112.3318 0.0089 GGACT −29.4351 0.0041 KRT71 12.0543 0.0346 APOL3 −28.88380.0248 CCDC153 11.7483 0.0213 DLEU1 −27.6186 0.0178 ZNF764 11.72690.0293 FAM231D −27.6104 0.0043 TCEB3B 11.6698 0.0124 C1orf233 −27.22630.0003 FEZ1 11.6487 0.0325 SPRR3 −26.4914 0.0291 C3orf49 11.6458 0.0428KCNIP4 −26.065 0.0108 VEPH1 11.5131 0.0442 TBX19 −26.0579 0.002 PDE9A11.2422 0.0133 HLA-DMA −24.1058 0.0485 GAGE2E 10.6926 0.0309 IL2RB−23.2681 0.0065 POU5F1B 9.2163 0.0141 GPR27 −23.088 0.0068 COL11A18.9606 0.0219 IL1RL1 −22.1689 0.0304 HBZ 8.9457 0.0418 AGTRAP −21.87110.0407 CCNI2 8.8795 0.0336 EDARADD −21.2019 0.0173 ADAMTS13 8.80910.0337 SH3BGR −21.0306 0.0263 CNDP1 8.5325 0.0328 IGFN1 −20.7897 0.0013CILP 8.2659 0.0326 GOLGA8R −20.0035 0.0361 ZYG11A 7.8521 0.0282 OCEL1−19.5751 0.0078 GEMIN6 7.5022 0.0424 MLKL −19.533 0.0114 PSD2 7.42610.0035 JPH3 −19.5114 0.0044 C10orf62 7.1923 0.0382 APOBEC3G −19.3710.0498 TAS1R3 7.0305 0.0281 TRPM2 −19.3403 0.0116 TMEM170B 6.8909 0.019KLHDC7B −19.2599 0.0288 APLN 6.8326 0.0141 GAS2L3 −19.2454 0.0293 ETNPPL6.094 0.0309 CYP27B1 −19.1669 0.0005 WBSCR17 5.8639 0.0307 LRRC70−19.1541 0.012 PPIAL4G 5.8596 0.0254 MMP25 −18.8131 0.0152 ZNF77 5.79360.035 SYNE4 −18.7815 0.0088 VWA5B2 5.5818 0.0325 KBTBD8 −18.5263 0.0145SLC2A10 5.3839 0.0367 FAM124A −18.2655 0.0016 PTGER1 5.3803 0.0305TVP23C-CDRT4 −18.1156 0.0453 NPR3 5.1731 0.0153 CD3G −17.8975 0.032ZSCAN1 5.0883 0.03 GSTT2B −17.5226 0.01 EFR3B 4.8859 0.0379 CYP4V2−17.304 0.0292 TFR2 4.7716 0.0294 H3F3C −17.2902 0.0113 FAM13C 4.58780.0335 RNF148 −17.2129 0.0324 CLEC4E 4.5778 0.0393 TICAM2 −17.07250.0315 GRM3 4.5593 0.0177 KLB −17.041 0.0008 CACNA1F 4.5255 0.046 RGS9−17.0012 0.0093 IL17B 4.5105 0.0334 BTN3A3 −16.4997 0.0129 METTL204.4939 0.0038 MTRNR2L3 −16.4822 0.0099 C1QL1 4.1931 0.0314 HIST4H4−16.3414 0.016 NID2 4.1828 0.0344 ZNF597 −16.2528 0.0094 FCER2 4.1210.0427 RCBTB2 −15.9872 0.0413 OR10A4 3.9713 0.0337 HMMR −15.6366 0.0345CLMN 3.9588 0.024 MYCL −14.709 0.0196 PDGFRL 3.8707 0.0374 C15orf65−14.6809 0.0435 MRAP2 3.8395 0.0207 RARB −14.6653 0.0069 OR7G1 3.78820.0319 KLHDC1 −14.5112 0.0068 LIN52 3.7792 0.0347 TMEM8A −14.3754 0.0124TAF1L 3.7768 0.0211 SKA1 −14.2437 0.0386 GOLGA6D 3.7667 0.03 SERINC4−14.1611 0.032 SIRT3 3.5852 0.0104 AHRR −14.1386 0.0113 SEMA4G 3.48660.0182 C1QTNF6 −14.0618 0.0401 IFT43 3.3886 0.0406 C4orf27 −13.94150.0386 STK16 3.3738 0.0102 FUT2 −13.8461 0.0133 ARMC7 3.3542 0.0291 PAEP−13.7052 0.0318 RFNG 3.3135 0.0482 TDRKH −13.6903 0.0359 CSAG1 3.24590.0299 C9orf172 −13.5475 0.0065 HRNR 3.1974 0.0406 AIMP2 −13.4501 0.0049RAB30 3.1613 0.0366 LZTS1 −13.3286 0.0122 TMEM174 3.1396 0.0293 NEK3−13.2495 0.0103 CCDC77 3.034 0.0054 ADAM21 −13.0459 0.027 PRR21 3.00380.0298 FAM216A −13.0367 0.0188 NHSL2 2.9573 0.0367 PIK3CG −12.91660.0341 C1orf123 2.9328 0.0095 SDF2L1 −12.8938 0.0335 ZNF787 2.91540.0486 LAIR1 −12.8913 0.0079 RUNX2 2.854 0.0347 ANGPTL3 −12.8408 0.0323ZNRF1 2.846 0.018 TTYH2 −12.6181 0.0382 ASB1 2.8451 0.0073 BEST1−12.5347 0.0434 BRINP2 2.8274 0.0325 SELPLG −12.4437 0.0426 PUSL1 2.81670.0119 PRKAR2B −12.4218 0.0276 TMEM108 2.7928 0.0414 NKX3-2 −12.410.0215 AP3M1 2.759 0.0024 SCO2 −12.3332 0.0427 PALD1 2.738 0.0142C20orf27 −12.1621 0.0076 BMF 2.7127 0.0084 RGS16 −11.9215 0.0266 UTP232.6966 0.0084 COQ6 −11.8346 0.0084 GTF2H3 2.6344 0.0211 TMEM158 −11.81290.0111 GLRX5 2.632 0.0211 PCDHB5 −11.6183 0.0119 PEPD 2.6262 0.0246WNT5A −11.6009 0.0168 DUSP23 2.5657 0.0093 PRR15 −11.4573 0.0264 EVA1B2.5237 0.0254 ERAP2 −11.3813 0.0071 ZNF444 2.4989 0.0432 LDHAL6A−11.3778 0.0299 FAM219A 2.4931 0.0252 MRPS28 −11.3045 0.022 HAUS4 2.47710.0144 PSG1 −11.2907 0.0327 VBP1 2.4476 0.018 GNB5 −11.2064 0.0374TMEM208 2.4346 0.0459 PILRB −11.1383 0.0126 NMRK1 2.4342 0.0178 SHCBP1−11.0917 0.0348 ARID3B 2.4294 0.044 MROH7 −11.0736 0.0466 MPLKIP 2.41180.0249 GBP3 −11.0394 0.0402 CAB39L 2.3956 0.0034 RFC4 −10.9808 0.0101ALKBH3 2.3941 0.0014 NHLH1 −10.9216 0.0478 RNF113A 2.3587 0.045 CTF1−10.7115 0.0433 LAMTOR5 2.3182 0.0433 BIN2 −10.651 0.0464 CHRNB1 2.31010.0383 ANKRD13B −10.6479 0.0091 PLCE1 2.304 0.0074 MAP1A −10.6232 0.0292NDUFB6 2.302 0.0393 PRMT6 −10.6027 0.0239 DDX55 2.2971 0.0036 WSCD2−10.4554 0.0099 TMEM14A 2.2938 0.008 KCNMB1 −10.2631 0.0151 C12orf292.2891 0.0062 PLIN1 −9.9343 0.0335 NUDT9 2.2659 0.0058 ARHGAP15 −9.92330.0439 THG1L 2.2594 0.0387 KIF18A −9.8102 0.0353 SERTAD1 2.2401 0.0403RAD51B −9.7928 0.0259 LSAMP 2.2351 0.0474 DNAJB5 −9.7628 0.0177 CHST152.2172 0.0329 LRRC8C −9.7212 0.0448 VARS2 2.2089 0.0391 CUZD1 −9.71110.0312 SMIM5 2.2004 0.0331 DISC1 −9.6567 0.031 CUEDC1 2.1963 0.0305ADCY7 −9.6462 0.0295 ZNF619 2.1826 0.0295 WAS −9.5953 0.0418 FAM89B2.1601 0.0223 CCBL1 −9.4587 0.028 MRPL14 2.154 0.0372 ZNF286B −9.39880.011 RPL36A 2.1513 0.0466 SLA2 −9.3314 0.0432 UQCC2 2.1142 0.0357PLA2G4C −9.2972 0.0301 ORAOV1 2.1074 0.0264 MAP1LC3C −9.2483 0.0288FAM96B 2.1 0.0496 DNAH9 −9.0277 0.026 GID4 2.0867 0.0078 MUC1 −9.01630.0362 LMLN 2.0845 0.0414 PROX1 −8.9899 0.0084 AKAP10 2.0712 0.0017SSC4D −8.7828 0.0307 RNF166 2.0613 0.0301 SLC9A4 −8.6475 0.0245 HMGCL2.0551 0.0228 ARHGEF39 −8.5813 0.0453 C11orf49 2.0425 0.0107 RAB3IL1−8.5209 0.0338 TSHZ1 2.0399 0.0324 TNFRSF8 −8.4521 0.0311 ERMARD 2.02670.0112 GINS1 −8.2901 0.0339 TATDN2 2.0046 0.0258 P3H3 −8.2773 0.0311GTF2H5 1.9878 0.0448 CD5 −8.1417 0.0371 REXO2 1.9865 0.0162 GPR34−8.1372 0.0496 PCCA 1.9856 0.035 HHIPL2 −8.1104 0.0338 ZNF780A 1.98370.036 NEFH −8.0898 0.0309 ZNF133 1.982 0.0114 PADI3 −8.0437 0.0436 RWDD41.9749 0.0011 NUGGC −8.02 0.0304 MAPK3 1.9741 0.0429 SEZ6L2 −8.0160.0399 CRY2 1.9599 0.0196 ETS1 −8.0143 0.0015 ZNF397 1.9584 0.044 CSF1R−8.0002 0.0498 TMEM68 1.949 0.0442 GPR89B −7.9587 0.0288 HLCS 1.9450.0079 MRPL24 −7.9498 0.0431 MRPL33 1.9409 0.0019 SLC25A25 −7.82020.0167 RAB3B 1.9339 0.05 LRRC37A3 −7.6832 0.0282 CSTF2 1.9291 0.0213C1orf109 −7.5885 0.0312 SMPD2 1.9171 0.0348 FBXO4 −7.5231 0.0207 DNAJA31.9077 0.0256 SGIP1 −7.4578 0.0426 BTF3L4 1.9049 0.0464 PRKG1 −7.4550.0108 RANBP9 1.9028 0.0221 TMC8 −7.4527 0.0388 MCFD2 1.9021 0.0091SRSF12 −7.3006 0.0399 CSNK1G3 1.8954 0.0037 GJA3 −7.2952 0.0494 SEPSECS1.8912 0.0246 LMAN2L −7.2387 0.021 TEX264 1.8749 0.0302 GALNT16 −7.22880.0388 AMOTL2 1.8745 0.0254 EN1 −7.2271 0.0387 ASAH1 1.8711 0.0255 FAXC−7.2246 0.0365 PMF1 1.8691 0.0335 MUC4 −7.0712 0.0231 ZNF865 1.86450.0376 CUX2 −7.0366 0.0244 RARS2 1.8549 0.0027 NDOR1 −7.0359 0.0256LYPLA2 1.8525 0.0495 TEX14 −7.0294 0.0352 MRPS10 1.8459 0.0267 PDIA5−7.0173 0.0134 MOAP1 1.8357 0.0331 FOSL1 −6.9778 0.0278 TFAM 1.81760.0399 FBX02 −6.9416 0.0381 LIPH 1.8045 0.0359 TGIF2 −6.9025 0.0367RDH11 1.8019 0.0418 EED −6.8688 0.0318 RNF41 1.801 0.0135 WNT4 −6.80020.0287 HAUS5 1.8 0.0223 IFT88 −6.6886 0.0348 FBXO8 1.7986 0.0334 GORAB−6.5339 0.0256 SUMF1 1.79 0.0494 ESRRG −6.5206 0.0362 CNNM3 1.78210.0452 NPAS3 −6.4759 0.0474 MRPL50 1.7811 0.0038 DNAJC25 −6.4515 0.0255DCAF17 1.7746 0.0223 CNGB1 −6.4413 0.0364 DCXR 1.7739 0.0098 AVPR1A−6.4102 0.0057 RPS6KB1 1.7721 0.0073 QTRTD1 −6.4086 0.0089 RAB11FIP21.7699 0.0432 C9orf64 −6.324 0.0389 SFMBT1 1.7681 0.028 NANOS1 −6.25750.0281 MANEA 1.766 0.0307 GTF2H2C −6.2444 0.0113 ZNF266 1.7643 0.0306ARMC9 −6.2366 0.0254 IKZF5 1.7618 0.004 PLSCR1 −6.1774 0.0038 EIF2AK41.7598 0.0298 PHTF1 −6.081 0.0316 CHMP6 1.7493 0.0065 EEF1E1 −6.02390.025 ZNF525 1.7492 0.0203 APOLD1 −5.9596 0.024 VPS33A 1.7483 0.0123ZBTB46 −5.9247 0.0184 MIDN 1.7458 0.0243 SLC22A18 −5.8962 0.0417 CMTM41.7449 0.044 SS18L2 −5.7458 0.0484 POLR1B 1.743 0.0122 SLC41A2 −5.74330.0427 TRIM11 1.736 0.0453 C3 −5.4761 0.0447 COX7A2 1.7329 0.029 FGFRL1−5.4726 0.0499 PRPF40B 1.7259 0.0039 DENND1C −5.3414 0.0459 SUPV3L11.7245 0.0369 TNFAIP8L1 −5.2489 0.033 CCP110 1.7177 0.0195 CILP2 −5.08740.028 PGRMC1 1.7171 0.0285 DUSP28 −4.9879 0.0366 PCDHGB7 1.7097 0.0003S1PR2 −4.8478 0.0438 PEX26 1.708 0.0374 C1orf74 −4.8217 0.0335 POLR2E1.6977 0.0057 IMPG2 −4.7994 0.0155 FHL2 1.6965 0.023 ACAN −4.6964 0.0344MCPH1 1.6935 0.0248 TARSL2 −4.6505 0.0001 RNASEH1 1.6927 0.0101 SARM1−4.4398 0.0485 TMEM70 1.6875 0.0425 ALPK3 −4.3531 0.007 CNOT7 1.68480.0393 SYCP2 −4.3321 0.0427 PPP1R37 1.681 0.0427 ZNF555 −4.2258 0.035PPP1R14B 1.6793 0.0471 NLRP2 −4.0548 0.0392 MAK16 1.6778 0.0286 ZNF34−4.0366 0.0336 TANK 1.6768 0.0342 GPRC5A −4.027 0.0387 APLF 1.67660.0132 CECR5 −3.8695 0.0009 MAGEF1 1.6717 0.0382 JMJD6 −3.8462 0.0024RUFY1 1.6712 0.0486 SPATA5L1 −3.8252 0.0241 CDK4 1.6694 0.046 MSRB2−3.8049 0.0441 SNRK 1.6669 0.0362 ZNF469 −3.6847 0.0105 GLOD4 1.66150.0101 SLC35E3 −3.677 0.0032 PHLPP1 1.6594 0.0478 FECH −3.5554 0.0407DCAF15 1.6546 0.0174 NOP16 −3.4316 0.0125 PSMB3 1.6539 0.0357 PTRHD1−3.3579 0.0037 ZNF467 1.6474 0.0454 SLC5A6 −3.276 0.0048 PIGV 1.64480.0392 SCARB1 −3.1716 0.0072 HCFC2 1.6409 0.0284 MSANTD4 −3.1499 0.0224C11orf57 1.6332 0.0143 HCN4 −3.0177 0.0496 PCNXL4 1.628 0.0195 RNF180−2.9924 0.0132 SLC25A44 1.627 0.0327 BCL2L12 −2.9658 0.0487 LRIG3 1.62630.0102 MRPL27 −2.8904 0.0058 HSPA4L 1.625 0.0216 XK −2.8026 0.0072 PTK2B1.6221 0.0409 CYB5R4 −2.7853 0.0352 DNAJC4 1.619 0.0326 VOPP1 −2.76410.0074 CCDC117 1.6127 0.0216 PDLIM7 −2.7221 0.0116 CAPG 1.6117 0.0371PAAF1 −2.7215 0.0266 ARHGEF5 1.6091 0.0483 INTS2 −2.663 0.0081 ENOSF11.6084 0.0226 CTGF −2.6517 0.0391 MAST2 1.6068 0.0397 ABCA7 −2.63280.048 ST6GALNAC6 1.6038 0.0293 TRUB2 −2.5715 0.034 NFYB 1.6025 0.0409NAV1 −2.5603 0.0495 TMED7 1.5976 0.01 NPIPB4 −2.5301 0.0001 SLIT3 1.59360.0152 IQCG −2.5235 0.0287 GLCCI1 1.5838 0.0275 ZNF124 −2.5084 0.0229ZNF765 1.5737 0.0229 GRIP1 −2.457 0.0246 BLOC1S1 1.5718 0.0327 NDC1−2.4318 0.0449 NDFIP2 1.5714 0.0352 HSF4 −2.4304 0.0246 PSME3 1.57080.0139 BACE1 −2.4226 0.0322 MED1 1.5663 0.017 EOGT −2.3483 0.0282 FAM60A1.5652 0.037 NAF1 −2.3137 0.0291 CAMK2D 1.5631 0.0411 BHLHE41 −2.3030.0448 DVL1 1.5627 0.0346 ESD −2.2919 0.0149 BIRC2 1.5623 0.0269 USP28−2.2862 0.001 PRPF4 1.5571 0.0306 PLXND1 −2.2778 0.0364 DOCK6 1.5560.0497 CKS1B −2.2471 0.0149 SPTLC1 1.5552 0.0179 PPT2 −2.2363 0.0313ACAD11 1.5517 0.0057 KATNAL2 −2.2113 0.0465 H2AFV 1.5491 0.0471 PRKAA1−2.1788 0.0108 SWAP70 1.5477 0.0129 FTSJ1 −2.1679 0.0383 MTCH1 1.54410.0494 RNF2 −2.1655 0.0306 RNF167 1.5393 0.0489 SPRY4 −2.1628 0.0463CD2BP2 1.5368 0.0199 PDE5A −2.1518 0.042 PHF8 1.5358 0.0185 CARD16−2.1372 0.0404 SKAP2 1.5355 0.0458 TAF6 −2.1197 0.0401 TSPAN6 1.5350.0218 FBXL4 −2.1123 0.0008 DCTN4 1.5348 0.0393 EGLN2 −2.0977 0.0151FBXO42 1.5336 0.0356 SLC39A14 −2.0906 0.0054 TOB2 1.5327 0.0261 ASPSCR1−2.0848 0.0392 SCAF1 1.5323 0.0107 DENND6A −2.0844 0.0439 KDM6A 1.52950.0406 HEXA −2.0705 0.0379 PHF1 1.528 0.0499 DHFR −2.0671 0.0452 RNPC31.5275 0.0134 ZNF43 −2.0455 0.0028 UBE2K 1.5234 0.0174 HEATR5A −2.02940.0497 ZNF91 1.5229 0.0369 SCFD2 −2.0009 0.0374 FOXO1 1.5207 0.0376 MLH1−1.9963 0.0116 STX7 1.5195 0.0324 GAA −1.9848 0.0214 CDC27 1.5186 0.0107FLOT2 −1.9772 0.0249 CGGBP1 1.5159 0.0362 TNPO1 −1.9693 0.023 CASC41.5117 0.0265 RNF8 −1.9597 0.0334 FBXO25 1.5103 0.0375 SHMT2 −1.91870.0211 CDK16 1.5005 0.0125 TAPT1 −1.9096 0.0401 MAPK7 1.4978 0.0237FBXO48 −1.9025 0.0471 XPO4 1.4976 0.0197 STARD9 −1.9024 0.0071 MAN2C11.4976 0.0354 ARL13B −1.8733 0.0425 MZF1 1.4936 0.0406 CNTN4 −1.85470.0318 EDC4 1.4913 0.0272 ZSCAN16 −1.8429 0.0495 RNF34 1.4882 0.0302CTPS1 −1.8415 0.0071 DCAF4 1.488 0.0472 HNRNPLL −1.8397 0.0417 LRP111.4853 0.0407 MRPL30 −1.8365 0.0311 WTAP 1.4772 0.0131 EXOC5 −1.820.0067 RBM23 1.4763 0.0487 PDCD7 −1.8129 0.0284 ZNF224 1.47 0.0286ARHGAP30 −1.8009 0.0447 ATP11A 1.4699 0.0275 MTHFD1 −1.757 0.0318 CLASRP1.4674 0.0108 RINT1 −1.7568 0.0087 CPSF2 1.4594 0.0498 DNMT3A −1.74560.0053 FAM50A 1.4579 0.0154 NAA10 −1.7147 0.034 PHF10 1.4546 0.011 RFX7−1.7118 0.0084 CDK2 1.454 0.0365 SDCCAG8 −1.7004 0.0196 EFR3A 1.44660.0044 TMX3 −1.6894 0.0168 SAR1A 1.4465 0.0258 NUP107 −1.6884 0.0315BUB3 1.4456 0.0398 DENND1A −1.6801 0.017 ATP5E 1.4441 0.0493 DAXX−1.6753 0.0009 MEA1 1.4435 0.0427 ACBD6 −1.6687 0.0051 TARDBP 1.43790.0185 WSB2 −1.6676 0.0268 LZTS2 1.4358 0.0223 KLHL9 −1.6617 0.0083ATP11B 1.4202 0.038 ABCA2 −1.6526 0.0369 ANKHD1 1.4186 0.0196 CHTF8−1.6523 0.0105 ANKS1A 1.4176 0.0489 TRIM66 −1.6518 0.0071 CD2AP 1.41740.0329 ARNTL −1.6485 0.0297 AGFG1 1.4156 0.0481 PLD2 −1.6456 0.0112EIF2A 1.4149 0.0096 IL6ST −1.6403 0.0389 METTL7A 1.4107 0.0426 ZNF551−1.6251 0.0289 HINT1 1.4073 0.0469 LIMA1 −1.6226 0.0124 REXO1 1.40690.0184 SYNJ1 −1.6023 0.0393 TBC1D22A 1.4003 0.0409 SRC −1.5899 0.0462ARHGAP5 1.4002 0.0338 MDM4 −1.5825 0.0135 CCDC174 1.3992 0.035 INTS3−1.5722 0.0436 SERINC1 1.3973 0.0367 HIVEP1 −1.559 0.0097 SAP18 1.39490.0338 DNHD1 −1.5442 0.0493 SEC16A 1.3849 0.0471 MEF2A −1.5306 0.0277RALBP1 1.3837 0.0264 TMSB10 −1.5295 0.0499 PRPF18 1.3802 0.0334 ARFRP1−1.5238 0.0468 STK24 1.3751 0.0431 MCC −1.5213 0.009 MPHOSPH10 1.37430.0484 P0LR3GL −1.5197 0.0308 AVL9 1.3659 0.0376 CABIN1 −1.5105 0.0072TRIM28 1.356 0.0239 BBS9 −1.4879 0.0404 UBTF 1.3536 0.0324 RAB2B −1.48170.0346 PAFAH1B2 1.352 0.024 BRAT1 −1.4566 0.0458 CDC5L 1.3516 0.0171TM7SF3 −1.4542 0.046 PAF1 1.3435 0.0396 WDR33 −1.4522 0.0167 SLMAP1.3356 0.003 WDR46 −1.4522 0.0116 IPO8 1.3307 0.0345 PLXNA3 −1.43310.0403 CALU 1.3268 0.0306 PAPD4 −1.4057 0.0355 KDM5A 1.3258 0.0157ATP2B4 −1.3949 0.0275 TRA2A 1.3241 0.003 0XSR1 −1.3411 0.0235 WNK11.3218 0.0276 TBC1D8B −1.3347 0.0297 NBAS 1.3148 0.0167 FBRSL1 −1.29750.0479 KAT6B 1.3111 0.0182 IMMT −1.2443 0.0452 TAOK3 1.2979 0.0453 ITGB11.2977 0.0489 PPP1R12A 1.2976 0.0249 RNF20 1.295 0.0097 SMC1A 1.29170.0156 ZC3H11A 1.2916 0.0229 DNAJC8 1.2892 0.02 RAB22A 1.2886 0.0406SPEN 1.2812 0.006 HNRNPD 1.2737 0.0326 YWHAZ 1.2704 0.0471 DNAJC131.2687 0.0317 IFNAR1 1.2677 0.0437 INO80D 1.2663 0.0096 TRIP11 1.26610.0404 ARID2 1.2649 0.0377 DDB1 1.2649 0.0221 TGOLN2 1.2605 0.0444C3orf58 1.2578 0.03 IARS2 1.2553 0.0436 PMPCB 1.2502 0.0285 USP47 1.24260.0201 PHIP 1.2382 0.0118 IQGAP1 1.2353 0.043 HNRNPK 1.2227 0.0282 NUMA11.2168 0.021 VPS36 1.2153 0.0257 FUBP1 1.1848 0.0447 ZNF638 1.14460.0493 KMT2C 1.1063 0.0278

Example 8: Characterization of Gene Expression During the Course ofTreatment

Skin tissue and corresponding RNA samples were collected fromindividuals enrolled in the clinical study of Example 7 at baseline andat Week 24. Table 17 and Table 18 list genes that were significantlymodulated (P<0.05) in responders and non-responders, respectively, bytreatment between baseline and week 24. These genes represent biomarkerswhich potentially correlate with therapeutic response.

TABLE 17 Genes Significantly Modulated Between Baseline and Week 24 inResponders Increased Expression from Baseline to Week 24 DecreasedExpression from Baseline to Week 24 Gene Fold Raw Gene Fold Raw SymbolChange P Value Symbol Change P Value OCEL1 98.7285 0.0205 HIST1H1B−359.79 0.0152 FMO4 90.1456 0.0179 HLA-DPA1 −276.107 0.0071 DPF1 87.00340.0042 C3orf14 −217.796 0.0158 TNNC2 63.2953 0.0223 HIST1H3D −200.860.0256 TMEM217 54.4275 0.0189 IFI6 −193.193 0.0044 FAM131C 48.5846 0.017PXMP2 −156.391 0.0107 RSG1 44.7652 0.032 HLA-DQB2 −150.163 0.0201 ADAM2141.0881 0.0176 IL32 −137.196 0.0231 FANK1 40.7236 0.0416 FUOM −131.6790.017 PCDHB8 37.0503 0.0472 GKAP1 −119.173 0.0059 CORO7-PAM16 31.39830.0399 RANGRF −118.714 0.0139 CORO6 30.762 0.0361 DCTPP1 −115.051 0.0166FSCN2 23.8405 0.0425 MT1E −93.8553 0.0438 VRTN 23.787 0.029 RGS14−87.6162 0.0125 ARHGEF39 22.5721 0.0222 GMNN −83.8834 0.0204 CNGA321.5758 0.025 THOC3 −77.7502 0.0434 ALPK3 20.8473 0.0354 SNRNP25 −76.0150.0248 PCDHB5 20.4521 0.0445 PARP8 −75.5333 0.0062 FKBP10 17.8669 0.0426PLXNC1 −74.1112 0.005 IMPG1 16.6877 0.0428 GPX7 −72.2 0.0167 ISCA214.3856 0.0448 HEY1 −72.0076 0.0212 LMAN2L 12.2518 0.0458 TBC1D3−71.9042 0.016 ETS1 11.5607 0.0096 APOBEC3A −70.5453 0.0174 RYR2 11.51530.03 CCDC121 −67.9646 0.0193 HSPA1L 11.2961 0.0162 HLA-DPB1 −67.5360.0315 AK1 8.8674 0.0244 GK −66.7528 0.0263 SLC35C1 6.2951 0.0025 GAMT−65.346 0.0418 SLC9A3R2 5.8779 0.007 TAS2R4 −64.2421 0.0193 ZNF6755.6136 0.0343 ZNF467 −61.8768 0.0421 MINPP1 5.1774 0.04 FOXM1 −60.85310.0133 SLC38A7 5.0401 0.0489 FABP7 −58.5431 0.0323 QPCT 5.0112 0.0401NRM −58.1637 0.036 NCBP1 4.902 0.0367 RAB15 −57.8193 0.0066 SLC22A154.8508 0.0409 TGFBI −57.5202 0.0386 DIRAS1 4.4943 0.0133 CXCR4 −54.48730.0208 EEF1E1 4.4432 0.0188 TMEM97 −52.6704 0.0122 TRPV1 4.3896 0.0349PSMB9 −51.5829 0.0487 FTSJ1 4.1583 0.0256 XRCC6BP1 −51.511 0.0118C5orf63 4.0234 0.044 ABCC4 −51.222 0.0244 DCTN5 4.0233 0.0115 CENPK−51.0641 0.0128 C15orf41 4.0134 0.0132 NEIL3 −50.7632 0.0149 PSCA 3.91620.0086 IL4I1 −49.4381 0.0349 SNX21 3.7733 0.0494 ZDHHC11B −47.59530.0232 GRB7 3.7309 0.0326 TMC4 −47.4074 0.0162 NAA38 3.666 0.0376TMEM263 −47.1555 0.0321 NUBP2 3.6297 0.0419 CASS4 −46.9763 0.0019 PTGER43.5756 0.0172 CEP57L1 −45.4386 0.0262 ALG14 3.5539 0.0073 HIST1H2BO−43.9862 0.0191 PPT2 3.5499 0.0105 AKAP7 −43.364 0.0314 FIS1 3.41670.0271 PKIB −42.739 0.0093 USP3 3.379 0.0407 DLK2 −41.1394 0.0393 KCTD103.3438 0.046 DZIP1L −41.1156 0.0486 PGBD2 3.279 0.0332 HIST1H3H −40.62580.0382 GATSL2 3.2773 0.0456 PDPN −40.5786 0.0437 SOCS5 3.2578 0.0187KREMEN2 −39.3427 0.0378 EHD4 3.2433 0.0438 CLSPN −39.1791 0.0211 ROBO43.2411 0.0113 GPR137C −39.0863 0.0252 IQCD 3.1765 0.0319 ZNF311 −37.77040.0275 MARS 3.1429 0.0258 CDCA5 −37.6608 0.0466 BCL7B 3.1189 0.0456 TRO−37.2777 0.0314 MGLL 3.0578 0.015 ENO2 −35.1392 0.0479 ARHGAP10 3.02770.0172 THEM6 −34.6052 0.0429 GLB1L 3.0025 0.0284 KLHL31 −34.4252 0.0433PAQR7 2.9935 0.0459 LUZP2 −33.8607 0.0235 PTRHD1 2.9473 0.0093 AARD−33.5312 0.031 C6orf47 2.9414 0.0121 AK8 −33.4846 0.0125 KSR1 2.92440.0335 CXCL8 −33.4768 0.0323 CANT1 2.8911 0.0328 ENTPD6 −32.7907 0.0471FAM73B 2.8863 0.0435 TRIM6-TRIM34 −32.6836 0.0241 SUCLA2 2.8802 0.0496ZEB2 −32.4325 0.0233 C1orf210 2.8715 0.0193 LAPTM5 −32.2047 0.0494ZNF782 2.8504 0.024 CD40 −31.8683 0.0481 KCNK1 2.8137 0.0373 RILP−31.6352 0.0131 WSB2 2.8047 0.0417 G0S2 −31.2738 0.0428 ARL2 2.79650.0378 MSTO1 −30.8368 0.0464 ANKRD42 2.7657 0.0482 SCN3B −30.7775 0.0159GTPBP1 2.7639 0.0485 ZC3HAV1L −30.4503 0.0473 NFATC2IP 2.7612 0.0103ANKRD23 −30.2129 0.0236 TMEM253 2.7155 0.028 TMEM173 −29.9866 0.0222COMMD5 2.6792 0.0082 L3MBTL3 −29.8492 0.0486 FAM83G 2.6336 0.0216 LRP5L−29.4901 0.0424 IFT122 2.6166 0.004 CCNI2 −29.2839 0.0151 NLK 2.59610.0162 HES5 −29.2459 0.0207 PLA2G12A 2.5949 0.0431 FSTL4 −28.8924 0.0349PPM1F 2.594 0.0339 EGF −28.8183 0.0221 SLC52A2 2.5563 0.041 CCDC150−28.7454 0.0365 HAGH 2.5495 0.0117 TRIQK −28.5707 0.0286 FBXO28 2.48640.0405 MAD2L2 −28.5107 0.0497 SELO 2.4697 0.0255 ADAMTSL3 −28.47290.0201 STAMBP 2.4509 0.0206 NUSAP1 −28.1331 0.0256 ASPSCR1 2.4269 0.0054GRB10 −27.4522 0.0421 NAA30 2.4218 0.0474 PLS1 −27.2378 0.0454 MRPL42.4063 0.0259 GPR61 −26.9031 0.0135 MTF1 2.4043 0.0388 EFCAB11 −26.86260.0487 COX6A1 2.3921 0.0239 GBP4 −26.5841 0.0375 FRAT2 2.3902 0.0095SLC29A2 −26.498 0.0277 RUVBL2 2.3867 0.0463 CDPF1 −26.3582 0.0401 TSG1012.378 0.0282 ITGA4 −25.7113 0.0416 DVL3 2.3747 0.0498 XRRA1 −25.61880.0375 HINFP 2.3697 0.0419 AURKA −25.5369 0.0379 ZNF662 2.3487 0.0398SRRM5 −25.4946 0.0467 COPE 2.3467 0.0345 SPARC −24.7261 0.0459 GPATCH2L2.3286 0.0373 LUM −24.2772 0.0348 ENTPD7 2.3284 0.0064 ZXDA −24.06190.0376 SEMA3F 2.3238 0.0191 ENTPD1 −23.4596 0.0498 EMD 2.3123 0.0004STK32C −22.7667 0.0425 TRIM23 2.2968 0.0071 SERPINI1 −22.7181 0.0432TMUB2 2.2907 0.0187 FAM107A −22.6607 0.0464 TMEM9B 2.2768 0.0362 C9orf40−22.4845 0.0491 EPHA2 2.263 0.0353 CAP2 −22.2152 0.0386 DDX52 2.26270.0483 ZFP2 −21.7457 0.0045 REEP3 2.2441 0.0449 IPMK −21.6486 0.0373CEBPA 2.2405 0.0112 MFSD2A −21.5646 0.0363 EVC2 2.2375 0.0369 VAV2−21.1989 0.0355 EGLN2 2.2283 0.0317 ZMAT1 −21.0583 0.0478 HCAR2 2.22140.0193 CORO7 −20.9029 0.0203 PAPD5 2.2071 0.0327 LSP1 −20.0737 0.0067PDK2 2.1998 0.0296 TSC22D3 −18.9586 0.0457 RNASEH2C 2.1987 0.0095 TYROBP−18.9243 0.0416 ST3GAL4 2.1983 0.0398 SRGN −18.9043 0.0443 CXCR6 2.17910.0068 MAATS1 −18.3625 0.0396 RPP14 2.1707 0.0185 IL17RB −17.4369 0.0484WDR81 2.1629 0.0205 PRRG3 −17.1027 0.0306 SPAST 2.1592 0.009 SLC9C1−16.544 0.0495 NAA16 2.1378 0.0301 GPN3 −15.3097 0.0391 ATP5D 2.13110.0476 CNR1 −15.2997 0.0457 SUPT4H1 2.1272 0.0193 ADAMTS13 −14.16360.0472 SETD8 2.1254 0.039 METTL12 −14.087 0.0349 SLC9A3R1 2.1031 0.049SLC25A2 −13.1634 0.0494 CCDC134 2.0952 0.0213 ZNF367 −13.0319 0.0373CHURC1 2.0922 0.0215 PCDH9 −12.9108 0.0143 TRMT44 2.0917 0.0174 CASC10−12.8107 0.0219 PCDHGA11 2.078 0.0385 PPP1R36 −12.6748 0.0398 SDHC2.0768 0.0403 IGFBP2 −12.6237 0.049 ERVK3-1 2.0744 0.0483 ANPEP −12.5490.0425 GATS 2.0689 0.0486 ARSK −12.4404 0.0344 OCLN 2.0494 0.0078 POSTN−12.3583 0.0333 CWC25 2.0441 0.0384 FBXL13 −11.8859 0.0247 APBB1 2.04320.0457 CLVS2 −11.6619 0.0472 SIL1 2.0414 0.0157 DGKD −11.6574 0.0365RPS19BP1 2.0293 0.0166 LDLRAD4 −11.5383 0.0411 TLE3 2.0263 0.0074 MTL5−11.153 0.0382 ATP13A1 2.0239 0.0365 LYRM9 −10.6131 0.0494 TMEM183A2.0144 0.0325 UAP1L1 −9.4021 0.0247 LLGL2 2.0135 0.0266 TFEC −8.95990.0356 MOSPD1 2.0108 0.0312 CEP85L −8.7638 0.0349 DCTD 2.0049 0.0357RALYL −8.212 0.0266 CPT1A 1.9939 0.0377 ZNF850 −7.7793 0.034 FAM104B1.9774 0.0319 NOVA1 −7.6282 0.0354 SHROOM3 1.9663 0.0218 LRFN1 −7.14620.0363 TRAPPC3 1.9631 0.0475 XRCC3 −7.0565 0.0167 MKRN1 1.9569 0.0426CSF3R −6.426 0.041 SMCR8 1.9398 0.0455 CCND2 −5.3947 0.0485 PLCG1 1.92530.0281 LY75 −5.1311 0.0378 RINT1 1.9171 0.048 CLMN −5.1058 0.032 CHTF81.9151 0.0364 PRKAA2 −4.4212 0.0248 NFATC1 1.8755 0.0219 LYRM7 −4.02580.0474 USP10 1.8733 0.0224 TTC22 −3.9781 0.0267 UQCRC1 1.8623 0.0135PTRF −3.1496 0.0381 ZNF768 1.858 0.0348 RWDD4 −3.1078 0.0381 ARHGEF41.8392 0.039 HAUS4 −2.5437 0.0062 RGL2 1.8375 0.0331 GPRIN2 −2.41110.0117 KMT2E 1.8351 0.0111 RANBP1 −2.3475 0.0498 ATG16L1 1.8253 0.0482TSHZ1 −2.2857 0.0482 MORC4 1.8195 0.0296 LETMD1 −2.241 0.0113 CNKSR11.8089 0.0318 MYD88 −2.1916 0.0221 IL1RL2 1.8089 0.0482 THUMPD3 −2.12720.01 CEBPD 1.8067 0.0328 TNFRSF14 −2.0876 0.0409 NIN 1.8008 0.0165 G3BP1−2.0353 0.0221 JARID2 1.8001 0.0468 NDUFS7 −1.9952 0.045 TNPO3 1.79890.0025 PCBP4 −1.979 0.0419 ZNF846 1.7963 0.0271 ESF1 −1.9593 0.041SLC35A4 1.796 0.0261 ASPH −1.9536 0.0392 COL16A1 1.795 0.0188 TXK−1.9424 0.02 HMCES 1.7861 0.0455 PMM2 −1.8767 0.0496 POLG 1.7796 0.0087LMNB2 −1.8177 0.0464 PPP1R2 1.7717 0.0359 TBC1D5 −1.8149 0.0495 KDELR21.7572 0.046 TSR1 −1.7509 0.0274 ANKRD27 1.7494 0.0096 PODXL2 −1.75080.0276 MXD4 1.7397 0.0476 SPG20 −1.7498 0.0493 NOMO2 1.7386 0.0434 TEF−1.6918 0.0026 HES4 1.7374 0.0348 PPT1 −1.6881 0.0025 NRIP1 1.737 0.0433PCDHGB7 −1.6049 0.0305 STIM1 1.7304 0.0311 ESYT1 −1.5984 0.032 CNOT31.7217 0.0154 AK2 −1.5761 0.0429 LYSMD4 1.7216 0.0257 TIMM13 −1.56720.0493 TBK1 1.7158 0.0454 ZNF362 −1.5589 0.0076 TCTN3 1.7114 0.0256ZNF587B −1.5566 0.0358 ABL2 1.7085 0.0454 TANC1 −1.4725 0.0328 KIFC21.7082 0.0109 MAP1B −1.4626 0.0344 ANAPC15 1.7032 0.0215 DARS −1.42860.0186 MAP2K4 1.7031 0.0194 GSTM4 −1.3866 0.0182 PPP6R2 1.7008 0.0182MAGED1 −1.3738 0.0231 GTF2F1 1.6812 0.0024 RPS21 −1.3622 0.0291 C1orf1981.6782 0.03 AARS2 −1.3422 0.0156 C7orf60 1.6728 0.0347 BCL6 −1.23510.0254 UBA2 1.671 0.0366 CDK3 −1.0356 0.0343 SLC25A23 1.6698 0.0444 VEZT1.6693 0.0199 LRRC8A 1.6682 0.0107 MFF 1.668 0.0175 PLEKHF1 1.663 0.0362SS18L1 1.6622 0.0051 AP1G1 1.6422 0.0372 ZNF384 1.6237 0.001 TECR 1.62320.016 ESRP2 1.6132 0.0294 NDUFA10 1.6132 0.0032 STOML2 1.6124 0.0395NIPAL1 1.6016 0.0363 HM13 1.5968 0.0147 FUS 1.5949 0.0207 DUSP22 1.58120.0095 RNPEPL1 1.5778 0.0145 SMURF1 1.5754 0.0378 PREP 1.5686 0.003RNF14 1.5649 0.0473 BLZF1 1.5621 0.0443 DNAJB2 1.5493 0.0241 FBXO181.5407 0.0438 EIF2AK1 1.5379 0.0193 C9orf69 1.5376 0.0281 PIGO 1.53370.0334 VDAC2 1.5215 0.0234 OTUD7B 1.5126 0.0025 FAM129B 1.5108 0.0435PAPOLA 1.4963 0.0227 RNF146 1.4909 0.0188 AGAP3 1.4896 0.0474 SSR31.4876 0.041 DDX27 1.4851 0.0137 MOGS 1.4775 0.0039 ZBTB11 1.477 0.0067CKAP4 1.4755 0.037 CHMP4B 1.4663 0.0441 ANKRD12 1.4549 0.0016 AHDC11.4542 0.0145 WDR46 1.4483 0.0317 PRDM2 1.4319 0.0069 C19orf43 1.42750.0378 SLC4A2 1.4219 0.0387 TTYH3 1.421 0.0163 PPP4R2 1.4207 0.0192RBM19 1.4204 0.0241 ACSL1 1.405 0.033 KAT7 1.4016 0.0307 SPTAN1 1.40.0331 ZNF654 1.3982 0.0419 KDM6B 1.3947 0.0467 CDC42SE1 1.3932 0.044CABIN1 1.3875 0.0067 TNFAIP2 1.3847 0.0109 UBE2Q1 1.382 0.0403 SON1.3584 0.0484 TXNDC16 1.3542 0.0441 NCOR1 1.3492 0.0045 FAM102A 1.33190.003 IPP 1.3303 0.008 NARFL 1.3288 0.0272 SUGP1 1.3045 0.0112 KLHL241.2912 0.0131 PLCH2 1.285 0.0126 NPIPB5 1.2724 0.0315 NUPR1 1.26950.0036 RBM18 1.2591 0.0292 ATP2B4 1.2529 0.0208 AACS 1.2472 0.0375 COX5A1.2307 0.0428 CUL2 1.2095 0.0484

TABLE 18 Genes Significantly Modulated Between Baseline and Week 24 inNon-Responders Increased Expression from Baseline to Week 24 DecreasedExpression from Baseline to Week 24 Gene Fold Raw Gene Fold Raw SymbolChange P Value Symbol Change P Value MADCAM1 27.6015 0.0007 GMFG−22.3167 0.0097 EVI2A 25.3613 0.0015 IL1RL1 −22.1689 0.0074 S100A521.2684 0.0021 NIPSNAP3B −21.7911 0.0031 HIST2H4B 16.2558 0.0112 FMO2−19.3532 0.0037 BCO1 15.2064 0.0035 LUZP6 −18.3831 0.0373 GPR52 14.59690.0262 TICAM2 −17.0725 0.0078 USP17L2 14.3178 0.0038 RNF148 −16.95740.0293 THBS4 13.9528 0.0008 ABHD14A −16.9299 0.0072 BIK 13.8984 0.0169SIGLEC10 −16.0127 0.0072 ZYG11A 11.6203 0.0016 DEFB103B −14.7613 0.0041RASGRP4 11.6041 0.003 RHOF −14.111 0.0338 CRYGS 11.5803 0.0283 RHCG−13.9626 0.0246 ENTPD8 11.3311 0.0386 CCL20 −13.8396 0.0339 THAP1011.1195 0.0101 LCE5A −13.4353 0.0063 MEP1B 10.2003 0.0314 C10orf128−13.3022 0.0129 RAB3A 10.1306 0.0064 IL37 −13.122 0.0158 UBE2Q2L 10.11670.0407 CYP27B1 −12.6505 0.0006 MLXIPL 9.975 0.0153 SH3BGR −12.366 0.0197MAPK12 9.6678 0.013 VNN3 −11.7831 0.0073 WBP2NL 9.3408 0.0155 PRR7−11.7235 0.0434 MROH7-TTC4 8.9094 0.0279 ADCY2 −11.6259 0.0144 ASIC18.8674 0.0041 KBTBD8 −10.5372 0.0222 MYEF2 8.7777 0.027 CD28 −10.32140.0352 TSLP 8.6794 0.004 SOX10 −10.3179 0.001 CHRNA7 8.5419 0.006 CD36−10.1313 0.0169 PSORS1C1 8.2205 0.0498 KRT3 −9.945 0.0064 ANKDD1A 8.11120.0214 TRIM36 −9.6633 0.0104 FBXO5 8.0028 0.0386 ARL4D −9.5441 0.0273BSCL2 7.7117 0.0307 IGFN1 −9.3742 0.0091 AS3MT 7.5298 0.0256 S100A12−9.2963 0.0413 DERL3 7.4784 0.0187 PROX1 −8.9646 0.0106 UFSP1 7.34880.0393 FAM19A5 −8.8138 0.0147 AGBL3 7.2792 0.0181 C19orf80 −8.659 0.0157AGBL4 7.2768 0.0176 APOBEC3A −8.5652 0.0249 RAB42 7.2584 0.0255 DLEU1−8.5213 0.0357 YPEL1 7.223 0.0121 PARVG −8.4144 0.0464 TPO 7.1394 0.0135GSTT2B −8.3303 0.0329 PYROXD2 7.0715 0.0268 SLCO4C1 −8.0891 0.0272 ASPDH7.0177 0.0177 ENG −7.819 0.0225 UTS2 6.6584 0.0276 RCBTB2 −7.7833 0.0232GRM3 6.5925 0.0324 GZMB −7.7809 0.0456 MPP3 6.5563 0.0365 OASL −7.73080.0217 TSPYL6 6.5459 0.0399 LY6K −7.6642 0.0325 NAGLU 6.5148 0.0428 VMO1−7.5022 0.0422 ARHGAP19-SLIT1 6.41 0.0434 LZTS1 −7.4675 0.0335 FAM69B6.234 0.0474 TF −7.3803 0.0431 RNASE2 6.2032 0.0428 AMDHD1 −7.38 0.0478ACKR3 6.2027 0.0272 SLFN12 −7.303 0.0095 COLGALT2 6.2027 0.0218 PPP1R14A−7.2477 0.0419 UGT1A4 6.1468 0.0348 MYPN −7.1862 0.0238 TEKT2 6.04150.024 JAKMIP1 −7.0395 0.0191 TMEM121 6.0361 0.0165 AHRR −6.9435 0.0297SULT1A1 5.8246 0.0382 LGALS2 −6.8965 0.0396 CYP4A11 5.8074 0.0283 TIGD3−6.7542 0.0288 PRB3 5.797 0.0347 GPRIN1 −6.7215 0.0187 NPIPA3 5.78050.0361 CHKB-CPT1B −6.6251 0.039 STK31 5.757 0.0349 NRN1 −6.6135 0.0139GRID1 5.75 0.0068 PIK3R5 −6.6118 0.0383 ZNF773 5.729 0.0488 SLAMF7−6.5562 0.0484 TMEM35 5.6621 0.0182 SRGN −6.5542 0.0169 SYCP2L 5.6420.026 RNF113B −6.434 0.0392 TMEM143 5.5559 0.0418 TRPV2 −6.4053 0.0239PDE9A 5.5511 0.0287 KRTAP5-1 −6.2339 0.0342 CNTN2 5.5263 0.022 TRAF5−6.1305 0.0317 RMDN2 5.505 0.0356 PDE6A −6.0672 0.0328 SV2A 5.38620.0348 CD244 −6.0509 0.0421 GPR182 5.3123 0.0107 FAM166B −5.9975 0.038CCDC74B 5.2571 0.0489 DTYMK −5.9009 0.0255 HPDL 5.2215 0.0128 CXCR2−5.8694 0.0155 SHC3 5.1772 0.0392 KLHDC1 −5.7732 0.0391 ZNF222 5.16630.0455 PLIN1 −5.742 0.029 KCTD14 5.1346 0.0421 KCNJ2 −5.7133 0.0236C4orf46 5.0848 0.0216 ASPN −5.6593 0.0227 CPLX2 5.0008 0.0333 SUV39H2−5.5883 0.0335 SYT2 4.9878 0.0383 ROPN1B −5.533 0.0381 MAT1A 4.92680.0432 VNN1 −5.4803 0.018 FOXE1 4.8759 0.0339 IFI27 −5.4264 0.0349 INA4.7583 0.0409 KCNG2 −5.3548 0.0268 ALX1 4.6257 0.0328 LAIR1 −5.34730.0371 KBTBD12 4.5979 0.0351 P2RX5 −5.3335 0.039 GINS4 4.5679 0.0456CHRM4 −5.2948 0.0336 RGS11 4.5219 0.0141 TOR4A −5.2677 0.004 DCDC2B4.5158 0.0323 HIGD1B −5.2371 0.042 ANKRD53 4.4706 0.0298 RGS2 −5.14840.0134 EBLN2 4.4504 0.0266 RNF224 −4.9675 0.0442 COX6B2 4.3655 0.0257AURKA −4.9118 0.0485 CHRM5 4.3036 0.0389 LGI2 −4.8099 0.0284 TTC34 4.2740.0394 SLC22A13 −4.7851 0.0416 ADPRM 4.2277 0.0448 MLC1 −4.7144 0.0305C9orf66 4.2211 0.0339 TLR3 −4.7066 0.0429 MAP1S 4.1703 0.0454 HHEX−4.7002 0.0388 CYP4F11 4.1295 0.0493 C8orf48 −4.6899 0.0382 LY6G5B 4.0930.0488 TIMM8A −4.5289 0.0318 HEATR4 3.9807 0.0423 TTC25 −4.4167 0.0396SHISA6 3.9742 0.0442 KRT72 −4.3577 0.0397 TPST1 3.9197 0.0379 KCNMB3−4.2805 0.0257 KCTD19 3.9047 0.0402 HAPLN4 −4.2381 0.0472 CDHR2 3.85180.0391 CCDC69 −4.203 0.0488 ZNF454 3.8193 0.0491 TMBIM4 −4.1761 0.0273DGKG 3.8179 0.0189 BMP5 −4.1521 0.0233 TRIM45 3.7012 0.0495 GPRC5A−4.1494 0.0183 PCYT1B 3.6534 0.0363 GPD2 −4.1448 0.0444 ZNF696 3.53960.0301 ZNF668 −4.1396 0.0428 RNF165 3.536 0.0369 SERPINB3 −4.0734 0.0235RBM44 3.5063 0.0106 PPP1R16B −4.0259 0.0093 PRICKLE4 3.4544 0.0447 NTSR1−3.9405 0.0434 PCDHAC1 3.3838 0.0156 PTAFR −3.9092 0.0477 MAST1 3.32580.0467 AVPR1A −3.907 0.0044 COL14A1 3.3194 0.0444 STARD8 −3.8533 0.0246ISY1-RAB43 3.2156 0.0306 C15orf53 −3.6751 0.0462 SPRED3 3.2113 0.004ADCY7 −3.6529 0.0156 DET1 3.1417 0.0322 PIK3R6 −3.6311 0.0264 CCDC1683.0629 0.0279 ZIC2 −3.6198 0.0249 FAM9C 2.9715 0.0439 ZNF490 −3.56510.0493 PDZD7 2.957 0.024 CLDN14 −3.5193 0.0385 GPR179 2.9457 0.0181NUDT2 −3.5151 0.0464 NPDC1 2.9016 0.0258 FOXP3 −3.4118 0.0275 KIF122.9003 0.0157 APBB1IP −3.3841 0.0244 DCHS1 2.7724 0.0288 EIF3C −3.32470.0213 KIF7 2.7666 0.017 ACTR5 −3.2145 0.0319 ZNF799 2.7127 0.0494RPS6KA5 −3.1343 0.0376 RPS6KL1 2.6129 0.04 C4orf27 −3.1257 0.0253 ZNF7172.5241 0.0163 FUT2 −3.0804 0.0348 ARMC7 2.4962 0.0019 LCE3E −3.07560.0024 ATHL1 2.3694 0.0467 HIST3H2BB −3.0463 0.0407 B3GNT9 2.3402 0.0426ARC −3.0248 0.0423 GIN1 2.2823 0.0085 SPRR2A −3.0167 0.0345 RNLS 2.26030.0203 DOCK11 −2.9427 0.0164 EFEMP2 2.2448 0.0377 KRT78 −2.8669 0.0053GDF11 2.2028 0.0292 WAS −2.8546 0.0369 VAMP1 2.1104 0.0086 RTL1 −2.8520.0458 PITPNM2 2.0924 0.044 TCEANC −2.8089 0.011 NUP35 2.0831 0.0019FAM25A −2.6398 0.0004 CDC25B 2.068 0.0423 G0S2 −2.6281 0.037 XPNPEP32.0478 0.0119 CD3G −2.5886 0.0351 ANKRD9 2.0415 0.0129 SPRR2G −2.57580.027 NID2 2.0359 0.0405 GPN3 −2.5708 0.0125 TK2 2.0105 0.0346 SEL1L3−2.5671 0.038 SLC47A1 1.998 0.0381 CSF1R −2.5368 0.0412 FAM20C 1.99030.0498 CETN3 −2.4829 0.0161 NSUN4 1.9577 0.0448 STXBP6 −2.468 0.0065ZDHHC1 1.9446 0.0171 MSRB2 −2.4649 0.0437 EIF3CL 1.9147 0.0137 CD209−2.4462 0.0496 ACACB 1.9112 0.0473 MRPL39 −2.4296 0.0129 FAM213B 1.89760.0267 NCOA7 −2.38 0.0136 GNB1L 1.8789 0.01 C9orf85 −2.3763 0.0349 NME61.8707 0.0097 PTPMT1 −2.3581 0.0248 ZNF358 1.8663 0.0053 COX14 −2.33460.0071 SOX8 1.8525 0.0332 LCE3D −2.2937 0.0431 C19orf48 1.8457 0.013SLC43A2 −2.2909 0.0474 RAC3 1.8405 0.0318 SLC20A1 −2.2879 0.0421 SMIM81.8085 0.0292 MLF1 −2.26 0.0347 DDX51 1.7997 0.0428 FAM185A −2.25220.0245 ZNF785 1.7908 0.0171 MRPL15 −2.2193 0.0185 RRP8 1.7884 0.0409B3GALT4 −2.2061 0.0213 POLR2H 1.786 0.0151 TBC1D12 −2.183 0.0436ARHGAP24 1.7854 0.0219 FCHSD1 −2.1791 0.031 ARNT2 1.785 0.0093 DNASE1L2−2.1662 0.0445 PCDH12 1.7803 0.0248 PNPLA1 −2.156 0.0076 IVD 1.76860.0312 ABHD17B −2.1475 0.0047 ZNF484 1.746 0.0095 CARD16 −2.1366 0.0288MARCH5 1.739 0.0152 IL6R −2.1301 0.0109 TFAM 1.7294 0.0052 HIST1H4B−2.1092 0.014 MRPL14 1.7167 0.0295 PTS −2.0901 0.0276 TSHZ1 1.71590.0484 ANAPC13 −2.0894 0.0188 FEM1A 1.7134 0.0187 DCTN5 −2.0889 0.001R3HCC1 1.7112 0.0105 FAM110C −2.0776 0.0038 C1orf174 1.7009 0.0292GOLGA8F −2.0534 0.0477 IPMK 1.6975 0.0123 SPRR2E −2.0439 0.0024 ZNF5001.6929 0.0455 GNA12 −2.0286 0.0443 TUBGCP5 1.6922 0.0484 ZNF584 −2.01690.0115 MR1 1.6913 0.0051 GPX3 −2.0139 0.0464 FAM89B 1.681 0.0222 RIPK2−2.0049 0.0083 TMEM80 1.677 0.0414 LCE6A −1.9922 0.0321 SLC44A3 1.65560.0416 RNF180 −1.9829 0.0073 PLTP 1.6543 0.0335 GNB5 −1.9531 0.0465FASTKD2 1.6536 0.0098 SDR9C7 −1.9516 0.0005 TYK2 1.6521 0.0414 DUSP5−1.9484 0.0168 CEP89 1.6498 0.0147 ETS1 −1.9476 0.0412 ANAPC4 1.64040.0187 PLA2G2F −1.9275 0.0379 TTYH1 1.6205 0.0301 YOD1 −1.9234 0.0003ZNF574 1.616 0.014 TRAPPC1 −1.9138 0.0339 PARP2 1.6149 0.0364 ZDHHC13−1.9113 0.0372 NEU1 1.6133 0.0305 MARVELD3 −1.9109 0.0275 STARD3 1.59940.046 ZNF16 −1.9062 0.0374 CBX7 1.5991 0.0137 PRELID3B −1.8833 0.0175CBLC 1.5975 0.0488 TMLHE −1.8685 0.0325 ZNF529 1.5958 0.0115 SLC36A1−1.8658 0.0376 CADM1 1.5941 0.0097 CCL22 −1.8563 0.0346 ABCB6 1.57530.0179 ZFAND2A −1.8553 0.0436 ZC2HC1A 1.5687 0.0397 MAP1LC3A −1.85220.0095 MTSS1L 1.5593 0.0181 RHOQ −1.8521 0.0337 LONRF1 1.5555 0.0374ARNTL −1.8509 0.0325 PAXBP1 1.5555 0.0102 INPP5D −1.8454 0.027 SMO1.5445 0.0114 SPTBN5 −1.8452 0.0221 THNSL2 1.543 0.0113 PRSS3 −1.84220.0492 TULP3 1.5357 0.0378 MPDU1 −1.8281 0.0308 CNGA1 1.524 0.0361 MPST−1.8255 0.0228 PACS2 1.519 0.0117 SMOX −1.8246 0.0122 RAB3IP 1.51340.0007 MRPL30 −1.8185 0.0147 TBC1D16 1.5078 0.0113 NOS3 −1.8178 0.0274ZNF316 1.5078 0.0084 ARNTL2 −1.8116 0.0408 CDK4 1.5049 0.0196 LIMS1−1.8077 0.0265 CTBP2 1.501 0.0397 BCKDK −1.7907 0.0102 NOL9 1.49910.0188 ABHD12B −1.783 0.003 MEX3D 1.4985 0.0228 HIST1H4C −1.7668 0.0292TC2N 1.4963 0.0044 SLC19A2 −1.7647 0.0356 NEIL1 1.4926 0.0479 RAP1B−1.764 0.0111 TMEM181 1.4892 0.0037 UBL3 −1.7629 0.0069 FZD8 1.4746 0.04NAA20 −1.7564 0.0237 MRPS16 1.4726 0.0412 EXOC5 −1.7555 0.0241 PCNXL41.4664 0.032 ZNF248 −1.7545 0.0341 TRIM8 1.4615 0.0303 TBC1D23 −1.75280.022 DHRS3 1.4609 0.0161 CCDC124 −1.7484 0.0352 RGL2 1.4604 0.0012RAB23 −1.7364 0.0327 EXOC3 1.4509 0.0025 PAPL −1.7334 0.0094 PER2 1.43690.0293 PHLDA2 −1.7326 0.0389 ASPH 1.4367 0.0368 TSSC1 −1.7263 0.0443HKR1 1.4322 0.0451 POLD3 −1.726 0.0298 ARL10 1.4309 0.0168 MPV17 −1.72460.036 TASP1 1.4307 0.0355 CEMIP −1.7239 0.02 RCN1 1.4224 0.0146 GULP1−1.7222 0.0476 TNS1 1.4221 0.0436 NCCRP1 −1.7216 0.0013 REV1 1.41680.0298 TM2D1 −1.7173 0.0044 BIN3 1.4116 0.0472 MYO1B −1.7131 0.0018 RHOV1.4116 0.0186 C2orf47 −1.7098 0.0486 PLAGL2 1.4073 0.0028 RNASE7 −1.69850.0398 FAM53C 1.4072 0.0213 TMEM127 −1.6948 0.0164 SCAF1 1.4053 0.0016TMEM11 −1.6876 0.0443 TSPYL5 1.3949 0.0198 NT5C3A −1.6864 0.0087 PDCD51.3899 0.0011 ESD −1.6832 0.0341 MEX3C 1.3871 0.0381 GADD45A −1.67930.015 ADPRHL2 1.3855 0.0444 AIM1 −1.6698 0.038 ZBTB4 1.3837 0.0237 GCOM1−1.6691 0.0128 SMPD4 1.3832 0.011 ACTR10 −1.6639 0.0274 FAM189B 1.3830.0178 AK9 −1.6629 0.0471 GYS1 1.3784 0.042 FAM98A −1.6616 0.007 FRAT21.3756 0.0102 TMEM86A −1.6601 0.0072 PKD1 1.374 0.0367 MRPL27 −1.65420.0028 ARID2 1.3706 0.0329 HERC6 −1.6508 5.71E−05 FGD1 1.3669 0.0188ERN1 −1.6493 0.0114 GPAA1 1.3609 0.038 NAA10 −1.648 0.0232 MYSM1 1.35780.0212 SLC10A6 −1.6437 0.0277 ZNF623 1.3561 0.0106 RBPJ −1.6436 0.029TOPBP1 1.3549 0.01 LCE2C −1.642 0.0318 CACNB1 1.3537 0.0424 SEMA7A−1.6327 0.0033 BTBD7 1.3428 0.0311 RNGTT −1.632 0.0064 PEX14 1.34040.0399 USP2 −1.6284 0.0306 STK35 1.3378 0.0185 CHURC1 −1.6274 0.0014NFXL1 1.3373 0.0184 SPATS2L −1.626 0.008 PLEKHG5 1.3348 0.0384 BZW1−1.6243 0.0034 MAN2B2 1.3277 0.026 ABHD5 −1.6219 0.0132 XPO7 1.32580.0498 HK2 −1.6217 0.0443 GAS1 1.3212 0.0324 AZGP1 −1.6203 0.0214 SNX171.3212 0.0206 CASP7 −1.6192 0.0045 MAST2 1.3045 0.033 SLC5A1 −1.6180.008 TRAF3IP2 1.2978 0.0286 RAP1GDS1 −1.6172 0.0033 UBE2I 1.2935 0.0322TVP23B −1.6152 0.0291 IGF1R 1.289 0.0067 MRPS25 −1.615 0.0317 LDB11.2829 0.0019 MINPP1 −1.612 0.0296 RIPK4 1.2752 0.0235 CPA4 −1.61020.0133 SRRT 1.2673 0.0313 ATG9B −1.6079 0.0419 TOM1L2 1.254 0.0306 CNFN−1.6073 0.02 NOTCH3 1.2513 0.03 UBB −1.6053 0.0014 SNRNP70 1.2481 0.046GNPTAB −1.6027 0.039 MBD6 1.246 0.0256 SNRPG −1.596 0.0494 VPS36 1.24540.0256 ARHGAP29 −1.5928 0.0322 ZNF207 1.2452 0.0386 USF1 −1.5874 0.0386KANSL1 1.2397 0.0313 ZNF330 −1.5849 0.0195 HNRNPD 1.2357 0.0209 NBN−1.583 0.0384 RNMT 1.2177 0.0422 HIST1H1B −1.5817 0.0218 SMAD5 1.21410.0237 PIM1 −1.581 0.04 ZFP36L1 1.2025 0.0203 GSDMA −1.5778 0.0068ATXN7L3 1.201 0.0141 UBE2D3 −1.5735 0.01 SIN3B 1.1983 0.0224 CDC34−1.5732 0.0273 IRX3 1.1959 0.0451 PCNP −1.568 0.0475 EFS 1.1946 0.0277SLC35E3 −1.5657 0.0156 PLCH2 1.1917 0.0243 YWHAH −1.5657 0.0098 CIC1.1774 0.0061 C18orf25 −1.5611 0.0313 CREBBP 1.1736 0.0258 RPRD1B−1.5569 0.0442 ZFP36L2 1.173 0.0168 UBE2J1 −1.5485 0.0292 DOCK7 1.17230.0045 MRPL32 −1.5465 0.0406 IQSEC1 1.162 0.048 ECHDC1 −1.5434 0.0362DDR1 1.1618 0.0261 PDE12 −1.5349 0.0472 SUV420H1 1.1548 0.0457 ZNF649−1.5338 0.0147 MBD2 1.119 0.0409 DNAJB1 −1.5334 0.0017 CHIC2 −1.53320.0359 CNST −1.5303 0.0152 NUP107 −1.5272 0.045 ZNF720 −1.5207 0.0359PLA2G4D −1.5181 0.0315 STXBP3 −1.518 0.0229 SSNA1 −1.5168 0.0398 BAG5−1.5158 0.0015 PRKCH −1.5157 0.01 ARHGAP30 −1.5151 0.0477 PPP1R18−1.5143 0.0216 USP38 −1.5138 0.0377 SLC31A2 −1.5136 0.0419 NUB1 −1.51010.0086 SEPT11 −1.5075 0.0388 SUB1 −1.5053 0.0269 TIMM21 −1.4994 0.0417MRPL49 −1.4981 0.0257 DENR −1.487 0.0274 TRABD −1.4869 0.0348 VMP1−1.4868 0.0465 FNDC3A −1.4825 0.0115 SIL1 −1.4815 0.0127 MAP1LC3B−1.4758 0.038 WWC1 −1.4749 0.0404 POLR3B −1.4745 0.0212 VSIG10L −1.47320.0134 BLOC1S1 −1.473 0.0469 SHPK −1.4715 0.0309 PI4K2A −1.4714 0.0311TNIP1 −1.471 0.0008 ZNF706 −1.4695 0.0366 CORO1C −1.4673 0.0345 PLEKHB2−1.4646 0.0055 ALDH7A1 −1.4641 0.0251 TOMM5 −1.4639 0.0399 ADTRP −1.4620.0229 SLC6A14 −1.4614 0.0223 CSRNP1 −1.4595 0.0091 FAF2 −1.457 0.0056MRPL44 −1.4529 0.0283 UGCG −1.4494 0.0216 SYNJ2 −1.4479 0.0404 PDLIM2−1.4444 0.006 AK3 −1.4361 0.0358 DERL1 −1.4357 0.0305 TMEM179B −1.43570.0194 SNF8 −1.4332 0.0489 MGLL −1.4306 0.0327 GSE1 −1.4247 0.0324CIRH1A −1.4201 0.0236 HEXA −1.417 0.0329 SYNJ1 −1.4159 0.0369 ZNF440−1.4142 0.0323 PPARD −1.414 0.0131 HYOU1 −1.4135 0.0046 ARL13B −1.41220.0417 PLCXD1 −1.4108 0.0348 CRCT1 −1.4069 0.0325 PPP1R15B −1.405 0.0255TTYH3 −1.4035 0.0153 GBA −1.4003 0.0395 ARRDC4 −1.3999 0.0042 DDX52−1.3964 0.0404 CFL1 −1.3955 0.0493 RABGEF1 −1.3923 0.0238 ARHGEF10L−1.3921 0.042 GNPAT −1.3896 0.0473 NFYA −1.3888 0.0287 SFT2D2 −1.3880.0387 ZNF213 −1.3874 0.0437 NADK −1.3873 0.0021 SH3BP5L −1.3827 0.0087MXD1 −1.382 0.0308 DHRS7 −1.3803 0.0389 RAB24 −1.3771 0.0378 LNX1−1.3769 0.0218 PSD4 −1.373 0.0093 ATP6V1C2 −1.3717 0.0136 TMED9 −1.3710.0377 PDCD7 −1.3706 0.0474 H2AFY −1.3699 0.049 ALAS1 −1.3692 0.032NCOA3 −1.3678 0.023 SDCCAG8 −1.3678 0.0196 KATNB1 −1.3677 0.0328 AP5Z1−1.3664 0.0149 ADIPOR1 −1.3654 0.0443 TMPRSS13 −1.3611 0.0285 SNX9−1.3605 0.0224 PPP2CA −1.3592 0.0465 GPR137B −1.3585 0.0428 EHD1 −1.35820.0131 DENND2C −1.3558 0.0144 CHTF8 −1.3535 0.0141 PLK3 −1.349 0.0139CTSB −1.3444 0.0441 PIEZO1 −1.3433 0.0008 ERH −1.3384 0.0422 ITFG1−1.3382 0.0356 RND3 −1.3368 0.0298 IRF2 −1.3364 0.0324 PTPN2 −1.33630.0424 FBXW11 −1.3355 0.0431 ITSN2 −1.3354 0.0054 MAP2K3 −1.3315 0.0374GTPBP2 −1.3304 0.0303 SBSN −1.3301 0.0467 LIMA1 −1.3288 0.0293 EPG5−1.3268 0.0308 TWISTNB −1.326 0.028 EPT1 −1.3252 0.0184 SPIRE1 −1.3240.0058 LAMP2 −1.3221 0.0175 COPB2 −1.3193 0.0325 GAS6 −1.3184 0.0451LMTK3 −1.3184 0.0421 BCR −1.3173 0.0251 TCP11L2 −1.3165 0.0246 AHCYL1−1.3145 0.0047 HMGN2 −1.3145 0.0141 MYO9B −1.3112 0.0113 PPP2R2C −1.30730.0332 ARPC5 −1.3065 0.0351 ATP2C1 −1.3047 0.0206 TBC1D20 −1.3043 0.0417MAPKAPK5 −1.3018 0.0068 WWTR1 −1.2981 0.0469 SDE2 −1.2972 0.0283 NDUFA13−1.2936 0.0337 EDEMI −1.2917 0.0304 HEATR5B −1.2866 0.0276 CHMP4C−1.2862 0.0302 CTTNBP2NL −1.2817 0.0229 RSF1 −1.2789 0.012 RPS26 −1.27580.0385 PRMT2 −1.2753 0.0261 RBM10 −1.2741 0.0361 TAF7 −1.2737 0.025JARID2 −1.2729 0.0219 PSMD3 −1.2716 0.0312 COL5A2 −1.2659 0.0478 ZNF212−1.2542 0.031 UBR1 −1.2539 0.0462 IMMT −1.2534 0.0354 TBC1D10B −1.24830.0209 FNBP1 −1.2453 0.0353 STAM2 −1.2398 0.0137 PCLO −1.2393 0.0119TTC19 −1.2369 0.0248 RAB7A −1.2359 0.0361 EPS15 −1.235 0.0398 PICALM−1.2347 0.026 PELI1 −1.2318 0.0416 CUL1 −1.2268 0.0027 ENSA −1.22220.0155 CYFIP1 −1.2184 0.0182 KDM1B −1.2178 0.0474 EPS8L1 −1.2091 0.047RTFDC1 −1.209 0.0493 MARVELD2 −1.2083 0.036 COPA −1.2072 0.0353 KPNB1−1.2072 0.0224 ITGAV −1.2026 0.0359 PCF11 −1.1978 0.019 NDUFS1 −1.18810.0323 ITPKC −1.1866 0.0212 KHSRP −1.1825 0.0257 PAPD4 −1.1728 0.0378DDX18 −1.1521 0.0177 GMFG −22.3167 0.0097 IL1RL1 −22.1689 0.0074NIPSNAP3B −21.7911 0.0031 FMO2 −19.3532 0.0037 LUZP6 −18.3831 0.0373TICAM2 −17.0725 0.0078 RNF148 −16.9574 0.0293 ABHD14A −16.9299 0.0072SIGLEC10 −16.0127 0.0072 DEFB103B −14.7613 0.0041 RHOF −14.111 0.0338RHCG −13.9626 0.0246 CCL20 −13.8396 0.0339 LCE5A −13.4353 0.0063C10orf128 −13.3022 0.0129 IL37 −13.122 0.0158 CYP27B1 −12.6505 0.0006SH3BGR −12.366 0.0197 VNN3 −11.7831 0.0073 PRR7 −11.7235 0.0434 ADCY2−11.6259 0.0144 KBTBD8 −10.5372 0.0222 CD28 −10.3214 0.0352 SOX10−10.3179 0.001 CD36 −10.1313 0.0169 KRT3 −9.945 0.0064 TRIM36 −9.66330.0104 ARL4D −9.5441 0.0273 IGFN1 −9.3742 0.0091 S100A12 −9.2963 0.0413PROX1 −8.9646 0.0106 FAM19A5 −8.8138 0.0147 C19orf80 −8.659 0.0157APOBEC3A −8.5652 0.0249 DLEU1 −8.5213 0.0357 PARVG −8.4144 0.0464 GSTT2B−8.3303 0.0329 SLCO4C1 −8.0891 0.0272 ENG −7.819 0.0225 RCBTB2 −7.78330.0232 GZMB −7.7809 0.0456 OASL −7.7308 0.0217 LY6K −7.6642 0.0325 VMO1−7.5022 0.0422 LZTS1 −7.4675 0.0335 TF −7.3803 0.0431 AMDHD1 −7.380.0478 SLFN12 −7.303 0.0095 PPP1R14A −7.2477 0.0419 MΥPN −7.1862 0.0238JAKMIP1 −7.0395 0.0191 AHRR −6.9435 0.0297 LGALS2 −6.8965 0.0396 TIGD3−6.7542 0.0288 GPRIN1 −6.7215 0.0187 CHKB-CPT1B −6.6251 0.039 NRN1−6.6135 0.0139 PIK3R5 −6.6118 0.0383 SLAMF7 −6.5562 0.0484 SRGN −6.55420.0169 RNF113B −6.434 0.0392 TRPV2 −6.4053 0.0239 KRTAP5-1 −6.23390.0342 TRAF5 −6.1305 0.0317 PDE6A −6.0672 0.0328 CD244 −6.0509 0.0421FAM166B −5.9975 0.038 DTYMK −5.9009 0.0255 CXCR2 −5.8694 0.0155 KLHDC1−5.7732 0.0391 PLIN1 −5.742 0.029 KCNJ2 −5.7133 0.0236 ASPN −5.65930.0227 SUV39H2 −5.5883 0.0335 ROPN1B −5.533 0.0381 VNN1 −5.4803 0.018IFI27 −5.4264 0.0349 KCNG2 −5.3548 0.0268 LAIR1 −5.3473 0.0371 P2RX5−5.3335 0.039 CHRM4 −5.2948 0.0336 TOR4A −5.2677 0.004 HIGD1B −5.23710.042 RGS2 −5.1484 0.0134 RNF224 −4.9675 0.0442 AURKA −4.9118 0.0485LGI2 −4.8099 0.0284 SLC22A13 −4.7851 0.0416 MLC1 −4.7144 0.0305 TLR3−4.7066 0.0429 HHEX −4.7002 0.0388 C8orf48 −4.6899 0.0382 TIMM8A −4.52890.0318 TTC25 −4.4167 0.0396 KRT72 −4.3577 0.0397 KCNMB3 −4.2805 0.0257HAPLN4 −4.2381 0.0472 CCDC69 −4.203 0.0488 TMBIM4 −4.1761 0.0273 BMP5−4.1521 0.0233 GPRC5A −4.1494 0.0183 GPD2 −4.1448 0.0444 ZNF668 −4.13960.0428 SERPINB3 −4.0734 0.0235 PPP1R16B −4.0259 0.0093 NTSR1 −3.94050.0434 PTAFR −3.9092 0.0477 AVPR1A −3.907 0.0044 STARD8 −3.8533 0.0246C15orf53 −3.6751 0.0462 ADCY7 −3.6529 0.0156 PIK3R6 −3.6311 0.0264 ZIC2−3.6198 0.0249 ZNF490 −3.5651 0.0493 CLDN14 −3.5193 0.0385 NUDT2 −3.51510.0464 FOXP3 −3.4118 0.0275 APBB1IP −3.3841 0.0244 EIF3C −3.3247 0.0213ACTR5 −3.2145 0.0319 RPS6KA5 −3.1343 0.0376 C4orf27 −3.1257 0.0253 FUT2−3.0804 0.0348 LCE3E −3.0756 0.0024 HIST3H2BB −3.0463 0.0407 ARC −3.02480.0423 SPRR2A −3.0167 0.0345 DOCK11 −2.9427 0.0164 KRT78 −2.8669 0.0053WAS −2.8546 0.0369 RTL1 −2.852 0.0458 TCEANC −2.8089 0.011 FAM25A−2.6398 0.0004 G0S2 −2.6281 0.037 CD3G −2.5886 0.0351 SPRR2G −2.57580.027 GPN3 −2.5708 0.0125 SEL1L3 −2.5671 0.038 CSF1R −2.5368 0.0412CETN3 −2.4829 0.0161 STXBP6 −2.468 0.0065 MSRB2 −2.4649 0.0437 CD209−2.4462 0.0496 MRPL39 −2.4296 0.0129 NCOA7 −2.38 0.0136 C9orf85 −2.37630.0349 PTPMT1 −2.3581 0.0248 COX14 −2.3346 0.0071 LCE3D −2.2937 0.0431SLC43A2 −2.2909 0.0474 SLC20A1 −2.2879 0.0421 MLF1 −2.26 0.0347 FAM185A−2.2522 0.0245 MRPL15 −2.2193 0.0185 B3GALT4 −2.2061 0.0213 TBC1D12−2.183 0.0436 FCHSD1 −2.1791 0.031 DNASE1L2 −2.1662 0.0445 PNPLA1 −2.1560.0076 ABHD17B −2.1475 0.0047 CARD16 −2.1366 0.0288 IL6R −2.1301 0.0109HIST1H4B −2.1092 0.014 PTS −2.0901 0.0276 ANAPC13 −2.0894 0.0188 DCTN5−2.0889 0.001 FAM110C −2.0776 0.0038 GOLGA8F −2.0534 0.0477 SPRR2E−2.0439 0.0024 GNA12 −2.0286 0.0443 ZNF584 −2.0169 0.0115 GPX3 −2.01390.0464 RIPK2 −2.0049 0.0083 LCE6A −1.9922 0.0321 RNF180 −1.9829 0.0073GNB5 −1.9531 0.0465 SDR9C7 −1.9516 0.0005 DUSP5 −1.9484 0.0168 ETS1−1.9476 0.0412 PLA2G2F −1.9275 0.0379 YOD1 −1.9234 0.0003 TRAPPC1−1.9138 0.0339 ZDHHC13 −1.9113 0.0372 MARVELD3 −1.9109 0.0275 ZNF16−1.9062 0.0374 PRELID3B −1.8833 0.0175 TMLHE −1.8685 0.0325 SLC36A1−1.8658 0.0376 CCL22 −1.8563 0.0346 ZFAND2A −1.8553 0.0436 MAP1LC3A−1.8522 0.0095 RHOQ −1.8521 0.0337 ARNTL −1.8509 0.0325 INPP5D −1.84540.027 SPTBN5 −1.8452 0.0221 PRSS3 −1.8422 0.0492 MPDU1 −1.8281 0.0308MPST −1.8255 0.0228 SMOX −1.8246 0.0122 MRPL30 −1.8185 0.0147 NOS3−1.8178 0.0274 ARNTL2 −1.8116 0.0408 LIMS1 −1.8077 0.0265 BCKDK −1.79070.0102 ABHD12B −1.783 0.003 HIST1H4C −1.7668 0.0292 SLC19A2 −1.76470.0356 RAP1B −1.764 0.0111 UBL3 −1.7629 0.0069 NAA20 −1.7564 0.0237EXOC5 −1.7555 0.0241 ZNF248 −1.7545 0.0341 TBC1D23 −1.7528 0.022 CCDC124−1.7484 0.0352 RAB23 −1.7364 0.0327 PAPL −1.7334 0.0094 PHLDA2 −1.73260.0389 TSSC1 −1.7263 0.0443 POLD3 −1.726 0.0298 MPV17 −1.7246 0.036CEMIP −1.7239 0.02 GULP1 −1.7222 0.0476 NCCRP1 −1.7216 0.0013 TM2D1−1.7173 0.0044 MYO1B −1.7131 0.0018 C2orf47 −1.7098 0.0486 RNASE7−1.6985 0.0398 TMEM127 −1.6948 0.0164 TMEM11 −1.6876 0.0443 NT5C3A−1.6864 0.0087 ESD −1.6832 0.0341 GADD45A −1.6793 0.015 AIM1 −1.66980.038 GCOM1 −1.6691 0.0128 ACTR10 −1.6639 0.0274 AK9 −1.6629 0.0471FAM98A −1.6616 0.007 TMEM86A −1.6601 0.0072 MRPL27 −1.6542 0.0028 HERC6−1.6508 5.71E−05 ERN1 −1.6493 0.0114 NAA10 −1.648 0.0232 SLC10A6 −1.64370.0277 RBPJ −1.6436 0.029 LCE2C −1.642 0.0318 SEMA7A −1.6327 0.0033RNGTT −1.632 0.0064 USP2 −1.6284 0.0306 CHURC1 −1.6274 0.0014 SPATS2L−1.626 0.008 BZW1 −1.6243 0.0034 ABHD5 −1.6219 0.0132 HK2 −1.6217 0.0443AZGP1 −1.6203 0.0214 CASP7 −1.6192 0.0045 SLC5A1 −1.618 0.008 RAP1GDS1−1.6172 0.0033 TVP23B −1.6152 0.0291 MRPS25 −1.615 0.0317 MINPP1 −1.6120.0296 CPA4 −1.6102 0.0133 ATG9B −1.6079 0.0419 CNFN −1.6073 0.02 UBB−1.6053 0.0014 GNPTAB −1.6027 0.039 SNRPG −1.596 0.0494 ARHGAP29 −1.59280.0322 USF1 −1.5874 0.0386 ZNF330 −1.5849 0.0195 NBN −1.583 0.0384HIST1H1B −1.5817 0.0218 PIM1 −1.581 0.04 GSDMA −1.5778 0.0068 UBE2D3−1.5735 0.01 CDC34 −1.5732 0.0273 PCNP −1.568 0.0475 SLC35E3 −1.56570.0156 YWHAH −1.5657 0.0098 C18orf25 −1.5611 0.0313 RPRD1B −1.55690.0442 UBE2J1 −1.5485 0.0292 MRPL32 −1.5465 0.0406 ECHDC1 −1.5434 0.0362PDE12 −1.5349 0.0472 ZNF649 −1.5338 0.0147 DNAJB1 −1.5334 0.0017 CHIC2−1.5332 0.0359 CNST −1.5303 0.0152 NUP107 −1.5272 0.045 ZNF720 −1.52070.0359 PLA2G4D −1.5181 0.0315 STXBP3 −1.518 0.0229 SSNA1 −1.5168 0.0398BAG5 −1.5158 0.0015 PRKCH −1.5157 0.01 ARHGAP30 −1.5151 0.0477 PPP1R18−1.5143 0.0216 USP38 −1.5138 0.0377 SLC31A2 −1.5136 0.0419 NUB1 −1.51010.0086 SEPT11 −1.5075 0.0388 SUB1 −1.5053 0.0269 TIMM21 −1.4994 0.0417MRPL49 −1.4981 0.0257 DENR −1.487 0.0274 TRABD −1.4869 0.0348 VMP1−1.4868 0.0465 FNDC3A −1.4825 0.0115 SIL1 −1.4815 0.0127 MAP1LC3B−1.4758 0.038 WWC1 −1.4749 0.0404 POLR3B −1.4745 0.0212 VSIG10L −1.47320.0134 BLOC1S1 −1.473 0.0469 SHPK −1.4715 0.0309 PI4K2A −1.4714 0.0311TNIP1 −1.471 0.0008 ZNF706 −1.4695 0.0366 COROIC −1.4673 0.0345 PLEKHB2−1.4646 0.0055 ALDH7A1 −1.4641 0.0251 TOMM5 −1.4639 0.0399 ADTRP −1.4620.0229 SLC6A14 −1.4614 0.0223 CSRNP1 −1.4595 0.0091 FAF2 −1.457 0.0056MRPL44 −1.4529 0.0283 UGCG −1.4494 0.0216 SYNJ2 −1.4479 0.0404 PDLIM2−1.4444 0.006 AK3 −1.4361 0.0358 DERL1 −1.4357 0.0305 TMEM179B −1.43570.0194 SNF8 −1.4332 0.0489 MGLL −1.4306 0.0327 GSE1 −1.4247 0.0324CIRH1A −1.4201 0.0236 HEXA −1.417 0.0329 SYNJ1 −1.4159 0.0369 ZNF440−1.4142 0.0323 PPARD −1.414 0.0131 HYOU1 −1.4135 0.0046 ARL13B −1.41220.0417 PLCXD1 −1.4108 0.0348 CRCT1 −1.4069 0.0325 PPP1R15B −1.405 0.0255TTYH3 −1.4035 0.0153 GBA −1.4003 0.0395 ARRDC4 −1.3999 0.0042 DDX52−1.3964 0.0404 CFL1 −1.3955 0.0493 RABGEF1 −1.3923 0.0238 ARHGEF10L−1.3921 0.042 GNPAT −1.3896 0.0473 NFYA −1.3888 0.0287 SFT2D2 −1.3880.0387 ZNF213 −1.3874 0.0437 NADK −1.3873 0.0021 SH3BP5L −1.3827 0.0087MXD1 −1.382 0.0308 DHRS7 −1.3803 0.0389 RAB24 −1.3771 0.0378 LNX1−1.3769 0.0218 PSD4 −1.373 0.0093 ATP6V1C2 −1.3717 0.0136 TMED9 −1.3710.0377 PDCD7 −1.3706 0.0474 H2AFY −1.3699 0.049 ALAS1 −1.3692 0.032NCOA3 −1.3678 0.023 SDCCAG8 −1.3678 0.0196 KATNB1 −1.3677 0.0328 AP5Z1−1.3664 0.0149 ADIPOR1 −1.3654 0.0443 TMPRSS13 −1.3611 0.0285 SNX9−1.3605 0.0224 PPP2CA −1.3592 0.0465 GPR137B −1.3585 0.0428 EHD1 −1.35820.0131 DENND2C −1.3558 0.0144 CHTF8 −1.3535 0.0141 PLK3 −1.349 0.0139CTSB −1.3444 0.0441 PIEZO1 −1.3433 0.0008 ERH −1.3384 0.0422 ITFG1−1.3382 0.0356 RND3 −1.3368 0.0298 IRF2 −1.3364 0.0324 PTPN2 −1.33630.0424 FBXW11 −1.3355 0.0431 ITSN2 −1.3354 0.0054 MAP2K3 −1.3315 0.0374GTPBP2 −1.3304 0.0303 SBSN −1.3301 0.0467 LIMA1 −1.3288 0.0293 EPG5−1.3268 0.0308 TWISTNB −1.326 0.028 EPT1 −1.3252 0.0184 SPIRE1 −1.3240.0058 LAMP2 −1.3221 0.0175 COPB2 −1.3193 0.0325 GAS6 −1.3184 0.0451LMTK3 −1.3184 0.0421 BCR −1.3173 0.0251 TCP11L2 −1.3165 0.0246 AHCYL1−1.3145 0.0047 HMGN2 −1.3145 0.0141 MYO9B −1.3112 0.0113 PPP2R2C −1.30730.0332 ARPC5 −1.3065 0.0351 ATP2C1 −1.3047 0.0206 TBC1D20 −1.3043 0.0417MAPKAPK5 −1.3018 0.0068 WWTR1 −1.2981 0.0469 SDE2 −1.2972 0.0283 NDUFA13−1.2936 0.0337 EDEM1 −1.2917 0.0304 HEATR5B −1.2866 0.0276 CHMP4C−1.2862 0.0302 CTTNBP2NL −1.2817 0.0229 RSF1 −1.2789 0.012 RPS26 −1.27580.0385 PRMT2 −1.2753 0.0261 RBM10 −1.2741 0.0361 TAF7 −1.2737 0.025JARID2 −1.2729 0.0219 PSMD3 −1.2716 0.0312 COL5A2 −1.2659 0.0478 ZNF212−1.2542 0.031 UBR1 −1.2539 0.0462 IMMT −1.2534 0.0354 TBC1D10B −1.24830.0209 FNBP1 −1.2453 0.0353 STAM2 −1.2398 0.0137 PCLO −1.2393 0.0119TTC19 −1.2369 0.0248 RAB7A −1.2359 0.0361 EPS15 −1.235 0.0398 PICALM−1.2347 0.026 PELI1 −1.2318 0.0416 CUL1 −1.2268 0.0027 ENSA −1.22220.0155 CYFIP1 −1.2184 0.0182 KDM1B −1.2178 0.0474 EPS8L1 −1.2091 0.047RTFDC1 −1.209 0.0493 MARVELD2 −1.2083 0.036 COPA −1.2072 0.0353 KPNB1−1.2072 0.0224 ITGAV −1.2026 0.0359 PCF11 −1.1978 0.019 NDUFS1 −1.18810.0323 ITPKC −1.1866 0.0212 KHSRP −1.1825 0.0257 PAPD4 −1.1728 0.0378DDX18 −1.1521 0.0177

Table 19 lists differentially expressed genes that were stably expressedin responders throughout the study and were not significantly modulatedby treatment between baseline and Week 24.

TABLE 19 Genes Stably Expressed Between Day 1 and Week 24 GenesIncreased But Not Significant Genes Decreased But Not Significant GeneFold Raw Gene Fold Raw Symbol Change P Value Symbol Change P ValueSERINC4 34.3284 0.0518 ESD −47.3843 0.0643 FAM153C 29.43 0.0795HIST1H2AK −45.1381 0.0531 ANGPTL3 26.1574 0.1792 DCAF4 −32.5166 0.1119ADCY7 23.0366 0.2193 MRAP2 −30.5134 0.0571 NUGGC 20.5734 0.0722 SIRT3−29.7841 0.0816 AGTRAP 20.0111 0.1793 C3orf49 −23.1537 0.0517 FOSL117.5836 0.1671 IYD −22.2703 0.1023 BEST1 16.5446 0.1629 TWIST2 −18.17270.0595 TBX19 15.0717 0.1436 CSF1R −17.8603 0.2654 RGS16 14.0051 0.0856ZNF224 −17.0106 0.1338 ESRRG 13.8518 0.0855 CCDC77 −15.6151 0.2115 KCNRG13.8334 0.1162 MANEA −13.6223 0.1211 KLB 12.4857 0.0761 ZNF619 −13.27490.1456 IL2RB 10.8092 0.1694 ZNF764 −13.1932 0.1349 COQ6 10.7709 0.1102MSRB2 −12.9185 0.1888 CILP2 10.7666 0.086 HLCS −12.7892 0.1489 RARRES310.0574 0.1796 TCEB3B −11.6698 0.1256 ZSCAN31 9.9201 0.1378 SLC39A14−11.5582 0.133 RGS9 9.873 0.2332 PLSCR1 −11.5506 0.1374 FGFRL1 9.84810.1008 CCDC78 −11.3228 0.1061 ABLIM2 9.6717 0.2161 VEPH1 −11.2508 0.059DNAJB5 9.3076 0.312 VARS2 −11.0178 0.1183 PSG1 9.1933 0.195 GAGE2E−10.6926 0.1817 EN1 9.1394 0.184 THG1L −10.688 0.0959 SPRR3 9.12 0.2347CCDC105 −10.3782 0.2109 PILRB 8.7256 0.0793 ZNF77 −10.3141 0.1357 MRPS288.6524 0.1779 KRT71 −10.2566 0.1144 CTAGE15 8.6356 0.2001 FAM13C−10.1912 0.1209 C10orf128 8.4822 0.1446 DRC3 −9.7252 0.2144 ZNF4698.2243 0.086 RPL36A −9.7145 0.2232 DENND1C 8.0945 0.3416 ERAP2 −9.60260.154 NHLH1 7.9637 0.1535 PLD2 −9.2801 0.2707 HLA-DMA 7.9418 0.2251BHLHE41 −9.1793 0.2438 CD3G 7.7405 0.1815 HBZ −8.9457 0.2065 ZNF597 7.60.1519 DERL3 −8.7066 0.152 DUSP28 7.4942 0.2359 LAMTOR5 −8.5578 0.2044SGIP1 7.0389 0.1875 TMEM14A −8.4019 0.1953 SLC9A4 6.9988 0.3613 KCNAB3−8.2478 0.1873 MTRNR2L3 6.9949 0.1884 TMEM68 −8.1349 0.2041 WNT5A 6.8730.2695 ACAD11 −7.9298 0.1781 CNGB1 6.6189 0.1883 APLN −7.9087 0.0998LAIR1 6.5911 0.1932 PDE9A −7.808 0.1511 GOLGA8R 6.5819 0.4926 NFYB−7.6596 0.2107 FAM231D 6.5529 0.3909 CSNK1G3 −7.4422 0.2146 QTRTD16.4476 0.0698 CDC27 −7.3554 0.2263 GGACT 6.3922 0.2153 SUPV3L1 −7.2450.1424 TDRKH 6.2265 0.302 TMSB10 −6.9475 0.3782 C3 6.1916 0.1921 NPIPB4−6.9423 0.2675 KCNIP4 6.1543 0.2061 ERMARD −6.8012 0.1415 CYP27B1 6.10440.1376 PRPF40B −6.7313 0.236 LRRC37A3 6.0566 0.2476 VBP1 −6.6425 0.2802HCN4 5.8493 0.1417 DDX55 −6.4281 0.242 PRR15 5.6279 0.1936 NDUFB6−6.3519 0.2601 SSC4D 5.5912 0.1798 DUSP23 −6.2692 0.2681 PADI3 5.58660.1831 FBXO4 −6.2466 0.207 NEFH 5.5755 0.201 PHF1 −6.1423 0.2155 TMEM8A5.5413 0.5101 STARD9 −6.1174 0.1875 MYCL 5.5065 0.1456 ETNPPL −6.0940.1817 C1QTNF6 5.461 0.2211 GTF2H3 −6.0361 0.1908 LRRC70 5.4331 0.0932ECE2 −5.9855 0.1135 S1PR2 5.3442 0.2721 MPHOSPH10 −5.9297 0.3449 CUX25.3366 0.1895 UTP23 −5.8203 0.3474 GAS2L3 5.1129 0.3695 PSMB3 −5.79260.3734 NDOR1 5.0487 0.3877 LRIG3 −5.7089 0.3642 NOP16 5.024 0.1491ZNF551 −5.6873 0.147 FUT2 4.8582 0.5052 PHF10 −5.6573 0.3747 SLC25A254.738 0.3423 FAM60A −5.5425 0.3226 SCARB1 4.7238 0.187 PPP1R14B −5.52170.407 PIK3CG 4.6587 0.1867 BTN3A3 −5.4241 0.2408 FAM216A 4.6515 0.1312PTGER1 −5.3803 0.1808 PRR5 4.6447 0.2381 CDK2 −5.32 0.3026 RAD51B 4.50650.3035 TFAM −5.3111 0.3205 VOPP1 4.4705 0.0567 PGRMC1 −5.2664 0.3723SERTAD1 4.4197 0.2114 KATNAL2 −5.2088 0.287 C9orf172 4.3974 0.4044COL11A1 −5.1339 0.2327 GPR27 4.2735 0.2146 IFT43 −5.0331 0.2865 MUC44.24 0.1784 SLC2A10 −5.028 0.2656 KBTBD8 4.1801 0.4819 SYCP2 −4.95320.2374 ARHGAP30 3.9568 0.1496 AP3M1 −4.7944 0.3675 TRUB2 3.8837 0.1049CASC4 −4.7642 0.3695 ARNTL 3.8384 0.1 MCPH1 −4.6727 0.3028 C1orf2333.8091 0.36 EIF2A −4.6478 0.4098 DNAH9 3.6983 0.4376 RUNX2 −4.25130.3311 CXCL11 3.6945 0.3739 PHTF1 −4.2207 0.3946 GTF2H2C 3.6605 0.3008SEPSECS −4.2127 0.3042 ATP11A 3.5782 0.2704 NUP107 −4.2013 0.2705 CUEDC13.5752 0.1938 NID2 −4.1828 0.1903 KCNMB1 3.5008 0.4613 GTF2H5 −4.15160.2765 PRR7 3.4892 0.1896 ZYG11A −4.1329 0.3724 FBXO42 3.4291 0.2361HSPA4L −4.128 0.4198 FAM124A 3.378 0.3654 FCER2 −4.121 0.2084 STK243.3537 0.2623 HAUS5 −4.1129 0.3442 RCBTB2 3.3151 0.3744 ARMC7 −4.09450.4073 GOLGA8Q 3.2905 0.3739 FBXO8 −4.0786 0.4089 ABCA7 3.2193 0.1371LIMA1 −4.0571 0.3427 APOLD1 3.1813 0.2989 UGT1A6 −3.9944 0.4743 TEX2643.1806 0.227 POLR3GL −3.9758 0.3695 GRM3 3.1721 0.47 PHIP −3.9114 0.4104GALNT16 3.1416 0.4283 C1orf123 −3.8754 0.4586 PAEP 3.1052 0.3739C10orf62 −3.8517 0.2469 MIDN 3.0971 0.2751 OR7G1 −3.7882 0.1842 NUDT63.0822 0.3739 IL6ST −3.7675 0.4524 TVP23C-CDRT4 3.0556 0.404 RNF8−3.7619 0.2934 CHRNB1 3.0434 0.2083 GEMIN6 −3.6995 0.3088 GSTT2B 3.03270.6084 NPR3 −3.6501 0.4355 WSCD2 2.9828 0.3739 MRPL50 −3.6073 0.4044CECR5 2.9502 0.2933 B3GNT4 −3.5538 0.22 HEATR5A 2.8966 0.1039 ZNF525−3.5313 0.1197 MAPK3 2.8872 0.252 XPO4 −3.5195 0.3389 DNAJC25 2.78940.5481 KLHDC1 −3.5157 0.2893 TTYH2 2.7783 0.6172 IFT88 −3.5102 0.2742PROXI 2.7543 0.4706 NUDT9 −3.4451 0.4643 NANOS1 2.7533 0.2919 TARSL2−3.3939 0.4891 IMPG2 2.7174 0.261 TSPAN6 −3.3845 0.4921 MRPL27 2.67110.1835 CSTF2 −3.238 0.4491 TAPT1 2.6433 0.1649 WBSCR17 −3.1432 0.2976FBRSL1 2.6305 0.225 TMEM174 −3.1396 0.1778 ARMC9 2.6302 0.4374 PSD2−3.1005 0.502 EFR3B 2.6266 0.4084 LMLN −3.0824 0.1291 RNF166 2.61090.2916 POLR1B −3.0821 0.4797 WNK1 2.5892 0.3235 FECH −3.0503 0.2444MSANTD4 2.5863 0.259 LRRC8C −3.0412 0.3776 GPRC5A 2.5842 0.6585 GAA−3.0326 0.4261 HIST1H2AB 2.5833 0.6394 NAF1 −2.971 0.4349 CXCL10 2.56780.3739 SCO2 −2.9595 0.7006 MAGEF1 2.5305 0.3842 TMEM108 −2.9127 0.5065HEXA 2.503 0.1697 STX7 −2.9038 0.2808 IL1RL1 2.4524 0.3739 SPRY4 −2.77010.4022 BRINP2 2.4455 0.5524 BMF −2.745 0.2732 NAA10 2.4343 0.1594 CTPS1−2.7178 0.4494 TAF6 2.4311 0.0976 RNF2 −2.6973 0.3165 TICAM2 2.43 0.3739KLHL9 −2.6271 0.487 CTGF 2.4076 0.519 CLEC4E −2.6141 0.3857 JMJD6 2.39590.276 CILP −2.5985 0.6722 SLC35E3 2.3844 0.1806 MUC1 −2.5194 0.2811 JPH32.3689 0.5395 CARD16 −2.4854 0.6097 RAB3B 2.3307 0.3433 TMC8 −2.47620.2767 H3F3C 2.325 0.5232 EVA1B −2.4551 0.2752 MMP25 2.3217 0.3739FAM89B −2.4267 0.2174 SELPLG 2.3087 0.572 KIF18A −2.411 0.3753 GJA32.3028 0.6892 SLC41A2 −2.4064 0.6077 LDHD 2.2804 0.3739 EOGT −2.39320.5402 DOCK6 2.2514 0.3618 ZNF34 −2.3565 0.6014 KDM6A 2.2454 0.1988USP28 −2.3453 0.5125 ZNF124 2.2406 0.1454 MRPL30 −2.3409 0.6064 NAVI2.2328 0.4401 CCBL1 −2.3295 0.4185 SEC16A 2.2099 0.374 GOLGA6D −2.32320.2298 TNFAIP8L1 2.1997 0.7021 CCDC153 −2.2569 0.6317 MRPL24 2.16840.7528 SCFD2 −2.2518 0.5973 CRY2 2.1667 0.4047 SYT12 −2.2414 0.5919DENND6A 2.1648 0.1827 RARS2 −2.2399 0.1675 MTCH1 2.1562 0.3584 HSF4−2.2397 0.4843 NUMA1 2.1528 0.2922 MTHFD1 −2.2305 0.1436 SEMA4G 2.15050.6416 ACVR1C −2.2172 0.6208 C15orf65 2.1386 0.1793 DNHD1 −2.1827 0.2773AMOTL2 2.1319 0.3229 FUBP1 −2.1687 0.2808 SNRK 2.1261 0.1386 PDGFRL−2.1564 0.603 RANBP9 2.1232 0.3506 MAST2 −2.1536 0.1942 RNF113A 2.11840.085 P3H3 −2.1322 0.6975 TOB2 2.0962 0.3623 PRKAR2B −2.1287 0.6693SPATA5L1 2.0888 0.6004 SS18L2 −2.1095 0.6267 HRNR 2.0402 0.3811 METTL20−2.1019 0.6083 MAP1A 2.0315 0.3767 HNRNPD −2.0951 0.3784 CMTM4 2.02120.2153 ASB1 −2.0551 0.2544 NDC1 2.0151 0.3282 CDK4 −2.0245 0.2923 PUSL12.0097 0.2397 APLF −2.0171 0.3156 SYNJ1 1.9876 0.0633 TFR2 −2.01110.4138 PPP1R37 1.9796 0.228 RBPMS2 −1.9965 0.5721 PRMT6 1.9643 0.7787ZSCAN16 −1.9784 0.6451 GNB5 1.961 0.7344 ARHGAP5 −1.9623 0.3827 PLA2G4C1.9518 0.3739 SHMT2 −1.9486 0.5957 C4orf27 1.8958 0.6437 RFX7 −1.93780.6311 TNFRSF8 1.8873 0.3739 SLC5A6 −1.9304 0.5922 SLC22A18 1.87130.2434 SARM1 −1.9262 0.5968 RARB 1.8708 0.6754 RNPC3 −1.9255 0.2359ZC3H11A 1.8698 0.2458 SMPD2 −1.9034 0.6971 ZBTB46 1.8681 0.6633 WAS−1.8976 0.7233 DAXX 1.8643 0.0535 NLRP2 −1.8924 0.755 NDFIP2 1.8590.4237 MLH1 −1.8922 0.669 ZNF91 1.8552 0.0999 CDC42EP5 −1.882 0.5718DHFR 1.8495 0.4613 GRIP1 −1.8766 0.4968 BLOC1S1 1.8131 0.2349 PDCD7−1.8491 0.6721 SLA2 1.8034 0.7068 RAB2B −1.8441 0.6726 FBXO2 1.79920.8145 USP47 −1.8253 0.436 C1orf109 1.7809 0.4762 PAAF1 −1.8155 0.514CD3E 1.7791 0.3739 CHST15 −1.8092 0.2302 TEX14 1.7603 0.3739 PLXND1−1.7959 0.1847 CUZD1 1.759 0.3739 DNAJC4 −1.7745 0.2067 AGFG1 1.75510.2009 ARHGAP19-SLIT1 −1.773 0.7896 ZNF555 1.7534 0.7649 INTS2 −1.76960.5495 TNPO1 1.7483 0.1871 POU5F1B −1.7681 0.5998 PLIN1 1.7401 0.3739ORAOV1 −1.7294 0.6659 NKX3-2 1.7255 0.6319 IARS2 −1.7082 0.3135 KAT6B1.7106 0.3438 GLRX5 −1.7067 0.3309 DVL1 1.7097 0.3346 LIN52 −1.70560.4296 NEK3 1.7075 0.7615 MAK16 −1.703 0.0719 C20orf27 1.7055 0.8231TMX3 −1.6985 0.7365 DISC1 1.7042 0.7978 SUMF1 −1.6964 0.2343 ZNF286B1.7019 0.7519 MLKL −1.6873 0.5389 WNT4 1.6975 0.5715 RNF34 −1.68020.4231 GPR34 1.6935 0.8137 BTF3L4 −1.6797 0.2736 RNF167 1.6858 0.3763PDE5A −1.6733 0.7035 RBM23 1.6704 0.19 MRPS10 −1.6705 0.3746 PEPD 1.65650.5091 BACE1 −1.6702 0.7311 MCC 1.6426 0.5683 HNRNPLL −1.6604 0.3086SCAF1 1.6323 0.385 CDC5L −1.6466 0.3951 LYPLA2 1.6236 0.1253 CCDC174−1.6461 0.4577 UBE2K 1.6227 0.1321 TATDN2 −1.6456 0.3546 EFR3A 1.61230.2674 LIPH −1.6288 0.5124 PTK2B 1.6073 0.4028 CKS1B −1.6266 0.7369HIST4H4 1.5911 0.8254 CNDP1 −1.6189 0.8338 ANKRD13B 1.5851 0.8084 VPS36−1.6136 0.4226 SDF2L1 1.5827 0.8375 TMEM158 −1.6135 0.5804 AIMP2 1.58080.0887 IQGAP1 −1.6109 0.5146 TM7SF3 1.5639 0.0593 SEZ6L2 −1.6078 0.5077RAB30 1.547 0.4934 PPP1R12A −1.6055 0.4244 TBC1D22A 1.5369 0.448 ZNF266−1.6029 0.1865 SLMAP 1.5335 0.2042 MROH7 −1.5865 0.7363 ARFRP1 1.51930.0729 BIN2 −1.5796 0.6686 TMEM170B 1.5059 0.6892 ZNF397 −1.5785 0.3393PIGV 1.505 0.4766 FBXL4 −1.5774 0.7773 TRIM28 1.5043 0.274 TRIM11−1.5759 0.2122 INTS3 1.5041 0.0505 GPR89B −1.5544 0.8646 LZTS1 1.50170.7977 FEZ1 −1.5533 0.8327 CTF1 1.4977 0.8095 HIVEP1 −1.5526 0.3101UQCC2 1.4965 0.2955 VWA5B2 −1.5496 0.8079 TRPM2 1.4962 0.3739 DNAJA3−1.5487 0.5153 REXO1 1.4924 0.4688 YWHAZ −1.5479 0.4545 RNF180 1.47470.6686 ZNF765 −1.5444 0.3564 NPAS3 1.4731 0.7784 MED1 −1.5396 0.0896C1orf74 1.4728 0.8286 CAPG −1.5363 0.1149 AHRR 1.465 0.7263 CYP4V2−1.5251 0.1835 MAN2C1 1.4567 0.0758 PRKAA1 −1.5203 0.7775 EED 1.45530.8591 MRPL14 −1.5169 0.4042 PRKG1 1.4537 0.3739 CCP110 −1.5123 0.5009ITGB1 1.4492 0.4447 SFMBT1 −1.5056 0.2177 PSME3 1.4428 0.4053 PDLIM7−1.5018 0.7639 ANKRD2 1.4367 0.9091 IQCG −1.4874 0.7796 ARHGEF5 1.43250.2892 PCCA −1.4865 0.5448 SKA1 1.428 0.6767 BCL2L12 −1.4692 0.7604RALBP1 1.4273 0.3882 HNRNPK −1.4474 0.2774 CD2AP 1.4177 0.1421 MPLKIP−1.441 0.4332 DNMT3A 1.4149 0.4164 BUB3 −1.4396 0.2793 ZNF43 1.4140.4897 IFNAR1 −1.4359 0.3819 DCTN4 1.4113 0.4838 SKAP2 −1.4226 0.4894FAM96B 1.4038 0.3508 H2AFV −1.4218 0.6944 GLCCI1 1.3978 0.5703 RNF148−1.4114 0.8068 SRSF12 1.3959 0.8318 METTL7A −1.4017 0.2471 PHF8 1.38950.4124 GBP3 −1.3999 0.5036 MDM4 1.3893 0.3667 XK −1.3803 0.7933 CD51.3884 0.853 SAP18 −1.3779 0.2244 PDIA5 1.3863 0.8711 ENOSF1 −1.37360.3875 WTAP 1.3809 0.1579 HINT1 −1.3666 0.4126 CAMK2D 1.3749 0.1579GINS1 −1.3548 0.7736 PHLPP1 1.3741 0.7485 CALU −1.3433 0.1939 GID41.3721 0.6957 GLOD4 −1.3325 0.5928 ZNF133 1.372 0.5126 OVCH2 −1.32930.8758 CNNM3 1.3706 0.2288 GORAB −1.3221 0.8934 TMEM70 1.3609 0.3956C11orf49 −1.3125 0.3291 AVPR1A 1.3591 0.3739 DNAJC13 −1.3096 0.4011LZTS2 1.3571 0.4819 SLIT3 −1.3076 0.4018 KMT2C 1.3569 0.3679 RDH11−1.3014 0.602 TGIF2 1.3531 0.8395 KCNJ1 −1.2995 0.8641 ARL13B 1.35210.1725 BIRC2 −1.2987 0.3168 FAXC 1.3426 0.8393 PEX26 −1.2922 0.7017AKAP10 1.319 0.5513 TMED7 −1.2914 0.0691 CD2BP2 1.3178 0.6314 HCFC2−1.2816 0.6402 ACAN 1.3116 0.3739 SPEN −1.2785 0.4115 CACNA1F 1.30990.8943 RAB11FIP2 −1.2759 0.5278 IL17B 1.305 0.9142 ZNF865 −1.267 0.5754VPS33A 1.2993 0.4692 CLASRP −1.2664 0.1703 BBS9 1.2922 0.6281 PLCE1−1.2662 0.6246 STK16 1.2893 0.5004 MRPL33 −1.257 0.6843 FAM219A 1.28550.6483 FLOT2 −1.2564 0.6178 SPTLC1 1.2852 0.3364 ZNF780A −1.2522 0.7068PAF1 1.2823 0.4648 DCAF17 −1.2447 0.718 RNF41 1.2814 0.7961 ALKBH3−1.2358 0.6155 RNASEH1 1.2812 0.4092 LSAMP −1.2332 0.8476 IKZF5 1.27660.1381 IPO8 −1.2249 0.5669 C12orf29 1.2735 0.4177 RPS6KB1 −1.2148 0.5212RAB22A 1.2722 0.3945 ZSCAN1 −1.2134 0.9296 RFNG 1.2708 0.6642 C11orf57−1.2087 0.4954 DDB1 1.2706 0.1924 IMMT −1.2053 0.6593 INO80D 1.25080.4856 ABCA2 −1.2051 0.7005 TARDBP 1.2486 0.1398 CNOT7 −1.1995 0.5429PRPF18 1.2444 0.2087 MCFD2 −1.1991 0.6668 APOBEC3G 1.2442 0.7607 SH3BGR−1.1988 0.9125 PPIAL4G 1.2426 0.8817 ASAH1 −1.1987 0.5587 MEA1 1.23450.6167 NHSL2 −1.1949 0.7177 ST6GALNAC6 1.2293 0.4843 C1QL1 −1.18990.9282 TRIM66 1.2138 0.2418 PMF1 −1.1896 0.7797 CGGBP1 1.2061 0.275PLXNA3 −1.1891 0.6238 UBTF 1.2001 0.5212 FBXO48 −1.185 0.8748 RUFY11.1823 0.515 CCDC117 −1.1845 0.5684 ANKHD1 1.1809 0.591 PMPCB −1.17870.5688 SLC25A44 1.1757 0.6893 PALD1 −1.1739 0.6174 MAPK7 1.1678 0.6886PAFAH1B2 −1.1689 0.7234 NMRK1 1.1673 0.6635 TAF1L −1.1551 0.919 LDHAL6A1.145 0.7744 PRPF4 −1.1498 0.6006 SLFN12 1.1371 0.9183 SMC1A −1.14810.5563 SMIM5 1.1305 0.765 ZNF638 −1.1466 0.5843 DCXR 1.1294 0.7353DENND1A −1.1447 0.7931 TRIP11 1.1237 0.2552 SDCCAG8 −1.143 0.7603 SHCBP11.1225 0.3253 KDM5A −1.1363 0.3314 IGFN1 1.1199 0.8295 TGOLN2 −1.13270.5785 CAB39L 1.1072 0.8469 TAOK3 −1.104 0.6469 SRC 1.1072 0.5551 TRA2A−1.101 0.2225 FOXO1 1.1054 0.6213 ZNF444 −1.1002 0.8229 TANK 1.10470.7836 CNTN4 −1.0998 0.7783 ZNF787 1.0984 0.5444 ARID2 −1.0958 0.8084DLEU1 1.096 0.9565 OXSR1 −1.0947 0.5115 HMMR 1.0897 0.3739 PAPD4 −1.09460.7857 EXOC5 1.0815 0.8585 ANKS1A −1.0933 0.5991 AVL9 1.074 0.5527 SAR1A−1.0872 0.7106 TBC1D8B 1.0706 0.8034 DNAJC8 −1.0817 0.709 ATP5E 1.06750.8835 FAM50A −1.0776 0.7436 ACBD6 1.0629 0.892 MEF2A −1.0722 0.732PCNXL4 1.0628 0.7428 SWAP70 −1.0719 0.8245 EDC4 1.0599 0.9017 FBXO25−1.0697 0.8649 RAB3IL1 1.0581 0.3739 HMGCL −1.0684 0.8143 WDR33 1.05780.7285 EDARADD −1.0652 0.3739 TAS1R3 1.0521 0.9485 DCAF15 −1.0498 0.8502ARID3B 1.0478 0.9345 NBAS −1.0482 0.8536 BRAT1 1.0445 0.9268 OR10A4−1.0478 0.9812 PRR21 1.0425 0.9631 MZF1 −1.0398 0.9022 FHL2 1.03950.9208 COX7A2 −1.0389 0.9275 LRP11 1.0388 0.8197 TMEM208 −1.0371 0.9409REXO2 1.0385 0.8612 SERINC1 −1.0329 0.8602 EIF2AK4 1.0361 0.9097 C3orf58−1.0285 0.9443 ATP11B 1.0356 0.8862 CPSF2 −1.0267 0.9367 CDK16 1.03420.6506 POLR2E −1.0177 0.9419 MOAP1 1.0256 0.9396 RNF20 −1.0155 0.9624RFC4 1.0201 0.9903 CSAG1 −1.0119 0.9945 ZNRF1 1.0196 0.9534 C9orf64−1.0033 0.9978 CHMP6 1.0111 0.9771

Example 9: Identification of Genes that Predict Responsiveness toTreatment with Ruxolitinib

Robust drug response genomic signatures were identified by selectingbiomarkers from the RNA-Seq data in Examples 7 and 8. Specifically,baseline genes were selected from Example 7 if there was an absolutefold change greater than 2.0 and p<0.05 between the expression inresponders and non-responders. The resulting genes were further analyzedto select those genes that were not significantly (less than absolutefold change of 1.5 and p>0.05) modulated between baseline and week 24.Table 20 illustrates the genes that met this criteria.

TABLE 20 Genes Differentially Expressed in the Skin Biopsies ofResponders Compared to Non-Responders and not Significantly ModulatedBetween Baseline and Week 24 Increased in Increased in RespondersNon-Responders at Baseline at Baseline OVCH2 SLFN12 ANKRD2 DLEU1 KCNJ1EDARADD TAS1R3 SH3BGR PPIAL4G IGFN1 ZSCAN1 APOBEC3G CACNA1F TRPM2 IL17BRNF148 C1QL1 HMMR OR10A4 SKA1 TAF1L AHRR STK16 LDHAL6A RFNG SHCBP1 CSAG1GBP3 PRR21 RFC4 NHSL2 CTF1 ZNF787 RAB3IL1 ZNRF1 GINS1 PALD1 CD5 ZNF444PRKG1 FAM219A SRSF12 TMEM208 FAXC NMRK1 PDIA5 ARID3B TGIF2 MPLKIP EEDCAB39L GORAB ALKBH3 NPAS3 PLCE1 AVPR1A C12orf29 C9orf64 LSAMP C1orf74SMIM5 ACAN UQCC2 RNF180 FAM96B BCL2L12 GID4 XK AKAP10 IQCG HMGCL ZNF43C11orf49

Example 10: Identification of Genes Differentially Expressed in Patientswith Vitiligo that are Responders to Treatment with Ruxolitinib Cream

Using non-invasive skin tape, skin tissue was collected from one hundredand twenty-three subjects with vitiligo enrolled in a study ofruxolitinib cream (INCB018424) for the treatment of subjects with aclinical diagnosis of vitiligo, depigmented areas including at least0.5% of the total body surface area on the face, and at least 3% of thetotal body surface area on nonfacial areas affected using the palmar (orhandprint) method (palm plus 5 digits). All subjects consented to theskin tissue collection and met the inclusion and exclusion criteriaoutlined in the clinical protocol. Once collected, skin tissue wasprocessed from the non-invasive skin tape into ribonucleic acid (RNA)for further analysis and subsequently analyzed using RNA sequencing.Samples were separated into to two groups based on clinical response totreatment with topical INCB018424. Specifically, samples were classifiedas “responder” (alternatively referred to as “early responder”) or“non-responder” (alternatively referred to as “late responder”) based ontheir therapeutic response at Week 24 of treatment (“F-VASI” refers tofacial-vitiligo area and severity index). Individuals were topicallyapplied INCB018424 either once or twice daily at dose strengths of0.15%, 0.5%, or 1.5%. Twice daily applications were at least 10 hoursapart in a cream formulation.

One hundred and twenty-six genes were identified from Examples 7 and 8and evaluated in RNA from each subject using the Illumina HiSeq 4000system. See Table 21. Data was then aligned and quality controlled inOmicSoft Array Studio using the Human Genome B38 library. The FragmentsPer Kilobase of transcript per Million (FPKM) mapped reads (the relativeexpression of a transcript) were generated and used in all downstreamanalysis.

TABLE 21 Targeted Analysis of 126 Genes ACAN CAB39L EGF IL17B NHSL2S100A1 XK ACVR1C CACNA1F FAM219A IL17RB NMRK1 SELPLG ZNF43 ADAM21 CCNI2FAM96B IL23 NPAS3 SerpinF1 ZNF444 ADAMTS13 CCR4 FAXC IL1RL1 OR10A4SH3BGR ZNF787 AHRR CCR5 GBP3 IL-1RL2 OVCH2 SHCBP1 ZNRF1 AKAP10 CD28 GID4IL32 PALD1 SKA1 ZSCAN1 ALKBH3 CD3E GINS1 IL36A PCDHB5 SLFN12 ALPK3 CD5GORAB IL4I1 PDIA5 SMIM5 ANKRD2 CNTF GPR61 IQCG PDE9A SOCS5 APOBEC3GCSAG1 GPR89B KCNJ1 PI3KCG SRSF12 ARID3B CTF1 HLA-DQB2 KRT16 PLCE1 STK16AurKA CXCL9 HMGCL KRT33A PPIAL4G TAF1L AVPR1A CXCL10 HMMR LDHAL6A PRKG1TAS1R3 BCL2L12 CXCL11 IFI6 LSAMP PRR21 TBC1D3 BCL7B CXCL8 IFNA MAKPK12PTPN22 TGIF2 C11orf49 CXCR4 IFNB MMP25 RAB3IL1 TICAM2 C12orf29 dkk2 IFNGMMP28 RFC4 TMEM208 C1orf74 DLEU1 IGFN1 MPLKIP RFNG TNFAIP8L1 C1QL1EDARADD IL15 MT1E RNF148 TRPM2 C9orf64 EED IL17A NLRP1 RNF180 UQCC2

RNA samples that did not have measureable gene expression in any of the126 genes outlined in Table 21 were removed from further analysis. Atotal of 52 baseline RNA samples were available for analysis with 27early responders and 25 late responders across the three treatment arms(0.5% QD, 1.5% BID, 1.5% QD). Twenty-five genes were increased and 11genes were decreased at baseline in responders compared tonon-responders (Table 22).

TABLE 22 Differentially Expressed Genes in the Skin Biopsies ofResponders Compared to Non-Responders Up-regulated in Responders vs.Down-regulated in Responders vs. Non-Responders at BaselineNon-Responders at Baseline Gene Fold Raw P- Gene Fold Raw P- SymbolChange value Symbol Change value PPIAL4G 2.946 0.0015 STK16 −16.6421.19E−06 CD5 2.7957 0.013 RFNG −9.1603 4.34E−05 IFI6 2.2036 0.0803 ZNRF1−8.1509 0.0002 CCR4 1.7699 0.0093 ARID3B −7.1425 0.0012 CNTF 1.59620.0103 WSB2 −5.7202 0.0057 CD28 1.5816 0.0652 JAK1 −4.9886 0.0131RAB3IL1 1.5178 0.0134 IL1RL2 −3.3798 0.0063 C1QL1 1.4941 0.0808 PALD1−3.2885 0.0274 VCAM1 1.4707 0.0378 S100A1 −2.5712 0.0829 ACAN 1.41530.0471 BCL2L12 −2.2394 0.0716 ETS1 1.4103 0.0668 FAM219A −1.796 0.0975GPR61 1.4101 0.0566 TSHZ1 −1.6083 0.0705 IFNG 1.3952 0.0597 KCNJ1 1.38980.0674 PDE9A 1.3878 0.0532 NPAS3 1.3709 0.0801 AVPR1A 1.3704 0.0677PRKG1 1.3694 0.0653 CSAG1 1.3646 0.0876 APOBEC3G 1.3633 0.0676 LDHAL6A1.3522 0.0993 ZSCAN1 1.3521 0.0993 HMMR 1.3416 0.0991 IL15 1.3367 0.0739SHCBP1 1.3109 0.099

1. A method of treating a human subject having, suspected of having, orat risk of developing vitiligo, comprising: measuring, in a firstbiological sample obtained from the human subject prior to administeringa JAK inhibitor, the concentration of CXCL9, CXCL10, CCL19, IL2-RA,CCL18, IL12, MMP12, GZMB, and/or Gal-9; administering the JAK inhibitorto the human subject; and measuring, in a second biological sampleobtained from the human subject after administering the JAK inhibitor, areduced concentration, as compared to the first biological sample, ofCXCL9, CXCL10, CCL19, IL2-RA, CCL18, IL12, MMP12, GZMB, and/or Gal-9,wherein the JAK inhibitor is ruxolitinib or a pharmaceuticallyacceptable salt thereof.
 2. The method of claim 1, comprising:measuring, in the first biological sample obtained from the humansubject prior to administering the JAK inhibitor, the concentration ofCXCL9; administering the JAK inhibitor to the human subject; andmeasuring, in the second biological sample obtained from the humansubject after administering the JAK inhibitor, a reduced concentration,as compared to the first biological sample, of CXCL9.
 3. The method ofclaim 1, comprising: measuring, in the first biological sample obtainedfrom the human subject prior to administering the JAK inhibitor, theconcentration of CXCL10; administering the JAK inhibitor to the humansubject; and measuring, in the second biological sample obtained fromthe human subject after administering the JAK inhibitor, a reducedconcentration, as compared to the first biological sample, of CXCL10. 4.The method of claim 1, comprising: measuring, in the first biologicalsample obtained from the human subject prior to administering the JAKinhibitor, the concentration of CXCL9 and CXCL10; administering the JAKinhibitor to the human subject; and measuring, in the second biologicalsample obtained from the human subject after administering the JAKinhibitor, a reduced concentration, as compared to the first biologicalsample, of CXCL9 and CXCL10.
 5. The method of claim 1, wherein the JAKinhibitor is administered to the human subject at least once a day for aperiod of at least 12 weeks.
 6. The method of claim 1, wherein the JAKinhibitor is administered to the human subject at least two times eachday for a period of at least 12 weeks.
 7. The method of claim 1, whereinthe JAK inhibitor is topically administered to the human subject.
 8. Themethod of claim 1, wherein the second biological sample is obtained fromthe human subject at least 12 weeks after the first administration ofthe JAK inhibitor.
 9. The method of claim 1, wherein the secondbiological sample is obtained from the human subject at least 24 weeksafter the first administration of the JAK inhibitor.
 10. The method ofclaim 1, wherein a second therapeutic agent is administered to the humansubject in combination with the JAK inhibitor.
 11. (canceled)
 12. Amethod of treating a human subject having, suspected of having, or atrisk of developing vitiligo, comprising: measuring, in a firstbiological sample obtained from the human subject prior to administeringa JAK inhibitor, the concentration of at least one protein selected fromthe group consisting of FAP, RET, CNTN5, FUCA1, ITGAV, ITGB5, THBS4,CD207, GDF-8, CDH6, MRC2, ICOSLG, TNXB, EDIL3, OSMR, GPC1, MIC-NB,TGFR-2, LRRN1, TLR3, KIM1, ROBO2, CD70, CLMP, N-CDase, FCRL5, CTSV,SCARF2, PLXDC1, PRTG, ERBB4, MAGED1, CEACAM1, TSHB, PTK7, TGFR-2, ADAM22, CTSC, DLK-1, USP8, SCARF2, TNFRSF13B, MB, TMPRSS5, NUDT5, MMP-3,MAEA, NEMO, IFN-gamma, IL18, AKT1S1, CASP-8, PPP1R2, ST2, VSIG4,SCGB3A2, HDGF, ICA1, IL13, PEBP1, PARK7, MAP4K5, FLI1, MMP-10, CCL24,TIMP4, MBL2, REG4, and CPA2; administering the JAK inhibitor to thehuman subject; and measuring, in a second biological sample obtainedfrom the human subject after administering the JAK inhibitor, a reducedconcentration, as compared to the first biological sample, of at leastone protein selected from the group consisting of FAP, RET, CNTN5,FUCA1, ITGAV, ITGB5, THBS4, CD207, GDF-8, CDH6, MRC2, ICOSLG, TNXB,EDIL3, OSMR, GPC1, MIC-NB, TGFR-2, LRRN1, TLR3, KIM1, ROBO2, CD70, CLMP,N-CDase, FCRL5, CTSV, SCARF2, PLXDC1, PRTG, ERBB4, MAGED1, CEACAM1,TSHB, PTK7, TGFR-2, ADAM 22, CTSC, DLK-1, USP8, SCARF2, TNFRSF13B, MB,and TMPRSS5, and/or an increased concentration, as compared to the firstbiological sample, of at least one protein selected from the groupconsisting of NUDT5, MMP-3, MAEA, NEMO, IFN-gamma, IL18, AKT1S1, CASP-8,PPP1R2, ST2, VSIG4, SCGB3A2, HDGF, ICA1, IL13, PEBP1, PARK7, MAP4K5,FLI1, MMP-10, CCL24, TIMP4, MBL2, REG4, and CPA2, wherein the JAKinhibitor is ruxolitinib or a pharmaceutically acceptable salt thereof.13. (canceled)
 14. A method of treating a human subject having,suspected of having, or at risk of developing vitiligo, comprising:measuring, in a first biological sample obtained from the human subjectprior to administering a JAK inhibitor, the concentration of at leastone protein selected from the group consisting of DDR1, NTRK2, CES2,SCARA5, GDF-8, BOC, PAEP, ARTN, CDNF, TMPRSS5, FLRT2, ROBO2, SIGLEC10,PRTG, SCARF2, CDH3, GFR-alpha-1, TSHB, CD200R1, RGMB, KYNU, HS3ST3B1,CHRDL2, CNTN1, VSIG4, ARHGAP1, B4GAT1, STX8, CRELD2, ARSA, BCAM, SCARF1,CA13, DAG1, LAIR1, GUSB, PMVK, PEAR1, GP1BA, TACC3, PARK7, ARHGEF12,SEMA7A, ESAM, FKBP5, ARHGAP1, SCAMP3, ABL1, EGF, TACC3, FKBP5, BID,PRDX5, STX8, CD63, SCARF1, PTPN1, CLEC1B, ARSB, FKBP1B, YES1, SRC,TNFSF14, PLXNB3, LRMP, CD164, DAG1, PVALB, NAA10, TRIMS, ARHGEF12, HGF,CA13, SNAP23, SORT1, GP6, CTSS, PPIB, CRKL, MAP2K6, MANF, PMVK, ABHD14B,GUSB, FATC1, MAD1L1, EDAR, CEACAM8, GLB1, ST3GAL1, ARSA, ADAM 8, CD40,IFI30, ECE1, AXIN1, WFDC2, TBCB, CXCL13, ST1A1, KIF1BP, DPP7, VEGFA,CETN2, TGF-alpha, CD84, SNAP29, CASP-8, S100A11, GSTP1, CRADD, PRKAB1,HGF, STK4, RNASE3, SERPINB6, OSM, MK, FADD, CLEC11A, CD69, LOX-1, ITGA6,CLEC5A, BCAM, FES, TXNDC5, LAT2, CXCL11, PARP-1, APBB1IP, GZMB, andCRNN; administering the JAK inhibitor to the human subject; andmeasuring, in a second biological sample obtained from the human subjectafter administering the JAK inhibitor, a reduced concentration, ascompared to the first biological sample, of at least one proteinselected from the group consisting of DDR1, NTRK2, CES2, SCARA5, GDF-8,BOC, PAEP, ARTN, CDNF, TMPRSS5, FLRT2, ROBO2, SIGLEC10, PRTG, SCARF2,CDH3, GFR-alpha-1, TSHB, CD200R1, RGMB, KYNU, HS3ST3B1, CHRDL2, andCNTN1, and/or an increased concentration, as compared to the firstbiological sample, of at least one protein selected from the groupconsisting of VSIG4, ARHGAP1, B4GAT1, STX8, CRELD2, ARSA, BCAM, SCARF1,CA13, DAG1, LAIR1, GUSB, PMVK, PEAR1, GP1BA, TACC3, PARK7, ARHGEF12,SEMA7A, ESAM, FKBP5, ARHGAP1, SCAMP3, ABL1, EGF, TACC3, FKBP5, BID,PRDX5, STX8, CD63, SCARF1, PTPN1, CLEC1B, ARSB, FKBP1B, YES1, SRC,TNFSF14, PLXNB3, LRMP, CD164, DAG1, PVALB, NAA10, TRIMS, ARHGEF12, HGF,CA13, SNAP23, SORT1, GP6, CTSS, PPIB, CRKL, MAP2K6, MANF, PMVK, ABHD14B,GUSB, FATC1, MAD1L1, EDAR, CEACAM8, GLB1, ST3GAL1, ARSA, ADAM 8, CD40,IFI30, ECE1, AXIN1, WFDC2, TBCB, CXCL13, ST1A1, KIF1BP, DPP7, VEGFA,CETN2, TGF-alpha, CD84, SNAP29, CASP-8, S100A11, GSTP1, CRADD, PRKAB1,HGF, STK4, RNASE3, SERPINB6, OSM, MK, FADD, CLEC11A, CD69, LOX-1, ITGA6,CLEC5A, BCAM, FES, TXNDC5, LAT2, CXCL11, PARP-1, APBB1IP, GZMB, andCRNN, wherein the JAK inhibitor is ruxolitinib or a pharmaceuticallyacceptable salt thereof. 15.-19. (canceled)
 20. The method of claim 14,wherein the concentration of the protein is measured by an immunologicalmethod.
 21. The method of claim 20, wherein the immunological method isselected from the group consisting of enzyme-linked immunosorbent assay,enzyme immunoassay, radioimmunoassay, chemiluminescent immunoassay,electrochemiluminescence immunoassay, latex turbidimetric immunoassay,latex photometric immunoassay, immuno-chromatographic assay, and westernblotting.
 22. The method of claim 1, wherein the concentration of theprotein is measured by mass spectrometry.
 23. (canceled)
 24. A method oftreating a human subject having, suspected of having, or at risk ofdeveloping vitiligo, comprising: measuring in a biological sampleobtained from the human subject a reduced expression level, as comparedto a control, of at least one gene selected from the group consisting ofSLFN12, DLEU1, EDARADD, SH3BGR, IGFN1, APOBEC3G, TRPM2, RNF148, HMMR,SKA1, AHRR, LDHAL6A, SHCBP1, GBP3, RFC4, CTF1, RAB3IL1, GINS1, CD5,PRKG1, SRSF12, FAXC, PDIA5, TGIF2, EED, GORAB, NPAS3, AVPR1A, C9orf64,C1orf74, ACAN, RNF180, BCL2L12, XK, IQCG, and ZNF43, and/or an increasedexpression level, as compared to a control, of at least one geneselected from the group consisting of OVCH2, ANKRD2, KCNJ1, TAS1R3,PPIAL4G, ZSCAN1, CACNA1F, IL17B, C1QL1, OR10A4, TAF1L, STK16, RFNG,CSAG1, PRR21, NHSL2, ZNF787, ZNRF1, PALD1, ZNF444, FAM219A, TMEM208,NMRK1, ARID3B, MPLKIP, CAB39L, ALKBH3, PLCE1, C12orf29, LSAMP, SMIM5,UQCC2, FAM96B, GID4, AKAP10, HMGCL, and C11orf49; and administering aJAK inhibitor to the human subject, wherein the JAK inhibitor isruxolitinib or a pharmaceutically acceptable salt thereof. 25.-27.(canceled)
 28. A method of treating a human subject having, suspected ofhaving, or at risk of developing vitiligo, comprising: measuring in abiological sample obtained from the human subject a reduced expressionlevel, as compared to a control, of at least one gene selected from thegroup consisting of STK16, RFNG, ZNRF1, ARID3B, WSB2, JAK1, IL1RL2,PALD1, S100A1, BCL2L12, FAM219A, and TSHZ1, and/or an increasedexpression level, as compared to a control, of at least one geneselected from the group consisting of PPIAL4G, CD5, IFI6, CCR4, CNTF,CD28, and RAB3IL1; and administering a JAK inhibitor to the humansubject, wherein the JAK inhibitor is ruxolitinib or a pharmaceuticallyacceptable salt thereof. 29.-34. (canceled)
 35. The method of claim 1,wherein ruxolitinib is topically administered to the human subject in acream comprising at least 0.15% ruxolitinib.
 36. The method of claim 1,wherein ruxolitinib is topically administered to the human subject in acream comprising at least 1.5% ruxolitinib. 37.-41. (canceled)